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1Abstract
A national screening programme could signiﬁcantly reduce mortality from epithelial ovar-
ian cancer (EOC). The biological events that occur in the early stages of development
of EOCs remain poorly understood, thus hindering the discovery of biomarkers of early
disease. This thesis describes the development of a three-dimensional heterotypic genetic
model of neoplastic transformation of normal ovarian surface epithelial (NOSE) cells.
hTERT, C-MYC, KRAS and BRAF are genes that are commonly mutated or overex-
pressed in EOCs. Ectopic expression of hTERT increased in vitro lifespan of NOSE
cells without inducing neoplastic transformation. Subsequent overexpression of CMYC
+/- KRASG12V /BRAFV 600E in immortalised NOSE (IOSE) cells induced a signiﬁcant in-
crease in anchorage-independent growth and invasive ability. In in vitro assays and gene
expression microarrays, phenotypic and molecular heterogeneity was associated with dif-
ferential oncogene expression. Physiological and biological features of NOSE cells grown
in 3D more closely resembled characteristics of NOSE cells in vivo than when grown by
classical two-dimensional (2D) approaches. 3D models of oncogene-expressing clones re-
vealed characteristics of malignant cells in vivo that could not be detected in 2D monolayer
cultures.
Gene expression microarrrays proﬁles of ∼25,000 genes were generated to identify novel
genes that are altered synergistically with the oncogenes that were introduced. A panel of
genes has been identiﬁed that provides novel candidates for detecting ovarian carcinomas
at the earliest, most treatable, stages of disease.
Finally, a role for ageing ﬁbroblasts in the initiation of EOC development was explored.
In 2D and 3D in vitro co-culture assays, pre-senescent and senescent ovarian ﬁbroblasts
diﬀerentially aﬀected proliferation, anchorage-independent growth, migration and invasion
of IOSECMY C cell lines but not of IOSE cells. These data provide in vitro evidence that
the ageing microenvironment can promote transformation of ovarian epithelial cells, and
that this is conditional upon mutation in the OSE.
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Introduction
1.1 Epithelial Ovarian Cancer
Survival rates from epithelial ovarian cancer (EOC) have improved very little over the last
four decades. The majority of ovarian cancer are diagnosed at an advanced stage (Stage
III or IV) and 5-year survival rates are under 30% (Figure 1.1). This is largely due to the
fact that EOCs are a complex group of tumours in terms of histology, molecular charac-
teristics, prognoses and clinicopathological features (Table 1.1). Early stage tumours are
characteristically asymptomatic, or any symptoms that are present are vague and non-
speciﬁc to the disease, and therefore do not aid early diagnosis. Consequently, researchers
have little access to early-stage tumour specimens, thus there is a genuine need for robust
in vitro models of EOC initiation and progression to increase our understanding of early
ovarian tumourigenesis. Futhermore, such models could be used to aid the development of
novel biomarkers that could be used to detect EOCs at the earliest, most treatable stages.
1.1.1 Subtypes of Epithelial Ovarian Cancer
Arguably, the one common feature of EOCs is their site of diagnosis. Epithelial ovarian
cancers show striking histological variability, and each of the subtypes is associated with
distinct molecular features, diverse biomarker proﬁles and distinct subtype-speciﬁc clini-
cal behaviour, as summarised in Table 1.1. As the need for rigorous subtyping of EOCs
has become more apparent, improved protocols for tumour classiﬁcation have been devel-
oped [Shih and Kurman, 2004]; [Koebel et al., 2008]. Standardised tumour subtyping ap-
proaches between pathologists and across hospitals and indeed countries greatly improves
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Figure 1.1: Stage at diagnosis and 5-year survival rates for epithelial ovarian cancer. Data shown
are for patients registered on the Thames Cancer Registry, diagnosed between 1992 and 1996.
the ability to study EOC subtypes eﬀectively with larger, collaborative studies, such as
the recent genome-wide association study which identiﬁed a new EOC susceptibility locus
on chromosome 9 [Song et al., 2009].
Epithelial ovarian tumours are described in terms of the epithelia of the genito-urinary
organs which they resemble (Table 1.1):
High-grade serous carcinomas (HGSCs)
HGSCs resemble the histopathology of the fallopian tube epithelium, and are the most
common type of malignant epithelial ovarian tumour. Patients with serous cystadenocar-
cinomas identiﬁed at Stage 1, when tumour growth is limited to the ovaries, have overall
survival rates of over 90%. However, the vast majority of HGSCs are detected when the
cancer has already progressed to FIGO Stage III/IV and disease has spread from either
one or both ovaries to form peritoneal metastases and involvement of the retroperitoneal
or inguinal lymph nodes.
Molecular analyses indicate that low-grade and high-grade serous tumours arise via dis-
tinct pathways. Mutation/loss of heterozygosity in BRCA1/2 and mutations in TP53 are
common genetic abberations in ovarian HGSCs but rarely occur in borderline tumours
[Russell et al., 2000]. HGSCs commonly express the cancer antigen 125 (CA125), oestro-
gen receptor (ER) and Wilms tumor 1 (WT1) biomarkers.
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Table 1.1: Epithelial ovarian cancer subtypes are diverse in terms of cellular origins, known ge-
netic alterations, biomarkers and clinical characteristics. Distribution in the UK of histotypes are
indicated. Typical histological appearance are shown by representative H&E sections. MMR
= mismatch repair, LMP = low malignant potential. Biomarker data are summarised from
[Koebel et al., 2008].
Borderline serous tumours (BSTs)
Although histologically similar to HGSCs and with a similar panel of associated biomark-
ers, borderline serous (or low-malignant potential, LMP) ovarian tumours have more
favourable prognosis than the high-grade counterparts. The molecular features of BSTs
are distinct from HGSCs. Analysis of borderline serous tumours (BSTs) and neighbour-
ing non-transformed epithelial cystadenoma (which are cytologically normal) identiﬁed
identical KRAS and BRAF mutations in both areas [Ho et al., 2004]. This suggests that
(i) BSTs may evolve from a normal lesion in which cells are harbouring KRAS/BRAF
mutations; and (ii) mutations in these genes are early events in ovarian tumourigenesis of
low-grade serous lesions [Shih and Kurman, 2005].
21Mucinous cystadenocarcinomas
Mucinous EOC resemble the glanduar epithelium of the endocervix or gastrointestinal
tract. These tumours generally have favourable prognoses, since a signiﬁcant proportion
of patients present with the disease at Stage I or Stage II when the disease is still con-
ﬁned to the ovaries. Mucinous tumours contain a large amount of mucus-like material,
produced by goblet cells that resemble cells lining the normal intestine. KRAS mutations
are found in frequencies of 40-60% in benign, borderline and malignant mucinous tumour
subtypes, with the highest frequencies observed in the latter [Gemignani et al., 2003];
[Jordan et al., 2006]; [Heinzelmann-Schwarz et al., 2006]. Mucinous tumours are thought
to arise in an adenoma → cystadenoma → carcinoma model [Russell and McCluggage, 2004].
This model is also supported by histological studies. EOC samples that consist of invasive
tissue with areas of benign or borderline histologies are more likely to be invasive mucinous
than the invasive serous subtype [Mayr et al., 2006]. A biomarker commonly expressed is
Matripase; notably absent is expression of CA125 and WT1.
Endometrioid and clear cell carcinomas
Endometrioid and clear cell tumours resemble the epithelium of the endometrium. The
vast majority of these tumours present at Stage III or Stage IV, where the disease has
metastasised to distant organs of the body. These two subtypes have similar genetic
alternations (loss of PTEN function and defects in the mismatch repair pathway) and
origins. A recent study of EOC biomarkers by Huntsman and colleagues (summarised
within Figure 1.1) has demonstrated that endometrioid and clear cell tumours may be
distinguished by oestrogen/progesterone receptor (ER/PR) expression (absent in clear
cell) [Koebel et al., 2008].
Undiﬀerentiated tumours
These occur at low frequencies and are usually high-grade. Very little is known about the
molecular features and biomarkers of undiﬀerentiated tumours, but some are thought to
be misdiagnosed serous or endometrioid tumours.
221.1.2 Diverse Cellular Origins of Epithelial Ovarian Cancers
It is apparent that EOCs arise from diverse cellular origins; predominantly from the ovarian
surface epithelium (OSE), but also from endometrial epithelia, fallopian tube epithelia, and
perhaps also endocervical epithelia, ectopically transported to the ovary as endometrioisis,
endosalpingiosis, and endocervicosis (Figure 1.2).
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Cervix
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Fallopian 
tube
Figure 1.2: Diverse cellular origins for EOCs. Current theory suggests that the majority of
epithelial ovarian carcinomas originate from epithelial cells of the ovary (ovarian surface epithelium,
OSE on the surface of the ovary or within inclusion cysts, IC); an as yet unquanitifed proportion of
high-grade serous EOCs are thought to arise in the epithelia at the distal end of the fallopian tube,
or from fallopian tube epithelial cells relocated to the ovary (endosalpingiosis). Endometrial and
clear cell tumours may arise from epithelium of the endometrium ectopically transported to the
ovary (endometriosis). Red arrows show hypothesised cell movements from diﬀerent organ sites to
the ovary, prior to ovarian cancer development. Diagram adapted from www.myhealth.ucsd.edu
and [Auersperg et al., 2001]
The Ovarian Surface Epithelium
Human ovaries are covered with a monolayer of ﬂat/cuboidal mesothelial-type epithe-
lial cells referred to as the ovarian surface epithelium (OSE) (Figure 1.2). These cells
are widely considered to be the origin of a large proportion of epithelial ovarian cancers
[Auersperg et al., 2001]; [Okamura and Katabuchi, 2001]. Primary normal OSE (NOSE)
cell cultures show considerable phenotypic plasticity and can exhibit both epithelial (pres-
ence of desmosomes; collagen IV, laminin and cytokeratin production) and mesenchymal
characteristics (no expression of E-cadherin; collagen I, collagen III and vimentin pro-
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Figure 1.3: The ovarian surface epithelium in vivo. (a) Normal OSE cells on the surface of the
ovary (arrow). Surface epithelial cells are loosely attached, and some epithelia have been lost from
this sample during processing into paraﬃn. (b) Epithelial invagination into the ovarian stroma
brings OSE cells into the ovarian cortex (arrow). These structures are thought to arise following
follicular rupture, and can lead to inclusion cyst formation if the invagination closes up at the
surface of the ovary. (c) Complex papillary structures (arrow) observed on the surface of an ovary
from a patient with a family history of ovarian cancer.
duction) [Auersperg et al., 1994]; [Dyck et al., 1996]. NOSE and immortalised OSE cell
lines also have an elongated, mesenchymal morphology in vitro, that resembles the ‘ep-
ithelial scattering’ phenotype observed when classic epithelial cells undergo an epithelial-
to-mesenchymal transition. In vitro culture of these cells was ﬁrst achieved by Auerperg
and collegues in 1984, and is described in Chapter 3 [Auersperg et al., 1984].
Neoplastic changes within ovarian cortical inclusion cysts (ICs) (p53 signatures) suggests
that the high-grade serous carcinoma subtype can originate within these relatively common
structures. The term ‘cortical inclusion cyst’ describes cystic structures within the ovarian
stroma (see Figure 1.2) that are below 100mm in diameter and are lined with epithelium.
ICs form from the invagination of the OSE during ovulation, or from papillary structures
commonly seen on the surface of ovaries (see Figure 1.3).
Inclusion cysts have a diﬀerent microenvironment to the surface of the ovary. When
trapped within inclusion cysts, ovarian epithelial cells are physically closer to the mito-
genic hormonal environment of the ovarian stroma. A basement membrane consisting of
collagen IV and laminin plus a thick collageous layer termed the tunica albuginea, separates
normal ovarian surface epithelial cells from the underlying stroma [Auersperg et al., 2001].
Basement membranes are present in all tissues as a sheet of ﬁbrillous matrix protiens un-
derlying epithelial or endothelial monolayers. The function of the basement membrane
is to anchor the epithelial/endothelial cells to the connective tissue below through cell-
matrix adhesions. Basement membranes also act as a physical barrier during the earliest
stages of neoplastic transformation. However, during the process of ovarian inclusion
24cyst formation, the basement membrane/tunica albuginea matrix layer is lost, and thus
the barrier separating the ovarian epithelial cells from the mitogenic stromal environ-
ment no longer exists [Auersperg et al., 2001]. It is likely that the close proximity of OSE
trapped within ICs to bioactive molecules (e.g. hormones and mitogens) in the stromal
milieu contributes to the rapid growth of these tumours. Elevated levels of oestrogen
or growth factors in the ovarian stroma may be required for this eﬀect to be signiﬁcant
[Wong and Auersperg, 2003].
Interestingly, BRCA1/2 mutation carriers and families with a history of breast and ovar-
ian cancer (groups with increased risk of EOC) have a higher frequency of inclusion cysts
[Werness et al., 2000]. One study analysed histopathological atypia along with expres-
sion of a number of cell cycle regulatory proteins in 94 prophylactically removed ovaries
of 50 Ashkenazi Jewish women carrying BRCA1 or BRCA2 mutations. Mutation car-
riers had signiﬁcantly more atypical features of the OSE and also a higher frequency of
inclusion cysts compared to controls. Furthermore, TP53 expression in the cortical inclu-
sions within ovaries of BRCA1/2 mutation carriers was found to be signiﬁcantly elevated
compared to controls [Kerner et al., 2005]. This suggests that, in mutation carriers at
least, pre-neoplastic areas of ovarian ICs have identiﬁable molecular features, and these
biomarkers could reveal the histological features and molecular proﬁle of the subsequent
tumour (BRCA1/2 tumours are mostly serous and TP53 mutations are very common in
this subtype).
Lessons from the Microenvironment and Developmental Biology
The cellular origins of EOCs have been extensively disputed in the literature over the
last several years. If all ovarian cancers do arise from the OSE, then this would indeed
require diﬀerentation of the uncommitted OSE cell. At most other organ sites, epithelial
cell tumours are characterised by a loss of tissue organisation and of features of diﬀeren-
tiation; the inverse is true for EOCs. EOCs are more diﬀerentiated than their proposed
cell of origin, and unlike other epithelia which become more mesenchymal with transfor-
mation, the OSE has mesenchymal characteristics which are lost during the process of
oncogenesis. Expression of the E-Cadherin adhesion molecule illustrates this paradox -
most epithelia express E-Cadherin and this molecule is important for cell polarity and
the formation of glandular epithelial stuctures, such as breast acini. Typically, loss of
E-Cadherin expression is associated with loss of tissue organisation and progression from
a quiescent, organised tissue to a hyperproliferative, disorganised structure (Figure 1.4).
The OSE somewhat unusually, does not express E-Cadherin, and E-Cadherin expression is
often acquired during EOC development, thus EOCs are more diﬀerentiated and demon-
25strate a higher level of tissue organisation than the precursor cell [Sundfeldt et al., 1997].
E-Cadherin expression is found in 27-100% serous, 40% mucinous and 22% of clear-cell
EOCs, suggesting that maintenance of E-Cadherin expression occurs in all of the major
EOC histotypes [Sundfeldt et al., 1997]; [Faleiro-Rodrigues et al., 2004].
In vitro, SV40-immortalised OSE cell expressing E-Cadherin undergo a mesenchymal
to epithelial transition [Auersperg et al., 1999]. An interesting observation is that the
epithelia lining inclusion cysts express E-Cadherin and CA125 [Sundfeldt et al., 1997];
[Miotti et al., 2005]; reviewed in [Auersperg et al., 2001]. Therefore, OSE lining ICs be-
comes more committed to an epithelial phenotype, thus displaying features of EOCs. This
suggests that the ovarian stromal-epithelial interactions may play a key role during EOC
initiation. The microenvironmental cues that may be responsible for this are not yet
known, though age-related changes may have a role, and are explored in Chapter 5 of this
thesis.
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Figure 1.4: EOC genesis: development gone awry? (a, b) Most other epithelia in the body loose
tissue organisation and features of diﬀerentiation when transformed (e.g. E-Cadherin expression,
polarity). The inverse is true for EOCs. (c, d) Common developmental origins of the OSE and
M¨ ullerian-derived epithelia suggest a role for the ovarian stroma in stimulating a M¨ ullerian-type
diﬀerentiation of the OSE within inclusion cysts.
The issue of the transdiﬀerentiation from uncommitted epithelial monolayer to diﬀeren-
26tiated epithelial cells by the OSE is often used as an argument against an OSE origin
for EOCs. This is backed up the the fact that EOCs resemble epithelia from the other
organs of the reproductive tract, as described above, leading some researchers to hypoth-
esise that all EOCs derive from ectopically located M¨ ullerian epithelia [Dubeau, 1999].
Ovarian and M¨ ullerian epithelia derive from the same embryological origins (the coelomic
mesothelium). During the development, the cells which will form M¨ ullerian duct-derived
epithelia migrate into the mesenchyme, gaining expression of CA125 (a diﬀerentiation
marker of normal M¨ ullerian-derived epithelia; also frequently expressed at high levels in
EOCs). The same coelomic mesothelium gives rise to the OSE, which does not undergo
migration but forms the cellular monolayer that covers the surface of the ovary. It is hy-
pothesised that OSE trapped in the ovarian stroma undergoes a M¨ ullerian diﬀerentiation
that mimics diﬀerentiation of other gynaecological epithelia during embryogenesis, and
that this is reﬂected by CA125 and E-Cadherin expression often observed in OSE trapped
in the ovarian cortex (Figure 1.4) [Roskelley and Bissell, 2002].
The approach to EOCs as ‘development gone awry’ is an attractive model for EOC gen-
esis, since it would answer many of the unresolved questions regarding origins of the
disease. Naora and collegues have modelled the eﬀects of inappropriate HOX gene ex-
pression in mouse ovarian surface epithelial (mOSE) cells and demonstrated that ectopic
expression of HOXA9, HOXA10, HOXA11 in tumourigenic mOSE induces growth of pap-
illary, endometrioid and mucinous tumours respectively (Figure 1.4) [Cheng et al., 2005].
Temporal expression of HOX genes follows location of the genes in the genome, and also
the frequencies of each associated tumour subtype.
Other Cellular Origins
Emerging evidence suggests that not all epithelial ovarian cancers originate from ovarian
surface epithelial cells, as shown in Table 1.1 and Figure 1.2. More recently, histopatho-
logic analyses and gene expression proﬁling have provided evidence that a proportion of
high-grade serous tumours arise from the fallopian tube epithelium [Marquez et al., 2005];
[Jarboe et al., 2008]. It is well established that over a third of endometrioid and clear cell
EOCs are associated with endometriosis (a benign condition in which endometrial cells
become hyperproliferative and are found ectopically located throughout the pelvis and
other parts of the body) [de la Cuesta et al., 1996].
Detailed histopathological examinations of fallopian tube tissue from prophylactic oophorec-
tomy procedures have found a high proportion of occult in situ carcinomas that are of
the serous subtype [Callahan et al., 2007]; [Jarboe et al., 2008]. These occult tumours are
27morphologically very similar to high-grade serous ovarian cancers (the most common EOC
subtype), which has lead to a shift in opinion in the ﬁeld. Many researchers now consider
the fallopian tube epithelia (FTE) to be the site of origin of the majority of the majority
of EOCs. Studies to date have used samples from women who have a high risk of EOC,
so it has yet to be established whether or not this is true for sporadic tumours. Evidence
to support this statement does not rule out a role for the OSE, and taken together, the
data suggest dual origins for high-grade serous carcinomas (HGSCs) (Table 1.2).
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Table 1.2: An OSE or FTE origin of EOCs? Diﬀerent interpretations of the evidence.
1.1.3 Risk Factors for Epithelial Ovarian Cancer
The relative risks for ovarian cancer are summarised in Table 1.3. The most signiﬁcant
risk factor for epithelial ovarian cancer is a mutation in either the BRCA1 or BRCA2 gene
(Table 1.3). After BRCA1/2 mutation, the two main risk factors for epithelial ovarian
cancer are (i) increased age: the highest incidence of EOC is in women over 75; and (ii)
family history (although over 90% of cases are sporadic). Other factors that can alter a
women’s risk of developing EOC include talcum powder use (increases risk), prophylactic
oophorectomy (reduces risk) and tubal ligation (also reduces risk) (references listed in
Table 1.3). Some of these epidemiological risk factors have also been modelled in vitro -
for example OSE from women with a family history show neoplastic features and talc can
increase proliferation of OSE cells [Auersperg et al., 1995]; [Buz’Zard and Lau, 2007].
Parity has a protective eﬀect against the development of EOCs: one full term preg-
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Table 1.3: Genetic and epidemiological evidence and the origin of epithelial ovarian cancers. OSE
= ovarian surface epithelium; EEC = endometrial epithelial cell; FTE = fallopian tube epithelium;
PE = peritoneal epithelium; OCP = oral contraceptive pill; EOC = epithelial ovarian cancer; BC
= breast cancer, FH = family history, RR = relative risk, HR = hazard ratio. †Calculated from
the cancer statistic registrations, Oﬃce for National Statistics: relative risk of malignant ovarian
neoplasm (C56) in the 60-over 85 age group compared to in the 20-49 age group.
29nancy confers a 40% reduction in the risk of developing EOC, with a further 10% re-
duction in risk for each successive birth (reviewed in [Elmasry and Gayther, 2006] and
[Edmondson and Monaghan, 2001]). The reduced risk of EOC taking the oral contracep-
tive pill (OCP) has been found in numerous epidemiological studies. This protective eﬀect
may apply to all histological subtypes of the disease, with the possible exception of mu-
cinous tumours, where some studies have observed a protective eﬀect and others do not
[Modugno et al., 2001]; [Risch et al., 1996]. The protective eﬀect is increased when OCP
use is over longer periods of time, and up to a 50% reduced risk of EOC is typically observed
after 5 years of OCP use. The reduced risk eﬀect continues even after use of OCP has
stopped [Whittemore et al., 1992]. For BRCA1/2 mutation carriers, the risk of developing
EOC is also signiﬁcantly reduced with long term OCP use [Whittemore et al., 2004].
The Incessant Ovulation Hypothesis
The protective eﬀect of pregnancy and the oral contraceptive pill is likely to be due to the
cessation of ovulation which stops the continual cycle of rupture, repair and regrowth of
the OSE (applicable to EOCs that originate from ovarian epithelial cells). The incessant
ovulation hypothesis for ovarian tumourigenesis was ﬁrst proposed by Fathalla in 1971,
and links the frequency of ovulation and incidence of EOC [Fathalla, 1971]. This theory
was modelled in domestic fowl, which represent a natural model of spontaneous ovarian
cancer [Blackmore, 1966]; [Goodchild, 1969]. In Fathalla’s experiment, the egg produc-
tion of birds was maximised by artiﬁcially maintaining 12-hour days, and this resulted in
ovarian adenocarcinomas arising in 17 out of 19 birds. Control hens kept with normal
seasonal variation in lighting did not develop ovarian tumours. In combination with epi-
demiological observations, such as the higher incidence of ovarian neoplasms in nulliparous
women, it was inferred that frequent trauma to the OSE caused by ovulation plus repeated
exposure to the mitogenic environment within the ovarian stroma is likely to play a role
in tumourigenesis of ovarian surface epithelial cells [Fathalla, 1971]. It has subsequently
been shown that oestrogen is mitogenic to OSE cells in vitro [Syed et al., 2001].
Ageing and Cancer
The risk of developing ovarian carcinoma increases with age (Figure 1.5). Over 80%
of all epithelial ovarian cancers are diagnosed in postmenopausal women [Yancik, 1993];
[Smith and Xu, 2008]. The strongest epidemiological data for EOC, (protective eﬀect of
OCP use and pregnancy), links EOC risk to pre-menopausal events [Pike et al., 2004].
However, high-grade serous tumours, the most common histopathological subtype of the
30disease, are rarely discovered at an early stage, suggesting that these tumours progress
rapidly. Thus, this model requires that pre-neoplastic biological and molecular changes
are induced in a precursor cell/lesion before the menopause and lie dormant, often for over
10 years, before tumourigenesis begins. Thus, if the beginnings of tumour growth precedes
menopause in the majority of cases, this suggests there may be microenvironmental triggers
(such as senescent stromal cells) that initiate proliferation of a dormant epithelial cell
harbouring somatic mutation(s).
There are many links between epithelial tumourigenesis and ageing. There is a striking
increase in the proportion of all epithelial carcinomas with advancing age - under 10%
of tumours diagnosed in children are epithelial compared to up to 85% of tumours di-
agnosed in adults over the age of 40 [Wu et al., 2005]. Mathematical modelling suggests
that accumulated spontaneous mutations alone are insuﬃcient for cancer development
(reviewed in [DePinho, 2000]). One hypothesis is that normal rates of senescence in local
stromal ﬁbroblast cells may create a microenvironment that promotes epithelial tumour
development. In this thesis I explore the hypothesis that age-related changes in the ovar-
ian stromal micrs in the epithelium to promote development of epithelial ovarian cancers.
This is discussed in more detail in Chapter 5.
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Figure 1.5: Analysis of the incidence of EOCs within diﬀerent age groups suggests there may
be a role for ageing related cellular changes in EOC development. Age related incidence of EOC
was calculated from the Thames Cancer Registry 2006. Known hormonal risk factors are pre-
menopausal hormonal exposures, yet most EOC incidences occur >10 years after the menopause.
C56 = diagnosis of cancer of the ovary
311.2 Genetic Pathways Commonly Dysregulated in EOCs
For the majority of known cancer associated genes, the mechanisms of somatic alteration
include: (1) Chromosomal alterations (e.g. translocations, interstitial chromosome dele-
tions and rearrangements and chromosome ploidy); (2) DNA alterations of speciﬁc genes
(e.g. coding sequence mutations, genomic deletions, rearrangements and ampliﬁcations);
(3) Gene expression changes resulting from transcript instability, splice-site mutation or
aberrant methylation of promoter sequences. (4) Alterations that aﬀect protein expression
or protein interactions and stability. As there are multiple mechanisms by which genes or
biological pathways can be interrupted, it has been diﬃcult to obtain accurate estimates
of the frequency with which speciﬁc genes are altered in epithelial ovarian cancers.
There are now several databases cataloguing the genes that are frequently involved in can-
cer, such as the catalogue of somatic mutations in cancer (COSMIC 1) [Forbes et al., 2006].
Gene speciﬁc databases also exist, such as the IARC TP53 database [Petitjean et al., 2007].
Current data suggest that the genes most commonly mutated in ovarian cancers are p53,
KRAS, CTNNB1, CDKN2A, PTEN, PIK3CA and BRAF. Tumour suppressor genes that
commonly show loss of expression in ovarian cancers, include BRCA1/2, RB1, ARH1
(NOEY2), GATA4, RNASET2, LOT1, DCC and FHIT. Oncogenes that are reportedly
ampliﬁed or overexpressed in ovarian cancers include CMYC, ERBB2, HRAS, CSF1R,
ECCF1, EGFR, P13K/AKT2, PTEN/MMAC1, FGF3, MDM2, BCL2, and also EGFR
[Fujita et al., 2003]; [Cvetkovic et al., 2004] [Lawrenson et al., 2009b].
From what is known of the genes that are somatically altered in ovarian cancers, it has
been possible to build up a picture of the molecular pathways that are critical in ovarian
cancer development. The most signiﬁcant pathways appear to be: (1) The DNA dou-
ble stranded break (DSB) repair pathway, particularly alterations in the BRCA1 and
BRCA2 genes: (2) The DNA mismatch repair (MMR) pathway, particularly alterations
in MMR genes, including MSH2 and MSH6; (3) The mitogen-activated protein kinase
(MAPK) pathway, particularly alterations in the KRAS and BRAF proto-oncogenes; (4)
The phosphatidylinositol 3-kinase (PI3K) pathway, particularly alterations in the PTEN
tumour suppressor gene and the proto-oncogene PI3K.
1.2.1 The DNA Double Stranded Break Repair Pathway
A strong family history of breast and ovarian cancer is the most signiﬁcant risk factor for
the disease, and up to 10% of EOC case are thought to be inherited [Auersperg et al., 2001].
1http://www.sanger.ac.uk/genetics/CGP/cosmic/
32BRCA1 and BRCA2 are the only genes to be currently identiﬁed as highly penetrant ovar-
ian cancer susceptibility genes [Gayther et al., 1999]. BRCA1 and BRCA2, on chromo-
somes 17q21 and 13q12-13 respectively, behave as classic tumour suppressor genes (TSGs)
and loss of function of these genes occurs in sporadic and inherited tumours. BRCA1/2
have roles in the repair of double-strand DNA breaks, and in normal cells with mutations
in these genes, the accumulation of DNA abberations induces a p53-dependent growth ar-
rest. However, in tumour cells with loss of functional BRCA1/2, growth arrest is avoided
(often by loss of function of p53) and DNA damage is repaired by alternative, more er-
ror prone mechanisms such as non-homologous end joining and single-strand annealing
(Figure 1.6).
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Figure 1.6: Illustration of the DNA double-stranded break repair pathways. In absence of func-
tional BRCA1/2, all DNA repair occurs via the non-homologous recombination pathway, which
is intrinsically more error-prone than homologous recombination repair of double-stranded DNA
breaks.
BRCA1 and BRCA2 mutation carriers show frequent loss of heterozygosity of the wild-
type allele at the BRCA1/2 loci [Ramus et al., 2003]. In ovarian cancer, the presence
of a BRCA1/2 mutation or a family history of breast/ovarian cancer aﬀects the pro-
33ﬁle of somatic genetic alterations that occur during tumourigenesis, suggesting there are
diﬀerent pathways for tumour development between these groups [Ramus et al., 2003];
[Israeli et al., 2003]. BRCA1/2-associated tumours also have distinct clinical features.
This group of tumours are more likely to be high-grade serous or poorly-diﬀerentiated,
and BRCA1/2 mutation carriers may also have a better survival that non-mutation car-
riers [Ramus and Gayther, 2009].
Sporadic tumours often have expression proﬁles similar to that of either BRCA1 or BRCA2
tumours (even though these proteins are rarely somatically mutated in sporadic cases).
This suggests either (i) hypermethylation/ other means of inactivation of the BRCA1/2
gene, mRNA or protein is common in sporadic cases (for example, aberrant intra-cellular
localisation), or (ii) there are common pathways involved in the majority of EOC cases
[Ramus et al., 2003]; [Wong and Auersperg, 2003]. BRCA1 and BRCA2 mutations may
cause the ovarian surface epithelium to be more susceptible to transformation. The nor-
mal phenotype of BRCA1/2 mutation-positive OSE cells in vitro diﬀers from that of non-
mutation carrying cells. Seemingly normal OSE cells from women with a strong family
history of breast and ovarian cancer have been found to have characteristics normally asso-
ciated with ovarian cancer cell lines (e.g. E-Cadherin expression) [Auersperg et al., 2002].
Additionally, the OSE of prophylactially removed ovaries from BRCA mutation carriers
show higher expression of TP53 and MIB1 (proliferation marker) when compared to ovaries
removed from non-mutation-carriers [Schlosshauer et al., 2003]. Despite a signiﬁcantly el-
evated risk of breast and ovarian cancer, not every woman with mutations in these genes
will develop gynaecological cancers, and greater understanding of the functional role of
the various BRCA1/2 mutations and interactions of these proteins within the cell may
give us insight into biological explanations for this.
BRCA1/2 mutations predispose to cancer in a tissue speciﬁc manner (mutation carri-
ers have a high risk of breast and ovarian cancer). Menstrual cycle hormones and the
hormonal environment within the ovary are likely to play an important role in EOC
and may interact in some way with BRCA1/2 as a predisposing factor to gynaecolog-
ical cancers. Since BRCA1/2 mutations cause a defect in DNA damage repair, mu-
tations can accumulate in BRCA1/2-mutant cells that may eventually lead to tumour
formation. Oestrogen levels in the ovarian stroma are one hundred times greater than
in the blood and oestrogen is mitogenic to OSE cell cultures in vitro [Syed et al., 2001];
[Wong and Auersperg, 2003]; [Sowter and Ashworth, 2005]. Hence, oestrogenic stimula-
tion of a cell with mutant BRCA1/2 could trigger to mitosis before DNA damage is fully
repaired.
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BRCA1 coding mutations have been found in ∼3% of ovarian cancers; but BRCA1 alter-
ation occurring by a combination of gene deletion (detected as LOH), loss of gene expres-
sion (by promoter methylation) or loss of protein expression have been reported in the ma-
jority of ovarian cancers [Russell et al., 2000]; [Welcsh and King, 2001]; [Wang et al., 2004].
BRCA1 mutations predispose to breast and ovarian cancers (as well as cancer of the fallop-
ian tube and peritoneum). Around 40% of women who inherit a mutated copy of BRCA1
will develop EOC by the time they reach age 70 [Edmondson and Monaghan, 2001]. Al-
though the precise functions of BRCA1 are yet to be fully understood, it is known that
this protein plays a role in DNA repair as part of the BRCA1 associated genome surveil-
lance complex (BASC). Downregulation of BRCA1 halts the cell cycle at the G2 to M
transition (a p53-dependant cell cycle checkpoint; this leads to apoptotic cell death or cell
cycle arrest [Edmondson and Monaghan, 2001], probably due to defects in the repair of
DNA damage. Knockout of this gene is embryonic lethal in mice [Gowen et al., 1996].
BRCA1 can also indirectly aﬀect the development of epithelial ovarian cancer, acting via
sex steroids that are secreted from ovarian granulosa cells. Chodankar and colleagues used
a Cre-loxP system to knockout BRCA1 alleles in the ovarian granulosa cells of mice and
found that over two-thirds of the homozygous mutant mice developed epithelial ovarian
cysts and uterine cysts. The cysts reportedly resembled human serous cystadenomas
[Chodankar et al., 2005]. The tumours did not have mutant forms of BRCA1. Chodankar
et al hypothesised that inactivation of BRCA1 in granulosa cells caused a diﬀerence in the
steroid hormones produced by these cells. Investigating the roles of hormonal variation in
the initiation and development of epithelial ovarian tumours is likely to give insight into
the complex interactions that occur in ovarian tumourigenesis.
BRCA2 (13q12-13)
Somatic mutations in the coding region of BRCA1 occur in only ∼2% of ovarian tumours;
but 30-50% of tumours show LOH and decreased expression [Welcsh and King, 2001].
BRCA2 has numerous putative functions including roles in transcriptional control and
in maintenance of genomic stability during mitotic replication. BRCA2 is also impor-
tant for the repair of double-stranded breaks by homologous recombination. In BRCA2-
deﬁcient cells, chromosomal abnormalities (often gross chromosomal rearrangements such
as translocations and large deletions) accumulate during mitotic replication, illustrat-
ing a role for BRCA2 in maintenance of chromosomal stability during DNA replication
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TP53
The p53 tumour suppressor gene is arguably the most important cancer-associated gene
discovered to date. This protein plays a fundamental role in cell cycle control, apoptosis,
and acts to maintain the integrity of the genome. p53 also interacts with BRCA1 as the
two proteins co-immunoprecipitate in vitro and in vivo. When a cell sustains DNA damage,
TP53 levels rapidly increase. The protein binds to DNA, inducing expression of p21 and
preventing the cell from entering S phase of the cell cycle until damage is repaired. If the
damage to the cells genome is too extensive to be repaired, TP53 will push the cell towards
an apoptotic pathway. It is therefore unsurprising that p53 is mutated in around half of
all cancers, and in cancers where elevated TP53 is observed, the protein is mutated and
ineﬀective. Mutations in TP53 are more common in tumours with BRCA1 and BRCA2
mutations than without [Ramus et al., 1999].
1.2.2 The DNA Mismatch Repair Pathway
Most cases of hereditary non-polyposis colorectal cancer (HNPCC) syndrome are caused
by germline mutations in one of the mismatch repair (MMR) genes, MLH1, MSH2 and
MSH6. Mutations in one of these genes causes an 80% risk of colorectal cancer in car-
riers, also increases susceptibility to gynaecological cancers; the lifetime risk of endome-
trial cancer has been estimated as 40-60% and the risk of ovarian cancer, around 12%
[Watson and Lynch, 2001]. This is thought to account for about 2% of all ovarian cancer
cases, and the age at diagnosis is considerably lower than it is for sporadic ovarian cancer
[Crijnen et al., 2005]; [Malander et al., 2006]. In a normal cell, mismatch repair proteins
play crucial roles in the repair of mismatched bases, insertions and deletions (Figure 1.7).
An error is identiﬁed by either hMutSα (a heterodimer that consists of MSH2:MSH6)
or hMutSβ (which consists of MSH2:MSH3). These assemble at the DNA mismatch and
recruit hMutLa (MLH1:PMS2 heterodimer), along with other proteins, to the site of dam-
age, and repair takes place. In a cell with MMR deﬁciency, errors are not repaired and are
replicated at mitosis. Consequently, both silent and potentially oncogenic DNA mutations
accumulate in the cell.
Microsatellite instability (MSI), a marker of MMR deﬁciency, has been identiﬁed in ∼15%
of ovarian tumours, although frequencies vary between studies (0-39%) [Allen et al., 2000],
[Buller et al., 2001]; [Helleman et al., 2006]. The most plausible explanation for this vari-
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Figure 1.7: Illustration of the mismatch repair pathway. In a normal cell, components of the
MMR pathway recognise and repair mismatched bases, insertions and deletions.
ability is the reported correlation between the occurence of MSI and the ovarian cancer
phenotype. MSI is commonly found in endometrioid ovarian cancers, relatively frequently
in clear cell tumours and tumours of mixed histology, but is rare in serous or mucinous
tumours [Fujita et al., 2003]; [Gras et al., 2001]; [Catass et al., 2004]. That MSI is asso-
ciated directly with genes in the mismatch repair pathway has been suggested from the
analysis of hMLH1; loss of hMLH1 expression due to promoter hypermethylation has been
found in around half of all MSI positive tumours, although somatic coding mutations of
the gene are rare [Strathdee et al., 1999]; [Geisler et al., 2003]; [Son et al., 2004].
There is evidence to suggest that MMR status could inﬂuence the eﬀectiveness of chemo-
therapeutic treatments for ovarian cancer. MLH1 or MSH6 deﬁcient ovarian cancer cell
lines show increased resistance to some platinum-based therapies, such as cisplatin. The
MMR pathway has a role in the recognition and repair of DNA adducts caused by exter-
nal agents, such as the cisplatin-induced cross-links between adjacent guanine residues.
Defects in MMR are associated with increased resistance to platinum-based chemothera-
pies, as cells deﬁcient in MMR function can divide without pausing to repair drug-induced
DNA damage [Brown et al., 1997]; [Vaisman et al., 1998]; [Strathdee et al., 1999]. How-
ever, clinical data examining the relationships between MMR defects, patient survival
and resistance to platinum-based chemotherapy for ovarian cancer are sparse and con-
tradictory. One study found that whilst loss of hMLH1 was observed in over 50% of 34
Stage III/IV ovarian cancers, loss of this protein was linked to improved survival in this
sample set [Scartozzi et al., 2003]. In contrast, Crijnen et al. found that ovarian can-
cer cases from HNPCC families showed no diﬀerence in survival compared to sporadic
cases [Crijnen et al., 2005]. However, loss of hMLH expression has been shown to be sig-
niﬁcantly higher in ovarian tumours post-chemotherapy compared to untreated tumours,
suggesting that exposure to chemotherapy induces positive selection for MMR deﬁcient
37tumour cells in vivo [Brown et al., 1997].
1.2.3 The Mitogen-Activated Protein Kinase Signalling Pathway
In EOCs genetic abberations of genes in the mitogen-activated protein kinase (MAPK)
signalling pathway occur in a subtype-speciﬁc manner, as summarised in Table 1.4. This
thesis looks in detail at the MAPK pathway and the diﬀerential eﬀects of KRASG12V
and BRAFV 600E in an in vitro model of EOC development. Mutations in RAS or RAF
are the most common mechanism by which the MAPK pathway becomes inappropriately
activated in tumours.
Histological Subtype
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Table 1.4: Subtypes of epithelial ovarian cancer have distinct molecular proﬁles. α 0% sig-
niﬁes mutations have not yet been identiﬁed in these subtypes. *Similar frequencies of muta-
tions found in benign, borderline and malignant tissue within same neoplasm. Adapted from
[Lawrenson et al., 2009b]
The mitogen-activated protein kinase pathway (RAS/RAF/MEK/MAPK) is a key path-
way in the transduction of a external mitogenic signal into the nucleus (Figure 1.8). When
a mitogen binds to a receptor tyrosine kinase (RTK, such as EGFR or ERBB2) on the cell
membrane, the external mitogenic signal is transduced into the nucleus via the mitogen-
activated protein kinase pathway. Activation of this pathway induces proliferation and
diﬀerentiation of a cell, and so unsurprisingly, components of this pathway are frequently
mutated in many types of cancer, including melanoma and colorectal carcinoma. Onco-
genic mutations activate the pathway in the absence of a mitogenic signal, causing the cell
to enter the S phase of mitosis and begin to divide without control. If cells divide before
any DNA damage is repaired, consequently, the daughter cells will contain mutations.
Should these mutations confer a growth advantage, for example by enabling the cell to
bypass apoptotic signals, growth of these cells will be selected for in that population.
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Figure 1.8: Illustration of the mitogen-activated protein kinase and phosphatidylinositol 3-kinase
pathways. The mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase
(PI3K) pathways are frequently activated in ovarian and other cancers, either by loss of tumour
suppressor genes, such as phosphatase and tensin homologue (PTEN) in the PI3K pathway, or
activation of oncogenes such as KRAS or BRAF in the MAPK pathway. Proto-oncogenes are
shown in green, tumour suppressor genes in red.
KRAS
A mutant copy of the RAS gene was the ﬁrst oncogene to be isolated and sequenced.
The RAS family of proto-oncogenes are small GTPases located on the cytoplasmic as-
pect of the plasma membrane, and play an important role in transducing extracellular
signals for proliferation and diﬀerentiation. RAS proteins are guanine nucleotide-binding
glycoproteins and to become active, the normal RAS protein must undergo a change in
tertiary conformation, triggered by the binding of a GTP molecule, transferred following
dimerisation of two receptor tyrosine kinases. Thus, Ras acts as a molecular switch, active
39when GTP is bound, inactive when GDP is bound. GTP-bound RAS molecules mediate
cellular signalling through the hydrolysis of GTP into GDP by their intrinsic GTPase
activity, when stimulated by a GTPase activating protien (GAP). RasGAP protiens in-
clude p21. In the case of RAS, son of sevenless, or SOS is a guanine exchange factor
that stimulates the release of the bound nucleotide (e.g. GDP) (Figure 1.8). Once GDP
is released the RAS protien is free to bind a fresh GTP from the cytosol. Hyperactive
mutated forms of RAS proteins are permanently in an active conformation, even in the
absence of an extracellular signal. When a RAS molecule is constitutively active, a signal
is continuously transduced to the nucleus, inducing the transcription of genes involved in
division or diﬀerentiation.
There are three RAS isoforms: HRAS, NRAS and KRAS, and often, mutations of one
isoform is associated with a particular cancer. Activating mutations in a RAS gene are
thought to be found in around one-quarter of all cancers [Schulze et al., 2004]. In EOCs,
KRAS mutations are present in approximately two-thirds of mucinous tumours and one-
third of low-grade and borderline serous ovarian tumours [Shih and Kurman, 2004]. Mu-
tations in HRAS or NRAS have not been detected in ovarian tumours to date. KRAS
mutations are also found in around 17% of endometrioid carcinomas, speciﬁcally in the
low-grade tumours [Geyer et al., 2009]. The majority of these mutations are a substitu-
tion at position 12 in the amino acid sequence replacing glycine with arginine (V12G).
This mutation leads to the constitutive binding of GTP, and thus constitutive sigalling by
the mutated Ras molecule.
BRAF
RAF is the ﬁrst protein kinase in the MAPK pathway. RAF proteins are serine/threonine
kinases that act downstream of RAS. RAF molecules transduce signals down the MAPK/ERK
pathway from RAS by phosphorylating serine or threonine residues on downstream eﬀector
molecules, namely MEK1 and MEK2. RAF proteins only bind GTP-bound RAS, which
recruits RAF to the membrane and activates the RAF molecule. BRAF mutations cluster
in or near the activation domain of the BRAF molecule and cause the activation domain
to be permanently in an active conformation, thus stimulating enhanced kinase activity
towards MEK1/2 substrates.
There are three RAF isoforms: ARAF, BRAF and CRAF, and (as with RAS) mutations
in each are associated with diﬀerent cancers, for example, BRAF mutations are common
in melanoma [Michaloglou et al., 2005]. Activating mutations in BRAF are also found in
around one-third of low-grade serous ovarian neoplasms, and interestingly, unlike KRAS
40mutations, several studies have reported that BRAF mutations are rare/absent in all other
subtypes of EOC [Mayr et al., 2006]; [Russell and McCluggage, 2004]; [Gemignani et al., 2003].
This is surprising, considering activation of the MAPK pathway is found in other ovarian
tumour histotypes, and adds to evidence that diﬀerent histological subtypes may arise from
distinct genetic pathways and that somatic genetic alterations determine the molecular
features and aetiology of the tumour.
C-MYC
C-MYC is one of the most well characterised proto-oncogenes. The family of MYC tran-
scription factors play critical roles in cell growth through the control of the transcription
of a broad range of genes involved in fundamental cellular processes, such as cell cycle
control, apoptosis, and DNA and protein synthesis. Like RAS, C-MYC has been impli-
cated in tumourigenesis of many diﬀerent tissues, which is unsurprising considering its
role in cellular proliferation and diﬀerentiation. C-MYC expression directly aﬀects levels
of cyclins and cyclin-CDK complexes to push the cell cycle forwards and induce prolifer-
ation. C-MYC interacts with the p21 tumour suppressor gene, removing the protective
cell senescence response and forcing the cell to stay in the cell cycle [Nasi et al., 2001]. In
a quiescent cell, forced expression of C-MYC causes the cell to re-enter the cell cycle. Fur-
thermore C-MYC-overexpression, in combination with OCT4, SOX2 and KLF4 induces
pluirpotency in diﬀerentiated cells [Takahashi et al., 2007]; [Aasen et al., 2008]. Finally,
C-MYC interacts with the TP53 and retinoblastoma tumour suppressor pathways, and
can remove inhibition of cell division imposed by these two tumour suppressor pathways.
Hence, C-MYC can play a role in tumourigenesis through its interactions in one or multi-
ple pathways critical in cell growth and diﬀerentiation. Analysis of EOC tumour samples
has detected ampliﬁcation or overexpression of the C-MYC gene at frequencies of around
35-76% [Nasi et al., 2001]; [Dimova et al., 2006].
v-myc is a viral homologue of CMYC, and is encoded in many retroviruses (e.g. MC29,
FTT, OK10) that are capable of transforming mammalian cell lines [Lee and Reddy, 1999].
v-myc diﬀers to CMYC in that it contains substitutions and deletions, mostly at the N-
and C-terminal regions. These mutations make the v-myc gene a more potent inducer
of neoplastic transformation than its human homologue [Lee and Reddy, 1999]. v-myc is
often used in in vitro models of transformation, but is not absolutely required, as overex-
pression of human CMYC, as commonly detected in human tumours, is often suﬃcent to
transform human cells in vitro.
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The epidermal growth factor receptor ERBB2 (Her-2/neu) gene is a member of the recep-
tor tyrosine kinase (RTK) superfamily of cell surface receptors. Ligand-binding induces
dimerisation of the ERBB2 receptor, and the resulting signal can activate various path-
ways including the MAPK, PI3K, PLC and STAT pathways. In ovarian cancer, ERBB2
overexpression occurs in about 10-20% of ovarian tumours but not in early stage (Stage I
and II) or borderline tumours. Increased ERBB2 gene copy number or elevated protein ex-
pression may be associated with poorer prognoses [Hogdall et al., 2003]; [Wu et al., 2004];
[Nakayama et al., 2006]. Lassus et al. also suggest that ERBB2 ampliﬁcation may corre-
late to TP53 mutation status [Nakayama et al., 2006]. Finally, it appears that mutations
of ERBB2, KRAS and BRAF may occur mutually exclusively, suggesting that onco-
genic mutation of any one of these genes has equivalent or saturating downstream eﬀects
[Tanner et al., 1998].
1.2.4 The Phosphatidylinositol 3-Kinase (PI3K) Signalling Pathway
Perturbations in normal PI3K pathway signalling are also common in cancers. This
pathway transduces extracellular signals associated with cellular growth, proliferation
and apoptosis. Phosphatase and tensin homologue (PTEN) negatively regulates the
PI3K pathway, through the dephosphorylation of a membrane-associated phospholipid
- phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3). PTEN acts in opposition
to PI3K, which generates this tri-phosphate. In this way, PTEN and PI3K indirectly regu-
late AKT, a downstream serine/threonine-speciﬁc protein kinase. Loss of PTEN function
causes PtdIns(3,4,5)P3 to accumulate and renders the pathway constitutively active.
The PIK3CA proto-oncogene encodes p110α, the catalytic subunit of PI3Ks. This protein
is ampliﬁed or mutated in a number of cancers, including breast, stomach, brain and lung
cancers. Most PIK3CA somatic missense mutations detected in advanced stage ovarian
carcinomas cluster at codon 545, a mutational ‘hotspot’ which lies within the helical
domain of the protein. These mutations substitute a negatively charged glutamic acid
for a positively charged lysine or hydrophobic glycine or alanine residue, and are thought
to aﬀect interactions between PIK3CA and other molecules, including lipid substrates
[Levine et al., 2005]. These activating mutations generate PI3K proteins with increased
catalytic activity, PtdIns(3,4,5)P3 is produced faster than it is degraded and signalling,
through the AKT and other downstream eﬀectors, increases. PIK3CA mutations occur
at the highest frequencies in mucinous and endometrioid tumours (Table 1.4).
42AKT2 is ampliﬁed in ovarian cancer cell lines and tumours [Cheng et al., 1992]. Down-
stream eﬀectors of AKT play roles in apoptosis and DNA repair (Mdm2, Bad, Caspase 9),
cell survival (NF-κβ), growth and protein synthesis (mTOR) and the cell cycle (GSK3α)
[Liang and Slingerland, 2003]; [Richardson et al., 2004]. Ovarian cancer cells with acti-
vated AKT signalling will apoptose when treated with a PI3K inhibitor (LY294002) sug-
gesting that, once activated, this pathway is critical for cancer cell survival. Further-
more, pre-treatment with LY294002 enhanced the eﬀect of cisplatin treatment in cell
lines with activated AKT signalling [Altomare et al., 2004]. Inhibition of mTOR, a down-
stream eﬀector of AKT, has equivalent but not additive eﬀects to LY294002 (suggesting
perturbed signalling at either mTOR or AKT saturates downstream signalling). Fur-
thermore, inhibition of mTOR signiﬁcantly increases the eﬀectiveness of cisplatin and
tamoxifen in ovarian cancer cells with activated AKT signalling in vitro and in vivo
[Treeck et al., 2006]; [Mabuchi et al., 2007]. AKT and mTOR phosphorylation are closely
related in ovarian cancers, as phosphorylation of mTOR results in protein synthesis
and ultimately is essential for progression through the cell cycle [Altomare et al., 2004];
[Pullen and Thomas, 1997]. Since AKT has a role in many critically important processes
in the organism (such as glucose metabolism), mTOR inhibitors are less likely have toxic
side eﬀects and therefore may have therapeutic role in ovarian cancers with elevated AKT
signalling.
1.3 A Dualistic Model to Classify EOCs
It is now clear that ovarian cancer subtypes develop through the disruption of distinct
genetic and biological pathways. A current popular model to categorize EOCs has been
developed by Shih and Kurman, and divides ovarian tumours into Type I and Type II tu-
mours [Shih and Kurman, 2004]. In this model, low-grade serous, mucinous, endometrioid,
clear cell and malignant Brenner tumours are grouped together as one subclass of ovar-
ian cancers (‘Type I’ tumours); high-grade serous carcinomas, undiﬀerentiated carcinomas
and malignant mixed mesodermal tumours represent another subclass (Type II tumours).
The features of each group are summarised in Table 1.5.
1.3.1 Type I Tumours
Type I tumours are typically slow growing, more often identiﬁed at lower grade, and evolve
from identiﬁable precursor lesions [Shih and Kurman, 2004]. This model is reminiscent of
the model for colorectal cancer (CRC) development, which represents the paradigm for
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Table 1.5: Type I and Type II Tumours have distinct clinical features
the linking of histological observations and genetics. A genetic model for CRC devel-
opment has been deﬁned within a phenotypic framework, starting with normal tissue
which accumulates somatic mutations in a stepwise manner, frequently in the KRAS,
p53 and APC genes [Fearon and Vogelstein, 1990]. Clinically, premalignant polyps are
observed which are known to have a high risk of developing into a malignant lesion
[Bates and Mercurio, 2005]; [Castagnola and Giaretti, 2005].
Low-grade serous carcinoma/serous borderline tumours
Low-grade and borderline serous ovarian cancers are remarkably similar in their molecular
features. 13% of serous carcinomas are classiﬁed as borderline serous tumours (BSTs)
and approximately two-thirds of low-grade serous carcinoma will contain areas of bor-
derline tumour tissue. BSTs show some phenotypic characteristics of high-grade serous
carcinomas, including metastatic potential and increased nuclear atypia, compared to
classical low-grade serous tumours [Malpica et al., 2004]. However, molecular analyses
suggest BSTs are unrelated to high-grade serous carcinomas; and clinicopatholgical data
indicate that they are much less aggressive, and associated with considerably better
prognoses than SCs [Singer et al., 2005]; [Bonome et al., 2005]. BSTs rarely harbour
p53 mutations; but KRAS/BRAF mutations are frequent, occurring in 60% of tumours
[Gemignani et al., 2003]; [Russell and McCluggage, 2004]; [Singer et al., 2005].
Interestingly, unlike KRAS mutations, several studies have reported that BRAF mu-
tations are rarely found in many subtypes of ovarian cancer [Gemignani et al., 2003];
[Russell and McCluggage, 2004]; [Mayr et al., 2006]. This is surprising, given that ac-
tivation of the MAPK pathway is found in other ovarian tumour subtypes, and supports
the hypothesis that diﬀerent histological subtypes of ovarian cancer have distinct molec-
44ular ﬁngerprints. BRAF mutations appear to be limited to the low-grade serous subtype
[Singer et al., 2003]; [Mayr et al., 2006].
Mucinous Tumours
The molecular data point to the development of mucinous tumours from a benign lesion
evolving into a borderline and then an invasive tumour with KRAS mutation often an
early event in tumourigenesis. Also, mucinous tumours can be clearly distinguished from
other subtypes by their gene expression proﬁles; unsurprisingly, it is common for genes
associated with mucin production to be upregulated in this subgroup, including MUC2,
MUC3 and MUC16. Mucinous ovarian cancers show molecular similarities with mucinous
carcinomas from other organs, such as the intestine [Heinzelmann-Schwarz et al., 2006].
Endometrioid & Clear Cell Carcinomas
A large proportion of endometrioid and clear cell ovarian carcinomas appear to originate in
a benign endometriotic lesion. In endometriosis, the uterine lining can be found outside of
the womb, often within the abdominal cavity, on the ovaries and fallopian tubes. Epidemi-
ological studies estimate that endometriosis aﬀects up to 8% of women of reproductive
age [Eskenazi and Warner, 1997]. Only a small proportion of women with endometrio-
sis go on to develop endometrioid ovarian cancer; but up to 40% of women diagnosed
with Stage I endometrioid or clear cell carcinoma present with synchronous endometrio-
sis and around one-third of these tumours arise from within an endometriotic lesion
[de la Cuesta et al., 1996]; [Willner et al., 2007]. The transformation of endometriotic le-
sions involves genes and pathways known to be disrupted in endometrioid and clear cell
carcinoma of the ovary and endometrium. Microsatellite instability is a feature of around
9-16% of all endometrioid and clear cell ovarian carcinomas [Gras et al., 2001]. hMLH1
promoter methylation occurs in around 50% of these tumours and is often accompanied by
the loss of expression of a second MMR gene, in particular hMSH2 [Geisler et al., 2003].
Microsatellite instability and hMLH1 promoter hypermethylation are found in regions of
endometrial hyperplasia within the uterus [Esteller et al., 1998].
Endometrioid tumours frequently display dysregulation of the PI3K pathway. Loss of
heterozygosity at the PTEN locus on chromosome 10q23 is typically found in 31-42%
of endometrioid tumours; somatic mutation of PTEN also occurs 20% of this tumour
subtype [Obata et al., 1998]; [Sato et al., 2000]; [Willner et al., 2007]. Somatic mutations
in the PTEN gene have been observed in 15-20% of benign endometrial cysts and en-
45dometriosis, suggesting that inactivation of this gene is an early event [Sato et al., 2000];
[Martini et al., 2002]. Mutations in the PI3K pathway, in the PIK3CA gene, are rela-
tively common in endometrioid and clear cell carcinomas (12% and 25% respectively), but
are rarely found in other EOC subtypes [Campbell et al., 2004]; [Nakayama et al., 2006];
[Willner et al., 2007]. Mutations in the Wnt signalling pathway are also found in around
one third of endometrioid ovarian cancers, with high frequencies observed in border-
line endometrioid tumours [Oliva et al., 2006]. Interestingly, aberrant signalling of the
Wnt or PI3K pathway does not appear to co-exist in a tumour with p53 mutation.
However, high-grade endometrioid ovarian cancers are characterised by mutation of p53
[Kolasa et al., 2006]; [Wu et al., 2007]. Recently, is has been suggested that a subset of
high-grade endometrioid tumours would be more appropriately classiﬁed with high-grade
serous EOCs, due to similarities in tumour aetiologies, mutational events and biomarkers
[Geyer et al., 2009]. Low-grade endometrioid tumours are characterised by β-catenin and
KRAS mutations - these alterations have not been identiﬁed in high-grade endometrial car-
cinomas [Geyer et al., 2009]. In high-grade endometrioid, KRAS and β-catenin mutations
are rare, p53 mutations are often found instead, suggesting high-grade andometrioid and
high-grade serous tumours may arise by common molecular pathways [Kolasa et al., 2006].
Malignant Brenner tumours
Malignant Brenner tumours are also known as transitional cell tumours. Identiﬁable
molecular features for malignant Brenner tumours have not yet been identiﬁed, proba-
bly because these tumours are rare and have not been studied in suﬃcient detail. The
available histopathological evidence suggests that benign Brenner tumours progress to
proliferating (or borderline) and then malignant Brenner tumours in a stepwise manner
[Monaghan and Williams, 2003].
1.3.2 Type II Tumours
Type II tumours include high-grade serous carcinoma, undiﬀerentiated carcinoma and
malignant mixed mesodermal tumours. Features associated with Type II tumours include
a poorer prognoses in patients, rapid growth and early metastasis. It has been hypothesised
that these tumours arise de novo from the surface epithelium or within ovarian inclusion
cysts [Scully, 1995]; [Singer et al., 2005]; [Okamura and Katabuchi, 2001].
46High-grade serous carcinomas
There is little evidence to suggest that Type I tumours can give rise to Type II tumours.
The distinct pathways by which low-grade/borderline and high-grade serous tumours arise
is reﬂected in the expression proﬁles and somatic mutations that are characteristic of each
group. Mutations in KRAS/BRAF are rare in high-grade serous carcinoma (HGSC). This
suggests that low-grade serous tumours are not precursors of high-grade serous carcinomas
and that aberrant MAPK signaling doesn’t play a signiﬁcant role in high-grade tumours
[Catass et al., 2004]; [Singer et al., 2003]. Rarely do these high-grade lesions contain be-
nign tissue adjacent to areas of neoplastic cells, possibly because the tumour growth has
taken over what remains of the precursor lesion [Jordan et al., 2006]. Mutations in p53 in
HGSCs occur at frequencies of 50-80% and AKT2 overexpression, or p16 promotor methy-
lation/mutation/gene deletion in 10-20% of tumours. However, it cannot be completely
ruled out that some high-grade serous carcinomas arise from low-grade or borderline tu-
mours since there have been incidental ﬁndings showing that high-grade and low-grade
tumours can co-exist. One study reported identical KRAS mutations in a borderline tu-
mour co-existing with a serous carcinoma which may suggest that a subset of high-grade
serous tumours evolve from atypical borderline tumours and low-grade micropapillary
serous carcinoma [Dehari et al., 2007].
Unlike in low-grade and borderline SCs, the PI3K pathway appears to play a role in the de-
velopment of a large proportion of high-grade serous carcinomas. Mutations in the AKT2
kinase domain are not present in this tumour type (nor in SBTs), but AKT2 does appear
to be ampliﬁed in about 18% of high-grade SCs [Cheng et al., 1992]. Similarly, mutation
of the PIK3CA gene; or ampliﬁcation and polyploidy associated with the PIK3CA locus
has been found in up to a third of HGSCs but is absent in normal ovaries and BSTs
[Wang et al., 2005]; [Nakayama et al., 2006].
Undiﬀerentiated carcinoma and malignant mixed mesodermal tumours
These tumours are rare. Consequently, little is known about their molecular features.
Both types of tumours are aggressive and associated with poor long-term survival. At
least 90% of ovarian malignant mixed mesodermal tumours harbour mutations in p53
[Shih and Kurman, 2004]; [Gourley et al., 2002].
471.4 In vivo Approaches to Modelling Epithelial Ovarian
Cancer
In general, the earliest models of EOC and cellular transformation looked at the disease in
rodent cells, both in vitro and in vivo. A major advantage of rodent models is that they
enable the study of disease within a living mammal. Earliest models of EOC predominantly
xenografted ovarian cancer cells lines into immuno-compromised rats and mice. It was
observed that whilst some cell lines eﬃciently form tumours that resemble the original
tumour, other cancer cell lines that grow well in vitro failed to form diﬀerentiated tumours
when injected into rodents, (reviewed in [Garson et al., 2005]).
1.4.1 Murine Models of Epithelial Ovarian Cancer
Tissue-speciﬁc promotors can been used to generate animal models with targeted, organ-
speciﬁc expression/knock-down of a gene or genes. The discovery of the ovary-speciﬁc
M¨ ullerian inhibiting substance receptor type II (MISIIR; also known as the M¨ ullerian In-
hibitory Factor Receptor 2, MIFR2) lead to the generation of transgenic mice expressing
the SV40 early region only in their ovarian surface epithelial cells (mOSE) [Connolly et al., 2003].
Within 13 weeks around half of the transgenic mice developed epithelial ovarian tumours.
However, this model provides little information about early stages of EOC since newborn
mice expressing SV40-T under the control of the MISIIR promotor are found to have
ovarian tumours: disease in this model is early onset, unlike human epithelial ovarian can-
cer which typically arises in post-menopausal women. Early ovarian neoplastic changes
have been modelled in a transgenic mouse model in which activated PIK3CA was ex-
pressed under the control of MISIIR. Ovarian hyperplasia developed in the mice but no
malignant transformation of OSE was observed in vivo [Liang et al., 2009]. However, the
applicabilty of the MISIIR promotor to the study of EOC origins may be limited as this
promotor may not speciﬁcally drive gene expression in the ovarian surface epithelium also
in the endometrium and fallopian tube epithelium (L.Dubeau, personal communication).
Cre-loxP systems are a popular technique for generating conditional genes knockouts and
transgenic organisms harbouring tissue speciﬁc deletions. Dinulescu and collegues created
a mouse model of early stages of ovarian neoplastic transformation by creating transgenic
mice harbouring a ﬂoxed KRASmut ‘stop’ sequence as well as parts of the PTEN gene. By
targetting expression of these oncogenic elements to the ovary they were able to initiate
endometrioisis and endometrioid ovarian tumours in mice [Dinulescu et al., 2005].
481.4.2 Rat Models of Epithelial Ovarian Cancer
In 2004, Stewart and colleagues created the ﬁrst rat model of the early stages of epithelial
ovarian cancer by exposing the animals to low doses of 7,12-dimethylbenz(a)anthracene
(DMBA) in combination with cycles of gonadotrophin treatments which were designed
to initiate cycles of proliferation reminiscent of the proliferation observed naturally in
the ovary during ovulatory cycles [Stewart et al., 2004]. After 6 to 12 months of the
treatment, ovarian carcinomas were observed in the group which received both DMBA
and hormone treatment, with early pre-neoplastic lesions detected at months 5-6. One
criticism of earlier models has been that the tumours seen in the animals do not reﬂect
the histopathological diversity of human epithelial ovarian tumours and so it is of note
that in this study, the tumours that developed were of varying histopathological subtypes.
Furthermore, 25% of the pre-neoplastic lesions and one out of the three tumours observed
harboured a cancer associated mutation in the Ki-RAS gene [Stewart et al., 2004]. KRAS
mutations are relatively common in epithelial ovarian cancers (discussed above).
Molecular comparison of malignant and non-malignant rat epithelial surface epithelium
(rOSE) lead to the discovery of the lot1 tumour suppressor gene, the human homologue of
which, ZAC1, was subsequently demonstrated to be downregulated in a large proportion
of human epithelial ovarian cancers [Abdollahi et al., 1997a]; [Abdollahi et al., 1997b];
[Cvetkovic et al., 2004]. Loss of function of ZAC1 occurs early in ovarian cancer develop-
ment, through epigenetic mechanisms including loss of heterozygosity at 6q24 or hyper-
methylation at this locus [Cvetkovic et al., 2004]. Expression of ZAC1 in ovarian cancer
cells reduces the rate of cellular proliferation and and increases the rates of apoptotic cell
death [Cvetkovic et al., 2004].
Limitations of Animal Models of Disease
Although rat and mouse models have been valuable tools in expanding our knowledge of
gene function in EOC, rodent models have so far only lead to the identiﬁcation of this one
gene, ZAC1, now known to be involved in human ovarian cancer. This is due in part to the
various limitations of using rodents as models of human disease. Fundamental diﬀerences
exist in the biology of a rodent and a human ovary, as well as in cellular physiology.
A bursal membrane that surrounds rodent ovaries is absent in humans and signiﬁcantly
aﬀects the process of metastasis [Garson et al., 2005]. There is also a marked diﬀerence
in telomere biology of human and rodent cells: normal rodent calls have longer telomeres
and telomere length does not appear to limit cellular life-span [Auersperg et al., 2001]. In
contrast, in normal human somatic cells, telomerase activity is downregulated and telomere
49shortening limits the replicative potential of normal human cells. Immortalisation, or the
bypass of senescence, is a crucial step in tumour development. A signiﬁcant proportion of
rodent cells immortalise spontaneously following repeated passageing in culture, but this
phenomenon is extremely rare when culturing human cells [Godwin et al., 1992].
Human cells also have more natural barriers to transformation than their rodent coun-
terparts. In murine ﬁbroblasts, inactivation of TP53 is suﬃcient for the cell to by-
pass senescence, and expression of one oncogene such as KRASG12V or C-MYC in an
immortalised rodent cell is suﬃcient for the cells to display oncogenic characteristics
[Orsulic et al., 2002]. However, in human cells, telomere length must be maintained for
the cell to bypass senescence (by the expression of telomerase or activation of the alter-
native lengthening of telomeres pathway). Subsequent expression of oncogenes, such as
KRASG12V or BRAFV 600E, usually induce senescence in the absence of additional onco-
genic signals [Michaloglou et al., 2005]; [Wei et al., 1999].
1.5 In vitro Models of Transformation
In vitro cell biology models are an alternative approach to modelling of disease. In vitro
models can be performed on human cells, and oﬀer a controlled system for the study of
complex pathways. The advantages and disadvantages of in vitro and in vivo modelling
are summarised in Table 1.6.
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Table 1.6: Comparison of the advantages and disadvantages in vitro and in vivo approaches to
modelling human diseases
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many normal and tumourigenic cell types are commercially available, although it is then
impossible to know what alterations may have been introduced through routine tissue
culture. Some cell types, including normal ovarian epithelial and ﬁbroblast cultures, are
not readily available and so have to be established in vitro as primary cultures, fully
characterised and then immortalised before further studies can be performed.
1.5.1 Cell Culture and Immortalisation
Non-tumourigenic cells have a limited lifespan in vivo and in vitro and eventually be-
come growth arrested and senescent [Hayﬂick, 1965]. Senescence is induced by multiple
stimuli including a reduction in telomere length to below a critical threshold (replica-
tive senescence) and expression of mutated RAS or RAF (oncogene-induced senescence)
[Bond et al., 2004]; [Takahashi et al., 2006]; [Drayton et al., 2003]. Senescent cells typi-
cally become enlarged and stop dividing, but are able to remain metabolically active over
quite large periods of time. Classic senescence markers include expression of senescence-
associated β-galactosidase (SA-β-gal), expression of p16 and p21 Cdk inhibitors, and up-
regulation of plasminogen activator inhibitor type 1 [Dimri et al., 1995]; [Wei et al., 1999].
Expression of the catalytic subunit of the human telomerase holoenzyme (hTERT) as a
means to enable primary cell lines to bypass replicative senescence was ﬁrst demonstrated
in retinal pigment epithelial (RPE) cells and foreskin (BJ) ﬁbroblasts [Bodnar et al., 1998].
Although immortalisation is a crucial step in tumourigenesis, cells expressing hTERT do
not acquire other cancer associated characteristics. Cells immortalised by the expression
of hTERT do not grow in anchorage-independent growth assays or form tumours in mice
[Morales et al., 1999]; [Jiang et al., 1999]. Furthermore, there are no signiﬁcant diﬀerences
in the responses of primary cells and their hTERT immortalised counterparts to serum
deprivation, cell density and treatment with hydroxyurea, (which induces p53-independent
arrest during early S-phase), or a combination of thymidine and aphidicolin, (which in-
duce cell cycle arrest at the G1/S transition) [Bodnar et al., 1998]; [Jiang et al., 1999];
[Morales et al., 1999].
However, not all cells can be immortalised by the ectopic expression of hTERT in the ab-
sence of other genetic alterations [Haga et al., 2007]. It has previously been suggested that
OSE cells also could not be immortalised by the expression hTERT alone, but in this labo-
ratory and others, it has been demonstrated that primary NOSE cells can be immortalised
by introducing hTERT alone, or through expression of hTERT in combination with an
siRNA targetting pRb or p53 [Davies et al., 2003]; [Li et al., 2007]; [Yang et al., 2007a];
51[Yang et al., 2007b]. NOSE cells immortalised by ectopic expression of hTERT in combi-
nation with siRNA targetted knockdown of pRb or p53 mRNA expression do not demon-
strate features of a neoplastic phenotype in vitro or in vivo. Yet, while cells do not form
tumours in nude mice or demonstrate an ability to form colonies in anchorage-independent
growth, in these models, cells do demonstrate diminished responses to γ-irradiation as well
as altered levels of cell cycle proteins and proteins of the p53 and pRb pathways. This is
unsurprising when these pathways have been disrupted by siRNA; however, the reduced
response to irradiation suggests that the immortalised cells are less capable of responding
to and therefore repairing DNA damage. Though these cells are non-tumourigenic, activa-
tion of hTERT in combination with perturbations in the p53 and pRb tumour suppressor
pathways are frequent abberations in EOC speciments, thus, these cells represent a model
of pre-neoplastic changes in the OSE [Yang et al., 2007a]; [Yang et al., 2007b].
1.5.2 In vitro Assays for a Transformed Phenotype
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Figure 1.9: Schematic representation of in vitro and in vivo phenotypic changes that are charac-
teristic of neoplastic and malignant transformation. All of these changes can be monitored in vitro
many can also be assayed in vivo
During the process of in vitro or in vivo malignant transformation, cells undergo a spec-
52trum of phenotypic changes including independence from apoptotic signals and growth fac-
tors; anchorage-independent growth; enhanced proliferation, invasiveness and migration.
Cells begin to exploit the local microenvironment by evading immune recognition and
promoting neovascularisation and development of a tumour stroma (Figure 1.9). These
changes can be monitored in vitro. The assays typically performed to test for a transformed
phenotype include:
Anchorage-Independent Growth Assays assess the ability of a cell line to grow in
an anchorage-independent manner, with the loss of a normal contact inhibition re-
sponse. Cell lines that readily form colonies in anchorage-independent growth assays
are showing tumourigenic characteristics.
Invasion Assays demonstrate the invasive ability of a cell line. In transwell invasion
assays, cells are placed atop a membrane which is coated with extracellular matrix
(ECM) protein, such as Matrigel. Cell lines must degrade the ECM to invade towards
a chemoattractant placed in the lower chamber. This assay is considered to be an
in vitro demonstration of the invasive potential of the cell line.
Migration Assays assess migrative ability of a cell line. Such assays may be transwell
assays (as above, but without coating of matrix protein on the membrane), or wound
healing assays (which assesses the ability of a cell line to migrate horizontally).
Proliferation/ Anchorage-Dependent Growth Assays Plating a known number of
cells, and then passaging and counting cells at regular intervals can be used to deter-
mine the population doubling time of a cell line and thus compare proliferative rates
or in vitro lifespan of cultures. Incubating cells with compounds such as thiazolyl
blue tetrazolium bromide (MTT) or Alamar Blue enables more sensitive detection of
proliferative rate within a deﬁned time period, and both represent higher-throughput
approaches to measuring cell proliferation. Other assays, such as measurement of
BrdU incorporation, enable the measurement of cell cycle distribution within a cell
population at a given time. Diﬀerent proliferation assays provide diﬀerent informa-
tion about the cell culture of interest. For example, with an MTT assay, the number
of viable cells at the endpoint is assayed, by the yellow tetrazole reagent being re-
duced to a purple formazan product by intracellular reductase enzymes. Higher rates
of conversion to formazan in a test cell line compared to controls, could result from
increased proliferation, reduced cell death, or higher cell density (e.g. due to loss of
contact inhibition of proliferation).
Heterotypic Assaya can be performed to monitor the eﬀect of transformed cells on co-
cultured endothelial, immune cells or other stromal cells. These assays can be used
53to test if any pro-angiogenic factors are being produced, for example. Tests can
also be performed to measure the ability of a cell line to illicit an immune response
or recruit stromal cells. Synthesis of speciﬁc molecules can also be measured by
Western blot or PCR ELISA.
Tumour Formation in Mice Cell lines can be injected into immuno-compromised mice
to assay tumour formation eﬃcienies in vivo. Xenograft injections can be into a
speciﬁc organ, the mammary fat pad, the peritoneum or a subcutaneous site. The
latency period, histopathology, metastatic activity and aggressiveness of the tumour
will give further insight into the characteristics of the in vivo transformed phenotype
of that cell line.
1.5.3 Transformation with Oncoproteins
Early in vitro models of cellular transformation treated cells with radiation and chemical
carcinogens to damage DNA and induce neoplastic transformation. Such techniques cause
widespread, non-speciﬁc damage to the genome. Hahn and collegues produced the ﬁrst
model of cell transformation using speciﬁc genetic elements in 1999 by expressing hTERT
in human epithelial and ﬁbroblast cell lines in combination with the SV40 large T antigen
and an oncogenic HRAS allele [Hahn et al., 1999].
The use of viral oncoproteins, such as SV40 polyoma virus small and large T and E6/E7
proteins from HPV16 virus have been used extensively in studies of transformation. The
E6 and E7 oncoproteins inactivate p53 and pRb, though without conferring the ability of
the cell to grow in an anchorage-independent fashion. The SV40 large T antigen (SV40-
T) also exerts an oncogenic eﬀect through the binding and inactivation of p53 and pRb.
The small t antigen (SV40-t) perturbs the PI3K pathway through protein phosphatase 2A
(PP2A). PP2A is a serine/threonine phosphatase that plays a role in the PI3K signalling
pathway and stability of C-MYC [Arroyo and Hahn, 2005]; [Boehm et al., 2005]. The
entire SV40 early region is required for transformation, and it has since been demonstrated
that inactivation of pRB and PTEN using shRNAs will have an equivalent eﬀect as the
introduction of SV40 T/t into BJ ﬁbroblasts expressing hTERT, C-MYC and activated
RAS in the presence of inactivated TP53 [Boehm et al., 2005].
Hahns model of transformation has since been applied to a variety of cell types, includ-
ing human mammary epithelial cells (HMECs) and NOSE cells [Elenbaas et al., 2001];
[Kusakari et al., 2003]; [Liu et al., 2004]. In HMECs expressing SV40-T, hTERT and
HRASmut, the tumourigenicity of the cells was directly proportional to the expression
level of oncogenic HRAS. Cells with >12-fold overexpression of mutant HRAS form tu-
54mours in nude mice at high frequencies. A threshold level of HRAS overexpression was
required for in vivo growth, cells with only 3.5-fold HRAS overexpression failed to form
tumours in mice [Elenbaas et al., 2001].
NOSE cells expressing both hTERT, SV40-T and either oncogenic HRAS or ERBB2
grew in soft agar and form undiﬀerentiated tumours in mice at frequencies of 40% and
50% respectively [Kusakari et al., 2003]. In NOSE cells which have been immortalised by
co-expression of hTERT and SV40T/t, expression of a mutated KRAS or HRAS gen-
erates highly tumourigenic cells that form large tumours when injected into nude mice.
The resulting tumours showed many characteristics of human ovarian epithelial cancers
[Liu et al., 2004].
1.5.4 Transformation with Deﬁned Genetic Elements
p53 and pRB have been identiﬁed as crucial targets of SV40T/t for tumourigenesis, but
these oncoproteins do have additional eﬀects within the cell [Arroyo and Hahn, 2005].
Thus, this study aimed to create genetic models of NOSE cell transformation through the
expression of oncogenes that are known to be involved in EOC, with an aim of mimicking
in vitro, early tumourigenesis of the ovarian surface epithelium through genetic events that
could feasibly occur in vivo.
This study will also identify the minimal number of genetic alterations required to induce
features of transformation in a phenotypically normal ovarian surface epithelial cells. In
Leiden cells, which are p16-deﬁcient, expression of hTERT, plus mutant HRAS or C-MYC
confers an ability to grow in an anchorage-independent manner. Leiden cells expressing
hTERT, HRASG12V plus C-MYC form tumours in nude mice [Drayton et al., 2004].
A recent study by Sasaki and collegues has investigated the role of diﬀerent cellular onco-
genes in transformation of the OSE [Sasaki et al., 2009]. Their results are summarised
in Table 1.7. They observed that one cell line was more susceptible to transformation
than the other, suggesting that genetic background plays an important role in neoplastic
development. A dominant negative p53 allele (DNp53) and KRASG12V was suﬃcient to
confer in vivo growth of immortalised NOSE cells, cells in this study were immortalised
with hTERT, Cdk4 and cyclinD1). The other cell line needed either additional expression
of mutant Akt, or mutant C-MYC and Bcl-2 overexpression in order to grow in vivo.
55N.R 12/12 +++ Intact p53 function + KRASG12V + CMYCmut + Bcl2
(1x106)      6/6
(1x107) 3/3
N.R N.R Extensive dissemination 
throughout peritoneum
+ Dnp53 + KRASG12V + CMYCmut + Bcl2
2/6 N.R N.R Small tumours + Dnp53 + KRASG12V
HOSE1C
(1x106)      9/9
(1x107) 3/3
N.R +++ ￿ apoptosis + Dnp53 + KRASG12V + CMYCmut + Bcl2
0/3 0/3 + No change in morphology + Dnp53 + KRASG12V + shRNA.PTEN
0/3 0/3 ++ ￿ proliferation; small, 
rounded cell morphology
+ Dnp53 + KRASG12V + PIK3CAmut
3/3
0/3
0/4
N.R
Growth in vivo -
subcut
N.R N.R
Genetic Alterations
(1x106)    10/16
(1x107) 3/3
++ Fibroblastic cell 
morphology
+ Dnp53 + KRASG12V + myr-Akt1
Growth in vivo 
– i.p.
Anchorage-
independent growth
Comments
+++
+
￿ proliferation; small, 
rounded cell morphology
￿proliferation
Extensive cell death 
0/10 + Dnp53 + KRASG12V + CMYCmut
0/9 + Dnp53 + KRASG12V
+ KRASG12V
HOSE2C
Table 1.7: Transformation of the OSE with deﬁned cellular oncogenes, results from Sasaki et al.
2009. N.R=not reported. The mutant C-MYC allele is more stable than wild-type C-MYC, thus
C-MYC protein accumulates in the cell. The mutant PIK3CA allele used in this study contains a
mutation commonly found in EOC. subcut = subcutaneous injection of cells, i.p. = intra-peritoneal
injection of cells. Numbers of xenografted cells are indicated in brackets.
1.6 Whole Transcriptome Proﬁling
Although nuclear DNA encoder the entire genome of the organism, only a portion of the
total gene complement is actively transcribed in each cell. A small number of housekeeping
genes, (e.g. GAPDH or 18S rRNA), are expressed in all cell types. However, the majority
of genes are expressed in a tissue-speciﬁc, cell-type speciﬁc or temporal-speciﬁc manner.
Many genes are only expressed transiently, in response to intra- or extracellular stimuli.
The complexity is compounded by the fact that during tumourigenesis, the gene expression
proﬁle of cells evolves as the tumour develops. Proﬁling the transcriptomic changes with
expression microarrays has become a common tool used by scientists to create molecular
descriptions of tumours and tumour subtypes. By identifying diﬀerentially expressed
genes many new potential cancer biomarkers have been identiﬁed. Additionally, markers
or proﬁle signatures have been identiﬁed that can predict patient outcome or therapeutic
responses.
561.6.1 Gene Expression Microarray Technologies
There are a number of diﬀerent microarray platforms available for performing transcrp-
tomic analyses. Some are based on Cy3/Cy5 labelling of test and reference samples that
are then co-hybridised to the same array chip and the relative intensities of each dye are
analysed. Due to the diﬀerent stability of the two dyes it is often necessary to perform
dye-swap experiments. Other platforms technologies do not use a reference sample, and
the signal intensity of each probe indicates transcript abundance.
Robust experimental design of gene expression microarray studies is key to obtaining
reliable data. At every stage there are important considerations:
Samples
What is the biological question being asked and how can this be modelled experimentally?
What comparisons will be made and which biological and technical controls must be in-
cluded?
Does this require human or animal tissues to be used?
Primarily it is important that all RNA samples are be collected, harvested and quantiﬁed
following an consistent protocol, to ensure that any diﬀerentially expressed genes identiﬁed
have not been due to diﬀerences in sample collection, harvesting or processing. Samples
with low RNA concentrations may require additional ampliﬁcation steps, if so it is impor-
tant to ensure consistency of pre-hybridization processing of the RNA samples within an
experiment.
Array Platform
The choice of array platform will be determined by the samples, the aim of the experiment
and the budget. The Aﬀymetrix U133A platforms are a widely used platform, and if meta-
analyses are to be performed it may be preferable to use this platform. Specialised arrays
are available to analyse expression of diﬀerent transcript isoforms, these arrays would be
ideal for proﬁling in detail the transcriptional eﬀects of a single gene.
The Illumina HT12 arrays used in this study are considerably cheaper that the Aﬀymetrix
U133A arrays but still have good coverage of the genome whilst enabling higher numbers of
replicates to be performed. By using the highest number of biological replicates possible,
the researcher increases the reliability of gene lists obtained. Furthermore, the Illumina
57BeadChips have been demonstrated to outperform other arrays in a number of technical
measurements [Consortium et al., 2006].
The Illumina HT12 arrays have a unique ‘bead-array’ design. 50-mer oligos are synthe-
sized that are complementary to speciﬁc gene targets. The probe sequences are selected
using a bioinformatic algorithm that considers many factors, including similarity to other
genes, sequence complexity and EST coverage, to ensure that probes are gene-speciﬁc and
match to multiple EST and cDNA databases. These carefully designed oligos are then
immobilized onto 3µm silica beads, and the beads are pooled. The beads are then loaded
onto a ‘BeadArray’. Each bead is found on the array at least 30 times, equating to a high
level of sequence redundancy and thus the ability to calculate average signal and variance
per gene. Other microarray platforms typically contain each probe only once. Replicate
beads are located throughout the BeadChip, thus reducing the chance of spatial eﬀects
distorting gene expression information.
Data pre-processing
Once arrays have been run, the extracted data must ﬁrst be subjected to a number of
pre-processing steps. Firstly, quality control (QC) analysis of the array data is performed
to check that across the whole experiment, the arrays have consistent values for labelling
controls, signal/noise ratios, hybridization controls, washing stringency controls and neg-
ative controls. Many array platforms spike the test RNA sample with control RNA that
is co-hybridized to the array along with the sample and acts as internal controls for this
QC step.
Pre-processing of microarray data prepares the data for gene-expression analyses by per-
forming background subtraction, transformation and normalisation steps. This is to ensure
that any changes in gene expression fold-change are not due to spatial eﬀects, hybridis-
ation artefacts or local background signal. Background correction is used to remove any
non-speciﬁc signal present on the array, prior to any analysis steps being performed. A
variance-stabalizing transformation (VST) step, is a logarithmic transformation algorithm
which utilises the variance across the techical replicates within each array (i.e. replicate
beads) to predict the conﬁdence intervals of the data. This step is most critical when
calculating the signiﬁcance of diﬀerentially expressed genes, in particular high fold-change
in the low expression range. Transformed data is then normalised to normalise data across
all chips in the experiment. There are many diﬀerent approaches to data normalisation,
including quantile normalisation, simple scaling normalisation and loess normalisation.
Robust spline normalisation (RSN) combines features of quantile and loess normalisation
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example, loess transformation assumes that the majority of genes are not diﬀerentially
expressed and that the data are symmetrically distributed, but assumptions may not be
applicable to all array datasets. With RSN normalistion, data are ﬁrst normalised using
a quantile normalisation algorithm; secondly a fold-change value is calculated for each
probe. Each method has basic assumptions which may make that technique more or less
appropriate to a speciﬁc experiment and so the researcher must decide which is appro-
priate to each speciﬁc experiment, though, as with all steps of data analysis there is no
agreement in the ﬁeld regarding which method is ‘correct’.
Data analysis
Firstly, to analyse and visualise the data from a microarray experiment, clustering of
the samples enables groups of data to be organised into hierarchical dendogram trees, in
which more closely related samples cluster together. Supervised clustering can also be
performed, in which prior knowledge or a training dataset may be used to intelligently
cluster the data. Clustering analyses are often employed to group tumour proﬁles, to look
for relatedness between samples and perhaps identify new molecular subgroups.
Secondly, normalised data from a microarray experiment can then be analysed to create
gene lists of diﬀerentially expressed genes. Ideally, the gene lists across biological replicates
can then be compared to create lists of interesting candidate genes that are common across
biological replicates. As with data normalisation there are many diﬀerent approaches to
the analysis of diﬀerentially expressed genes from microarray experiments. Genes lists
can be generated, detailing the most statistically signiﬁcant changes in gene expression.
Alternatively, genes can be ranked by fold-change in gene expression. Typically, change
in gene expression of a test sample is calculated relative to a control sample. A fold-
change cut-oﬀ may be applied - usually a two-fold increase or decrease in gene expression
between the test and control sample. With this approach it is extremely important to
have appropriate controls for each test sample. It is also important to have technical
and biological replicates to reduce frequency of false-negative and false-positives hits that
occur by chance in each array. In platforms that do not return absolute values of gene
expression for each gene, it is important to have an appropriate biological control and
consistent labelling and hybridisation eﬃciencies to identify statistically diﬀerent changes
in gene expression across diﬀerent arrays. This is the approach required for the Illumina
HT12 platform. Other array platforms enable the co-hybridisation of two samples, by co-
hybridising a common control RNA sample across a set of arrays it is possible to calculate
absolute measurements of gene expression. Many packages are available for the analysis of
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experiment. A popular choice is the Linear Models of Microarray’ or ‘limma’ package which
can be used in ‘R’ [Smyth, 2004]. Limma enables the simultaneous analysis of many RNA
targets across arrays, data are corrected for multiple testing and the resulting expression
data matrix can then be used to either identify the top diﬀerentially expressed genes or
perform clustering analyses.
1.6.2 Functional follow-up of candidate biomarkers
The gene expression proﬁle of a cell contains a wealth of information that correlates to
cell behaviour and phenotype, yet understanding the function of individual genes remains
immensely challenging. The Human Genome Project has annotated the whole human
genome, yet the function of only a minority of the encoded genes and DNA sequences is
understood. Understanding the functional biology of a speciﬁc gene is usually laborious,
technically challenging, and requires lengthy in vitro and in vivo experimentation. The
scientist is often challenged by diﬀerent mRNA or protein isoforms of that gene, the dif-
ferential regulation of transcription or protein activity, by protein-protein interactions and
by cell type or cell context dependent changes in gene function. Gene expression patterns
are controlled by many genetic enhancers, which themselves may be active only in speciﬁc
contexts. Thus, many projects now aim to use bioinformatic tools to identify molecular
ﬁngerprints of tumours that indicate the tumour origin, stage, diﬀerentiation, histotype, or
clinical behaviour. Such approaches reiterate the fact that that mRNA proﬁles represent
many complex interacting biological pathways that co-ordinate to ultimately determine
cellular phenotype and, in the case of tumours, tumour features and behaviour. When
working with in vitro models, this approach is dependent on good collaborations between
bench scientists and expert bioinfomaticians who, importantly, need to be working with a
common goal in mind.
1.7 The Role of the Microenvironment
In vitro models of human disease are limited by the restricted ability of the scientist
to reproduce in vivo environments within the laboratory. Changes in cell shape, tissue
geometry, matrix proteins, oxygen and nutrient gradients and the absence of other cell
types will all alter cellular phenotype and therefore may interfere with the study of a
biological process. Three-dimensional (3D) and heterotypic models aim to restore in vitro
some features of the tissue in vivo that may be lost under rountine 2D culture conditions.
601.7.1 Three-dimensional Cell Culture Models
In vivo, cells are surrounded by a complex extracellular matrix (ECM). Cells contact and
communicate with a host of diﬀerent cell types through receptors distributed throughout
the entire cell surface. However, a 2D monoculture consists of clonally derived cells that
only communicate along a small proportion of their membrane. This is a major limita-
tion, and so 3D culturing techniques can be employed to try to re-create tissue features
and geometry and thus improve the biological relevance of in vitro models. There is now
substantial evidence to suggest that 3D cultures more closely resemble the in vivo mi-
croenvironment than 2D cultures, and that culturing cells in 3D can cause phenotypic and
molecular changes that reﬂect the in vivo biology of the cell more closely than 2D cul-
tures [Knuechel et al., 1990]; [Zietarska et al., 2007]; [Ghosh et al., 2005]. Additionally,
cells that are traditionally diﬃcult to culture in 2D, such as primary hepatocytes, can of-
ten be maintained in vitro for longer periods when grown in 3D [Khaoustov et al., 1999].
The precedent for modelling the microenvironment was set by Mina Bissell and col-
legues in the 1990s. Human mammary epithelial cells (HMECs) grown in laminin rich
Matrigel formed polarised, growth arrested structures with a central lumen, structures
that were closely reminiscent of breast acini [Petersen et al., 1992]; [Weaver et al., 1995];
[Howlett et al., 1995]; [Weaver et al., 1997]. Initially, growing cells in 3D was considered
to be costly and time-consuming, without inferring a signiﬁcant advantage over conven-
tional 2D culturing techniques. Yet Bissell and many other groups have now demonstrated
that growing breast epithelial cells in 3D cultures restores functional diﬀerentiation of
cells. HMECs in 3D express milk proteins (caseins) [Weir et al., 2006]. Caseins are never
expressed by these cells when in 2D culture, but expression of these proteins are charac-
teristic of HMECs in vivo. Many cell types have now been shown to restore expression of
functionally relevant proteins when transferred from a 2D to a 3D modelling system.
Several diﬀerent approaches can been used to establish 3D cell culture models. The most
well described is the growth of cells in 3D using ECM protein gel scaﬀolds (such as collagen
gels or Matrigel). Synthetic scaﬀolds can also be used, plus other techniques which prevent
cell adherence to tissue culture plastics and hence encourage cells to adhere to each other
and form multicellular aggregates. Such systems include the rotary cell culture system
(RCCS) or polyHEMA coating tissue culture plastics. Reports of culturing ovarian cancer
cells in 3D focus on the tumour cell aggregates found in ascitic ﬂuid which have been
used to model EOC metastasis in vitro [Burleson et al., 2004a]; [Burleson et al., 2004b];
[Burleson et al., 2006] [Zietarska et al., 2007]. 3D culturing of normal ovarian epithelial
cells has also been described [Kwong et al., 2009]; [Lawrenson et al., 2009a] (Table 1.8).
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Table 1.8: Three-dimensional cell culture techniques, advantages and disadvantages ∗ Reviewed in
[Lee et al., 2008]. Published 3D models of ovarian epithelia (normal or malignant) are summarised.
Diﬀerent 3D culture techniques are not equivalent in their eﬀectiveness. In one study,
Ghosh et al. cultured melanoma cells in collagen gels and found gene expression pro-
ﬁles were similar to that of cells in 2D; and yet when cells were grown on polyHEMA
coated plates, they observed the diﬀerential expression of >150 genes. Many of the genes
upregulated in polyHEMA 3D cultures were consistent with their upregulation in vivo
[Ghosh et al., 2005]. Thus, in this present study, two 3D culture techniques were com-
pared as models of primary NOSE cells in vitro [Lawrenson et al., 2009a]. The purpose
of this approach was to evaluate the biological eﬀects of two diﬀerent 3D culturing tech-
niques on the culture of primary normal ovarian surface epithelial cells, and to establish
a 3D model of NOSE cells that could be used to study the earliest stages of neoplastic
transformation in epithelial ovarian cancer. The optimisation of 3D modelling techniques
is described in Chapter 3 and applications of the 3D models in Chapters 4 & 5.
1.7.2 A Role for Senescent Fibroblasts in Ovarian Epithelial Tumouri-
genesis?
3D cultures aim to restore tissue geometry. An alternative tool that cell biologists use
to improve conventional 2D in vitro monoculture models is heterotypic culturing. In
heterotypic cultures, it is hypothesised that the diﬀerent cell types surrounding the cell of
interest can aﬀect the target cell phenotype and may be important for normal functional
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Figure 1.10: Stromal extracellular matrix proteins (ECMs) and molecules secreted by stromal
cells (e.g. ﬁbroblasts and granulocytes) can aﬀect epithelial phenotype. Such molecules include
hormones (e.g. oestrogen) and a myriad of proteins sythesised by ﬁbroblasts. Upon senes-
cence, ﬁbroblasts become increasingly secretory (the “senescence-associated secretory phenotype”
[Coppe et al., 2008]. Ovarian surface epithelial cells within inclusion cysts have a more committed
epithelial phenotype (E-Cadherin+, CA125+), presumed to be due to closer interactions with the
mitogen rich stroma.
diﬀerentiation. In this present study, the eﬀect of ageing stromal ﬁbroblasts on epithelial
transformation is explored.
In vivo, stromal ﬁbroblasts play the central role in the structure of tissue architecture,
though dynamic regulation of the extracellular matrix components (Figure 1.10). As an
organism ages, the senescent ﬁbroblasts accumulate in the tissue stroma, gradually re-
placing pre-senescent cells [Herbig et al., 2006]; [Jeyapalan et al., 2007]. Senescent cells
are metabolically active, and the proﬁle of secreted proteins has been demonstrated to
be vastly diﬀerent than their non-senescent counterparts [Coppe et al., 2006]. The induc-
tion of senescence induces a senescence-associated secretory phenotype (SASP); senescent
ﬁbroblasts secrete a myriad of growth factors (including VEGF), extracellular matrix pro-
teins, proteases, chemo- and cyto-kines (Figure 1.10). This spectrum of molecules aﬀects
the phenotype of neighbouring epithelium directly and indirectly (through remodelling
of the extracellular matrix or the eﬀects on other cell types, such as endothelial cells)
[Coppe et al., 2006]; [Coppe et al., 2006]. Furthermore, senescent cells have enhanced ex-
pression of proteins associated with an acute inﬂammatory response, such as matrix metal-
loproteinases (MMPs) [Parrinello et al., 2005]. In vivo xenograft modelling also suggests
that the pro-tumourigenic eﬀect of senescent ﬁbroblasts may be due in part to the en-
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hanced ability of senescent ﬁbroblasts to illicit an inﬂammatory response compared to
normal ﬁbroblasts [Liu and Hornsby, 2007].
1.8 Aims of this study
Molecular events that occur during EOC initiation remain poorly understood. Progress
in in vitro modelling of EOC tumourigenesis has been hindered by diﬃculties in culturing
the normal cell precursor. Therefore, 3D models were hypothesised to be an approach
of NOSE cell culture that may more closely reﬂect the cells in vivo than traditional 2D
monolayer cultures. This is described in Chapter 3.
This study aimed to create an in vitro model of neoplastic transformation of the ovarian
surface epithelium. Genes known to be involved in low-grade and high-grade serous EOCs
and mucinous EOCs, namely CMYC, KRASG12V and BRAFV 600E were introduced into
immortalised OSE cells to create a stepwise model of transformation (Chapter 4). The
transformed phenotype associated with the expression of each gene/gene combination
were analysed using a panel of in vitro assays. Gene expression proﬁles were generated
to proﬁle transcriptomic changes associated with CMYC, KRASG12V and BRAFV 600E-
driven transformation. In Chapter 4 novel genes are described that represent potential
biomarkers of early-stage disease.
Finally, heterotypic models were developed, consisting of epithelial and ﬁbroblastic cell
lines. The eﬀects of senescent and pre-senescent ﬁbroblasts on the neoplastic phenotype
of ovarian epithelial cells was assayed using 2D and 3D co-culture assays (Chapter 5).
This ﬁnal Chapter explores functional modelling of an epidemiological observation (most
EOCs occur in older women), using an in vitro cell biology model.
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Materials and Methods
2.1 Cell Culture & Establishment of Primary Cell Lines
2.1.1 General Equipment and Solutions
All cell culture was performed in a laminar-ﬂow safety cabinet (Heraus), and cells were
incubated in an Heracell incubator (Heraus) at 37 ◦C with 5% or 10% CO2, according to
the requirements of each cell line. Cells were grown in tissue-culture treated disposable
60mm, 100mm and 145mm dishes, 25 cm2, 75 cm2, 175 cm2 ﬂasks, or multiwell plates (all
Greiner). Disposable 15ml or 50ml tubes (Greiner) were used to centrifuge cell suspensions.
All glassware was cleaned and autoclaved by heating to 121oC for 15 minutes at a pressure
of 103kPa to sterilise.
2.1.2 General Tissue Culture Methods
Media and Solutions
All tissue culture media were stored at 4 ◦C. Antibiotic and growth factor solutions were
stored at −20 ◦C. G418 (Sigma) and blasticidine S hydrochloride (Sigma) solutions were
prepared in double distilled water (DDW) and ﬁlter sterilised through a 0.2µM ﬁlter.
Puromycin solutions (Sigma) were prepared in methanol (Sigma). Zeocin (Invitrogen) and
Hygromycin (Calbiochem) were purchased as solutions from the manufacturer and used
as provided or diluted 1:10 in sterile DDW. Cells were washed with sterile 1X phosphate-
buﬀered saline (PBS) (VWR). A 10X PBS solution was diluted 1:10 with DDW and the
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1X solution was then autoclaved to sterilise.
Foetal bovine serum (FBS) was purchased from Invitrogen or Lonza and batch tested
before use. Brieﬂy, cells were selected which were known to be particularly sensitive to
serum (normal ovarian ﬁbroblasts or syrian hamster embryonic ﬁbroblasts). Cells were
mass cultured in the test serum for a minimum of 7 days before plating at clonal density
(100 cells per well in a 6 well plate, in triplicate). Cultures were re-fed every 2-3 days and
stained with crystal violet. To stain cells, cultures were ﬁxed in 100% methanol (VWR)
for 10 minutes and then rinsed with DDW. Cultures were then stained with 0.5% crystal
violet (Sigma) solution (in DDW). After 10 minutes plates were rinsed extensively with
DDW and allowed to air dry. Colonies were then counted. Colony formation eﬃciency
(CFE) was calculated using the following formula.
CFE (%) =

Total Number of Colonies
Inital Number of Cell Plated

∗ 100%
Mass cultures were continued in parallel and observed under the light microscope for gross
changes in culture morphology.
Passaging, Cryopreservation and Counting of Cells
To split or passage cells, cell monolayers were washed with 1X PBS and cells were detached
using 1X Trypsin-EDTA (Invitrogen). After 2 to 5 minutes incubation at 37 ◦C, cells
detached from the plastic ﬂask or dish. Trypsin was then neutralised with an equal volume
of complete media, and the cell suspension was collected and centrifuged at 1,500g for 5
minutes to pellet cells. The supernatant was then aspirated and the cell pellet resuspended
in complete media for replating, or in a freezing solution for cryopreservation.
Freezing solutions were prepared using 10% DMSO (Sigma) in FBS or Newborn Calf
Serum (NCS) (Invitrogen). 1ml of cells suspended in freezing solution was aliquotted into
1.8ml freezing vials (Nunc) and the vials were stored in a Mr Frosty container for at least
3 hours, to slowly cool at 1 ◦C per minute before cells were transferred into liquid nitrogen
for storage at −196 ◦C.
To count cells, cells were detached from the tissue culture dish or ﬂask by trypsinisation.
Cell suspensions were centrifuged at 1,500g for 5 minutes with an equal volume of complete
medium. The supernatant was aspirated and cell pellets ﬂicked to loosen from the side of
the tube. Cells were then completely resuspended in growth medium and counted using a
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hemocytometer (Neubauer).
2.1.3 Mycoplasma Screening
Cell cultures were regularly tested for the presence of contaminating mycoplasma. My-
coplasma infections can persist in cell cultures without causing turbidity of the cell culture
media. Such infections induce gene expression and phenotypic changes in host cells, and
are diﬃcult to eliminate from cultures once infected. Furthermore, mycoplasmas are often
resistant to many of the antibiotics routinely used in tissue culture media.
Two methods of mycoplasma detection were used: Hoescht staining and polymerase chain
reaction (PCR). Hoescht ﬂuorescently stains DNA, and hence mycoplasma are visible
with a ﬂuorescent microscope. This method can detect mycoplasa at a concentration of
>106cfu/ml, thus, prior to staining, cells were incubated for a minimum of two weeks in
antibiotic-free media to allow any low-level infections to expand. Cell cultures, grown on
coverslips, were ﬁxed in freshly-made Carnoy’s ﬁxative (3:1 methanol:acetic acid, both
Sigma) using the following protocol:
1. 3mls ﬁxative was added to cell culture media, and incubated for 5 minutes at room
temperature
2. Fixative solution was then aspirated, replaced with 5 mls fresh ﬁxative and incubated
for 5 minutes
3. Step 2. was repeated, and coverslips washed with DDW and air dried
4. 50µl Hoescht bisbenzimide 33258 solution (Sigma, 0.05µg/ml in DDW) was then
added to coverslips, and cells were visualised by ﬂuorescent microscopy. Positive
cells can be identiﬁed by bright spotty cytoplasmic staining (mycoplasma DNA).
In cultures that are free of contaminating mycoplasma, only the cell nuclei should
be detected. For analysis of staining, positive and negative controls were stained in
parallel.
For mycoplasma screening by PCR, 1ml medium was removed from cell cultures (pre-
incubation without antibiotics is not required for this protocol). Media aliquots were spun
at 13,000rpm for 30 minutes, and the majority of the supernatant removed (to leave 20µl
remaining). Pellets were resuspended in 50µl of TE buﬀer (10mM Tris-HCl with 1mM
EDTA) with added Proteinase K (Sigma, 200µg/ml ﬁnal concentration), and incubated
for 1h at 55 ◦C. Finally the enzyme was deactivated by incubation at 98 − 100 ◦C for 10
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min (both incubations were performed in dry heating blocks to avoid contamination risk
of water baths).
The following primers detect of all members of Mollicutes class, which include all my-
coplasmas (and also ureaplasmas and spiroplasmas). All diﬀerent mycoplasma species can
be detected with the following primers, targeting the 16S rRNA gene:
Forwards primer (MYCO-F): 5’-GGGAGCAAACAGGATTAGATACCCT-3’
Reverse primer (MYCO-R): 5’-TGCACCATCTGTCACTCTGTTAACCTC-3’
A standard PCR was run, with a negative control (water) and a mycoplasma contaminated
cell line as a positive control.
Reagent Volume per reaction
milliQ H20 7.38µl
25mM MgCl2 1.5µl
2.5mM dNTPs 1.5µl
10X buﬀer (Promega) 1.5µl
Forwards primer 1µl
Reverse primer 1µl
Taq Polymerase (Promega) 0.12µl
Sample 1.00µl
2.1.4 Culture Conditions: Non-Ovarian Cells
NIH3T3 Swiss mouse kidney ﬁbroblast cells were grown in Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM, Sigma) supplemented with 10% NCS and 2mM L-Glutamine (Invitro-
gen). The cells were incubated at 37 ◦C, 10% CO2.
BRM-1 human embryonic ﬁbroblast cells were grown in DMEM supplemented with 15%
FCS and 2mM L-Glutamine. The cells were incubated at 37 ◦C, 5% CO2.
293T human embryonic kidney cells (gift from M.Anesti) were grown in DMEM supple-
mented with 15% FCS, 2mM L-Glutamine, 1X Non-Essential Amino Acids (NEAA) and
2mM Sodium Pyruvate (both Sigma). The cells were incubated at 37 ◦C, 5% CO2.
Phi-Nx cells (Orbigen), a 293T-based packaging cell line, were grown in DMEM supple-
mented with 15% FCS and 2mM L-Glutamine. The cells were incubated at 37 ◦C, 10%
CO2.
MCF7 breast cancer cells were grown in DMEM supplemented with 10% FCS and 2mM
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L-Glutamine. The cells were incubated at 37 ◦C, 10% CO2.
When required, 1X Penicillin and Streptomycin (Invitrogen) were added although the use
of antibiotics was avoided where possible.
2.1.5 Tissue Collection
All tissues were collected from University College Hospital. All tissues were collected with
informed consent from donors, according to a protocol approved by the Joint UCL/UCLH
Committees on the Ethics of Human Research (Committee Alpha).
For collection of primary tissue, 50µg/ml gentamicin sulphate (Sigma) was added to the
collection medium. Ovarian surface brushings or stromal biopsies were collected in com-
plete growth medium and taken immediately to the laboratory for processing, as described
below.
2.1.6 Establishment of Normal Ovarian Surface Epithelial Cell Lines
A modiﬁed growth medium (NOSE-CM), is recommended for the culture of primary nor-
mal ovarian surface epithelial (NOSE) cell isolates [Li et al., 2004a]. This medium consists
of MCDB105 and Medium 199 (both Sigma) in a 1:1 ratio and supplemented with 15%
FBS, 34µg protein/µl bovine pituitary extract (BPE) (Invitrogen), 5µg/µl insulin, 10ng/µl
epidermal growth factor (EGF), and 0.5µg/µl hydrocortisone (all Sigma). MCDB105 was
purchased as a powder and prepared, according to manufacturers instructions, to pH6.5
and then ﬁlter sterilised into sterile bottles.
Normal ovarian surface epithelial cells were collected from patients with disease-free ovaries
undergoing total laparoscopic/abdominal hysterectomy. The surface of the ovaries were
gently scraped using a sterile Transwab brush swab (Medical Wire and Equipment Ltd)
and the cells were plated in NOSE-CM by shaking the cytobrush in a tube of complete
medium, and then transferring the medium in a 25cm2 ﬂask at 37 ◦C and 5% CO2. Cul-
tures were left undisturbed for 5-7 days, until the cells begin to colonise. The medium was
then replaced every 2-3 days, and cells were incubated until ﬂasks become around 50%
conﬂuent. Cells were then trypsinised as described above, and split in a ratio of 1:2-1:5,
depending on the growth characteristics of each individual cell line.
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2.1.7 Establishment of Normal Ovarian Fibroblast Cell Lines
Normal ovarian ﬁbroblast cells were grown in MCDB105:Medium 199 in a 1:1 ratio, sup-
plemented with 15% foetal bovine serum and 2mM L-glutamine. A piece of ovarian stroma
was isolated by a Pathologist following removal of the specimen from the patient. Tis-
sue was removed from the collection medium and washed twice with 1X PBS to remove
loosely attached epithelial cells. Tissues were then placed into a P100 dish, and minced
using sterile forceps and a scalpel. 20mls of medium was then added to the dish and cells
were then incubated, undisturbed, for 7 days. Cultures were then refed every 2-3 days
and the growth of ﬁbroblastic colonies (swirling clone morphology, cells have an elongated
morphology compared to OSE) was monitored using a light microscope.
Fibroblastic colonies were isolated using either ring cloning or cloning disks (Sigma).
Clones were incubated in 6-well plates and stained for ﬁbroblastic and epithelial markers
(see below) before immortalisation.
2.1.8 Drug Dose Response Assays
A conﬂuent P100 dish of cells was trypsinised and split equally into 10 P60 dishes. The
following day the media was changed and varying concentrations of the drugs was added:
Puromycin 0-1000 ng/ml, G418 0-1000 µg/ml, hygromycin B 0-100 units/ml, blasticidine
S hydrochloride 0-10 µg/ml.
The cells were incubated undisturbed for 7 to 10 days, and the media was replaced every
3 to 4 days. After the 7 to 10 day incubation, plates were ﬁxed and then stained with
Coomaasie blue (Sigma), dissolved in DDW. To stain the cells the media was discarded
and cells ﬁxed with 5ml methanol for 10 minutes. Cells were washed with water and then
stained with Coomaasie blue for 10 minutes. Excess dye was rinsed oﬀ with DDW and
plates air dried and cell colonies were counted by naked eye or by light microscopy.
Kill curves were performed to obtain the optimal doses of selective antibiotics. 10-30U/ml
hygromycin was used to isolated hTERT-expressing clones. Single mutant clones were
selected with 400ng/ml puromycin or 125µg/ml G418. IOSECMY C cells were tolerant of
much higher concentrations of G418 than the IOSE cell lines. IOSE11CMY C.KRAS clones
were selected with 333µg/ml G418; IOSE19CMY C.KRAS clones were selected with 1mg/ml
G418; and all IOSECMY C.BRAF clones were selected with 400ng/ml puromycin.
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2.1.9 Transfection with FuGeneTM6
Cells were plated at 50 to 80% conﬂuency one day prior transfection with FuGeneTM6
(Roche) transfection reagent. On the day of transfection the reagent was prepared in
serum free media (SFM) according to manufacturers instructions. To transfect a P100
dish at a 3:1 ratio of reagent to DNA, 18µl FuGeneTM6 transfection reagent was added
to 582µl SFM in a sterile 1.5ml microcentrifuge tube, without allowing the reagent to
touch the plastic sides of the tube. The mixture was then vortexed for one second and
incubated at room temperature for 5 minutes. 6µg DNA was then added to the diluted
reagent (keeping the total volume of added DNA solution to between 0.5 and 50µl). The
mixture was then vortexed for 1 second to mix and incubated for 15 minutes minimum at
room temperature. A control plate was transfected with reagent only, and DNA solution
was substituted for SFM.
Cells to be transfected were then removed from the incubator. Removal of complete growth
medium containing serum is not required. The contents of each microcentrifuge tube was
then added dropwise to a P100 dish, and the medium was then swirled to distribute the
transfection mixture throughout the dish. Cells were then returned to the incubator,
passaged the following day, and antibiotic selection was begun on day 4.
2.1.10 Immunoﬂuorescence Cytochemistry of Cultured Cells
Cells were grown on coverslips. The growth media was aspirated, and cells were washed
with ice cold PBSAg (0.3% v/v ﬁsh skin gelatin (Sigma) in 1X PBS). Cells were then
ﬁxed for 10 minutes in cold 3% formaldehyde (VWR), the ﬁxative was then aspirated and
the cells rinsed well in PBSAg. Cells were then permeabilised by immersing the coverslips
for 5 minutes at room temperature in 0.3% v/v Triton X-100 (Sigma) in PBSAg. Cells
were rinsed in PBSAg and incubated for 10 minutes at room temperature in 50µl 1% v/v
non-immune goat serum (Invitrogen). Serum was then gently aspirated oﬀ, and 50µl of
optimally diluted primary antibody was immediately applied to the coverslips:
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Anti-Ck7 (clone LP5K) 1:1000 dilution (CRUK)
Anti-ﬁbronectin (FN-3) 1:1000 dilution (CRUK)
Anti-pan cytokeratin (clone AE1/AE3) 1:1000 dilution (Dako)
Anti-calretinin 1:1000 dilution (Dako)
Anti-BerEP4 1:1000 dilution (Dako)
Anti-CA125 1:1000 dilution (Dako)
Anti-E-Cadherin 1:2500 dilution (Cell Signalling)
Anti-FSP 1:1000 dilution (Sigma)
Anti-Factor 8 Related Antigen (clone F8/86) 1:1000 dilution (Lab Vision)
The cells were then incubated with antibody at room temperature for 1 hour, before the
primary antibody was completely rinsed oﬀ with PBSAg and an Alexa Fluor-488 (1:2500
dilution, Invitrogen) secondary antibody applied. The cells were then incubated with the
secondary antibody at room temperature for 30 minutes and protected from light. The
cells were then rinsed in PBSAg and were incubated for 10mins in Evans Blue solution
(Sigma), diluted in DDW 1% w/v . Coverslips were washed in 1X PBS and ﬁnally water
before mounting onto a slide with mounting medium and 5µl DAPI (Vector Laboratories,
Inc) was added before covering the cells with a coverslip. The mounted cells were then
incubated for 30 minutes before viewing with an Olympus BX64 ﬂuorescence microscope.
Images were captured and analysed using Cytovision Genus 3.6 software.
2.1.11 Three-dimensional cell culture
Two protocols were tested for the generation of three-dimensional spheroids. Seeding den-
sities, coating volumes and secondary assays for diﬀerent 3D approaches are summarised
in Table 2.1.
PolyHEMA coating of plastics
Poly-hydroxymethylacrylate (polyHEMA) solutions were prepared in 95% ethanol/5% dis-
tilled water. PolyHEMA solutions were incubated at 65 ◦C for 1-2 hours, until completely
dissolved. Working within a tissue culture laminar ﬂow safety hood, tissue culture plastics
were then coated with the polyHEMA solution (4-5ml per P100 dish or F75 ﬂask, also see
Table 2.1). Coated plastics were then allowed to dry before a second coat was applied.
Once completely dried, sterile coated plates were stored at ambient temperature until use.
To generate 3D cultures polyHEMA-coated plate/ﬂask were washed with 1xPBS for 5
minutes. 2D monolayer cells were trypinised, pelleted and enumerated, as described above.
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polyHEMA or 
agarose solution 
volume
Approximate cell 
numbers 
(examples)
Recommended 
culture media 
volume 
Examples of Secondary Assays
RCCS 10mls N/A 1-2 x 10
6 10mls
RCCS 50ml N/A 3-5 x 10
6 50mls
P100/F75 4-5mls 2-4 x 10
6 20mls
F175 15mls 6-8 x 10
6 50-80mls
6-well plate 3mls 5-8 x 10
5 5-7mls
12-well plate 1.5mls 3-5 x 10
5 2mls
24-well plate 500µl 1-2 x 10
5 1.5mls Confocal microscopy; electron microscopy; 
moderate-throughput screens
48-well plate 250µl 5-8 x 10
4 500µl In vivo xenografts; high-throughput screens
96-well plate 50µl 1-5 x 10
4 200µl High-throughput screens; side population 
sphere formation assays 
Confocal microscopy; electron microscopy
Rotary Cell Culture System
Immunohistochemistry; FACS; molecular 
analyses (gene/protein expression) 
Static 3D cultures 
Immunohistochemistry; FACS; molecular 
analyses (gene/protein expression)
Table 2.1: Cell seeding densities and secondary assays for RCCS and polyHEMA 3D cultures.
Volumes of polyHEMA coating solutions used are also shown.
Cell suspensions were then inoculated onto polyHEMA-coated plastics with an appropriate
volume of complete medium (20mls for a P100 dish) Spheroid formation was be monitored
by phase-contrast microscopy. To refeed 3D cultures, dishes or ﬂasks were rested at an
angle to allow spheroids to settle at one corner (such as by resting one side of the vessel
on a pipette). After 10-20 mins, cultures were inspected to ensure the spheroids had
completely settled before refeeding (longer resting periods were necessary for cultures that
contain smaller spheroids). Up to 80% of the culture medium was carefully removed with
a pipette. Fresh medium was then slowly added.
The rotary cell culture system
Sterile rotary cell culture vessels (Synthecon) were rehydrated with complete tissue culture
medium for 10min. Medium was then removed. 2D monolayer cells were trypinised,
pelleted and enumerated, as described above. Rotary cell culture vessels (10ml or 50mls)
were inoculated with an appropriate number of cells (see Table
Cells were incubated undisturbed and refed twice a week. To refeed, rotation was stopped
and the vessel was removed from the base and placed in tissue culture hood. The vessel
was rested in an upright position with the ﬁlling hole at the top. After approximately 20
minutes, spheroids collected at the bottom of the vessel. Two-thirds of the medium was
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then carefully removed and slowly replaced with fresh medium. Air bubbles were removed
as above.
Fixing of 3D cultures and Processing for Immunohistochemistry
3D cultures were removed from the incubator and culture medium containing MCS was
poured into 50ml v-bottomed tube. Spheroids were allowed to settle for 10-20 mins, cell
culture medium was then removed and replaced with neutral-buﬀered formalin (VWR).
At the University College Hospital Histology Services, samples were then processed into
paraﬃn for immunohistochemistry. Immunohistochemistry was performed at University
College Hospital Advanced Diagnostic Laboratory.
2.1.12 Heterotypic Culture Protocols
Fibroblast cultures were used at 80% conﬂuency. Freshly prepared, ﬁlter sterilised hydro-
gen peroxide solutions were added to cell culture medium for 2 hours. Cells were then
passaged at a ratio of 1:2 and stained for senescence associated β-galactosidase expression
after 24 hours.
3D Co-culture Assays
Cells were grown as 3D dimensional multicellular spheroids on plastic dishes coated twice
with a 1.5% solution of poly-2-hydroxyethyl methacrylate (polyHEMA) from Sigma, pre-
pared in 95% ethanol (Sigma). Fibroblasts were plated onto polyHEMA coated plates and
allowed to form spheroids for 7 days, before the culture was inoculated with epithelial cells
at a ratio of 4:1 ﬁbroblasts:epithelial cells. 3D heterotypic cultures were maintained in BM
for two weeks and re-fed twice weekly, before multicellular aggregates were harvested, ﬁxed
in neutral-buﬀered formalin (VWR) and processed into paraﬃn (at the CR-UK Histology
Service).
2.1.13 Electron Microscopy
For primary ﬁxation: (note that for scanning EM cells were ﬁrst washed in 1X PBS to
remove proteins and the ﬁxative was ﬁltered before use). Samples were ﬁxed for 1-2 hours
in 2% fresh paraformaldyhyde, 1.5% glutaraldehyde in 0.1M cacodylate buﬀer, pH 7.3 (all
Sigma). For 2D cells, cells were grown on coverslips, the media removed and replaced
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with ﬁxative. For 3D cultures: spheroids were spun down, the media removed and the
spheroids resuspended in ﬁxative. Fixed samples were then washed in 0.1M cacodylate
buﬀer, then incubated in 1% OsO4 (Sigma) in 0.1M cacodylate buﬀer, pH 7.3 for 1 hour
in the fridge. Samples were then washed in 0.1M cacodylate buﬀer for 5 min, the washed
in DDW for 5 min. Samples were incubated in 0.5% uranyl acetate in DDW for 20 min,
then washed once more in DDW for 5 min. Samples were then dehydrated with increasing
concentrations of ethanol: 25% ethanol/5 mins, 50% ethanol/5 mins, 70% ethanol/5 mins,
90% ethanol/5 mins, 100% ethanol/5 mins x 4 incubations.
Dehydrated samples were then embedded in resin. These steps were performed in a glass
petri dish. 2 parts propylene oxide was mixed with 1 part resin mix, the mixture was
added to samples and incubated for 1 hour. The resin mix was then replaced with a mix
of 1 part propylene oxide and 1 part resin mix for 1 hour. Finally, this was replaced with 1
part propylene oxide:2 parts resin mix for 1 hour. Samples were then submerged in 100%
resin mix overnight. Fresh resin was replaced the following day, and to create a block, a
beem capsule was ﬁlled with resin so that there is a slight convex surface. A cover slip
was then placed atop the resin of the beem capsule (all reagents for EM were obtained
from Sigma).
The recipe for the epoxy resin mix (medium hardness) ie:
Agar resin:
Agar 100 12gm
DDSA 8gm
MNA 5gm
DBMA 0.65gm
Epon:
Taab 812 19.2gm
DDSA 7.6gm
MNA 13.2gm
DBMA 0.8gm
For scanning electron microscopy, samples were mounted on carbon stubs and gold-coated
before viewing using a JEOL 7401 series FEGSEM. For transmission electron microscopy,
samples were examined on a JEOL 1010 transmission electron microscope (both JEOL
Ltd).
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2.2 Preparation and Manipulation of Plasmid DNA
KRASG12V was cloned from the pcDNA3.1 vector into pLNCX (BD Biosciences) (Figure
2.1).
Figure 2.1: KRASG12V cDNA was cloned into the multiple cloning site (MCS) of the pLNCX
retroviral vector.
The plasmids used in these experiments all contain an ampicillin resistance gene under the
control of a bacterial promotor sequence, enabling selection with ampicillin for isolation of
bacterial colonies containing the plasmid of interest. All bacteria will contain ampliﬁed,
replicated plasmid DNA as well as the bacterial genome. The plasmid DNA can then be
isolated.
2.2.1 Transformation of DH5aTMT1 R  Competent E.coli
One Shot R  MAX Eﬃciency Competent Cells DH5 aTMT1 R  competent E.coli (Invitro-
gen) were used for preparation of plasmid stocks, according to the manufacturers protocol.
DNA must be free from alcohol, detergent or protein contaminants that may remain fol-
lowing enzymatic manipulation of the DNA, as these will inhibit bacterial transformation.
For each transformation experiment, one tube of bacterial cells was transformed with
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pUC19 as a positive control, or no DNA as a negative control.
1-2µl of DNA was added to a tube containing 50µl DH5aTMT1 R  competent E.coli on
ice. The tube was then gently tapped to mix and the mixture was incubated on ice for
30 minutes. E.coli were then heat shocked by incubating for exactly 30 seconds at 42 ◦C.
Cells were then placed on ice before 250µl of room temperature SOC medium was added.
Tubes were then shaken at 37 ◦C for 1 hour at 225 rpm. 20 to 100 µl of the transformation
reaction was plated onto LB-agar plates containing 100µg/ml ampicillin. The bacterial
solutions were spread onto the plates using the quadrant streaking technique to achieve
well spaced bacterial colonies. Plates were incubated inverted overnight at 37 ◦C.
LB agar plates were prepared using the following recipe:
5g Tryptone 2.5g NaCl
2.5g Yeast Extract 1.5 % Agar
Distilled water to 500ml
The solution was then sterilised by autoclaving and allowed to cool to below 60 ◦C before
adding ampicillin (dissolved in 70% ethanol). The LB-agar with antibiotic was then poured
into sterile 100mm petri dishes within a laminar ﬂow hood, and allowed to cool and set
before replacing the lid and storing at 4 ◦C.
2.2.2 Preparation of Plasmid DNA
Plasmid DNA was prepared using a QIAgen Maxi Plasmid DNA Isolation kit.
100ml of LB medium plus 100µg/ml ampicillin was inoculated with a discrete colony
picked from a streaked plate using a sterile tip. The medium was then incubated at 37 ◦C
overnight in a shaking incubator with shaking at 225rpm.
The following day bacterial cells were pelleted by centrifugation at 6,000g for 15 minutes
at 4 ◦C in a Sorvall RC 5C Plus centrifuge. The supernatant was discarded and the cell
pellet resuspended in 10mls of lysis buﬀer. The suspension was vortexed to ensure no
cell clumps remained. 10mls of buﬀer was then added and the container was inverted 4
to 6 times to ensure complete mixing before the suspension was incubated for 5 minutes
at room temperature. 10 mls of chilled buﬀer P3 was then added to precipitate cellular
protein and the mixture was incubated on ice for 20 minutes. The cell suspension was
then centrifuged twice for 30 minutes then 15 minutes at 20,000g at 4 ◦C to remove cell
debris. A QIAgen ﬁlter tip 500 was equilibriated with buﬀer QBT and the bacterial
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supernatant was then passed through the ﬁlter by gravity ﬂow. Two 30ml washes with
QC buﬀer were followed by elution with 15mls buﬀer QF. Isopropanol preciptation and
ethanol precipitation was then used to clean up the DNA solution to remove any residual
protein - 0.7vols room temperature isopropanol (Sigma) were added to the DNA solution,
the tube was inverted to mix and centrifuged for 30 minutes at 15,000g at 4 ◦C. The
supernatant was then carefully discarded and the resulting DNA pellet washed with 5 mls
70% ethanol and centrifuged for 10 minutes at 15,000g at 4 ◦C. The plasmid DNA pellet
was then allowed to air dry at room temperature. The DNA was then dissolved in 1ml
10mM Tris-EDTA buﬀer.
A NanoDrop R  Spectrophotometer determine the concentration and purity of DNA solu-
tions.
2.2.3 Enzymatic Manipulation of Plasmid DNA
Restriction Enzyme Digests
KRAS was excised from pcDNA3.1 using BamH1 and Xho1. the pLNCX2 vector was
opened by digestion of the multiple cloning site using BglII and Sal1. All enzymes were
purchased from NEB. To ensure enzyme activity and to ensure there is no contamination
of DNA other than sample DNA, two control digests are included in the experiment. The
ﬁrst contains sample DNA and no restriction enzyme, and the second contains no DNA
and restriction enzyme is added. When the former control digest is run on an agarose gel,
the uncut vector DNA should migrate faster than fully digested or nicked circular vector
DNA. A two- to tenfold excess of restriction enzyme to substrate DNA was always used.
When double digests were performed, 0.5µl of each enzyme was used so that the total
volume of enzyme remained the same. When performing double digests it was ensured
that both enzymes had suﬃcient activity in the buﬀer used in that reaction.
The following reagents were added to a 1.5ml microcentrifuge tube:
Reagent Sample DNA Uncut DNA No DNA
Volume (µl)
RE 10X buﬀer 2.0 2.0 2.0
Acetylated BSA (10µg/µl) 0.2 0.2 0.2
DNA (1µg/µl) 1 1 0
Restriction enzyme 1.0 1.0 1.0
Sterile deionised water Makes reaction volume up to 20µl
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Restriction enzyme were taken out of the freezer immediately before use and were added
last to the reaction mixture. The complete digest mixture was then mixed by pipetting,
and centrifuged at 13,000 rpm for a few seconds. The samples were then incubated for
1 to 4 hours at 37 ◦C. When required, enzymes were heat inactivated by incubation at
65 ◦C for 20 minutes.
Following incubation, digest products were separated by agarose gel electrophoresis, with
the percentage of agarose in the gel adjusted according to the size of the fragments to
be separated. The digested vector and insert fragments were identiﬁed by size, the cor-
responding bands were excised from the gel and the DNA was then puriﬁed using the
QIAgen Gel Elution Kit (see 2.4.1). DNA’s were eluted in 28µl Tris.Cl, pH 8.5, and
quantiﬁed using a Nanodrop Spectrophotometer.
2.2.4 Ligation with NEB Quick LigaseTMKit
50ng of restriction enzyme (RE) digested vector (pLNCX2) were added to a 1.5ml mi-
crocentrifuge tube, along with 150ng of RE digested insert (KRAS) DNA, containing
complementary sticky ends. A excess of insert DNA increases the eﬃciency of a ligation
reaction. To increase the number of intermolecular reactions - vector DNA should always
be <10ng/µl. DDW was added to make the DNA mixture up to a volume of 10µl. The
following control reactions were also prepared in separate 1.5ml microcentrifuge tubes:
Uncut vector To test transformation eﬃciency and antibiotic resistance of that speciﬁc
plasmid.
RE digested vector DNA + no insert + no enzyme This control checks for uncut
vector in the ligation reaction. It may be necessary to purify open vectors by agarose
gel electrophoresis as uncut vector will compete with ligated vector during bacterial
transformation.
Vector DNA + no insert + Quick T4 DNA ligase This reaction will check the ac-
tivity of the ligase enzyme and ensure the integrity of the sticky ends of the DNA.
The number of transformed colonies obtained when transforming cells with this DNA
should be around 60% of the number of colonies obtained when transforming cells
using uncut vector DNA.
The DNA mixtures were then incubated at 65 ◦C for 5 minutes to break any unwanted
insert-insert or vector-vector bonds. The samples were then centrifuged for 30 seconds
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and cooled on ice. 10µl 2X Quick Ligation Reaction buﬀer (NEB) was then added to each
tube and samples were mixed by pipetting the mixture up and down. 1µl Quick T4 DNA
Ligase was then added to each tube and samples were mixed thoroughly. Tubes were then
centrifuged brieﬂy and incubated at room temperature for 5 mins.
Following the 5 minute incubation, samples were chilled on ice to stop the reaction. DNA
was clean-up by standard ethanol precipitation or using a Qiagen QIAquick PCR Puriﬁ-
cation Kit spin column. This step will remove T4 DNA Ligase and PEG (in the ligase
buﬀer) from the reaction as these both inhibit transformation of bacteria.
Cleaned-up ligation reaction products were then used to transform DH5aTMT1 R  compe-
tent E.coli cells, as described above. 1µl is was suﬃcient to get transformed colonies.
Transforming bacteria with too much DNA reduces transformation eﬃciency, as at higher
concentrations of DNA (eg. 500ng instead of 20ng in a transformation) competition be-
tween transforming and non-transforming DNA (eg. linear vector, insert only) is higher.
2.2.5 Colony PCR
In order to screen for bacterial colonies that had been transformed by a complete vec-
tor:insert molecule, colony PCRs were performed. E.coli colonies were picked using a
sterile pipette tip, inoculated into 1ml of LB medium containing 100µg/ml ampicillin and
incubated at 37 ◦C with shaking for 5-6 hours.
The following mastermix was prepared and 14µl was aliquotted:
Reagent Volume per reaction
dd H20 7.38µl
25mM MgCl2 1.5µl
2.5 mM dNTPs 1.5µl
10x buﬀer (Promega) 1.5µl
Forwards primer 1µl
Reverse primer 1µl
Taq Polymerase (Promega) 0.12µl
Sample 1.0µl
1µl of each E.coli solution was then aliquotted into each reaction, plus two control reac-
tions: (i) the original vector from which the gene was cloned (ii) no DNA (water).
The PCR was run on the following program:
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20 minutes at 95 ◦C to disrupt the bacterial wall
45 cycles of 95 ◦C/45 seconds, 58 ◦C∗/1 minute, 72 ◦C/1 minute
72 ◦C/10 minutes, 4 ◦C/10 minutes
(*annealing temperature was optimised for each set of primer pairs.) PCR products were
analysed on an agarose gel and products of the expected size were excised from the gel.
2.2.6 Sequencing
All vectors used in these experiments were sequenced to verify the cDNA sequences were
complete and contained no mutations acquired during the cloning process. The presence
of the KRASG12V and BRAFV 600E cell lines was conﬁrmed.
2.2.7 Testing Oncogene Constructs in NIH3T3 Cells
In vitro transformation of NIH3T3 cells is well documented, and so oncogene constructs
were tested for their transforming ability by expression in NIH3T3 cells. 600,000 NIH3T3
cells were plated per P100 dish the day before transfection with the cDNA constructs.
Gene expression and in vitro tumourigenicity were assayed by RT-PCR and foci formation
assays respectively.
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Figure 2.2: Neoplastic features are induced in NIH3T3 cells by the introduction of common
oncogenes. (a) C-MYC, KRASG12V and BRAFV 600E confer diﬀerent abilities to form foci in
NIH3T3 cells. (b) (i) A clone expressing KRASG12V ; (ii) A clone expressing KRASG12V and C-
MYC; (iii) Untransfected control cells; and (iv) cells transfected with C-MYC cDNA alone. Cells
were stained with Coomaasie Blue and dark staining of foci can be clearly seen in (i,ii,iv) (arrows),
where loss of contact inhibition allows cells to grow at high densities. (c) Gene expression of total
C-MYC or KRAS in clones transfected with C-MYC +/− KRASG12V .
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2.3 Gene Delivery by Retroviral Transduction
When working with sensitive primary cells, it is necessary to use a system for gene delivery
that has a higher eﬃciency of gene delivery than transfection reagents. Natural retrovirus
systems have been engineered to enable the generation of replication-deﬁcient virions that
deliver DNA into host cells at frequencies of over 90%. Upon infection of a cell, the virus
will inject its RNA genome which is then reverse transcribed and the DNA molecule will
integrate into the genome of the cell, hence enabling the generation of cell lines with stable
expression of the gene of interest.
Firstly, the two packaging vectors contain expression cassettes for gag, pol and env. These
genes contain the minimal requirements for the generation of a replication-deﬁcient retro-
virus capable of delivering DNA into a host cell. Gag is a gene encoding the proteins
that comprise the internal structure of the virus, the pol gene encodes the enzymatic
component of the virus, namely the reverse transcriptase and integrase, and the env gene
contains the sequence for production of the virus envelope. In these experiments the pV-
Pack system (Stratagene) was used for production of replication-deﬁcient virion particles.
This system is based on the Moloney Murine Leukemia Virus (MMLV). The pVPack-GP
plasmid contains both the gag and pol sequences in a bicistronic expression cassette and
pVPack-10A1 contains the env gene. This env protein recognises the same cell surface
receptor as an amphotrophic MMLV virus, but in combination with a second receptor,
hence gene delivery is even more eﬃcient.
The third plasmid required contains the gene of interest cloned between two 600 bp
long terminal repeat sequences (LTR). Within these sequences are the retroviral promo-
tor/enhancer region (U3), the viral polyadenylation signal (R) and the sequences required
for retroviral transcription (U5 and R). Upstream of the multiple cloning site (MCS) into
which the gene of interest is ligated, is the viral packaging signal (ψ+) which is required
for packaging of the RNA sequence between the two LTRs to be packaged into the head
of the virus particle.
2.3.1 Production of Retrovirus
Extra care must be taken when working with retroviruses, in particular in these experi-
ments where virions are designed for eﬃcient delivery of oncogenes into human cells. This
work falls within NIH Biosafety Level 2. All glassware and solutions used in viral work
were not used for non-viral work and gloves and a lab coat worn at all times. The laminar
ﬂow hood and any pipettes used were UV irradiated for 1 hour following retroviral work.
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The packaging cell line(s) were transfected using FuGeneTM6 (Roche) transfection reagent
as described above, using a 3:1 ratio of transfection reagent to plasmid DNA. In these ex-
periments the pVPack-GP and pVPack-10A1 packaging vectors were used plus the follow-
ing plasmids containing the genes of interest: pLNCX.neo.KRASG12V , pBabe.hygro.hTERT
(Addgene), pWZL.Blast.CMYC (Addgene), pBabe.puro.BRAF (a kind gift from D. Peeper,
Netherlands Cancer Institute). As three plasmids were used to transfect the cells, 2µg
DNA of each was used per transfection. An outline of the protocol is shown in Figure
2.3. Cells were transfected at the end of day 1, and the media was replaced the following
morning with 10mls of complete media per P100 dish. Cells were then incubated for 48
hours post-transfection before the media containing retrovirus was collected, aliquotted
into sterile 15ml tubes, snap-frozen in liquid nitrogen and stored at −80 ◦C. The media
was replaced and viral supernatant collected 72 hours post-transfection. This was repeated
a third time to obtain viral supernatant 96 hours post-transfection. Packaging cells were
then discarded.
Figure 2.3: Production of retrovirus and gene delivery into target cells, experimental overview
Co-transfect with :
1.Retroviral plasmid 
containing gene of interest
2. pVPackGP
3.pVPack10A1
48-92 hours
Harvest supernatant
Overnight 
infection
Selection with 
antibiotics
2-4 weeks
Pick 
individual 
clones
NOSE cells
Virus producer cells
2.3.2 Optimisation of Infection Conditions
Retrovirions containing the lacZ reporter gene were produced from early passage 293T
and Phi-Nx cells by transfection with pVPack-GP, pVPack-10A1 and pBMN-Z (Orbigen).
A P100 plate of NIH3T3 cells was split 1:12 into a 6 well plate and six 15ml tubes, as
shown in Figure 2.4.
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Figure 2.4: Optimisation of packaging cell line and infection conditions, experimental overview.
NIH3T3 cells have been previously shown to be susceptible to retroviral infection and so were used
in the experiments optimising virus protocols
Infected by overnight incubation
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lacZ virus control virus lacZ virus
lacZ virus control virus lacZ virus
Producer cells :293T
Producer cells :Phi-Nx
lacZ virus control virus lacZ virus
lacZ virus control virus lacZ virus
Infection by Overnight Incubation with Retrovirus
Cells were allowed to adhere overnight and at the end of the day the media was aspirated
and 1ml of virus applied to each well in duplicate. The ﬁnal wells were infected with 1ml
’empty virus’. 1ml of complete media containing 4µg/ml DEAE-dextran hydrochloride
(Sigma). The cells were placed in the incubator overnight and the media replaced with
3ml complete media.
Infection by Gentle Centrifugation
Cells were trypsinised and pelleted and the media aspirated. Cell pellets were then re-
suspended in 1ml of complete media containing 4µg/ml DEAE-dextran hydrochloride and
1ml of virus. The tubes were then spun for 1 hour at 22 ◦C at 1,000g. The viral super-
natant was then removed, the cells were resuspended in complete media and transferred
to a well of a 6-well plate, as shown diagrammatically in Figure 2.5.
Cells were incubated for two days and then assayed for lacZ expression as described below.
As shown in Figure 2.5, there was no observable diﬀerences between the two infection
methods described above. However, 293T cells produced retroviral supernatant which
infected NIH3T3 cells with a higher eﬃciency than retrovirus produced by the Phi-Nx
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packaging cell line (Figure 2.5 a-d).
Optimisation of Timepoint for Retrovirus Harvesting
Primary BRM-1 cells were infected with hTERT retrovirus in order to test the eﬀects
of increasing time between transfection of packaging cell line and collection of retroviral
supernatant. BRM-1 cells were split equally onto 8 P60 plates and allowed to adhere
overnight. The following day, the cells were infected (in duplicate) overnight. Selection
with 10-20U/ml hygromycin was maintained for 3 weeks, before cells were ﬁxed with
methanol and stained with Coomaasise blue. 48 hours post-transfection was optimum for
virus harvesting, as shown in Figure 2.5.
(c) (d) (a) (b)
Retrovirus produced by Phi-Nx cells Retrovirus produced by 293T cells
(e) (f) (g) (h)
100µm 100µm 100µm 100µm
Figure 2.5: Optimisation of harvesting time-point and producer cells for retroviral production.
(a,b) 293T cells produce retroviral supernatants that infect NIH3T3 cells with higher eﬃciency
than Phi-Nx cells (c,b). Cells were infected by centrifugation (a,c) or overnight incubation (b,d).
Infected cells are blue. (e-f) Increasing time between transfection and collection decreases infection
eﬃciency. Primary human ﬁbroblasts (BRM-1) cells were infected with either empty virus (e), or
hTERT retroviral supernatants collected 48 (f), 72 (g) and 96 (h) hours post-transfection of the
293T virus producer cells. Colonies were stained 3 weeks post infection, following selection with
hygromycin. Images show representative cultures.
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2.4 In Vitro Assays for a Transformed Phenotype
2.4.1 hTERT Immortalisation of Primary Ovarian Cells
Early passage normal ovarian surface epithelial (NOSE) cells (n=3) or normal ovarian
ﬁbroblast (NOF) cells (n=1) were infected with hTERT retroviral supernatants. Follow-
ing transduction, cells were left undisturbed in the incubator for 2 to 3 days before the
medium was replaced with fresh complete medium containing a low dose of the appropri-
ate selective antibiotic (10U/ml hygromycin). Media were then changed every 5-7 days,
with all subsequent media containing a high dose of the selective antibiotic (hygromycin
at 20U/ml for NOSE cultures, 30U/ml for NOF cultures). Following 2 to 3 weeks of
selection, independent colonies were picked from plates and replated in a 25 cm2 ﬂask.
Isolation of Total Cellular DNA
A P100 plate of cells was taken at 80% conﬂuency. Cells were trypsinised and pelleted and
the DNA extracted with a QIAgen DNeasy kit, according to the manufacturer’s protocol.
Brieﬂy, pelleted cells were resuspended in 200µl PBS and then lysed by incubation with
proteinase K at 56 ◦C for 10 minutes. Buﬀer AL and 100% ethanol were added to each
sample and the mixture pipetted into a QIAgen DNeasy mini spin column. The column
was then spun at maximum speed for 1 minute and the ﬂow through discarded. The
column was then washed with wash buﬀer AW1 and then buﬀer AW2. To elute the DNA,
up to 200µl of buﬀer AE or water was added to the column, and the column spun at
maximum speed for 1 minute to collect the DNA into a fresh microcentrifuge tube.
2.4.2 Telomere Restriction Fragment Length Analysis
To detect telomere restriction fragment (TRF) length, the TeloTAGGG Telomere Length
Assay (Roche) was performed, according the manufacturers instructions. Brieﬂy, 1µg DNA
from each cell line was digested by incubation for 2 hours at 37 ◦C with frequently cutting
enzymes (Hinf1 and Rsa1). These enzymes restrict non-telomeric DNA into low molecular
weight fragments, leaving sub-telomeric and telomeric regions of chromosomes intact. Re-
striction products were then separated by agarose gel electrophoresis, and Southern blot-
ted, by overnight capillary transfer, onto a nylon membrane. DNAs were UV-crosslinked
onto the membrane, and the membrane washed with 2xSSC (0.3M NaCl, 0.03M Sodium
citrate, pH7.0). The membrane was prehybridised by incubation with for 1 hour with 25ml
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DIG Easy Hyb Solution (provided in the kit) at 42 ◦C. Blotted fragments then hybridised
for 3 hours with 1µl of a digoxigenin (DIG)-labelled telomere-speciﬁc probe per 5ml DIG
Easy Hyb Solution. The membrane was then washed twice (5 mins) with 2xSSC/0.1%
SDS at ambient temperature, then for 20mins with 0.2xSSC/0.1% SDS at 50 ◦C. The
membrane was then washed with washing buﬀer and blocked for 30 mins with blocking
solution (both in the kit). The blot was then incubated for 30 mins with anti-DIG-AP
(alkaline phosphatase) diluted in blocking buﬀer. The membrane was then washed a ﬁ-
nal time in washing buﬀer and then incubated with detection solution for 5 mins. The
membrane was then incubated for 3ml with ∼3mls chemiluminescent substrate solution
and then exposed using a standard ﬁlm developer. TRF lengths were calculated using a
molecular weight marker run on the gel.
2.4.3 Analysis of Telomerase Activity
To detect telomerase activity, the TeloTAGGG Telomerase PCR ELISAPLUS assay (Roche)
was performed, according the manufacturers instructions. Cell extracts were prepared by
pelleting 2x105 cells in a sterile eppendorf. Cells were washed once in 1X PBS. Pellets
were resuspended in 200µl lysis buﬀer (in the kit) and incubated on ice for 30 mins. the
lysates were centrifuged at 16,000g at 4 ◦C for 20 mins. The supernatant was then re-
moved to a fresh tube for the telomeric repeat ampliﬁcation protocol (TRAP) reaction.
For each sample, 25µl reaction mixture and 5µl internal standard was pipetted into a PCR
tube. Negative controls (heat-treated immortalised cell line extract to destroy telomerase
activity, plus a lysis buﬀer only negative control) were included in each experiment. 1µl
control template was pipetted into a separate PCR tube. Each tube was made up to 50µl
with nuclease-free water. The tubes were then incubated in a thermal cycler (Applied
Biosystems) and run on the following program:
25 ◦C/30 mins
30 cycles of 94 ◦C/30 secs, 50 ◦C/30 secs, 72 ◦C/90 secs
72 ◦C/10 mins
74 ◦C/hold
10µl denaturation solution was then added to 2 tubes per sample, 2.5µl sample was added
to each and the reaction incubated at room temperature for 10 mins. Hybridisation buﬀer
T was then added to one tube, and hybridisation buﬀer IS added to the other tube.
Samples were vortexed and then 100µl of each transferred the MP modules provided in
the kit. The modules were then covered in foil and incubated at 37 ◦C for 2 hours, with
shaking at 200 rpm. The hybridisation solutions were then removed and the wells washed
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3x with 250µl washing buﬀer (in the kit). 100µl Anti-DIG-HRP (horse-radish peroxidase
coupled secondary antobody) was then added to each well and the plate incubated at 37 ◦C
for 30 mins, with shaking at 200 rpm. The wells were then washed 5x with 250µl washing
buﬀer and then 100µl TMB substrate solution was added to each well. The colour was
allowed to develop for 20 mins before 100µl Stop reagent was added. The absorbance of
each well at 450nm (with a reference of 690nm) was read using a Varioskan microplate
platereader. Telomerase activity was calculated using the following formula:
Relative Telomerase Activity (RTA) =
"
(AS-AS,O)/AS,IS
(ATS8-ATS8,0)/ATS8,IS
#
∗ 100
AS absorbance of the sample
AS,O absorbance of heat-treated sample
AS,IS absorbance of internal standard of the sample
ATS8 absorbance of control template
ATS8,O absorbance of lysis buﬀer
ATS8,IS absorbance of internal standard of the control template
2.4.4 Growth Curve Experiments
To assess the rate of population doubling for cell lines, cells were trypsinised, counted and
100,000 cells were plated in 60mm dishes in triplicate. After 7 days or when cells became
over 80% conﬂuent, cells were trypsinised, passaged at a ratio of 1:2-1:8 and counted.
The rate of population doubling (PD) was then calculated using the following formula:
PD = log2

Total Number of Cells
Inital Number of Cell Plated

Cumulative population doublings were plotted, or average population doubling time cal-
culated.
2.4.5 Analysis of Cellular Karyotype
Cell cultures were seeded at 60-80% conﬂuency in complete medium in a F25cm2 ﬂask.
Karyotypic analyses were performed at The Doctors Laboratory, 60 Whitﬁeld Street,
London W1T 4EU. Cytogenetic proﬁles were analysed by a Senior Cytogeneticist (Mr.
Terry Ballard).
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2.4.6 Foci Formation
1x106 cells were plated in a P100 cell culture dish. Cells were refed three times per week
and stained with Coomaasie blue solution after 14 days.
The foci formation eﬃciency was calculated using the following formula:
FFE(%) =

Total Number of Foci
Inital Number of Cell Plated

2.4.7 X-gal Staining for β-galactosidase Expression
For analysis of expression of the lacZ reporter gene: Cells were stained 24 hours post-
infection. Media was aspirated from the cells and cells were ﬁxed with 2mls 0.05%
glutaraldehyde in 1x PBS and incubated at room temperature for 5 minutes. 0.05%
glutaraldehyde was then discarded into proper waste and cells were washed in 2mls 1X
PBS and then incubated in 2mls 1X PBS for 10 minutes at room temperature. PBS
was aspirated before adding suﬃcient X-gal solution to cover cells. To make up X-gal
solution: X-gal (Promega) was added to a ﬁnal concentration of 1mg/ml X-Gal/5mM
K4Fe(CN)6.3H2O/5mM K3Fe(CN)6/1M MgCl2/PBS. Cells were then incubated at 37 ◦C
and 5% CO2 for 2-24 hours before inspection under the light microscope. Positive cells
turn blue.
For senescence-associated-β-galactosidase expression, the X-gal solution was prepared to
pH6, and used as described above.
2.4.8 Flow cytometry
For analysis of externalization of phosphatidyl-serine (indicator of early apoptosis) cell
cultures were trypsinised, centrifuged, and cell pellets resuspended in FACS buﬀer, with or
without the anti-annexin-FITC antibody, according to manufacturers instructions (Roche,
Basel, Switzerland). Samples were run on a Becton Dickinson FACS Scan (Franklin Lakes,
NJ, USA) and the annexin-V-positive population measured. For cell cycle analysis, cells
were incubated with 1mM 5-bromo-2-deoxyuridine (BrdU) (Sigma) for 2 hours. Cells were
then washed in PBS and ﬁxed by dropwise addition of 70% ethanol with constant agitation.
Samples were incubated at 4 ◦C overnight before extraction of labeled nuclei using standard
pepsin digestion protocols. Pelleted nuclei were incubated with an anti-BruU antibody
(Beckton Dickinson), washed twice with IFA (10mM HEPES, pH 7.4; 150mM NaCl; 0.1%
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sodium azide; (all Sigma); 4% fetal bovine serum (Lonza)) then incubated with an Alexa
Flour488 coupled secondary antibody (Invitrogen). Washed nuclei were resuspended 100
g/mL propidium iodide (Sigma) diluted in PBS, and analysed as above.
2.4.9 Anchorage-Dependent Growth Assays
Cell cultures were trypsinised, pelleted and enumerated, as described above. Cell solutions
were prepared (in complete growth medium) at 200 cells/ml, and P100 dishes were inoc-
ulated with 500µl cell solution. 14.5ml complete medium was then added to each P100
dish. Three to six replicates were performed for each experiment. Cells were allowed to
attach for 24 hours, and the following day complete media were replaced with test media if
required. Cultures were refed every 2-3 days, and, after 14 days, stained with Coomaasie
blue solution as described above.
Colonies were counted and graphically represented. Alternatively, Colony Formation Ef-
ﬁciencies (CFE %) were calculated using the formula described in Section 2.1.2.
2.4.10 Anchorage-Independent Growth Assays
Assays for anchorage-independent growth were performed as follows. 100mg/ml bactopep-
tone solutions containing 3.3% or 6% Noble agar (both Sigma) were prepared in DDW,
and sterilised by autoclaving. Liquid agar solutions were then incubated at 65 ◦C until
required. In 6-well plates, a base layer of complete medium (pre-warmed to 37 ◦C) con-
taining 0.6% Noble agar was prepared and allowed to set. Cells were then trypsinised,
pelleted and enumerated, and solutions prepared in prewarmed, complete medium, at the
appropriate concentration (in these experiments, 0.33-6.6x104 cells/ml were used to plate
0.01-2x104 cells/well). Cell suspensions were then inoculated with 1/10 vols of the 3.3%
agar solution. 3ml of cell suspension/medium/agar solution were then added to each well
and allowed to set before incubation at 37 ◦C, 5% CO2. Three to ﬁve replicates were
plated for each cell line. As control, anchorage independent growth was evaluated simul-
taneously for the TOV112D endometrioid ovarian cancer cell line. After 4 weeks, cells
were ﬁxed with methanol and stained overnight at 37 ◦C with 1% p-iodonitrotetrazolium
violet (Sigma). Colony formation was observed and number of colonies counted. Colony
forming eﬃciencies (CFE %) were calculated as described above.
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2.4.11 Invasion Assays
24-well Chemicon QCM ECMatrix Flourimetric Invasion Assay kits were purchased from
Millipore. Cells were trypsinised, pelleted and washed in 1X PBS. Cells were then resus-
pended in serum-free medium (SFM) and counted. Cell solutions were then prepared at
a concentration of 0.5x106. Meanwhile, 24-well ﬂourimetric invasion chambers (Millipore)
were brought to room temperature and rehydrated with 300µl SFM. After 30mins, 250µl
of the rehydration medium was removed and replaced with 250µl of cell suspension. 500µl
of medium containing 10% FBS was then added as a chemoattractant.
Assays were incubated for 24hrs at 37 ◦C, 5% CO2. Invasion chambers were then removed
from the plate and the medium within the chamber aspirated. The chambers were then
placed into 225µl cell detachment buﬀer (in the kit) and incubated at 37 ◦C for 30 mins,
with occasional rocking. Finally, 75µl of a 75:1 mixture of CyQuant Dye and lysis buﬀer
was added to each well. After a 15mins incubation at ambient temperature, 200µl of
solution was taken from each well and transferred to a 96-well plate for reading. In each
experiment, control wells (no cells) were included.
Heterotypic Invasion and Migration Assays
Standard invasion and migration assays were modiﬁed to use normal and senescent ovarian
ﬁbroblasts as a chemoattractant. 9x104 ﬁbroblasts were plated in 24-well plates. The
following day the cells w ere washed twice with PBS and then 500µl serum free media was
added. Migration chambers (Greiner) or re-hydrated invasion chambers (Millipore) were
placed atop the ﬁbroblast monolayers and 3 x104 (for migration assays) and 12.5 x104 (for
invasion assays) epithelial cells were plated within the chamber. Assays were incubated at
37 ◦C5% CO2 for 24 hours before detection of invaded/migrated cells. For invasion assays,
invaded cells were detached from the membrane, lysed and a quantitative ﬂourimetric dye
added, using reagents from the 24-well Chemicon QCM ECMatrix Flourimetric Invasion
Assay kit (Millipore). Relative ﬂuorescence units were read on a Varikoscan platereader.
For migration assays, migrated cells were quantiﬁed as above, or membranes were stained
in situ with 1% crystal violet (Sigma) in 100% methanol, washed twice with distilled
water, and air-dried. The migrated cells were counted in ten ﬁelds of view per membrane.
In all experiments, 10% FBS as a chemoattractant was also plated.
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2.4.12 2D and 3D Proliferation Assays
Alamar Blue (Promega) is a colourimetric reagent which can be used to measure prolif-
eration of cells in 2D or 3D. Cell numbers were optimised to ensure the reagent would
not become fully reduced during the course of the experiment. For the cell lines used in
this thesis, the optimium cell number was 1000-5000 cells/ml. Cells were counted and
plated in 48-well plated in complete medium containing 10% Alamar Blue. Medium alone
and medium containing reagent but no cells were included as a control. At the desired
timepoints, plates were read on a Varioskan Platereader.
2.5 Assaying Gene Expression
2.5.1 Isolation of Total Cellular RNA
RNA molecules are unstable and extremely vulnerable to degradation by RNase enzymes.
Therefore the bench and all pipettes were cleaned with RNA-Zap (Ambion) prior to per-
forming RNA extractions to remove any RNase enzymes present on the workstation. Also,
all solutions were made up with RNase-free water and only tubes or plastics certiﬁed as
RNase and DNase free were used. RNase-free water may be substituted with DDW con-
taining 0.1% diethylpyrocarbonate (DEPC), as this chemical is a strong (but not absolute)
inhibitor of RNase activity. Finally, all samples containing RNA were stored at −80 ◦C,
and the number of times samples were freeze-thawed was kept to a minimum.
Isolation of total RNA from cells was performed using the QIAgen RNeasy Mini kit,
according to the manufacturers protocol. This procedure uses a silica-based membrane
and a series of high salt buﬀers that enable binding of up to 100µg of RNA (over 200
bases in length). Therefore the process eﬀectively enriches for preparation of mRNA
content, as most RNA smaller than 200 bases in length are excluded - such as tRNAs
and 5M rRNA. Furthermore, the cells are lysed and homogenised in buﬀer that contains
guanidine-thiocyanate and β-mercaptoethanol. This creates a denaturing environment
that inactivates degradative RNase enzymes immediately.
Cells were grown until 80% conﬂuency. The RNeasy spin columns have a RNA binding
capacity of 100µg. Cells were trypsinised and pelleted as described above and the cell
pellet was loosened by ﬂicking the tube before addition of 600µl lysis buﬀer containing
10µl/ml β-mercaptoethanol. Cell lysates were then homogenised by pipetting the lysate
through a QIAshredder spin column (QIAgen) and centrifuging at room temperature for
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2 minutes at full speed. 1 volume of 70% ethanol was then added to the homogenised
lysate and the solution was mixed by pipetting. The samples were then carefully applied
to an RNeasy spin column, in 700µl aliquots and tubes were centrifuged for 15 seconds
at ≥8,000g. The ﬂow-through was discarded and the column washed with 700µl of buﬀer
RW1 by spinning for 15 seconds at ≥8,000g. 500µl of buﬀer RPE was then carefully
applied to the RNeasy spin column and the tube was then centrifuged for 2 minutes at
≥8,000g to wash the membrane. The spin column can be placed in a new 2 ml collection
tube for an optional extra spin at full speed for 1 minute to reduce the chance of carryover
of residual buﬀer.
The spin column, containing RNA bound to the silica-based membrane, was then placed
into a new 1.5 ml microfuge tube and RNA was then eluted with 2 x 30µl RNase-free
water, applied carefully to the membrane of the spin column. The samples were then
centrifuged for 1 minute at ≥8,000g. Using a second elution step increases the overall
RNA yield.
The quality and concentration of RNA samples was determined using the RNA 6000 Nano
chip (Agilent).
2.5.2 DNase Treatment of Total RNA
To remove any genomic DNA contamination from the RNA preparations, the samples were
treated either (i) subjected to on-column DNase treatment using QIagen DNase kit or (ii)
post-extraction, treated with RQ1 RNase-free DNase (Promega). RNA was normalised to
1µg/µl in a RNase-free 1.5µl microcentrifuge tube. The following reaction was then set
up and incubated at 37 ◦C for 1 hour:
Total RNA 15µl
DNase Buﬀer (transcription buﬀer) 10µl
RQ1 RNase free DNase 1µl
RNasin R  1 µl
RNase-free H20 23µl
Total reaction vol 50µl
Following the 1 hour incubation, 50µl RNase-free H20 was added to each tube. An equal
volume of citrate-buﬀered phenol:chloroform (100µl) was then added before the mixture
was vortexed for 10 seconds and centrifuged for 5 mins at 13,000 rpm. The upper, aqueous
phase from each tube was then transferred to a new 1.5µl microcentrifuge tube and 1µl
glycogen/tRNA (Promega) was added to each tube to act as a carrier during the RNA
93Chapter 2 2.5 Assaying Gene Expression
precipitation. To precipitate RNA, 1:5 vol 10M ammonium acetate (Sigma) and 2.5 vol
100% ethanol was added, and the mixtures were incubated on on dry ice for 30 mins.
Samples were then centrifuged for 15mins at 13,000rpm and the resulting supernatant was
carefully poured oﬀ. RNA pellets were then washed with 1ml 75-80% ethanol (made up
with RNase-free water). The pellets were centrifuged for 10 minutes at 13,000 rpm before
ethanol supernatant was decanted and RNA pellets allowed to air-dry at room tempera-
ture. 15µl RNase-free water was then added to each pellet and tubes were incubated at
55 ◦C for 10 minutes to redissolve the RNA.
2.5.3 Reverse Transcription of mRNA
Random hexamers (Promega) were used as primer for the synthesis of cDNA by a viral
reverse transcriptase enzyme. The ﬁrst step of the procedure is as follows: the following
reagents are added to a clean 1.5µl microcentrifuge tube, including DNase-treated RNA
prepared as described above:
DNase treated RNA (1µg/1µl) 2µl
Random hexamers 2µl
RNase-free water 10µl (to a ﬁnal volume of 14µl)
Samples were then incubated at 75 ◦C for 5 minutes and then cooled on ice for 5 minutes
in order to denature the random hexamers and allow annealing of these primers to RNA.
The following reagents were then added to the reaction:
M-MLV Reaction Buﬀer (Promega) 5µl
Nucleotide pool (Promega) 5µl
M-MLV RT enzyme (Promega) 1µl
The samples were incubated at room temperature for 10 minutes, followed by an incubation
at 50 ◦C for 50 minutes. The volume of the samples was then made up to 100µl with
RNase-free water. Reverse transcribed samples can be stored at −20 ◦C.
2.5.4 Real-Time PCR
TaqManTMpre-designed and pre-optimised probes (AB) were used to perform Real-Time
Polymerase Chain Reaction (RT-PCR) experiments. Real-Time PCR enables quantiﬁca-
tion of mRNA abundance by ampliﬁcation of cDNA. In any PCR, the amount of PCR
product theoretically doubles with every cycle - when DNA cycle number and the amount
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of DNA are plotted on a logarithmic scale the relationship between the two variables is lin-
ear. PCR ampliﬁcation of DNA is a logarithmic reaction. Since there are limited amounts
of reagents in the PCR mastermix, the reaction will eventually reach a plateau phase. The
point at which the exponential phase of the PCR reaction ceases and the reaction enters
the plateau phase will vary considerably, even within replicates. Therefore, in RT-PCR,
the PCR product is quantiﬁed during the logarithmic phase of the reaction.
The TaqManTMreaction uses a system of probes with a ﬂourescent dye incorporated onto
the 5’ base of the oligonucleotide, usually FAM or VIC. A quenching dye, TAMRA, is
incorporated onto the 3’ base of the probe, and during the course of the PCR reaction the
5’exonuclease activity of the polymerase will cleave the probe, separating the 5’ﬂourescent
dye from the 3’quenching dye. This emits ﬂuorescence, and the amount of ﬂourescence
emitted will be proportional to the amount of probe that has been cleaved within that
cycle of the PCR.
In these experiments a δδ-Ct method was employed to analyse RT-PCR data. Primers
and probes for ampliﬁcation of 18S rRNA were loaded into each reaction as an internal
control. The change in mRNA expression levels for each target gene is normalised so that
each value for the gene of interest is relative to the expression of an endogenous gene (18s
rRNA). This is achieved by calculating the diﬀerence between the cycle threshold (Ct)
value for 18S rRNA and the Ct value for the gene being tested. These delta-Ct values
(δCt) are averaged for each sample. The average δCt values for each test cell line is then
compared to the δCt of the control cell line.
The following pre-made primers and probes were used in this study: BRAF, Hs00269944-
m1; KRAS , Hs00270666-m1; C-MYC, Hs00153408-m1; 18S RNA internal control (Ap-
plied Biosystems).
The following real-time PCR mastermix was prepared:
Reagent Volume per sample (µl)
TaqManTMUniversal PCR Master Mix 12.50
18S rRNA pre-made primer/probe 1.25
Gene of interest pre-made primer/probe 1.25
Water 8.00
cDNA sample 2.00
Total 25.0
The appropriate volume of PCR mastermix was prepared for each gene to be analysed and
23µl aliquotted into the correct number of wells in a 96-well plate. 2µl of cDNA were then
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added to the plate in triplicate. The plate was then placed into an Applied Biosystems
7900HT Fast Real-Time PCR System and the samples were run on a program consisting
of the following thermal cycling conditions:
50 ◦C/2 minutes, 95 ◦C/10 minutes
40 cycles of 95 ◦C/15 seconds, 60 ◦C/1 minute
Data analysis was performed using SDS software (Applied Biosystems).
2.5.5 RFLP PCR
For detection of the KRAS restriction fragment length polymorphism, PCR was per-
formed using KRAS-F primer: 5’-GACTGAATATAAACTTGTGGTAGTTGGACCT-3’
and KRAS-R primer 5’-TCCTCTTGACCTGCTGTGTCG-3’, with the following PCR
conditions:
72 ◦C/2 minutes
50 cycles of 95 ◦C/30 seconds, 58 ◦C/30 seconds, 72 ◦C/30 seconds
72 ◦C/10 minutes
1µg puriﬁed PCR product was then digested with BstN1 overnight at 60 ◦C as previously
described [Sato et al., 2006]. Digested products were electrophoresed on a 3% agarose gel.
2.5.6 Western Blot Analysis
Cells were grown to 80% conﬂuence, washed twice in ice cold 1X PBS, then lysed with lysis
buﬀer: 1% NP40, 30mM Hepes pH7.4, 150mM NaCl, 1mM EDTA containing 17µg/mL
aprotinin; 1µg/ml pepstatin; 1µg/ml leupeptin, 100µg/ml AEBSF, and 1X phosphatase
inhibitor cocktails (all Sigma). Lysed cells were collected with a cell scraper (Greiner),
transferred to a sterile microfuge tube and incubated on ice for 20 mins. Cellular debris
was then cleared from the lysates by centrifugation at 14,000 rpm for 10 mins at 4 ◦C.
Proteins were quantiﬁed using a Bradford assay (Pierce). Proteins were then reduced and
denatured in Laemmli sample buﬀer by boiling for 5 min at 100C: 50mM Tris pH6.8, 10%
(v/v) glycerol, 2% SDS (w/v), 0.1% (w/v) bromophenol blue, 2% β-mercaptoethanol (all
Sigma).
1D SDS-polyacrylamide gels of an appropriate % were poured and 10µg protein loaded and
electrophoresed. Gels were electro-blotted onto polyvinylidene ﬂuoride (PVDF) membrane
(Millipore) using a wet transfer tank in transfer buﬀer :(195 mM glyine, 25 mM Tris, 20%
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(v/v) methanol). The membrane was soaked in methanol before placing onto the gel.
Membrane blocked for 1h with 5% (w/v) BSA in Tris buﬀered saline (50 mM Tris pH 8,
150 mM NaCl) with 0.05% Tween-20 (TBS-T). The membrane was then incubated for a
minimum of 1h in a primary antibody solution, diluted in TBS-T. Antibody solution was
removed and the membrane washed in TBS-T three times for 15 mins. The membrane
was then probed with the appropriate horseradish peroxidase (HRP)-coupled secondary
antibody for 1 hour before three ﬁnal TBS-T washes. Immunoprobed proteins were visu-
alised using enhanced chemiluminescence liquid (mixed 1:1) (Pierce) and the ﬁlm exposed
in dark room.
The following antibodies were used in these experiments:
anti-C-MYC, clone 9E10 1:500 dilution (CRUK)
anti-MAPK 1:5000 dilution (Promega)
anti-active-MAPK 1:5000 dilution (Promega)
2.6 Gene expression microarrays
Sample Preparation
RNA samples were prepared as described above. Again, great care was taken to avoid
contamination with RNases. The work area, all pipettes and racks were cleaned with
RNAZap (Ambion) prior to use for RNA work. Filter tips were used at all times and
only double-autoclaved milliQ water used. Cell lines were grown for 14 days in 3D on
polyHEMA coated plates (described above). Multi-cellular spheroids were harvested by
centrifugation and washed with sterile 1X PBS. RNA was isolated with the QIAgen RNA
extraction kit, as described above, but with an additional step during lysis, as spheroids
had to be processed as a solid tissue specimen. Washed spheroids were transferred to a ster-
ile 1.5ml eppendorf and 600µl RLT lysis buﬀer (containing 10µl/ml β-mercaptoethanol)
added. Using a sterile 22-gauge needle attached to a sterile 2ml syringe, spheroids were
mechanically disrupted by passing through the needle 20 times. Lysed samples were then
applied to the QIAshredder column and RNA extracted as described above. RNA sample
concentration and quality were assayed using the Agilent 2100 BioAnalyser (Agilent).
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Reverse Transcription, Labelling and Array Hybridisation
All reverse transcription and labelling experiments were performed by the UCL Genomics
Facility. Brieﬂy, RNA was ampliﬁed and labelled using the Ambion Illumina TotalPrep
RNA Ampliﬁcation kit (Ambion), according to manufacturer’s instructions. 500ng RNA
was reverse transcribed to cDNA, then biotinylated NTPs were incorporated during in
vitro transcription overnight to generate labelled cRNA. Hybridisation, staining and scan-
ning was carried out according to the Illumina Whole-Genome Gene Expression Direct
Hybridisation Protocol. 750ng of biotin-labelled cRNA was hybridised to the Illumina
Human HT-12 Expression Beadchip (Illumina). Chips were incubated at 58 ◦C for 16-20
hours. Following hybridisation, chips were washed and then stained with Streptavidin-Cy3
dye. Chips were scanned in the Illumina iScan scanner and data produced via the Illumina
GenomeStudio v1.0 software (both Illumina).
Data Analysis
Data were exported from the Illumina GenomeStudio software as ‘.txt’ ﬁles without prior
background subtraction or data normalisation. The R language and environment for sta-
tistical computing was used for all data analysis [R Development Core Team, 2009]. The
‘lumi’ package was used to perform data pre-processing, quality control and normalisation
steps [Du et al., 2008]. The ‘bgAdjust’,‘forcePositive’ background correction was used to
correct background signal. This algorithm forces all values to be positive, this is achieved
by adding an oﬀet value. The oﬀset value is calculated using the control probe data.
This method of background correction prepares the data for transformation. A variance-
stabalizing transformation step, was then performed to predict the conﬁdence intervals of
the data. This step is critical for calculating the signiﬁcance of diﬀerentially expressed
genes, in particular high fold-change in the low expression range. Data were normalised
using the robust spline method. Data pre-processing, quality control, normalisation and
analysis are also discussed in Chapters 1 & 4.
Normalised data were then analysed using the Linear Models of Microarray’ or ‘limma’
package [Smyth, 2004]. Limma enables the simultaneous analysis of many RNA targets
across arrays. To identify genes that were diﬀerentially expressed, data were ﬁrst ﬁltered
to select (i) only expressed genes and (ii) only genes which showed statistically signiﬁcant
diﬀerences in gene expression relative to the control cell line (IOSE) (P≤0.05). Bayesian
statistics in ‘limma’ were then used to ﬁt pre-processed expression data to a linear model,
using similar statistics to ANOVA or multiple regression, but with every gene being anal-
ysed simultaneously. The ‘decideTests’ function in limma was then be used to classify
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the value for each probe as signiﬁcantly diﬀerent from zero or not. This method adjusts
for multiple testing. ‘Top’ tables of diﬀerentially expressed genes were created from the
‘decideTests’ data matrix, and sorted by statistical signiﬁcance. To plot the expression
of individual genes, normalised but non-VST transformed expression data were exported
from ‘R’ and analysed in excel to create ‘bar-chart’ representations of gene expression
changes.
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Three-Dimensional Modelling of
the Ovarian Surface Epithelium
3.1 Introduction
Understanding the biological and molecular characteristics of the ovarian surface epithe-
lium (OSE) and the earliest stages of ovarian tumour development has been hampered
in the past by the lack of suitable in vitro models of normal OSE (NOSE). This is
partly because primary OSE cells have proved diﬃcult to establish in culture and have
a short lifespan in vitro. Since the ﬁrst description of OSE culture in 1984, optimisa-
tion of collection techniques and culture media has increased the in vitro lifespan of these
cells [Auersperg et al., 1984]; [Auersperg et al., 1994]; [Li et al., 2004a]. However, there
remain limitations to culturing NOSE cells as standard two-dimensional (2D) monolayers
and NOSE cells still lose some of their epithelial characteristics, even when cultured in
enriched media [Li et al., 2004a]; [Salamanca et al., 2004]. Cells demonstrate considerable
plasticity and will respond dramatically to their environment. A transcriptome that pro-
motes growth within an organism is unlikely to provide the cell with an optimal phenotype
for growth in 2D. Three-dimensional (3D) culture of other diﬃcult-to-culture cell types
has lead to dramatic improvements in in vitro lifespan and maintenance of in vivo phe-
notypic features (discussed in more detail in Chapter 1). Therefore, I hypothesised that
a 3D culturing system would represent a good in vitro model of the OSE, and that 3D
cultures of the OSE may be biologically more similar to the OSE in vivo than traditional
2D cultures.
There are many diﬀerent approaches that can be employed to grow cells in a 3D mod-
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els, the most widely used being gels consisting of extracellular matrix (ECM) proteins.
Commercially available gels typically consist of a single matrix protein, such as collagen,
laminin or ﬁbronectin; more complex gels consist of two to three diﬀerent matrix proteins,
although in these preparations the relative quantities of constituent proteins cannot be
easily altered. In 3D models of breast epithelial cells it is well documented that varying
the ECM substrate upon which cells are grown can dramatically alter the transformed
phenotype and cell-ECM interactions are integral for organogenesis to occur (reviewed in
[Fata et al., 2004]). In vivo, a complex admixture of ECM proteins makes up the structure
of the ovary; hence, growing NOSE cells within commercially available matrices would not
necessarily be a good representation of the tissue. In this study two 3D culturing tech-
niques were compared. In both systems the cells lay down matrix protein that forms and
stablises the 3D structure:
PolyHEMA-coating of tissue culture plastics Poly(2-hydroxyethyl methacrylate) is
a hydrogel. Hydrogels are hydrophilic compounds and when prepared by thermal
polymerization at 65 ◦C in 95% ethanol (at a concentration of 1.5%), polyHEMA
dissolves and expands within the 5% water content to generate a sterile solution
that can be used to coat tissue-culture plastics. Upon drying and evaporation, the
solidiﬁed hydrogel coats the entire surface of the vessel, and the modiﬁed surface is
an ultra-low/non-adherent surface, to which many cell types cannot attach. Thus,
cells grow in suspension and many cell types will spontaneously aggregate in such
conditions.
The Rotary Cell Culture System (RCCS) The RCCS was designed by NASA as an
improvement on traditional spinner ﬂasks. Spinner ﬂasks are bottle-shaped and
contain a magnetic paddle. Cultures are inoculated into the ﬂask, and the ﬂask is
placed upon a stirrer within the cell culture incubator (see Figure 3.1a). The culture
is stirred at 10-250 revolutions per minute (rpm) and constant movement of the
medium maintains cells in suspension. Although this technique has been proved to be
optimal for the culture of suspension cell lines (such as lymphoma cell lines) there are
limitations to the applicability of this technique to the generation of 3D multicellular
spheroids (MCS) of adherent cell lines. Primarily, the movement of the paddle
generates high shear forces that may destroy loosely-formed cellular aggregates or
easily disrupt the structure of mature spheroids. In the RCCS, (Figure 3.1b) the
vessel constantly spins, thus preventing cells from adhering to the vessel to promote
the formation of MCS [Navran, 2008]. Around 14 rpm is recommended for optimal
spheroid formation [Becker and Blanchard, 2007]. RCCS vessels were designed to
reduce minimal mechanical shear forces on the cells. All air bubbles are removed and
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gas exchange occurs by diﬀusion through a specialised liquid-impermeable membrane
on the back of the vessel.
(a) (b)
Figure 3.1: (a) In traditional spinner ﬂasks, a magnetic paddle (white arrow) spins when the
ﬂask is placed atop a magnetic stirrer. (b) The rotary cell culture system (RCCS). Individual
vessels (black arrow) are controlled by a powerpack. Revolutions per minute can be individually
controlled. Images from (a) www.sigmaaldrich.com and (b) www.synthecon.com.
The working hypothesis for this Chapter is:
• Normal ovarian surface epithelial cells established as 3D in vitro models would more
closely resemble OSE in vivo than the same cells cultured using traditional 2D
monolayer techniques
The following objectives were designed to test this hypothesis:
• To isolate ovarian surface epithelial cells from normal ovaries and characterise the
growth properties and marker expression of primary cultures
• To establish three-dimensional (3D) cultures of NOSE cells
• To characterise and compare the morphology, ultrastructure, ECM expression and
apoptotic rate of OSE cells in 2D culture and 3D culture and compare to OSE in
vivo
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3.2 Isolating and Characterising Primary Normal Ovarian
Surface Epithelial (NOSE) Cells
Primary normal ovarian surface epithelial (NOSE) cells were collected during gynaeco-
logical surgical procedures at University College Hospital. Patient information is listed
in Table 3.1. OSE cells were harvested by gently brushing the surface of the ovary with
a sterile cytobrush, as previously described [Li et al., 2004a]. Gross morphology of the
ovaries was conﬁrmed as normal in theatre, by the operating surgeon, and tissues were
examined subsequently for abnormal features by a Gynaecological Pathologist (Dr E. Ben-
jamin, UCL/UCH Department of Histopathology). Only ovaries that were conﬁrmed as
normal by gross morphology, initial Pathologists’ inspection and subsequent histopatho-
logical examination (where available) were used in this study.
Following collection, NOSE cells were immediately transferred into a 25cm2 ﬂask and in-
cubated undisturbed for 5-7 days before refeeding. Flasks were then examined by light
microscopy for the growth of epithelial colonies (Figure 3.2). NOSE cells were isolated
and maintained in growth factor rich NOSE-CM [Li et al., 2004a]. NOSE-CM is similar
200µm 200µm
200µm
(a) (b)
(d)
200µm
Passage 3
Passage 1 Passage 1
Passage 1 (c)
Figure 3.2: In vitro morphology of normal ovarian surface epithelial cells. (a) A passage 1 (p1)
clone at low magniﬁcation, cells have a cuboidal morphology. (b) Cells have a regular ‘cobblestone’
morphology, are closely opposed and tightly packed at the centre of the clone. (c) NOSE cells with
a more ﬁbroblastic morphology, and cells are scattered. (d) Following passaging, all NOSE cell
lines acquired a ﬁbroblastic morphology.
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N/A Enlarged uterus
Lost through bacterial contamination passage 1
46 NOSE6/NOSE7
N/A
Endometrial mullerian-type tumour (very large)
Cells not collected from other ovary as was not 
grossly normal
63 NOSE5
Lost through bacterial contamination
￿ Endometrioid endometrial carcinoma grade I 
plus cervical clear cell carcinoma
62 NOSE 3/ NOSE 4
￿
￿
￿
￿
x
x
￿
￿
￿
N/A
Suitable for 
this Study?†
Endometrial carcinoma Pa. no 169 NOSE 24/ NOSE 25
Endometrial carcinoma Pa. no 165 NOSE 22/ NOSE 23
Endometrial carcinoma Pa. no 154 NOSE 20/ NOSE 21
Severe endometriosis
(cells exhibit anchorage independent growth)
32 NOSE 16/ NOSE 17
Cervical carcinoma 39 NOSE 18R/ NOSE 19L
CIN Stage III with stromal microinvasion
(HepC+, patient has had radiotherapy)
44 NOSE 14R/ NOSE 15L
Clear cell endometrial carcinoma Pa. no N14 NOSE 13
Hyperplasia of endometrium and ovarian stroma
NOSE12 lost through bacterial contamination
48 NOSE 11/NOSE12
Endometrial adenocarcinoma stage III 61 NOSE 9/ NOSE 10
NK NOSE1/NOSE2
Pathology Patient 
Age/Number
Cell Line
Table 3.1: Primary NOSE cell line collection. Patient age/number and diagnosis. Cell lines
highlighted in red were taken forwards for subsequent experiments. †Samples were suitable for the
study if ovary was conﬁrmed as normal and free of tumour by pathological examination. CIN =
cervical intra-epithelial neoplasia. NK = not known.
to medium in its constituents to Mammary Epithelial Growth Medium (MEGM) in that
it contains hydrocortisone, insulin, epidermal growth factor and bovine pituitary extract
plus an additional 15% foetal bovine serum. MEGM has been demonstrated to dramati-
cally increase yield and eﬃciency of collection of human mammary epithelial cells whilst
maintaining a diﬀerentiated epithelial phenotype witn culturing (diﬀerentiated human
mammary epithelial cells are characteristically cytokeratin (Ck) 14 and Ck18 positive,
and Ck19 negative) [Hammond et al., 1984]. For the collection of NOSE cells described
here, of 24 brushings taken from 13 patients, 5 were lost through bacterial contamina-
tion; thus eﬃciency of the collection protocol was 79%. At the ﬁrst passage, a variety
of diﬀerent cell morphologies were observed, including cobblestone, cuboidal and ﬁbrob-
lastic morphologies (Figure 3.2). This is typical for NOSE cells, which characteristically
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demonstrate phenotypic plasticity in vivo and in vitro [Auersperg et al., 1984].
Growth curves were established for ﬁve of the primary cell lines collected (Figure 3.3(a)).
Cell cultures showed in vitro growth characteristics that were typical of NOSE cell cul-
tures from other studies [Li et al., 2004a]. The in vitro lifespan of NOSE cells was under
60 days and cultures became increasingly senescent with passaging (enlarged, ﬂattened
morphologies, observed under the phase microscope, see Figure 3.4). Senescence was also
induced when cells were split at too high a ratio (over > 1:5). This reinforced a need to
immortalise cells in order to facilitate further studies of NOSE cells. Immortalisation of
NOSE cells is described in Chapter 4.
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Figure 3.3: Characterisation of primary NOSE cell cultures. (a) Growth curves, lifespan of
primary cultures is limited to under 60 days. (b) Immunoﬂourescent cytochemistry: NOSE cells
are typically positive for epithelial markers (Ck7, AE1/AE3, BerEP4) and negative for markers of
ﬁbroblastic (FSP) and endothelial contaminants (Factor VIII). Cell lines highlighted in red were
taken forward for further studies. Positive cell lines used were EN-TRL71T (endometrial cancer
primary cell line), 1BR3.7(immortalised human skin ﬁbroblast cell line) and HUVEC (human
umbilical vein endothelial cell line), for staining images, see Chapter 4. nd = not done - no
additional information would be provided by these markers.
Using immunoﬂourescent cytochemistry, eight NOSE cultures were characterised for the
expression of epithelial markers or markers of contaminant cell types (Figure 3.3):
Anti-cytokeratin, clone: AE1/AE3 Identiﬁes two epitopes present on most epithelial
cytokeratin molecules.
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Anti-cytokeratin, clone: 7 This cytokeratin molecule is known to be expressed in var-
ious epithelial and mesothelial cells.
BerEP4 An epithelial marker, also known as EPCAM, this antibody recognises two cy-
toplasmic and cell surface glycoproteins present in nearly all epithelial cells with few
exceptions.
Anti-Fibroblast Surface Protein. Recognises an antigen present on the cell surface
membrane and in lysosomes of ﬁbroblasts, this marker was used to detect any ﬁ-
broblastic contamination from the stroma. Although this antigen has been shown
to be present on the surface of synovial, mammary, foreskin and thymic ﬁbroblasts,
its function is not yet known.
Anti-CA125 Cancer antigen 125 (CA125) is an antigen expressed highly in many ep-
ithelial ovarian cancers. This marker is used to test ovarian cells (and EOC patients
blood sera) for malignancy, although normal ovarian surface epithelium can also stain
positive for this marker. Diﬀerentiated M¨ ullerian epithelia also express CA125.
Factor VIII This antibody binds to a cytoplasmic glycoprotein (F8 antigen) present in
endothelial cells. This tests for any contamination of NOSE cultures by cells from
blood vessels.
Negative controls (i.e. no primary antibody plus a negative cell line) were included in
each experiment. Positive control cell lines were also used to assist in the interpretation
of the staining (for reference see Figure 4.10 in Chapter 4). This was particularly im-
portant for ﬁbroblast surface protein (FSP) since OSE cells typically show considerable
phenotypic plasticity and often demonstrate weak-to-moderate positivity for this marker.
One cell line demonstrated strong reactivity with FSP (NOSE10) and so was not se-
lected for further study. No cell line tested stained positive for Factor VIII, suggesting
that no cultures were contaminated by endothelial cells. Primary NOSE cell isolates all
stained positive for epithelial markers (cytokeratin 7 or AE1/AE3) and negative for an
ovarian cancer marker (E-Cadherin). Using immunoﬂourescent cytochemistry and also
immunohistochemistry (described in Chapters 4 & 5) NOSE cells and their derivative
cell lines repeatedly demonstrated more widespread staining with cytokeratin 7 than with
pan-cytokeratin (AE1/AE3) suggesting Ck7 is a better marker of OSE cells in vitro. Fi-
nally, as previously reported in the literature, early passage normal OSE cultures can
express CA125, which is also expressed by normal epithelia of the female reproductive
tract [Auersperg et al., 1997].
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3.3 Establishing Three-Dimensional NOSE Cell Cultures
From the panel of normal ovarian surface epithelial cell lines described above, three were
selected (NOSE4, NOSE11, NOSE19L3, see Table 3.1 and Figure 3.3) to establish as
three-dimensional (3D) models. Patient information and in vitro two-dimensional (2D)
and three-dimensional (3D) phenotype data are summarised in Table 3.2. Soft agar assays
were performed to verify that cell lines exhibited a non-tumourigenic phenotype. None of
the cell lines displayed any ability to grow in an anchorage-independent manner (2x105
cells/well). The in vitro growth characteristics of each cell line were analysed by establish-
ing long-term growth curve assays. NOSE11 cells had the shortest population doubling
time and the longest lifespan of the three primary cell isolates. This may be because
NOSE4 cells were derived from a post-menopausal woman and are therefore likely to have
a reduced lifespan in vitro (Figures 3.3 and Table 3.2). NOSE19L3 was a clone isolated
from a brushing, and thus originates from a smaller initial population, hence the reduced
lifespan observed for this culture. Due to contamination of initial brushings by blood cells
and other debris, it was not possible to start growth curve assays at passage 1, and so the
true in vitro lifespan of NOSE cells exceeds the values calculated here.
0 9.7 83.6 Pre 39 NOSE19L3
0 17.8 57.2 Peri 48 NOSE11
n=5
(63.90-125.60)
171.98
n=11
(80.92-252.40)
91.053
n=11
(32.70-152.00)
78.25
0 7.6 82.4 Post 62 NOSE4
Average MCS Diameter (µM) 
(range)3
CFE in Soft 
Agar2
Max. No. 
PDs
PD  Time1
(hrs)
Menopaus
al Status Age
3D multicellular spheroids Cells grown as 2D monolayers Patient Characteristics
Primary Cell 
line
Table 3.2: 1Population doubling (PD) times calculated from the exponential growth phase;
2Colony forming eﬃciency (CFE); 3Multicellular spheroids (MCSs) grown in 3D by polyHEMA
coating of tissue culture plastics, size measured under the scanning electron microscope.
NOSE4, NOSE11 and NOSE19L3 were then established as three-dimensional (3D) cul-
tures. The aim was to compare morphological and biological characteristics of the same
cells grown as 2D cultures, and with primary ovarian tissues. Two approaches were em-
ployed to generate 3D cultures: (1) polyHEMA coating of plastic tissue-culture dishes/ﬂasks
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and (2) the Rotary Cell Culture System (RCCS). The MCF7 breast cancer cell line was
plated on polyHEMA-coated plastics as a control [Ghosh et al., 2005]. All three NOSE
cells lines formed multicellular spheroids (MCSs) using both techniques. Cells were cul-
tured in 3D for 14 days. MCSs grown on polyHEMA-coated plates (PH-MCSs) were
typically 70-170µm in diameter (Table 3.2). NOSE19L3 cells formed signiﬁcantly larger
PH-MCS than NOSE4 or NOSE11 cells (P<0.0001 and P=0.025 respectively, two-tailed
unpaired T-test). MCSs formed in the RCCS (RCCS-MCS) grew to 1-2mm in diameter
and were limited to 1-2 in number per vessel. MCSs appeared solid and smooth under the
light microscope (Figure 3.4)
(a) (b)
100µm 100µm
Figure 3.4: (a) NOSE4 in 3D culture, typical spheroids formed by culture on polyHEMA coated
plastics. (b) The MCF7 breast carcinoma cell line, plated as a control, forms loose multicellular
aggregates when cultured on polyHEMA coated plates [Ghosh et al., 2005].
The internal architecture of MCSs was examined following paraﬃn embedding, sectioning
and staining with hematoxylin and eosin. For all three primary cell lines, PH-MCSs have
a deﬁned internal architecture: a central core of matrix protein, surrounded by aligned
elongated cells (Figure 3.5a & b). The cells form a ring around the matrix core, often as a
‘cap’ to one side, which resembles papillary structures sometimes observed on the surface
of normal ovaries in vivo (Figure 3.5e & f). The matrix core often contains degenerate
nuclear debris. When cells were grown in the RCCS, the resulting MCSs had a less
organised arrangement of cells. Cells within the centre of the RCCS spheroids tended to
be more rounded, with a 1-2 cell deep layer of cells around the edge of the MCS that had
an elongated morphology (Figure 3.5c & d).
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Figure 3.5: Hematoxylin and eosin stained sections of multicellular spheroids from 3D cultures.
(a, b) NOSE cells form multiple small 3D multicellular structures when cultured on polyHEMA
coated plates. The matrix cores of PH-MCS are clearly visible (black arrow); the cells form either
a ring around the matrix or a cap on one side (white arrow). (c, d) When cultured in the RCCS,
NOSE MCS were large and contained abundant ECM (M). Viable cells (arrow) surround the MCS,
many degrading nuclei were distributed throughout the centre of the spheroids. (e, f) PH-MCSs
show architectural resemblance to 3D structures observed on the surface of the ovary in vivo, where
surface papillary projections consist of epithelial cells around stromal cores with matrix protein
(black arrows).
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3.4 Biological Characterisation of 3D NOSE Cell Cultures
3.4.1 Ultrastructure of PH-MCS
The polyHEMA-MCSs appeared architecturally interesting, and so both transmission and
scanning electron microscopy (TEM and SEM) were used to study their ultrastructure
compared to the same cells grown in 2D. Desmosomes, which are characteristic of epithelial
cells, can be identiﬁed using TEM, and were present in all 2D and 3D cultures (Figure
3.6b).
Transmission electron microscopy revealed that in polyHEMA-MCSs, outer cells were often
up to 8 cell layers thick but sometimes were only 1-2 cells thick. Outer cells were elongated
and aligned. Peripheral cells were longer in shape compared to cells located towards the
core of the spheroid, where cells were rounder and less densely packed (Figure 3.6c).
Cells towards the centre of polyHEMA-MCS tended to have an extensive and dilated
rough endoplasmic reticulum, well developed Golgi apparatus and an open nucleolus.
Some central cells were observed to be secreting a discontinuous basement membrane and
matrix-like material in the extracellular space. This extracellular matrix material was
abundant in the core of the MCSs. Gap junctions and desmosomes connect neighbouring
cells and indicate complex intercellular signalling within spheroids (Figure 3.6b & c)
When examined by SEM, 2D monolayers also had very few surface features; the cells
were unremarkable, except that there were long surface projections extending between
cells, similar to those seen on PH-MCSs (Figure 3.7a). Cells on the outer surface of the
polyHEMA-MCS had ﬂattened morphologies and very few surface features. Although
microvilli were absent, there were often many surface projections connecting adjacent
cells in the PH-MCS (Figure 3.7b &c). The absence of microvilli may be due to loss of
polarisation as a result of culturing of the cells on glass. It may be possible to overcome
this by growing NOSE cells with oestrogen for example, or a synthetic basement membrane
in an attempt to maintain polarisation and microvilli formation [Saridogan et al., 1997];
[Bai et al., 2000]. Dead cells were observed both on the surface of the PH-MCS and in 2D
cultures. Early-stage cell death was identiﬁable by the holes in the membrane and later-
stage degraded cells were observed budding oﬀ the PH-MCSs and 2D cultures (Figure
3.7d).
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Figure 3.6: Transmission electron microscopy of NOSE cells in culture and from primary tissues.
(a) NOSE cells in 2D. Cells are unpolarised and have lipid-rich vacuoles (white arrows). Cell
nucleus is indicated (N). (b) In 3D cultures, desmosomes can be seen between adjacent cells (white
arrow). (c) In PH-MCSs, ﬂatter and closely opposed cells at the periphery form concentric rings
(e.g. cell B). Cells within the inner region of the PH-MCS have a more rounded morphology
and are less tightly packed (cell A). Cells towards the core of the MCS are full of electron dense
vesicles (white arrow, inset), which may illustrate a trend to a more secretary phenotype towards
the centre of the spheroids. Extracellular material (M) is abundant in the cores of PH-MCS. (d)
Within the PH-MCS, gap junctions connect the cytoplasm of neighbouring cells. (e) Section of
quiescent ovarian epithelium. Note the cuboidal shape of the cell, condensed chromatin within the
nuclei (N), basement membrane (black arrow), desmosomes (white arrow, inset) and age related
storage structures (lipofuscin, L). 111Chapter 3 3.4 Biological Characterisation of 3D NOSE Cell Cultures
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Figure 3.7: Scanning electron microscopy of NOSE cells in culture and from primary tissues. (a)
2D NOSE monolayers show few surface features, indeed cell boundaries are diﬃcult to distinguish
unless the cell is dividing (white arrow). (b) The surface morphology of PH-MCS. The ﬂattened
cells form a patchwork with no obvious orientation. Many surface projections between cells are
visible on the surface of the MCS (black arrows). (c) High power SEM image illustrates the
variation in the number of cellular projections often observed within a single spheroid, from few
(black arrow) to many (white arrow). Surface cells have an enlarged, ﬂattened morphology (also
observed by TEM). (d) A dead cell budding of a polyHEMA spheroid. Many holes puncture the
cell membrane, indicating late-stage apoptosis and degradation of the cell.
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NORMAL
2D PH-MCS RCCS-
MCS
2D PH-MCS RCCS-
MCS
2D PH-MCS RCCS-
MCS
OSE IN 
VIVO
AE1/AE3
Collagen IV 2
Fibronectin
1
Laminin
1
Vimentin 3 3
MARKER NOSE 4 NOSE 11 NOSE 19L3
Table 3.3: Tabulated intensities of immunostaining data. Diﬀerential expression of pan-
cytokeratin (AE1/AE3), laminin, vimentin and collagen IV, detected by immunohistochemistry
in 2D and 3D cultures and in primary normal ovarian tissues. Graded shading denotes extent of
staining. White denotes negative staining; crosshatched grey denotes weak or focal staining; light
grey represents that 20-50% cells stain positive and dark grey shading indicates over 50% cells
stain positive.1Secreted matrix material also shows positive staining for ﬁbronectin and laminin.
2Focal staining of collagen IV in NOSE11 PH-MCS. 3NOSE11 and NOSE19L3 show limited focal
staining for vimentin around mitoses in 2D.
3.4.2 Expression of Extracellular Matrix (ECM) Proteins in 2D and 3D
Cultures
Previous studies have shown that culturing cells in 3D may alter cell-cell interactions,
including the expression of extracellular matrix (ECM) proteins, receptors and corre-
sponding degradative enzymes. NOSE cells produce a variety of ECM molecules in
vitro [Kruk et al., 1994]. Therefore, immunohistochemical staining was performed to test
whether any ECM proteins were diﬀerentially expressed between 2D and 3D cultures (Fig-
ure 3.8 and Table 3.3). Fibronectin was expressed in 2D and 3D cultures in all three cell
lines. Vimentin staining was absent in 2D cultures, with the exception of weak focal vi-
mentin staining around some mitoses (2/3 cell lines). However, strong positive vimentin
staining characterised all 3D cultures and the OSE in vivo. Laminin and AE1/AE3 were
not expressed in 2D cultures, but strong expression of these markers was observed in PH-
MCSs, RCCS-MCSs and in the epithelium of normal ovarian tissues. Within spheroids,
ﬁbrous ﬁbronectin, laminin and vimentin ﬁlaments were observed between cells, suggesting
that these proteins play a role in maintaining the structure of MCSs.
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Figure 3.8: Expression analysis of pan-cytokeratin (AE1/AE3) and extracellular matrix proteins
by immunohistochemistry of NOSE cells from representative 2D and 3D cultures and in primary
NOSE from tissue sections of normal ovaries. Here, staining patterns demonstrate that primary
NOSE from normal ovarian tissues express a range of extracellular matrix proteins (e.g. vimentin,
ﬁbronectin, laminin). Staining proﬁles of 3D cultures more closely resemble that of primary OSE
than 2D cultures. Vimetin staining in 2D was absent, except some focal staining around mitoses
(in 2/3 cell lines). Scale bars represent 100µm. PH = polyHEMA, RCCS = rotary cell culture
system, MCS = multicellular spheroid
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3.4.3 Apoptosis in 2D and 3D cultures
The proportion of apoptotic cells in the cultures was analysed using staining with an anti-
annexin-V antibody and propidium iodide (PI), followed by ﬂow cytometry (Figure 3.9).
PI staining identiﬁes the necrotic component of cell cultures; anti-annexin-V recognises
externalised phosphatidylserine, which is an indicator of the early stages of apoptosis. In
RCCS-MCSs, the proportion of cells that stained positive for annexin-V was at least 2.5-
fold higher than the same cells grown in 2D cultures and PH-MCSs. For two cell lines, there
was no signiﬁcant diﬀerence in the proportion of apoptotic cells in PH-MCSs compared to
2D cultures. In NOSE19L3 there was more apoptosis in PH-MCSs (borderline signiﬁcance,
p= 0.047 using two-tailed paired T-test) compared to 2D cultures. This may be due to
accumulation of apoptotic cells at later passages. There were signiﬁcant diﬀerences in
the proportion of annexin-V positive cells in RCCS-MCSs compared to 2D cultures and
PH-MCSs for all three cell lines (NOSE4, p=0.0176; NOSE11, p=0.0164; and NOSE19L3,
p= 0.0152 using two-tailed paired t-tests). For one cell line (NOSE11) a signiﬁcantly
larger necrotic component was also identiﬁed by PI staining in RCCS-MCSs compared to
2D and PH-MCSs (p= 0.0242, two-tailed paired t-test). Thus, for NOSE11 there was a
statistically signiﬁcant increase in the proportion of cells at all stages of apoptosis in RCCS
cultures compared to cultures grown in 2D or on polyHEMA coated plates. Indeed, cells
at all stages of apoptosis were distributed throughout the RCCS-MCSs (e.g. karyoretic
nuclei, as indicated in Figure 3.9b). There was no observable pattern of apoptotic cell
distribution related to spheroid size, or depth of the cell within a spheroid.
Untransformed epithelial cells undergo anoikis (programmed cell death) upon detachment
from the basement membrane. Although there was a trend for more Annexin-V positive
staining in the PH-MCS, no statistically signiﬁcant increase in apoptosis was observed
when polyHEMA spheroids were compared to 2D cultures, which suggests that the NOSE
cells were not undergoing anoikis under these conditions. In both 3D systems, cells were
plated at high densities and spheroids began to form within 24 hours. It thus appears
that the process of aggregation was rapid enough to preventing anoikis.
3.5 Discussion
The aim of this Chapter was to establish and characterise a panel of normal ovarian surface
epithelial (NOSE) cell lines and then to evaluate 3D methodologies for growing NOSE cells
in vitro and compare with the phenotypes of the same cells grown in 2D.
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Figure 3.9: Apoptosis in 2D and 3D cultures. (a) Levels of apoptosis (as measured by annexin-
V expression) are signiﬁcantly higher in 3D cultures from the RCCS-MCS, compared to similar
proportions of apoptotic cells detected in 2D and PH-MCS cultures. Error bars = standard error
of the mean (S.E.M.) (b) Apoptotic cells (arrow) are distributed throughout the RCCS-MCS,
identiﬁable by degrading nuclei.
The primary NOSE cell lines used in this study demonstrated typical staining and growth
characteristics in vitro, as previously shown by other studies [Auersperg et al., 1984];
[Li et al., 2004a]. The in vitro lifespan of NOSE cultures maintained in a growth fac-
tor rich medium was less than 60 days. NOSE cells demonstrate phenotypic plasticity
and can co-express epithelial and ﬁbroblastic markers in vitro and in vivo. In highly
mitogenic medium (NOSE-CM) NOSE cells have a ﬁbroblastic morphology, which is pro-
moted by the inclusion of hydrocortisone (HC) and epidermal growth factor (EGF) in the
medium [Salamanca et al., 2004]; [Ahmed et al., 2007]. However, without HC and EGF,
the growth potential of primary OSE cultures is reduced signiﬁcantly, by around 2/3rds
[Salamanca et al., 2004]. Thus all NOSE cultures and their derivatives were maintained
in NOSE-CM for the experiments described in this thesis. Highly mitogenic NOSE-CM
culture medium, however, is not optimal for reproducing the phenotype of a typically
quiescent ovarian epithelial cell and may more closely reﬂect the phenotype of NOSE cells
during wound repair, at the site of ovulation. In addition, NOSE-CM may contribute to
tumourigenesis through incessant stimulation of pathways involved in growth and prolif-
eration (including the MAPK pathway, discussed in Chapter 4).
The OSE is typically described as a monolayer of cells, but it nonetheless has a three-
dimensional (3D) geometry that cannot be replicated by culturing primary NOSE cells in
two-dimensional (2D) cultures on an adherent plastic surface. Thus, 3D cultures of NOSE
cells were established to investigate whether 3D in vitro models were a closer representation
of OSE in vivo than traditional 2D techniques. In these experiments, NOSE cells formed
three-dimensional structures (multicellular spheroids; MCSs) when cells were prevented
116Chapter 3 3.5 Discussion
from adhering to tissue culture surfaces either by chemical treatment of tissue culture
vessels or by maintaining cells in constant rotation. In the rotary cell culture system
(RCCS), NOSE cell clusters were larger and had a chaotic internal structure compared to
cells grown on polyHEMA-coated plastics. NOSE cells grown in polyHEMA coated vessels
formed concentric layers around a core of matrix protein. These data demonstrate that in a
static microenvironment NOSE cells can spontaneously form organised three-dimensional
multicellular structures.
Within each spheroid there exists a number of diﬀerent microenvironments, and diﬀerent
selective pressures inﬂuence cellular phenotype depending on the part of the spheroid
in which a cell is located. Other reports describing 3D cell aggregates of other cells
types have observed two distinct regions within homotypic MCS - an inner area of cells
that are smaller and less proliferative than surrounding cells on the periphery of MCS
[Sutherland et al., 1986]; [Ghosh et al., 2005]. In one study, Freyer and Sutherland found
that cells on the surface of MCSs formed from mouse mammary tumour cells were similar
in size to an exponentially growing 2D cell culture, but with 60% fewer cells in S-phase
[Freyer and Sutherland, 1980]. My observations of the structure of RCCS-MCSs (by light
microscopy) and polyHEMA-MCSs (by light and transmission electron microscopy) are
consistent with these ﬁndings; instead of a continual reduction in cell size from the outer
to inner core of spheroids, there was a clear distinction in morphology observed between
cells on the outer layers compared to cells within the spheroids. Cells within the MCS
also had rounder morphologies compared to the elongated cells at the periphery.
Measurements of apoptosis in 2D and 3D cultures suggested that a greater proportion of
cells grown in the RCCS are apoptotic compared to 2D and polyHEMA 3D cultures. This
was conﬁrmed by the observation of many apoptotic nuclei distributed throughout the
RCCS-MCS (in H & E stained sections of paraﬃn embedded samples). The explanation
for this is unclear; but it could be that the continual motion of spinning the cells in
the RCCS causes mechanical damage to cells, which in turn induces apoptosis. Thus,
the increased apoptosis levels observed in RCCS-MCSs may be an experimental artefact.
Apoptosis is low in the ovarian epithelium in vivo since these cells are usually quiescent.
Unlike cancer cell spheroids, a central core of extensive apoptosis and necrosis was not
observed in NOSE spheroids. Conditions at the centre of the RCCS-MCS are unlikely to
be hypoxic (which would induce cell death) in comparison to the in vivo microenvironment
- the oxygen concentration in the pelvis is 5.5% (measured at the cervix) but cells were
cultured in 20% oxygen in this present study [Juul et al., 2007]. Furthermore, cell death
induced by hypoxia would result in a distinct distribution of apoptotic cells throughout
the spheroids: cell death would be lowest near the surface and gradually increase towards
the core. In largest spheroids, one would expect that chronic hypoxic conditions would
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results in a necrotic central region. However, apoptotic cells were distributed throughout
the spheroid, independently of spheroid size or cell depth within the spheroid, suggesting
that in this system cell death was not induced by hypoxia. This suggests that the increased
rates of apoptosis observed in RCCS-MCS are a consequence of mechanical damage. In this
laboratory, it has been observed that prolonged culture in the RCCS results in spheroids
that consist mainly of degenerated cells (observation, KL and B. Grun).
Examination under the transmission electron microscope enabled analysis of cellular and
spheroid ultrastructure. PolyHEMA-MCS cells contained swollen endoplasmic reticulum
and Golgi bodies and had an open nucleolus, which is indicative of active protein synthesis
and transcription. Cells within central regions of polyHEMA-MCS were actively producing
and appeared to be secreting a basement membrane-like matrix which was abundant in the
core of MCSs. Extracellular matrix (ECM) molecules play a vital role in tissue architecture
and are reporte to be essential for the formation of hepatoma spheroids [Lin et al., 2006].
Both RCCS- and PH-MCSs contained an abundance of the extracellular matrix (ECM)
proteins laminin, ﬁbronectin and vimentin, but did not express collagen IV. 2D cultures
showed widespread expression of ﬁbronectin and collagen IV but not laminin, and vimentin
was only expressed focally at mitoses (2/3 cultures). Increased expression of vimentin and
a concurrent decrease in expression of collagen IV in 3D could indicate an epithelial-
to-mesenchymal transition. However, upregulation of pan-cytokeratin indicates a more
epithelial phenotype. These patterns of protein expression reﬂect the phenotypic plasticity
that is characteristic of NOSE cells: in both 2D and 3D cells show both epithelial and
mesenchymal features.
The importance of the extracellular matrix cannot be understated, since dysregulation of
cell-ECM interactions have been demonstrated to have a role in many critical processes in
tumourigenesis beyond invasion and metastasis, including chemotherapeutic resistance and
development of minimal residual disease [Damiano et al., 1999]; [Matsunaga et al., 2003];
[Sherman-Baust et al., 2003]. Remodelling of the basement membrane and stromal ECM
proteins occur during during follicular maturation (in non-neoplastic ovaries) and the
development of ovarian carcinomas [Capo-Chichi et al., 2002]; [Lind et al., 2006]. Down-
stream pathways of cancer cell interactions with the extracellular matrix may represent
important therapeutic targets [Ahmed et al., 2007]. In NOSE spheroids, the complex
ECM observed was synthesised autonomously by the NOSE cells, since no synthetic ma-
trix proteins were introduced in the cultures. This is a signiﬁcant advantage of both
the RCCS and polyHEMA methods described here, since the heterogeneous ECM closely
resembles the ECM of the organ.
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Microenvironment - phenotype over genotype?
When suspended in laminin rich ECM gels, human mammary epithelial cells (HMECs)
form organotypic acini structures and express milk proteins [Weir et al., 2006]. In con-
trast, breast carcinoma cell lines form disorganised aggregates in ECM gels, displaying
a loss of tissue diﬀerentiation [Weaver et al., 1995]. However, acini structure can be re-
established in vitro, and thus the malignant phenotype reversed, by altering carcinoma cell
interactions with the extracellular matrix [Weaver et al., 1997]. This demonstrates that
the microenvironment can dominate over cellular genotype to control a neoplastic pheno-
type, which has important implications for studying cell transformation. These models
also oﬀer a new approach for the development of therapeutic drugs which reverse the
malignant phenotype as an alternative to inducing cancer cell death.
As with HMECs, 3D models of ovarian epithelial cells are likely to increase our understand-
ing of the biology of normal and malignant cells in vivo. For example, the mechanisms of
wound repair following follicular rupture remain poorly understood, yet could have impli-
cations for understanding the biology of EOC. Ovarian inclusion cysts develop from crypts
formed following ovulation and appear to be the site of initiation of a large proportion
of EOCs. It is known that remodelling of the ECM (and changes in the relative propor-
tions of constituent proteins) preceeds ovulatory rupture [Lind et al., 2006]. By adding
synthetic ECM proteins to the 3D spheroids, such changes could be replicated in vitro
and the NOSE cell phenotype monitored. Additionally, wound healing requires an EMT
and extensive proliferation of NOSE cells. Understanding the molecular mechanisms and
microenvironmental signalling that governs these processes in normal tissues is likely to
provide valuable insight into tumour development and EOC cell behaviour.
Implications for the Study of Epithelial Ovarian Cancer
Collection of primary normal ovarian surface epithelial cells is challenging and the number
of cells that can be isolated from each ovary is small, as the OSE is a monolayer and the
ovary is a small organ (1-2cm diameter). Normal OSE samples serve as necessary controls
for many diﬀerent studies, such as gene expression microarray proﬁling of normal and
cancer tissues or biomarker validation by analysing mRNA or protein. Gene expression
microarray studies have often used pooled ovarian brushings or pieces of whole ovary (the
majority of which is stroma) as normal controls. The control used for comparisons of
gene expression proﬁles of normal versus EOC cells will signiﬁcantly aﬀect the outcome
of the analyses. Zorn and colleagues found limited overlap between the lists of diﬀeren-
tially expressed genes when EOC gene expression proﬁles were compared to the proﬁles
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of whole ovarian biopsies, OSE brushings, short-term OSE cultures, SV40-immortalised
OSE or telomerase-immortalised OSE [Zorn et al., 2003]. 3D models of NOSE cells could
be used as an alternative normal control for studies that require relatively large amounts
of material e.g. analysis of the transcriptome and proteome. Another approach would be
to use cores taken from formalin-ﬁxed paraﬃn embedded (FFPE) 3D cultures in tissue-
microarrays (TMAs) for analysis of biomarker expression by immunohistochemistry. Many
commercially available FFPE normal ovaries and TMAs contain little or no epithelium,
as it constitutes such a small portion of the organ and is loosely attached and therefore
easily lost during processing.
The origin of EOCs has yet to be fully understood, and current in vitro, in vivo and
histological evidence support multiple origins for ovarian tumours of diﬀerent histotypes.
However, what is not yet understood is whether EOCs in humans arise from a normal ovar-
ian stem cell precursor. Wound repair of ovulatory sites in the murine ovary are repaired
by a small population of slowly cycling progenitor ‘stem-like’ cells. To repair the site of
follicular rupture, this population of cells undergoes rapid cell division to repopulate the le-
sion on the surface of the ovary [Szotek et al., 2008]. Whether ovulatory sites are repaired
by stem-like progenitor cells in humans has yet to be elucidated. For EOCs there are data
to suggest that populations of stem-like cells exist within tumours [Alvero et al., 2009];
[Curley et al., 2009]. However, markers of normal or malignant ovarian stem cells have
yet to be conﬁrmed. 3D models represent an organoid model for studying EOC origins
and a role for stem cells in tumour initiation, development and metastases.
Conclusions
The next stages of my study, described in Chapters 4 & 5, require the use of an appropriate
3D modelling approach. Having tested the RCCS and polyHEMA methods for culturing
NOSE cells in 3D, it was concluded that the RCCS would not be an appropriate model
for the next stages of the study, as (1) elevated levels of apoptosis were observed in cells
cultured in the RCCS, (2) only a small number of replicate experiments (n=5) can be
performed simultaneously and (3) RCCS vessels are costly. The polyHEMA models tested
and presented here were considered to represent a ﬂexible tool for examining many diﬀerent
aspects of EOCs. In our laboratory, polyHEMA models are now being used to study
NOSE cell transformation (Chapter 4), the biology of normal fallopian tube epithelial
cells, stromal-epithelial interactions in cancer, chemoresistance and stem cell biology. The
polyHEMA models were also subsequently employed in a functional study of a candidate
ovarian cancer tumour suppressor gene [Dafou et al., manuscript in preparation].
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Finally, it was concluded that the 3D NOSE models could provide the basis for establish-
ing more complex three-dimensional cultures. Heterotypic 3D models comprising ovarian
stromal ﬁbroblasts as well as epithelial cells may assist in developing an understanding of
the role of stromal-epithelial interactions during epithelial tumourigenesis, this is explored
in Chapter 5. Two major advantages of the polyHEMA approach to 3D spheroid formation
are the low cost and the ﬂexibilty of the technique - any tissue culture plastic can be used.
An additional advantage of the polyHEMA (and also RCCS) over the popular gel-based
3D culturing methodologies is that the cells create the extracellular matrix autonomously,
and the data presented here show that the ECM of the spheroids reﬂects the ECM of the
ovary in vivo. Therefore, the polyHEMA technique was chosen for the further 3D mod-
elling work described in the following chapters. it is hoped that this three-dimensional in
vitro tool can provide a more biologically relevant model not only for modelling disease,
as described in this thesis, but also for high-throughput screening of candidate biomarkers
of disease, or for testing novel therapeutics. 3D models are likely to be more accurate at
predicting eﬃciencies of novel therapeutic compounds than 2D systems, which often fail
to translate in an in vivo or clinical setting [Friedrich et al., 2007].
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In Vitro Transformation of the
Ovarian Surface Epithelium
4.1 Introduction
The scarcity of tissues derived from early-stage epithelial ovarian cancers (EOC) means
that little is known about the cellular molecular and phenotypic changes that occur early
in the development of EOCs. In addition, progress in understanding the molecular features
of early ovarian carcinogenesis has also been hindered by a shortage of good in vitro models
of ovarian cancer. Previously established models introduced viral oncogenes into ovarian
surface epithelial (OSE) cells to induce neoplastic transformation. The resulting cells
formed tumours in mice that express cytokeratins and resemble epithelial ovarian tumours
[Li et al., 2004b]; [Kusakari et al., 2003]. Recently, the ﬁrst description of transformation
of the OSE with deﬁned genetic elements was reported [Sasaki et al., 2009].
Mutations in a handful of genes, including BRCA1/2, KRAS, BRAF, PTEN, PIK3CA and
β-catenin occur in a subtype-speciﬁc manner in EOCs. Diﬀerent subtypes of EOC diﬀer
in their histological features, biomarker expression, and prognoses. However, there are few
descriptions of correlations between genetic mutation and in vitro phenotype of OSE cells.
All in vitro studies to date have been performed using traditional 2D monolayer cultures.
Additionally, molecular proﬁles associated with KRAS/BRAF mutation in the OSE have
not been described in in vitro or in in vivo studies. This project aimed to investigate the
role of speciﬁc genetic alterations in an in vitro model of early EOC development with the
following hypothesis:
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• In vitro neoplastic transformation of normal ovarian surface epithelial cells can be
achieved through the introduction of deﬁned oncogenic elements
The aims of this Chapter were to address the following questions:
1. Can stepwise transformation of NOSE cells be achieved by the introduction of
hTERT, C-MYC, plus KRASG12V or BRAFV 600E?
2. Are phenotypic diﬀerences detected in vitro that are induced by the diﬀerent onco-
genes?
3. Does 3-dimensional modelling reveal features of neoplastic transformation visible in
tumour specimens but not detectable in traditional 2D cultures?
4. Do the gene expression proﬁles of 3D cultures at each stage of the transformation
model reveal novel genes that are altered in synergy with the genes introduced,
which may be candidate markers of early disease? Is there molecular heterogeneity
associated with transformation mediated by the diﬀerent oncogenes?
We hypothesised that features of transformation can be induced in normal ovarian sur-
face epithelial cells by sequentially introducing alleles commonly found to be mutated or
overexpressed in EOC specimens. Cellular phenotype can be monitored with a series of
in vitro assays to measure the transformed phenotype. In vitro and in vivo, changes in
the cellular phenotype observed as a cell becomes increasingly transformed may include:
increased proliferation and anchorage-dependent growth; acquired anchorage-independent
growth; up-regulation of pro-angiogenic factors; increased invasiveness; enhanced migra-
tive ability; reduced apoptosis and increased dependence from growth factors. Changes in
cellular metabolism may also occur. These changes can be monitored in vitro and a panel
of assays can be selected according to the question being addressed.
4.2 Immortalisation of Primary NOSE Cells
One of the major origins of EOCs is the ovarian surface epithelium, a monolayer of
epithelial-mesothelial cells covering the surface of the ovary [Auersperg et al., 1984]. Iso-
lation and characterisation of primary normal ovarian surface epithelial (NOSE) cells is
described in detail in Chapter 3. Primary normal ovarian surface epithelial (NOSE) cells
have an average in vitro lifespan of only 10-15 population doublings. In 1965 Hayﬂick
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ﬁrst described what was coined the ‘Hayﬂick Limit’, which describes how explanted nor-
mal somatic cells have a limited lifespan in vitro before cells will undergo irreversible
replicative senescence [Hayﬂick, 1965]. It was, therefore, necessary to extend the in vitro
lifespan of NOSE cultures to enable the cells to bypass replicative senescence and thus
facilitate the introduction of further genetic alterations. This was achieved by ectopically
overexpressing the catalytic subunit of the human telomerase holoenzyme, hTERT.
Immortalisation of NOSE cells with hTERT has been previously described [Li et al., 2004a].
A cDNA encoding hTERT was delivered into cells by retroviral transduction. In these
experiments, a retroviral system based on the Moloney Murine Leukemia Virus (MMLV)
was employed. Retroviral supernatants harvested at 48-hours post-transfection of 293T
cells and used to infect NOSE4, NOSE11 and NOSE19 cell lines. Optimisation of retrovi-
ral production and transduction protocols are described in Chapter 2. Transduced clones
were selected using 10-30U/ml hygromycin, and clones were isolated by ring cloning 3-4
weeks post-infection. hTERT-clones were denoted ‘immortalised ovarian surface epithe-
lial’ (IOSE) cells (e.g. IOSE4.1, to describe a clones from hTERT infection of NOSE4
cells, clone number 1).
In the ﬁrst instance, a minimum of 2 clones per NOSE parental cell line were maintained
in culture for up to 10 passages to ensure that the cells bypassed replicative senescence.
The length of in vitro lifespan of NOSE and IOSE cell lines was measured. Growth char-
acteristics of 2-3 clones per primary culture were analysed to assay growth characteristics
over a period of 80 days. Not all clones that were analysed displayed extension of in
vitro lifespan, suggesting that some clones were expressing levels of telomerase that were
insuﬃcient to maintain telomere length and bypass senescence (Figure 4.1).
IOSE4.1, IOSE11.1 and IOSE19.1 were maintained in culture as long-term growth curve
experiments beyond day 80. From this point, that these cell lines are denoted IOSE4,
IOSE11, IOSE19. Lifespan of NOSE cell lines was around 50 days, whereas the intro-
duction of hTERT increased the lifespan of these 3 cell lines to over 200 days (Figure
4.2a). At this point the cell lines were considered to be “immortalised” and the growth
experiments were discontinued. IOSE cells displayed a ﬁbroblastic epithelial morphology
when visualised by phase-contrast microscopy (Figure 4.2b). There were no changes in
gross morphologies of cell cultures following immortalisation.
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Figure 4.1: Immortalised ovarian surface epithelial (IOSE) cell lines: growth curves to assay in
vitro lifespan. IOSE clones taken forwards for further experiments are indicated in green. NOSE
cell lines are shown in red and other IOSE cell lines in blue. IOSE4.2 and IOSE19.2 did not bypass
replicative senescence and grew slowly in culture. Error bars show standard deviation.
4.2.1 Fluorescent Immunocytochemistry
Primary NOSE and IOSE cells were examined for the expression of epithelial (cytokeratin-
7, Ck7; pan-cytokeratin, AE1/AE3), mesothelial (calretinin), ﬁbroblastic (ﬁbroblast sur-
face protein, FSP) and ovarian cancer markers (cancer antigen 125, CA125; E-Cadherin)
(Figures 4.3, 4.4, 4.5, 4.6, 4.7 & 4.8 and summarised in Table 4.9). Positive control cell
lines were included in each staining experiment; representative images of positive staining
for each antigen can be found in Figure 4.10. NOSE and IOSE lines demonstrated very
similar staining proﬁles when examined by ﬂourescent immunocytochemistry. All NOSE
and IOSE cultures stained positive for Ck7, and, to a lesser extent, AE1/AE3. Keratins
are structural proteins in epithelial cells, and the staining detected in NOSE and IOSE cul-
tures was correctly localised to the cytoplasm. Cytokeratin-7 was a more reliable marker
than AE1/AE3 of the epithelial status of normal ovarian surface epithelial cells - 40-70%
of cells stained positive for the Ck7 antigen. Some cross-reactivity was observed when
cultures were stained for FSP, but FSP expression was absent or low when compared to a
positive control cell line (a normal ovarian ﬁbroblast cell line, INOF2 or a skin ﬁbroblast
cell line, 1BR3). Furthermore, extensive testing of this antibody within this laboratory has
demonstrated that this antibody frequently cross-reacts with non-ﬁbroblast cells. Weak
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Figure 4.2: Immortalised ovarian surface epithelial (IOSE) cell lines: long-term growth curves
and cell morphologies of 3 IOSE cell lines to be used in further experiments. (a) Lifespan of
ovarian epithelial cultures cultures is extended to over 200 days following the introduction of
the catalytically active subunit of human telomerase (hTERT). The lifespan of NOSE cultures
is limited to under 60 days. (b) IOSE cell lines have an epithelial-ﬁbroblastic morphology when
visualised by phase-contrast microscopy.
staining of calretinin was observed in the majority of clones tested, suggesting NOSE and
IOSE cells maintain some mesothelial characteristics in vitro. E-cadherin, often expressed
in EOC specimens but absent in normal OSE cells in vivo, was not expressed in any of
the NOSE or IOSE cultures tested. Staining proﬁles of NOSE and IOSE were consistent,
suggesting that no gross changes in cell diﬀerentiation or neoplastic transformation were
induced by immortalisation with hTERT (Table 4.9).
In some cell types, including human prostate epithelial cells and keratinocytes, inactivation
of the p16INK4a is a pre-requisite for immortalisation; and so p16 expression was examined
by ﬂuorescent immunostaining. p16 expression was detected in nuclear and cytoplasmic
regions of IOSE cells, suggesting that loss of this cell-cycle checkpoint was not required for
immortalisation (Figures 4.3, 4.4, 4.5, 4.6, 4.7 & 4.8). This is similar to the observed
p16 status after immortalisation of human mammary epithelial cells, embryonic lung
ﬁbroblasts and ovarian surface epithelial cells from other studies [Herbert et al., 2002];
[Darbro et al., 2006]; [Milyavsky et al., 2003]; [Li et al., 2007]; [Shao et al., 2008].
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Figure 4.3: Fluorescent immunocytochemistry (NOSE4 part 1): staining proﬁles of NOSE4 and
IOSE4 show that immortalisation does not induce changes in marker expression. Both cell lines
stain positive for cytokeratin 7. Weaker positivity/absent staining with the BerEP4 antibody was
detected; staining for pan-cytokeratin (AE1/AE3) epithelial marker was absent. No staining for
FSP was observed. All images are 200X magniﬁcation and exposure times were consistent for each
antigen. In the top panel for each cell line, Evans blue (red colour) staining of cellular cytoplasm
is shown, green ﬂuorescence indicates antigen positivity, nuclei are stained blue with DAPI. In the
lower panel for each cell line, only the antigen of interest and nuclei are shown.
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Figure 4.4: Fluorescent immunocytochemistry: staining proﬁles of NOSE4 & IOSE4, part 2. No
expression of cancer-antigen 125 (CA125) or E-cadherin was detected. Discrete cells stain positive
for mesothelial marker calretinin (arrow). Nuclear and cytoplasmic staining for p16 was detected
in NOSE4 and IOSE4 cells. All images are 200X magniﬁcation and exposure times were consistent
for each antigen. In the top panel for each cell line, Evans blue (red colour) staining of cellular
cytoplasm is shown, green ﬂuorescence indicates antigen positivity, nuclei are stained blue with
DAPI. In the lower panel for each cell line, only the antigen of interest and nuclei are shown.
128Chapter 4 4.2 Immortalisation of Primary NOSE Cells
N
O
S
E
1
1
Ck7 BerEP4 AE1/AE3 FSP
*Ck7 *BerEP4 *AE1/AE3 *FSP
I
O
S
E
1
1
Ck7 BerEP4 AE1/AE3 FSP
*Ck7 *BerEP4 *AE1/AE3 *FSP
Figure 4.5: Fluorescent immunocytochemistry (NOSE11 part 1): staining proﬁles of NOSE11
and IOSE11 show that immortalisation does not induce changes in marker expression. Both cell
lines stain positive for cytokeratin 7. Note that mitotic cells express higher levels of cytokeratin
(white arrow). Weak positivity for BerEP4 was detected in NOSE11. Staining for pan-cytokeratin
(AE1/AE3) epithelial marker was absent. No expression of ﬁbroblast surface protein (FSP) was
detected. All images are 200X magniﬁcation and exposure times were consistent for each antigen.
In the top panel for each cell line, Evans blue (red colour) staining of cellular cytoplasm is shown,
green ﬂuorescence indicates antigen positivity, nuclei are stained blue with DAPI. In the lower
panel for each cell line, only the antigen of interest and nuclei are shown.
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Figure 4.6: Fluorescent immunocytochemistry (NOSE11 part 2): staining proﬁles of NOSE11 and
IOSE11 show that immortalisation does not induce changes in marker expression. No expression
of cancer-antigen 125 (CA125), E-cadherin was detected. Nuclear and cytoplasmic staining for
p16 was detected in NOSE11 and IOSE11 cells. All images are 200X magniﬁcation and exposure
times were consistent for each antigen. In the top panel for each cell line, Evans blue (red colour)
staining of cellular cytoplasm is shown, green ﬂuorescence indicates antigen positivity, nuclei are
stained blue with DAPI. In the lower panel for each cell line, only the antigen of interest and nuclei
are shown.
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Figure 4.7: Fluorescent immunocytochemistry (NOSE19 part 1): staining proﬁles of NOSE19 and
IOSE19 show that immortalisation does not induce changes in marker expression. Both cell lines
stain positive for cytokeratin 7. Weak positivity for the BerEP4 and pan-cytokeratin (AE1/AE3)
epithelial markers was also detected. Weak expression of ﬁbroblast surface protein (FSP) was
detected in NOSE and IOSE cultures. All images are 200X magniﬁcation and exposure times were
consistent for each antigen. In the top panel for each cell line, Evans blue (red colour) staining of
cellular cytoplasm is shown, green ﬂuorescence indicates antigen positivity, nuclei are stained blue
with DAPI. In the lower panel for each cell line, only the antigen of interest and nuclei are shown.
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Figure 4.8: Fluorescent immunocytochemistry (NOSE19 part 2): staining proﬁles of NOSE19 and
IOSE19 show that immortalisation does not induce changes in marker expression. No expression
of cancer-antigen 125 (CA125) or E-cadherin was detected. Weak expression of calretinin (a
mesothelial marker) was detected in NOSE and IOSE cultures. Nuclear and cytoplasmic staining
for p16 was detected in NOSE19 and IOSE19 cells. All images are 200X magniﬁcation and exposure
times were consistent for each antigen. In the top panel for each cell line, Evans blue (red colour)
staining of cellular cytoplasm is shown, green ﬂuorescence indicates antigen positivity, nuclei are
stained blue with DAPI. In the lower panel for each cell line, only the antigen of interest and nuclei
are shown.
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Figure 4.9: Fluorescent immunocytochemistry summary - NOSE and IOSE clones derived from
patients 4, 11 and 19 (Chapter 3). Cell lines that were taken forwards for further experiments
are indicated in red. Cell lines were stained by ﬂuorescent immunocytochemistry for epithelial,
ﬁbroblastic and ovarian cancer markers. Staining proﬁles of NOSE and IOSE are consistent for each
patient, suggesting that immortalisation does not signiﬁcantly aﬀect cellular diﬀerentiation, nor
does immortalisation induce neoplastic transformation or promote an epithelial-to-mesenchymal
transition. n.d. = not done. lp = late passage
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Ck7 BerEP4 AE1/AE3 FSP
CA125 ECad Calret p16
EN-TRL71T Bre80-hTERT2
INOF2 Bre80-hTERT2
Bre80-hTERT2
EN-TRL71T EN-TRL71T
LP9
Figure 4.10: Fluorescent immunocytochemistry, staining of control cell lines. EN-TRL = an en-
dometrial cancer cell line, Bre80-hTERT2 = an immortalised breast epithelial cell line, INOF2 =
an immortalised normal ovarian ﬁbroblast cell line. Nuclei are stained with DAPI (blue), cyto-
plasm is stained with Evan’s Blue (red), test antigens are lebelled with a FITC-coupled secondary
antibody (green). Cytokeratin (Ck7, AE1/AE3) and BerEP4 staining is cytoplasmic and membra-
nous; CA125 and FSP staining is localised to the cell membrane. Positive staining for calretinin
should be localised to the cytoplasm, E-cadherin staining localises to cell-cell adhesions, and p16
staining can be nuclear or cytoplasmic. In summary, staining of the control cell lines, as shown
above, was used to score NOSE and IOSE staining, with attention paid to staining intensity and
localisation.
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4.2.2 Analysis of Telomere Length & Telomerase Activity
The telomere biology of IOSE4, IOSE11, IOSE19 was then analysed. It was necessary to
identify (a) telomere length - telomere length should be maintained or increased follow-
ing the ectopic expression of hTERT; and (b) that relative telomerase enzymatic activity
was increased in hTERT-infected cells. Telomeric DNA preparations were Southern blot-
ted onto a nylon membrane and detected using a digoxigenin (DIG)-labelled probe that
recognises telomeric repeats (TTAGGG in all vertebrates). The mean telomere restriction
fragment (TRF) length was calculated using the molecular weights of the DNA ladder as
a reference. In the 3 primary samples, NOSE19 had the longest TRF length (7.26 kbp),
(Figure 4.11 a & b). The patient from which this cell line originated was 39 years old, and
the youngest of the 3 patients from which the three NOSE cell lines originated. NOSE4
and NOSE11 (patient ages 62 and 48 respectively) had TRF lengths of 3.5 kbp and 4.11
kbp respectively. This is consistent with the idea that telomeres shorten with advancing
age.
All three IOSE cell lines have TRF lengths longer than the parental NOSE cultures. For
NOSE4, TRF length was increased by 11.54 kbp in the immortalised cell line (IOSE4)
relative to the primary cell lines. For NOSE11 and NOSE19 the increase in TRF lengths
in the IOSEs clone tested were 6.13 kbp and 6.50 kbp repectively. This indicated that
telomere length was increased in all IOSE cell lines relative to the NOSE cultures (Figure
4.11). To conﬁrm that the increase in telomere length was due to transduction with
telomerase and not due to activation of a telomerase-independent mechanism of telomere
maintenance named alternative lengthening of telomeres (ALT), the levels of activity of
the telomerase holoenzyme were assayed by PCR-ELISA. Telomerase activity was not
detected in primary cultures but was present in all three immortalised cell lines (Figure
4.11c).
Transformed cells frequently display atypical karyotypes, and immortalisation of some cell
types will induce karyotypic changes or genomic stability [Ramirez et al., 2004]. Thus, the
karyotype of each NOSE and IOSE cell line was analysed. The predominant karyotype for
each NOSE and IOSE cell line was 46,XX (Figure 4.12). Irregular karyotypes, detected
in a subset of cells in 5/6 karyotypic analyses, were examined by a Clinical Cytogeneticist
and designated as culturing artefacts. This suggested that culturing and immortalisation
of NOSE cell lines did not induce genomic instability in these three cell lines.
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Figure 4.11: (a) Southern blot of telomere restriction fragments. The probe binds telomeric
repeats. Included on the blot are a low molecular weight control (ControlLMW) and a high molec-
ular weight control (ControlHMW) (some bleaching of the ﬁlm was observed). (b) Mean telomere
restriction fragment length is increased in immortalised OSE (IOSE) cell lines relative to normal
OSE (NOSE) parental cell lines. (c) Telomerase activity, detected by PCR-ELISA, is absent in
primary cultures but present in immortalised cell lines.
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46,XX,-8,-12 (1 cell)
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Figure 4.12: Karyotype analysis of primary and immortalised ovarian surface epithelial cell lines.
(a) 20 karyotypes per cell line were analysed, except for NOSE19 where only 10 metaphase nuclei
could be scored due to the restricted in vitro proliferation of this cell line. The modal karyotype
for each NOSE and IOSE cell line is 46,XX (shown in bold). (b) A representative modal karyotype
for each cell line is shown. p=passage number of the cell line
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4.3 Expression of Individual Oncogenes in IOSE Cultures
4.3.1 Overexpression of C-MYC in IOSE Cultures
A full-length C-MYC cDNA clone was introduced into IOSE cells by retroviral transduc-
tion in an attempt to induce the early stages of neoplastic transformation. Clones were
selected using 3µg/ml blasticidine-S-hydrochloride. Firstly, the anchorage-independent
growth rates of all 3 IOSE and 9 IOSECMY C cell lines were tested. Colony formation eﬃ-
ciency (CFE, %) was calculated following 4-week culture of cells suspended in 0.33% Noble
Agar gels. 7/9 IOSECMYC cell lines grew signiﬁcantly more in anchorage-independent
growth assays than the IOSE cell line from which they were derived (P≤0.05, two-tailed
paired Student’s T-Test) (Figure 4.13). At high densities (40,000 cells/well) some growth of
IOSE11 and IOSE19 was observed. No IOSE cell line grew at densities <20,000 cells/well
(in 6-well plates).
Clone morphologies were examined. The growing anchorage-independent colonies of all
IOSE4CMY C and IOSE11CMY C cell lines were typically smooth on the surface and com-
pact in appearance. However, anchorage-independent colonies of IOSE19CMY C cell lines
were large and had irregular morphologies. When plated at low densities (1000 cells/well),
to better observe this characteristic, up to 50% of the clones were observed to have a pe-
ripheral region of cells which were invading out of the core of the clone and into the agar
(Figure 4.13 (b, ii)). This phenotype was not observed for any of the IOSE4 or IOSE11
clones that overexpress CMYC, and has not previously been observed in this laboratory for
any of the EOC cell lines tested [Dafou et al., 2009]; [Grun et al., 2009]. This suggested
that IOSE19CMY C clones have an aggressive in vitro phenotype in anchorage-independent
growth assays. Indeed, the CFE of 2/3 IOSE19CMY C cell lines were >15%, thus exceeding
the reported CFEs of many ovarian cancer cell lines (TOV112D, CFE=6.50%; TOV21G
CFE=8.35%; OV-TRL12B, CFE=3.07%) [Dafou et al., 2009]; [Grun et al., 2009].
From each IOSE cell line, the clone with the highest rate of anchorage-independent growth
was selected and a broader panel of assays were performed to measure neoplastic pro-
gression. The clones selected were IOSE4CMY C1, IOSE11CMY C2 and IOSE19CMY C3.
(From this point onwards the clones are denoted without the clone number - IOSE4CMY C,
IOSE11CMY C and IOSE19CMY C).
The expression of C-MYC mRNA and protein were analysed in the IOSE4, IOSE11 and
IOSE19 and IOSE4CMY C, IOSE11CMY C, IOSE19CMY C. Firstly, expression of C-MYC
mRNA was analysed by real-time PCR. C-MYC mRNA expression levels were increased
80 to 501-fold relative to IOSE cells (Figure 4.14a). The diﬀerences in C-MYC mRNA ex-
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Figure 4.13: Overexpression of C-MYC in three IOSE cell lines increased colony formation eﬃ-
ciency in anchorage-independent growth assays in 7/9 clones. Three IOSECMY C clones per IOSE
cell line were screened for anchorage-independent growth. (a)(i-iii) Colony formation eﬃciency
(CFE) of IOSE and IOSECMY C cell lines, plated at high density (40,000 cells/well in a 6-well
plate). Statistically signiﬁcant diﬀerences in CFE, (signiﬁcance level of P≤0.01), are highlighted
in red. (a, i) In IOSE4, clones 1 and 3 grew signiﬁcantly more in anchorage-independent growth
assays than the parental IOSE cell line. (a, ii) In IOSE11, clones 1 and 2 grew signiﬁcantly more
in anchorage-independent growth assays than the parental IOSE cell line. (a, iii) In IOSE19, all
3 clones tested grew signiﬁcantly more in anchorage-independent growth assays than the parental
IOSE cell line. One IOSECMY C clone was selected per IOSE parental cell lines to take forwards
for more detailed phenotypic analyses (indicated by red boxes). (b, i) Representative ﬁelds of view
of anchorage-independent growth assays; 20,000 cells/well were plated. (b, ii) IOSE19CMY C cells
demonstrate an aggressive in vitro phenotype: anchorage independent growth eﬃciencies exceed
many ovarian cancer cell lines and cells invade out of the colony and into the agar (arrow). Cells
were plated at low density (1000 cells/well). (b, iii) Anchorage-independent growth rates of IOSE
and IOSECMY C cell lines, plated at low density (1000 cell/well) at passage 28-30. (* P≤0.01)
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pression levels were signiﬁcantly elevated in IOSECMY C cells compared to parental IOSE
lines. It was observed that in the parental lines, IOSE4 displayed signiﬁcantly lower expres-
sion of endogenous CMYC mRNA than IOSE11 and IOSE19 (Figure 4.14b). IOSE19 also
expressed the CMYC transcript at levels signiﬁcantly higher than IOSE11. As described
in this thesis, IOSE19 appeared to be more susceptible to neoplastic transformation in
vitro than IOSE4 and IOSE11, this may be due in part, to the higher CMYC expression
observed in this experiment. Secondly, western blotting of total cell lysates with an anti-
C-MYC antibody was performed to see if increased levels of C-MYC protein could be
detected. However, there were no visible diﬀerences detected in the expression of C-MYC
protein (Figure 4.14b). This may be due to the short half-life of the C-MYC protein;
proteins with a short half-life are diﬃcult to detect by Western blotting as they can be
degraded very rapidly during sample collection. Alternatively, the transforming eﬀects
observed may be mediated by the CMYC mRNA transcript.
*
IOSE4
CMYC
IOSE4
IOSE11
CMYC
IOSE11
IOSE19
CMYC
IOSE19
0.1
1
10
100
1000
C
M
Y
C
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
r
e
l
a
t
i
v
e
 
t
o
 
1
8
s
 
r
R
N
A
C-MYC
β-actin
+ hTERT
CMYC
(a)
+
+
-
+
+
+
-
+
+
+
-
OSE4 OSE11 OSE19
(c)
* * *
IOSE4
IOSE11
IOSE19
0
1
2
3
C
M
Y
C
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
r
e
l
a
t
i
v
e
 
t
o
 
1
8
s
 
r
R
N
A
(b)
* **
**
*
Figure 4.14: Detection of C-MYC overexpression in IOSECMY C cell lines. (a) Expression of
C-MYC mRNA, relative to an 18s rRNA internal control. (b) Endogenous expression of CMYC
mRNA is signiﬁcantly higher in IOSE19 compared to IOSE11 and IOSE4. * P≤0.05, ** P≤0.05
(c) Western blot analysis of C-MYC protein expression in total cell lysates. β-actin represents a
loading control.
IOSE cells that overexpress C-MYC also displayed altered cell morphology when visualised
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by phase-contrast microscopy. Cell size was decreased and cell shape became more cuboidal
and more classically epithelial than the characteristic ﬁbroblastic morphology of IOSE
clones when grown in growth-factor rich medium (Figure 4.15). NOSE cells typically show
phenotypic plasticity, both in vitro and in vivo, and commitment to an epithelial phenotype
is associated with ovarian cancer progression. Anchorage-dependent growth was tested
to assay clonogenicity and proliferation of the IOSE cell lines compared to IOSECMY C.
IOSECMY C cell lines formed signiﬁcantly more colonies in anchorage-dependent growth
assays than the IOSE cell lines (P≤0.01, paired T-Test) (Figure 4.16).
IOSE4CMYC IOSE4
IOSE11CMYC IOSE11 IOSE19CMYC IOSE19
100µm 100µm 100µm 100µm
100µm 100µm
Figure 4.15: IOSE cultures overexpressing C-MYC have a more classic cuboidal-epithelial mor-
phology than IOSE cell lines. The ﬁbroblast-like elongated morphology of IOSE cultures changes
to a more typically epithelial (cuboidal) morphology upon C-MYC overexpression. Commitment
to an epithelial phenotype is a hallmark of epithelial ovarian cancer cells. OSE cells in vitro and
in vivo are able to convert between epithelial, mesenchymal or mesothelial phenotypes. Cell size
is also visibly reduced.
A hallmark of transformation is reduced apoptosis and increased independence from pro-
apoptotic signals [Hanahan and Weinberg, 2000], thus the proportion of apoptotic cells
was analysed. Cell suspensions were labelled with anti-annexin-V-FITC and the percent-
age of apoptotic cells analysed using ﬂow cytometry. Anti-annexin-V labels externalised
phosphatidyl-serine, a marker of cells which are undergoing early apoptosis. A statisti-
cally signiﬁcant reduction in the percentage of apoptotic cells was observed in all three
IOSECMY C cell lines compared to the IOSE cells (P≤0.05) (Figure 4.17 (a)). This sug-
gested that IOSECMY C clones had reduced rates of apoptosis compared to the IOSE cell
lines from which they were derived.
C-MYC is known to play a role in proliferation and progression through the cell cycle. Fur-
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Figure 4.16: IOSE cultures overexpressing C-MYC show enhanced clonogenicity in anchorage-
dependent growth assays (* P≤0.05). Representative plates with colonies stained with Coomaasie
blue, are shown. In plates where CFE appears to exceed 100%, it was observed that conﬂuent
colonies shed cells into the medium, and it is hypothesised that these cells then form secondary
colonies
thermore, transformed cells are often more proliferative than non-transformed cells in vitro
and in vivo. Therefore, cell cycle analysis was performed using 5-bromo-2-deoxyuridine
incorporation (Brd-U), followed by labelling and ﬂow cytometry. Brd-U is a synthetic
thymidine analogue and, when added to cell culture medium, becomes incorporated into
cellular DNA during S-phase of the cell cycle. Nuclei can then be harvested from the
cultures, and the relative proportion of cells in each phase of the cell cycle calculated by
labelling Brd-U positive nuclei and total DNA with propidium iodide. For this experi-
ment, the percentage of cells in G2 phase was tabulated to determine the proportion of
cells that are approaching mitosis within the timeframe of Brd-U exposure. A signiﬁcant
increase in the proportion of cells in G2 phase of the cell cycle was observed in IOSECMY C
cells, compared to IOSE parental cell lines (P≤0.05) (Figure 4.17). Therefore, these data
suggest that an increase in the proliferative rate was associated with the introduction of
C-MYC into IOSE cell lines. However, an alternative explanation could be that an in-
creased in CMYC expression may aﬀect timing of the cell cycle and induce a prologued
G2 phase.
Finally, Pearsons’ Rank analyses were performed to test for correlation between C-MYC
mRNA expression and in vitro phenotype. Firstly, a test was performed to identify any
signiﬁcant correlation between relative fold-change (FC) in C-MYC mRNA expression lev-
els and colony formation eﬃciency (CFE) in anchorage-independent growth experiments.
These two variables, CFE and mRNA fold-change, were signiﬁcantly correlated (r2=0.8,
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Figure 4.17: Analysis of apoptosis and cell cycle distribution in IOSE and IOSECMY C cell lines.
(a)(i) IOSE cultures over-expressing C-MYC show reduced apoptosis and (ii) enhanced progression
through the cell cycle, compared to parental IOSE cell lines. A minimum of three replicate samples
were stained per cell line. (* P=0.05, paired T-test). (b) Representative scatter plots of IOSE4
and IOSE4CMY C showing Brd-U staining (FL1-H) plotted against propidium iodide (PI) staining
(FL2-H). Cells in G1 phase of the cell cycle have no Brd-U incorporated into cellular DNA, and
2n chromosomes; therefore staining by Brd-U is low/absent (below 101) and PI staining is half
of that observed for cells in G2. Cells in S-phase of the cell cycle are actively undergoing DNA
replication, and so a classic ‘horse-shoe’ plot is observed as DNA material is replicated and Brd-U
is simultaneously incorporated. In G2 phase, chromosomes have been replicated and so staining
with PI is double that of the cells in G1 phase. Cells in G2 phase also have high FL1 staining as
Brd-U has become incorporated during DNA synthesis.
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P=0.0156, α =0.05). Relative FC in C-MYC mRNA expression levels was also correlated
to the percentage of apoptotic cells in the cultures (r2=-0.5750, P=0.0333, α =0.05), but
not to CFE in anchorage-dependent growth assays (r2=0.6295, P=0.0596, α =0.05), or
the proportion of cells in G2 phase of the cell cycle (r2=0.5200, P= 0.1058, α =0.05). It
may be that higher numbers of cell lines would need to be assayed to have the power to
detect further correlations.
These tests suggest that increasing relative FC of C-MYC mRNA expression in these cell
lines is correlated to rates of apoptosis and the degree of tumourigenicity in anchorage-
independent growth assays. Correlation does not imply a ‘cause’ but a relationship be-
tween two variables and in this instance, this correlation suggests a trend in which increas-
ing expression of C-MYC mRNA is positively correlated to colony formation eﬃciency
in anchorage-independent growth assays and negatively correlated to the proportion of
apoptotic cells in a culture. It can be inferred that C-MYC overexpression level may be
proportionally related to the neoplastic phenotype. This trend could be validated and fur-
ther investigated by increasing the total number of clones and thus increasing the number
of data points for testing correlations. Also, shRNA/siRNAs targetting C-MYC could be
used to knock-down expression of this gene and quantify any reversal of the transformed
phenotype that is associated with subsequent depletion of the transcript.
4.3.2 Expression of Mutant KRAS and BRAF in IOSE Cell Lines
IOSE cell lines expressing KRASG12V or BRAFV 600E (the most common RAS/RAF mu-
tations in EOC) were generated by transducing IOSE with retroviruses containing the
sequences for these genes. Selection of these clones was achieved using an antibiotic se-
lectable marker that confers resistance to G418 (for KRAS) or puromycin (for BRAF).
4.3.3 KRAS/BRAF-Associated Senescence in IOSEKRAS Cell Lines
Expression of β-galactosidase (SA-β-gal) activity at pH6 is a marker of cellular senescence
[Dimri et al., 1995]. KRAS and BRAF mutations classically induce senescence of normal
cells in the absence of other pro-tumourigenic mutations [Denoyelle et al., 2006]. There-
fore, clones that had been transduced with KRASG12V or BRAFV 600E were screened for
expression of SA-β-gal and cell morphologies were closely observed.
In IOSE4, it was only possible to generate 2 IOSE4KRAS cell lines that could be main-
tained in culture. These cell lines grew very slowly in vitro and cells displayed senescent
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morphologies (enlarged size, vacuolated cytoplasm). Staining for senescence-associated-β-
galactosidase (SA-β-gal) conﬁrmed that 100% of cells were senescent in the two IOSE4KRAS
clones at passage 11. Only ∼10% of cells were positive for SA-β-gal in IOSE4/IOSE4AP
(control cell line that expresses alkaline phosphatase) (Figure 4.18). Only ∼1% of cells in
the IOSE4CMY C culture were senescent.
IOSE4p12
IOSE4KRAS1 p11
IOSE4KRAS2 p11
100µm
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IOSE4AP2.1 p12
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Figure 4.18: IOSE4 cultures expressing mutant KRAS stain positive for senesence-associated-β-
galactosidase bioactivity, indicated by positive (blue) staining for β-galactosidase activity at pH6.
(a) In two KRAS clones 100% of cells are senescent (blue). In IOSE4 and IOSE4AP, around 10%
of the cells are senescent. In IOSECMY C, the proportion of senescent cells is least, only around
1% of cells stain positive for β-galactosidase at pH6. IOSE4AP = control cell line, transduced with
the gene for alkaline phosphatase. (b) In the control cell lines 100% of cells stain positive (purple)
for alkaline phosphatase (AP). Staining for AP was absent in all other cell lines.
However, from IOSE11 and IOSE19 transductions with KRASG12V , many clones were
isolated that could be propagated in culture. Three clones from each cell line were assayed
for SA-β-gal bioactivity. All of these clones were maintained in culture for over 20 passages.
When stained for SA-β-gal, only IOSE11KRAS1 showed an elevated proportion of senescent
cells (around 10%) compared to the parental IOSE11 cell line (around 1%).
It was not possible to generate clones that stably express BRAF from IOSE4 as all clones
senesced at an early passage. Clones were generated from IOSE11 and IOSE19. In both
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Figure 4.19: Senescence in IOSE11, IOSE19 and clones expressing KRASmut. Only one clone
(IOSEKRAS2) contained a higher proportion of senescent cells than the IOSE parental cell line or
the control cell line (IOSEAP). Blue cells indicate positive staining for SA-β-gal bioactivity
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IOSE11 and IOSE19, BRAFmut induced higher rates of senescence than KRASmut. This
strongly suggested that BRAF had been introduced into IOSE cell lines and was a more
potent inducer of senescence than mutant KRAS. Control cell lines, expressing alkaline
phosphatase (AP) did not show rates of senescence that were diﬀerent to the IOSE parental
cell lines. Three BRAF clones were derived from both IOSE11 and IOSE19. BRAF clones
proliferated slowly in culture and rates of cellular senescence were observed that exceeded
parental, control and IOSECMY C cell lines (Figure 4.19 & 4.20).
IOSE19BRAF1 p6
IOSE11BRAF1 p15 IOSE11BRAF2 p15
IOSE19BRAF2 p8 IOSE19BRAF3 p8
100µm 100µm 100µm 100µm
100µm 100µm 100µm 100µm
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IOSE11BRAF3 p8
Figure 4.20: Senescence in IOSE11, IOSE19 and clones expressing BRAFmut. All IOSEBRAF
clones contained a higher proportion of senescent cells than the IOSE parental cell line.
4.3.4 Analysis of KRAS/BRAF Expression
To assay expression of the mutant KRAS alleles in the clones from IOSE11 and IOSE19,
restriction fragment length polymorphism (RFLP) digests were performed on cDNA prepa-
rations [Sato et al., 2006]. RNA was isolated from selected clones, and reverse transcribed
to create cDNA transcripts. A region spanning the KRASG12V mutation was ampliﬁed
by PCR. PCR-ampliﬁed cDNA fragments of KRASG12V have lost a BstN1 restriction site
that spans the G12V mutation. Therefore, RFLP analysis can be used to distinguish
mutant and non-mutant strands of ampliﬁed cDNA. cDNA PCR products that carry the
G12V mutation remain undigested by the BstN1 enzyme (see schematic in Figure 4.21a).
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All 6 single mutant clones screened expressed mutant KRAS exclusively, or the majority
of KRAS transcripts were the mutant allele (Figure 4.21b). Two IOSE19KRAS clones
(clone 1 and 2) co-expressed detectable, albeit low levels of non-mutant KRAS. However,
the other 4 clones did not express levels of non-mutant KRAS mRNA that were detectable
by this method (with the assumption that both transcripts are ampliﬁed with equal ef-
ﬁciencies). IOSE and control cell lines that express alkaline phosphatase (IOSEAP) only
expressed non-mutant KRAS transcripts. Since the transcriptional response the signalling
down the MAPK pathway has a cell autonomous feedback component, it may be that
when a constitutively active allele of KRAS is introduced into the cells, the endogeneous
gene is then downregulated in response to elevated MAPK signalling [Schulze et al., 2001];
[Schulze et al., 2004]. It would be possible to test this hypothesis using a shRNA target-
ting mutant KRAS alleles, although such experiments were not within the aims of this
project.
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Figure 4.21: RFLP-PCR detection of KRASmut expression. (a) Non-mutant strands are digested
by BstN1 to remove a 30bp fragment from the 5’ end of the PCR product. (b) RFLP-PCR analysis
of KRAS mutation status at codon 12 (i) IOSE11 and clones, (ii) IOSE19 and clones. Control
cell lines expressing alkaline phosphatase (AP) do not express KRASG12V . IOSE19KRAS1 and
IOSE19KRAS2 have detectable levels of expression of non-mutant KRAS cDNA (white arrows).
These analyses are semi-quantitative.
Gene expression of total KRAS mRNA was assayed in all cell lines by real-time PCR. 3/6
IOSE11KRAS and IOSE19KRAS clones expressed relative levels of KRAS mRNA that were
elevated 50- to 500-fold compared to the IOSE and IOSEAP cell lines (P≤0.01 two-tailed
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paired T-Tests) (Figure 4.22 a & b). This suggested that elevated MAPK signalling in
IOSEKRAS cell lines occurs via two mechanisms: (i) expression of a constitutively active
KRAS allele and (ii) elevated expression of total KRAS (where the majority of transcripts
are carrying the G12V mutation). These data indicate that IOSE11 and IOSE19, phe-
notypically normal cell lines, can tolerate expression of KRASG12V . IOSEKRAS2 was the
clone with the highest expression of KRAS and also the clones with noticably increased
rates of senescence, suggesting that there may be a correlation between high expression
of KRASmut and cellular senescence in IOSE11 clones. In IOSE19 cells, IOSE19KRAS1
expressed highest levels of KRAS, but there was no identiﬁable increase in cellular senes-
cence. However, total KRAS expression was 1/10th of that detected in IOSE11KRAS2.
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Figure 4.22: Real-time PCR analysis of (a,b) total KRAS or (c,d) total BRAF expression. mRNA
from all cell lines was reverse-transcribed to cDNA and the expression of total KRAS/BRAF
mRNA calculated, relative to an internal control (18s ribosomal RNA). Clonal variation in total
gene expression in clones was observed. Error bars = standard deviation. P≤0.01.
Detection of BRAFmut by RFLP-PCR has been previously described [Watanabe et al., 2009].
However, even with extended incubation times (16 or 24 hours), digestions did not run
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to completion. Varying protocol for the clean-up of PCR products (using QIAgen PCR
clean-up kit, ethanol precipitation or drying with the vacuum centrifuge) did not improve
the digest. However, the SA-β-gal results strongly suggest that these clones were express-
ing mutant BRAF alleles. Expression levels of total BRAF mRNA were not signiﬁcantly
diﬀerent in transduced clones, parental cells and the control cell line (Figure 4.22), sug-
gesting that BRAFV 600E was a more potent inducer of cellular senescence than KRASG12V
in the three IOSE cell lines tested.
Finally, anchorage-independent growth assays were performed to measure any neoplastic
phenotype that was induced by the expression of KRASG12V and BRAFV 600E in IOSE11
and IOSE19. IOSE19 KRASG12V clones did show a signiﬁcant increase in colony formation
eﬃciency (Figure 4.23). KRAS expression levels did not correlate to CFE in anchorage-
independent growth assays. Rates of anchorage-independent growth were low in all clones.
Also, in both cell lines, 6/6 clones transduced with BRAFV 600E had signiﬁcantly lower
rates of anchorage-independent growth than IOSE cell lines (plated at high density, 40,000
cells per well) (P≤0.05, paired Student’s T-Test). This may be due to senescence-induced
growth arrest reducing the proliferative ability of the transduced cell lines.
IOSE11
BRAF1
IOSE11
BRAF2
IOSE11
BRAF3
IOSE11
IOSE19
BRAF1
IOSE19
BRAF2
IOSE19
BRAF3
IOSE19
0
1
2
3
Clone
C
o
l
o
n
y
 
 
F
o
r
m
a
t
i
o
n
 
E
f
f
i
c
i
e
n
c
y
 
(
%
)
IOSE11
KRAS1
IOSE11
KRAS2
IOSE11
KRAS3
IOSE11
IOSE19
KRAS1
IOSE19
KRAS2
IOSE19
KRAS3
IOSE19
0
1
2
3
Clone
C
o
l
o
n
y
 
 
F
o
r
m
a
t
i
o
n
 
E
f
f
i
c
i
e
n
c
y
 
(
%
)
(a) (b)
*
*
*
*
*
* *
*
*
Figure 4.23: Anchorage-independent growth rates in IOSE cells transduced with (a) mutant
KRAS or (b) BRAF alleles. Cells were seeded at a high density (40,000/well). * P≤0.05.
4.4 Co-expression of Oncogenes in IOSE Cell Lines
To investigate the phenotypic eﬀects of combining oncogene expression, KRASG12V and
BRAFV 600E were transfected into two IOSECMY C clones, IOSE11CMY C and IOSE19CMY C,
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thus generating cell lines that stably overexpress CMYC and also express a mutant
KRAS/BRAF allele. KRAS/BRAF mutations occur mutually exclusively in ovarian tu-
mours, suggesting saturating eﬀects of mutant alleles of these two genes [Singer et al., 2003].
Attempts to create double-mutant KRAS/BRAF lines were not successful.
Anchorage-independent growth assays were performed on three clones for each gene and
for each cell line. This was to ensure that any diﬀerences observed were reproduced in
more than one clone. Clonal variation was observed, but in 75% of clones there was
a signiﬁcant increase in anchorage-independent growth rates upon the introduction of
KRASG12V /BRAFV 600E into IOSECMY C cell line (Figure 4.24a). Colonies were typically
smooth and regular in shape, with the largest colonies observed in IOSE11CMY C.KRAS
clones. As with the IOSE19CMY C cells, the IOSE19 clones co-expressing C-MYC plus
mutant KRAS/BRAF displayed irregular morphologies that were often invasive (Figure
4.24d).
One clone per gene per cell line was taken forwards for further analyses: KRAS clone
2 and BRAF clone 3 from IOSE11CMY C, and KRAS clone 2 and BRAF clone 3 from
IOSE19CMY C. From this point these cell lines shall be denoted IOSE11/19CMY C.KRAS
and IOSE11/19CMY C.BRAF. Expression of total KRAS and BRAF mRNA was assayed,
relative to an internal 18s rRNA control. In IOSE11CMY C.KRAS, total KRAS mRNA
expression was increased by nearly 80-fold relative to IOSE. In IOSE19CMY C.KRAS, total
KRAS mRNA was increased 5.92 -fold, relative to IOSE. As with the ‘single-oncogene’
mutant cell lines, no signiﬁcant diﬀerences in expression of total BRAF mRNA were
detected.
Expression of mutant KRAS was detected by RFLP-PCR, as described above. Tran-
scripts harbouring KRASG12V mutations were detected in 3/3 IOSE11CMY C.KRAS and
3/3 IOSE19CMY C.KRAS clones. IOSE cell lines, IOSECMY C and IOSECMY C.AP did not
express mutant (undigested) KRAS mRNA.
BRAF expression of mutant/non-mutant alleles was not detectable by RFLP-PCR, so
downstream extracellular-signal regulated kinase (ERK) activity was analysed by Western
blotting. ERK1/2 are the ﬁrst two kinases in the MAPK pathway. Phosphorylation of
ERK1/2 was detected with a phosphorylation-speciﬁc antibody, as constitutively active
alleles of KRAS and BRAF result in increased signalling down the MAPK pathway.
IOSE11 cell line were starved of serum and growth factor supplements for 48 hours and
then stimulated with epidermal growth factor (EGF). Lysates were collected at 0 mins, 2
mins, 10 mins and 30 mins. IOSE11 demonstrated rapid activation of MAPK signalling
following stimulation with EGF, as indicated by increase phosphorylation of ERK (p-
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Figure 4.24: Anchorage independent growth of IOSE, IOSECMY C, IOSECMY C.KRAS and
IOSECMY C.BRAF. (a) IOSE11 and clones and (b) IOSE19 and clones. Cells were plated at a
low density (1000 cells/well). * P≤0.01. (c) One clone per gene per cell line was taken for-
wards for further analyses (red boxes). Representative images of stained agar gels are shown. (d)
IOSE19 double mutant cell lines have an invasive phenotype in anchorage-independent growth
assays. IOSE19CMY C.KRAS cell lines are shown, with the invasive region indicated (arrows).
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Figure 4.25: Relative expression of total KRAS and BRAF mRNA in IOSECMY C.KRAS and
IOSECMY C.BRAF cell lines. Gene expression is calculated relative to an 18s ribosomal RNA
internal control (by the δδCt method)
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Figure 4.26: RFLP analysis of KRASG12V expression in IOSE11CMY C and IOSE19CMY C.
KRASG12V mutations are detected in 3 IOSE11CMY C.KRAS, 3 IOSE19CMY C.KRAS clones. IOSE
cell lines, IOSECMY C and IOSECMY C.AP (control cell line co-expressing alkaline phosphatase) did
not express mutant (undigested) KRAS mRNA .
153Chapter 4 4.4 Co-expression of Oncogenes in IOSE Cell Lines
ERK1/2). Activation of MAPK signalling was sustained for over 30 mins (Figure 4.27a).
Basal levels of p-ERK (timepoint 0 mins) in IOSE11 and IOSE11CMY C were low, but
there was strong expression of p-ERK in unstimulated IOSE11CMY C.BRAF cells. MAPK
signalling at ERK was also elevated in IOSE11CMY C.KRAS. Thus, IOSE19 and clones
were tested for levels of basal pERK1/2 only and, as with IOSE11, IOSE19CMY C.BRAF
had the highest expression of phosphorylated ERK1/2 (Figure 4.27b).
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Figure 4.27: Western blot analysis of MAPK activation in oncogene-expressing cell lines. (a)
With IOSE11 and derivative cell lines, an EGF timecourse was performed, starved cells were
unstimulated (time=0 mins) or stimulated with epidermal growth factor (EGF) for 2, 10 or 30 mins.
Activation of the MAPK pathway is indicated by phosphorylation of ERK1/2. Basal expression
of phosphorylated ERk1/2 is visible in IOSE11CMY C.KRAS/BRAF(b) IOSE19 and derivative cell
lines, were tested for basal expression of pERK (timepoint = 0 mins)
The morphology of cell lines was observed by phase-contrast microscopy. Clones expressing
mutant KRAS and mutant BRAF had a more regular, classically epithelial morphology
than IOSE cells. Cell shape was more cuboidal than the elongated, ﬁbroblastic-epithelial
morphology of IOSE cells (Figure 4.28). Double-oncogene cell lines were tightly packed
in the monolayer and did not show the cell scattering phenotype that was observed in
IOSE cell lines. Cytokeratin-7 (Ck7) expression was analysed by immunoﬂuorescence.
Ck7 expression was detectable in up to 40-70% of IOSE cells, but expressed in 100%
of IOSECMY C.KRAS and IOSECMY C.BRAF cells. This suggested a commitment to an
epithelial phenotype had occurred in these cell lines. However, in 2D monolayer cultures
all cell lines were negative for CA125 and E-Cadherin by immunoﬂuorescence, thus all cell
lines were lacking these features of diﬀerentiated M¨ ullerian epithelial cells, markers which
are expressed in many ovarian cancer specimens.
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Figure 4.28: Cellular morphology and cytokeratin expression in IOSE, IOSECMY C,
IOSECMY C.KRAS, IOSECMY C.BRAF, by phase-contrast and ﬂuorescent microscopy. Cells have
a progressively increasing epithelial morphology with increasing neoplastic phenotype. Cell size
also decreases. All ﬂuorescent images are 200X magniﬁcation and exposure times were consistent
for each antigen.
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Enhanced invasive ability is often associated with neoplastic transformation. Also, ac-
tivation of the MAPK pathway has been shown to induce upregulation of genes in-
volved in invasion [Schulze et al., 2001]. The invasiveness of all cell lines was compared.
IOSECMY C cells were not signiﬁcantly more invasive than IOSE parental cell lines, how-
ever, IOSECMY C.KRAS and IOSECMY C.BRAF were signiﬁcantly more invasive than the
IOSE parental cell line (P≤0.05, Student’s paired T-Test).
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Figure 4.29: Transwell invasion assays reveal invasiveness is enhanced when CMYC is co-expressed
with KRASG12V or BRAFV 600E. Invaded cells were lysed and stained with a ﬂuorescent dye,
invasiveness is proportional to ﬂuorescence emitted.
4.5 3D Models of Transformed IOSE Cell Lines
Optimisation of 3D modelling techniques for the growth of NOSE cell spheroids was de-
scribed in Chapter 3 and have been published [Lawrenson et al., 2009a]. In this laboratory,
3D models of primary ovarian cancer cells have also been established and compared to the
primary tumour and the same cells grown in 2D [Grun et al., 2009]. In both reports, it
was observed that 3D models of ovarian epithelial cells are more representative of ovarian
tissue in vivo than 2D monolayer cultures. Therefore, the cell lines described above were
established as 3D spheroid models, by culturing cells on polyHEMA coated plastics.
Firstly, the proliferation of cell lines were compared between 2D and 3D models. In 2D,
no signiﬁcant diﬀerences were observed in cell proliferation rates for IOSE, IOSECMY C,
and IOSECMY C.BRAF cell lines. IOSE11/19CMY C.KRAS clones were signiﬁcantly less pro-
liferative in 2D monolayer than both parental IOSE cell lines (Figure 4.30). This suggests
that expression of mutant KRAS was associated with a reduction in 2D proliferation.
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Figure 4.30: 2D and 3D proliferation of IOSE and oncogene-expressing cell lines. Clones express-
ing one or two oncogenes show enhanced growth in 3D proliferation assays, when compared to
IOSE cell lines and 2D proliferation assays. Cell lines in 2D and 3D were incubated with 10%
Alamar Blue and the ﬂuorescence emitted recorded every 48 hours.
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In 3D culture IOSE cell lines rapidly (within 4-5 days) underwent growth arrest and ceased
proliferating in spheroid cultures. Overall, 6/8 cell lines were signiﬁcantly less proliferative
in 3D than 2D (Figure 4.31). The IOSE11CMY C.BRAF and IOSEaaCMY C.KRAS cell lines
were not signiﬁcantly less proliferative in 3D than 2D, although the trend was similar to
that observed in the other cell lines. Speciﬁcally, cell lines overexpressing C-MYC, with
or without mutant KRAS/BRAF were observed to have growth rates in 2D and 3D that
were were less divergent than the 2D/3D growth rates of IOSE cell cultures (Figure 4.31).
This suggested that the transformed cell lines did not undergo the growth arrest observed
in IOSE cell lines, and that the cells continued to be highly proliferative even under non-
adherent conditions. IOSECMY C.BRAF cell lines were the most proliferative in spheroid
cultures.
4.5.1 Histological Analysis of Spheroid Cultures
PolyHEMA-coated ﬂasks were inoculated with 8x106 cells and allowed to form MCS. At
this high density, spheroid formation was observed within 2-3 days of culture under non-
adherent conditions. Dynamics of spheroid formation were monitored by phase-contrast
microscopy (Figures 4.32 & 4.33). All cell lines formed loose aggregates within 24 hours
of culture on polyHEMA coated plastics. Within 48 hours, spheroids became smooth in
appearance and began to increase in size. After 48 hours, IOSE cultures remain static and
no signiﬁcant changes in spheroid morphology were observed during the remaining 12 days
of 3D culture (Figure 4.32). This is consistent with the Alamar Blue data, which indicate
that IOSE cells undergo growth arrest and become quiescent when cultured as spheroids.
In oncogene-expressing clones however, spheroids continued to increase in number and
size between day 3 and day 14. From day 4 onwards, the spheroids began to aggregate
to form irregular poly-aggregate structures (Figure 4.33). The oncogene-expressing clones
were highly proliferative in 3D spheroid culture.
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Figure 4.31: Growth characteristics of each cell line in 2D and 3D culture. Cell lines with more
genetic alterations introduced tended to proliferate more in 3D culture than the parental IOSE cell
lines. The growth rates in 2D and 3D or more transformed cell lines were less diﬀerent than the
2D v 3D growth rates of IOSE cell cultures. Signiﬁcant P values are indicated in red (signiﬁcance
level = 0.05).
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Figure 4.32: Spheroid formation of IOSE cells under low-adherent conditions, at time of seeding
and 1-14 day timepoints. Loose aggregates start to form within 24 hours (white arrows) and
smooth spheroids appear within 48 hours (black arrows). Once spheroid formation has occurred,
appearance of the culture does not signiﬁcantly alter during the remainder of the experiment.
Cell lines were cultured in 3D for 14 days before ﬁxation with formalin and paraﬃn
embedding. Sections were cut from the paraﬃn-embedded samples, and stained with
hematoxylin and eosin (H&E) and for a panel of biomarkers by immunohistochemistry.
Spheroids stained by H&E were examined by light microscopy to observe spheroid and
cellular morphologies (Figure 4.34). IOSE cells form regular, rounded spheroids with
uniform architectural features. IOSE spheroids contain small foci of matrix material and
spheroids are mostly cellular. IOSE19 spheroids tended to be more cellular than IOSE11
(Figure 4.34). No central regions of apoptosis or necrosis were observed, which correlated
with the the 3D NOSE cultures described in Chapter 3. In 3D spheroid cultures, IOSE
cells have a spindled ﬁbroblastic-epithelial morphology, also observed in 2D cultures of
NOSE and IOSE cell lines.
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Figure 4.33: Spheroid formation of IOSE19CMY C.BRAF, under low-adherent conditions, at time of
seeding and 1-14 day timepoints. This is representative of all IOSECMY C.KRAS.BRAF cell lines and
IOSE19CMY C. Aggregation begins within 24 hours (white arrows) and spheroids start to condense
within 48 hours (black arrows). At day 5, spheroids begin to aggregate to form poly-aggregate
structures which continued to grow in size and number until the 14 day endpoint.
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Figure 4.34: Cellular and spheroid morphology in 3D cultures. Sections of paraﬃn-embedded
spheroids were stained with hematoxylin and eosin. (a) IOSE19 and derivation clones expressing
oncogenes. Low power images, light microscopy. Note the regularity of spheroid architecture in
the IOSE compared to the irregular, chaotic appearance of IOSE19CMY C, IOSE19CMY C.KRAS
and IOSE19CMY C.BRAF (b,c) IOSE11, IOSE19 and oncogene-expressing clones. IOSE cells are
quiescent. Matrix desposition is observed (M) in greater abundance in IOSE cell lines than in the
cell lines expressing CMYC/KRAS/BRAF. Cell lines expressing two oncogenes are more cellular,
with areas of necrosis (N) and rapid proliferation visible.
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IOSE clones overexpressing CMYC grew more numerous 3D structures than the IOSE
parental cell lines. This was more striking for IOSE19CMY C than for IOSE11CMY C.
Mitoses were observed in IOSE11/19CMY C, indicating that the cultures were actively pro-
liferating when harvested. Typically, the centre of larger aggregates had foci of apoptotic
cells and these apoptotic foci were larger in the larger spheroids (Figure 4.34). Architec-
tural features also included ﬂattening of cells at the surface. The IOSE19CMY C cell line in
particular contained many regions of both extensive apoptosis and extensive proliferation.
In this cell line some aggregates were necrotic at the core with 1-2 layers of active cells at
the surface of the MCS. Syncytial cell structures were also visible (two nuclei with shared
cytoplasm), indicative of rapid uncontrolled proliferation and aberrant cell division. In
CMYC-overexpressing cell lines, prominent nucleoli were observed and nuclei were often
pleomorphic or polygonal in shape (an irregular morphology for nuclei). Prominent nucle-
oli have been linked to CMYC ampliﬁcations in tumours where ampliﬁcation of this gene
is common (eg. neuroblastoma, lung cancer) [Kobayashi et al., 2005].
Cell lines overexpressing CMYC, in the absence or presence of KRAS/BRAF activa-
tion, formed spheroids with irregular architectures (Figure 4.34). Spheroids aggregated
to form large irregular poly-aggregate structures (Figure 4.33). Cells expressing CMYC
plus mutant KRAS/BRAF tended to have rounded morphologies. Cell lines expressing
two oncogenes were very cellular, with areas of apoptosis and rapid proliferation visible
(Figure 4.34). Expression of BRAF alleles tended to be associated with necrosis rather
than apoptosis in the MCS, whereas little necrosis was observed in cell lines expressing
KRASG12V . Mitoses were observed on the periphery of MCS. Cells in spheroids from
IOSE11/19CMY C.KRAS/BRAF lines tended to contain large nucleoli.
H&E analysis of mass-cultures is a good way to observe morphological trends and gross
appearance of cells grown in 3D. However, little other information can be gleaned from
H&E-stained sections and few quantiﬁable characteristics can be measured using this
approach. Therefore, sections of 3D spheroids were stained, by immunohistochemistry,
for the epithelial markers (cytokeratin-18, Ck18 and cytokeratin-7, Ck7); the ovarian
cancer markers CA125 and WT1; a proliferation marker (MIB1) and an apoptosis marker
(Bcl2) (Figure ??). All cell lines expressed Ck18 and Ck7 but did not express CA125. In
IOSE cell lines, some staining of MIB1 was detected, and this was localised to peripheral
regions of the MCS. In the peripheral regions, cells had a notably elongated mesenchymal
morphology, whereas in the centre of MCS, cells had a plump, rounded cell morphology
(Figures 4.35 and 4.36). This suggested a more ﬁbroblastic morphology was associated
with proliferation of IOSE cells in 3D spheroids, which reﬂects the phenotype of NOSE
cells during wound repair (NOSE cells are more mesenchymal at post-ovulatory sites).
IOSE19CMY C and IOSE19CMY C.KRAS/BRAF cell lines were highly proliferative in 3D
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spheroids, as indicated by the high proportion of nuclei staining positive for MIB1 (Figure
4.35). Although apoptotic regions of spheroids were detectable in the H & E stained
sections, no staining for Bcl2 was observed in any of the cell lines tested. This indicated
that apoptosis in the spheroids was not associated with expression of the Bcl2 apoptosis
marker.
WT1 was expressed at low levels in IOSE19, and expression was increased in the trans-
formed cell lines (Figures 4.35 and 4.36). WT1 is often expressed by ovarian carcino-
mas [Koebel et al., 2008]. WT1 was expressed in spheroid cultures of the IOSE11CMY C,
IOSE19CMY C and IOSE19CMY C.KRAS/BRAF cell lines. WT1 is expressed in ovarian
carcinomas, and interestingly, has previously been shown to be upregulated in 3D cul-
tures of EOC cells [Hylander et al., 2006]; [Barbolina et al., 2008]. WT1 expression may
also be associated with enhanced invasion and metastases and poorer patient prognoses
[Netinatsunthorn et al., 2006]; [Barbolina et al., 2008].
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Figure 4.35: Biomarker expression in IOSE11 3D cultures. FFPE spheroids were stained by
immunohistochemistry. All multicellular spheroids (MCS) stain positive for cytokeratins-18 and
7. The highest expression of these markers was in IOSE11CMY C. IOSE11 MCS have a low
proliferative index, few cells stain positive for MIB1. MIB1 expression in elevated in the cell lines
expressing oncogenes. WT1 expression was observed in the nuclei of IOSE11CMY C. No MCS
stained positive for Bcl2 or CA125. Light microscopy, positive stain indicated by brown colour,
counterstain is blue. Scale bars = 100µm 165Chapter 4 4.5 3D Models of Transformed IOSE Cell Lines
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Figure 4.36: Biomarker expression in IOSE19 3D spheroid cultures, immunohistochemical stain-
ing of FFPE spheroids. IOSE19 culture were the least proliferative, as indicated by low MIB1
staining, note that the MIB1-positive proliferative cells are localised to a discrete peripheral region
(P, indicated by a dashed line). All oncogene-expressing clones express WT1, with the highest
expression observed in IOSE19CMY C.BRAF (arrows). No MCS stained positive for Bcl2 or CA125.
Light microscopy, positive stain indicated by brown colour, counterstain is blue. Scale bars =
100µm
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4.6 Proﬁling Transcriptomic Changes Associated with NOSE
Cell Transformation
The aim of these experiments was to identify genes that were altered in synergy with the
genetic alterations introduced in the step-wise genetic model of transformation of NOSE
cells described above. The cell lines described have deﬁned genetic alterations stably
introduced, these array experiments aimed to analyse the transcriptome of each cell line.
The hypothesis of these experiments was that gene expression microarray proﬁling would
give insight into the transcriptomic eﬀects of transformation mediated by the prolonged
expression of speciﬁc genes/gene combinations in ovarian surface epithelial cells. As the
model represents early transformation of NOSE cells, it was hypothesised that the genes
identiﬁed in these experiments would be candidate biomarkers of the early stages of ovarian
cancer.
Gene expression analyses were performed on two independent cell lines and three biologi-
cal replicates. Proﬁles were generated for IOSE11, IOSE19, IOSE11CMY C, IOSE19CMY C,
IOSE11CMY C.KRAS, IOSE19CMY C.KRAS, IOSE11CMY C.BRAF and IOSE19CMY C.BRAF
cell lines. For detailed analysis of immediate transcriptional eﬀects of a single gene, con-
trol vector cell lines represent a good reference cell line. However, as this is a model of
progressive transformational changes it was decided that the proﬁles of IOSE cell lines
would serve as an appropriate baseline control.
KRASG12V
C-MYC Primary 
NOSE
hTERT Immortalised 
OSE 
BRAFV600E
p10-12 p5-7 p28-30
p20-21
p20-21
Figure 4.37: Schematic representation of genetic alterations introduced into NOSE cells and the
corresponding passages (p) at which gene expression microarrays were performed
Cell lines were taken at a deﬁned passage number: IOSE at passage 10-12, IOSECMY C
at passage 28-30, and IOSECMY C.KRAS and IOSECMY C.BRAF at passage 20-21. Passage
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numbers for derivative cell lines represent passages since genetic manipulation occurred
(see Figure 4.37). The passage numbers also represent the point in the parental cell line
at which the next genetic element was introduced, for example, C-MYC was introduced
into IOSE at passage 10-12. Cell lines at the indicated passage number were grown in 3D
cultures, in triplicate, for 14 days, and the RNA was then harvested. RNA samples were
quantiﬁed, reverse-transcribed, labelled and hybridised to Illumina HT12 gene expression
microarrays at the UCL Genomics Facility.
4.6.1 Data Analysis of Microarray Experiments
Data Pre-processing and Quality Control
A schema showing the workﬂow for data analysis of gene expression microarrays is shown
in Figure 4.38. There are many approaches to data pre-processing, as discussed in Chapter
1. The ﬁrst step was to analyse the quality control (QC) output for control probes on the
array to check for consistency across the arrays in terms of (i) hybridisation eﬃciency, (ii)
washing stringency, (iii) RNA labelling, (iv) background signal (v) signal to noise ratios.
All arrays in this study showed consistent signals for the control probes.
Pre-processing:
Normalisation,        
Background subtraction, 
Quality check
LUMI LIMMA
Data analysis
Generation of lists of 
differentially 
expressed genes
‘R’
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Figure 4.38: Microarray data analysis work ﬂow, using the ‘Lumi’ and ‘Limma’ packages in ‘R’
In these experiments, image analysis was performed by BeadStudio software, and raw data
exported with no background subtraction or normalisation steps performed. This enabled
these steps to be done in-house. Pre-processing steps were performed in ‘R’ using the ‘lumi’
package, designed for pre-processing of Illumina bead arrays [Du et al., 2008]. Boxplots
and MA plots were created of the raw data, and background signal subtracted. Data were
transformed using the variance-stabalisation normalisation algorithm and normalised to
remove signal that is not due to diﬀerential gene expression but due to variation introduced
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by technical variables such as spatial eﬀects and diﬀerential biotinylation. The ‘lumiN’
robust spline normalisation technique used in these arrays had been previously validated
using an in vivo mouse model of ovarian cancer [D. Sproul, personal communication].
Hierarchical Clustering of Gene Expression Proﬁles
Unsupervised hierarchical clustering was performed to test the relatedness of the cell lines.
Outlier detection is based on the sample distance to the hypothetical ’centre’. The two
IOSE cell lines are more closely related to each other than to the derivative IOSECMY C
cell lines. This suggests that there are large transcriptional changes between the IOSE
and IOSECMY C cell lines (Figure 4.39). Cell lines harbouring activating mutations in the
MAPK pathway also cluster together, with IOSE11CMY C.BRAF clustering more closely to
IOSE19CMY C.KRAS/BRAF than IOSE11CMY C.KRAS.
4.6.2 Using Gene Expression Microarrays to Identify Genes Dysregu-
lated in Early EOC Development
Normalised, transformed data were then analysed using the Linear Models of Microarray
or ‘limma’ package [Smyth, 2004]. Details of data analysis steps can be found in Chapter 2.
Numbers of diﬀerentially expressed genes induced by expression of oncogenes was analysed
in each cell line. Control (IOSE) cell lines were ﬁrst compared to IOSECMY C cell lines.
IOSECMY C were subsequently compared to the IOSECMY C.KRAS/BRAF cell lines to iden-
tify the numbers of genes which were diﬀerentially expressed in association with each onco-
gene. IOSE11 versus IOSE11CMY C has 3253 genes which showed diﬀerential expression
between the two cell lines (Figure 4.40). In total 1038 and 1023 of these genes overlapped
with the changes observed in IOSE11CMY C.BRAF and IOSE11CMY C.KRAS respectively. A
total of 2079 genes were in common in IOSE11CMY C.KRAS and IOSE11CMY C.BRAF com-
parisons with IOSE11CMY C, which is unsurprising as it is known that KRAS and BRAF
have many common transcriptional eﬀects. All 3 groups showed upregulation of a core set
of 2130 genes. Frequencies of diﬀerentially expressed genes were similar in the IOSE19 cell
lines, except that the numbers of diﬀerentially expressed genes in the IOSE19CMY C.KRAS
group were only 29% of that observed for IOSE11CMY C.KRAS (Figure 4.40).
A gene list was generated for each cell line of the top 30 most statistically signiﬁcant
changes (up- or downregulation) in gene expression, with genes sorted by P-value (Tables
4.1 & 4.2).
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Figure 4.39: Unsupervised hierarchical clustering of normal and transformed cell lines using
normalised gene expression microarray proﬁles. IOSE cell lines cluster together, as do IOSECMY C
cell lines, suggesting that large diﬀerences in the transcriptional activity of IOSE cells is induced
by the overexpression of CMYC. Cell lines with activation of the MAPK pathway cluster together.
The IOSE19 ‘double-mutant’ clones were more closely related than the IOSE11 ‘double-mutant’
clones.
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Figure 4.40: Venn diagram to show numbers of diﬀerentially expressed probes by oncogene ex-
pression in IOSE11 and IOSE19.
Eight genes were in common across the two cell lines. These genes were THBS1, FEZ1,
PITX1, RGS4, VGF, MOCOS, CTGF and HIST1H4C. Thromobospondin-1 (THBS1)
expression was reduced over 17-fold in the IOSECMY C cell lines relative to IOSE. In
the cell lines also expressing mutant KRAS or BRAF the expression of THBS1 was
reduced 68.8-fold and 57.5-fold respectively. Expression of FEZ1, RGS4 and CTGF was
signiﬁcantly reduced in the transformed cell lines, including the IOSECMY C cell lines
(Figure 4.41). These 4 genes are interesting candidate tumour suppressor genes, expression
of which may be lost early in the development of ovarian cancers. Three new candidate
oncogenes have also been identiﬁed: PITX1, MOCOS and HIST1H4C. VGF was also
present in the lists of genes for both IOSE11 and IOSE19, but exhibited opposite eﬀects
in the two cell lines: VGF was highly overexpressed in IOSE11CMY C, IOSE19CMY C
and the IOSE19CMY C.KRAS/BRAF clones, but downregulated in IOSE11CMY C.KRAS/BRAF
(Figure 4.41). The most interesting candidates are arguably those genes that show highly
signiﬁcant, correlated changes in gene expresison in both cell lines.
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Table 4.1: Top 30 diﬀerentially expressed genes in IOSE11 transformed cell lines. Genes were
ranked by statistical signiﬁcance. Genes highlighted in red were also found within the list of the top
30 diﬀerentially expressed genes for IOSE19. logFC = average log of fold change in gene expression
(value is a log of the normalised signal intensity)
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Table 4.2: Top 30 diﬀerentially expressed genes in the IOSE19 transformation model, ranked by
P-value. Genes highlighted in red were also found in the top 30 diﬀerentially expressed genes in
IOSE11. logFC = average log of fold change
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Figure 4.41: Expression of the 8 most signiﬁcant genes diﬀerentially expressed in both cell lines.
Normalised, background subtracted signal intensities are tabulated.
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4.6.3 Expression of Genes Known to be Dysregulated in EOCs
The gene expression proﬁles for this transformation model were examined to analyse the
expression of genes already known to be involved in ovarian cancer. These genes are
described in detail in Chapter 1, and are components of main pathways in EOC: the DNA
double-strand break (DSB) repair pathway, the mismatch repair (MMR) pathway, the
mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol 3-kinase
(PI3K) pathway. All genes were analysed for expression across biological replicates, to
ensure that any observed variation was reproducible between the two cell lines.
Expression of BRCA1 and BRCA2 was low in all transgenic cell lines. There is some
evidence (in 2/4 probes) of enhanced BRCA1 expression in the IOSECMY C.KRAS/BRAF
cell lines, and, relative to the IOSECMY C cell lines, BRCA2 expression was reduced by
35% and 42% in IOSECMY C.KRAS and IOSECMY C.BRAF cell lines respectively. As TP53 is
upregulated in response to DNA damage induced by loss of BRCA1/2 function, expression
of p53 mRNA was also examined. p53 expression was found to be upregulated by 1.8-fold
in the IOSE11/19CMY C.KRAS/BRAF cell lines, relative to the IOSE/IOSECMY C cell lines.
There were no signiﬁcant changes in p53 mRNA expression in the IOSE cell lines versus
the IOSECMY C cells.
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Figure 4.42: mRNA expression of genes involved in the double-stranded break repair pathway
Components of the MAPK pathway were also examined to identify any diﬀerential ex-
pression induced by the expression of CMYC+/-KRASmut and BRAFmut. Firstly, ex-
pression of alternative RAS, RAF isoforms and receptor tyrosine kinases was exam-
175Chapter 4 4.6 Proﬁling Transcriptomic Changes Associated with NOSE Cell Transformation
ined. ERBB2 and HRAS expression was signiﬁcantly downregulated in the IOSECMY C,
IOSECMY C.KRAS and IOSECMY C.BRAF cell lines, relative to the IOSE cultures. The most
signiﬁcant downregulation of these genes and of CRAF and ARAF occurred in the cell
lines expressing mutant KRAS or BRAF, which suggests that cells downregulate endoge-
nous MAPK signalling in an attempt to suppress the enhanced MAPK signal transduction.
Results from both cell lines were highly correlated, as indicated by the low standard de-
viation observed. Downstream kinases in the pathway showed that heterogenous levels of
expression were induced by the diﬀerent oncogenes (e.g MAPKAPK5). There was some
indication that EGFR expression was elevated in the IOSECMY C.BRAF cell lines, which
may indicate activation of the autonomous EGFR-dependent feedback look previously
described as being associated with activation of this gene [Schulze et al., 2004].
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Figure 4.43: Gene expression of other RAS and RAF isoforms and receptor tyrosine kinases. Some
probes, such as probe 1 for HRAS and EGFR, perform better than alternative probes included on
the array (e.g. probe 2 for both of these genes).
The phosphatidyinositol 3-kinase pathway is commonly dysregulated in ovarian carcino-
mas. This pathway interacts closely with the MAPK signalling, as RAS also activates
signalling down the PI3K pathway. AKT2 did not show any diﬀerences in gene expression
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Figure 4.44: mRNA expression of genes in the PI3K pathway
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Figure 4.45: Genes involved in mitosis induction are diﬀerentially expressed in transformed cells.
IOSE cells show enhanced responses to growth factors (indicated by elevated expression of cyclin
D1), but transformed cell lines have higher expression of genes involved in signal transduction and
mitosis (cdk4, cyclin A and cyclin E).
in the normal and oncogene-expressing cell lines. PTEN negatively regulates signalling
down the PI3K pathways, and was upregulated in the IOSE11 lines expressing mutant
KRAS/BRAF alleles, suggesting that this is a negative feedback mechanism induced by
enhanced transduction of growth signals.
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Genes Involved in Cell Cycle Regulation
The gene expression microarray data were also examined for any changes in the expression
of cell cycle regulation. Immortalised cell lines underwent rapid growth arrest in 3D
culture, whereas the transformed cell lines continued to proliferate rapidly in 3D. When
an external growth signal is received by a cell, levels of cyclin D1 increase rapidly. IOSE
cells had an enhanced response to growth factor signalling (growth factors in the tissue
culture medium), indicated by the high cyclin D1 expression, despite the fact that the cells
are in a growth arrested state (Figure 4.45). Whilst cyclinD1 expression was lower in the
transformed cell lines, these cell lines had high expression of downstream genes, including
cyclin A and cyclin E (mitotic genes). pRb levels did not show any large changes across the
cell lines, but activity of this protein is regulated mainly by changes in phosphorylation,
not abundance.
4.6.4 Expression of Genes Associated with EOC Susceptibility
This laboratory recently led the ﬁrst genome-wide association study (GWAS) for EOC
and identiﬁed a panel of single nucleotide polymorphisms (SNPs) that are associated
with ovarian cancer risk [Song et al., 2009] and [S.Gayther, unpublished data]. Suscep-
tibility studies are designed with the hypothesis that some of the common natural so-
matic genetic variation that occurs in the general population can have small risk ef-
fects on individuals susceptibility to developing a disease. To identify low-penetrance
susceptibility alleles, researchers analyse the SNP genotypes of thousands of cases and
controls, usually using DNA isolated from peripheral blood samples. In recent years,
GWASs have found genetic variants that alter a person’s risk of many diﬀerent diseases,
including prostate, breast and ovarian cancer [Easton et al., 2007]; [Eeles et al., 2008];
[Ghoussaini et al., 2008]; [Song et al., 2009].
For ovarian cancer, the top 5 most signiﬁcant loci are distributed throughout the genome
at chromosomes 8q24, 9p22, 19p13, 2q31 and 3q25. However, only two out of the ﬁve
SNPs fall within genes, and not one of the top SNPs lies in a coding region. SNPs
represent a marker for a local haplotype block, in which a region of the genome is in linkage
disequilibrium (LD). Homologous recombination within this LD block is restricted, and so
a SNP within this region gives information about the genotype of other SNPs held in tight
linkage disequilibrium with the identiﬁed susceptibility SNP. It is therefore very likely that
a SNP identiﬁed in a GWAS is not the causal SNP, but is linked be association to the
causal variant. It also follows that the gene of interest may not even be the nearest gene
to the susceptibility SNP. The complexity is compounded by the likelihood that causal
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Figure 4.46: The top ﬁve loci associated with ovarian cancer risk. Per-allele OR describes the
odds ratio, or risk of developing disease in patients carrying the rare allele. Data are pooled in
that genotype frequencies in all EOC patients are compared to genotype distributions in control
women, who do not have ovarian cancer
SNPs in non-coding regions could be modifying the expression of distant genes, or even
genes on other chromosomes.
Determining the functional eﬀects of susceptibility SNPs is therefore immensely challeng-
ing, especially as eﬀects are likely to be subtle. However, it is also true that even if the
risk associated with a single SNP is small, it does not mean that that gene will not be
important in disease. A good example of this can be found in the case of heart disease,
in which enzyme CoA was identiﬁed as a risk locus. Although the risk associated with
this gene was not large, the clinical impact of this gene is enormous, as illustated by the
widespread use and eﬃcacy of statins. It is likely that susceptibility SNPs have an eﬀect
early in disease development, therefore I identiﬁed genes in the regions spanning suscepti-
bility loci and examined diﬀerential expression in the oncogene-expressing cell lines, using
the model of OSE transformation described above.
One SNP was found at 8q24, ∼50 kbp distal to the CMYC gene. In this in vitro transfor-
mation model, CMYC was overexpressed the transformed cell lines, which was conﬁrmed
using the gene expression arrays data (Figure 4.47). There are few other genes in this
region other than CMYC, although this region also includes DDEF1, POUSF1B, GSDMC
and a handful of pseudogenes. POUSF1B did not show diﬀerential expression in the dif-
ferent cell lines tested. However, analysis of expression of two DDEF1 probes from the
array data indicated that this gene was signiﬁcantly downregulated in the transformation
model, suggesting that DDEF1 may have a tumour suppressor role.
At 9p22, there are 4 genes within the 2800 Kbp region spanning the susceptibility SNP.
These genes are C9orf93, BNC2, CNTLN and SH3GL2. Whilst expression of C9orf93
and SH3GL2 did not seem to be signiﬁcantly diﬀerent in the various transgenic cell lines,
expression of BNC2 was reduced in all oncogene expressing clones. CNTLN expression
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Figure 4.47: Expression of genes local to the 8q24 susceptibility locus. Few genes are located
within the 2930 kbp spanning this susceptibility loci.
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was signiﬁcantly elevated in IOSECMY C cell lines and also in the cell lines over-expressing
CMYC in combination with mutant KRAS/BRAF.
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Figure 4.48: Expression of genes in the 2800 kbp spanning the 9p22 ovarian cancer susceptibility
locus
At the chromosome 19p13 locus, the nearest genes, namely MERIT40, ANKLE1 and
USHBP1 did not show any diﬀerential expression in this cellular transformation model.
However, NR2F6 and MRPL34 were upregulated in both the IOSECMY C.KRAS and
IOSECMY C.BRAF cell lines.
One region of the genome identiﬁed as a susceptibility locus for EOCs lies within a region
on chromosome 2p31, which is dense with homeobox genes: HOXD1, HOXD3, HOXD4,
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Figure 4.49: Expression of genes local to the 19p13 susceptibility locus
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Figure 4.50: Expression of genes local to the 2p31 susceptibility locus. Grouped analyses are
shown (all IOSE, all IOSECMY C, etc are analysed together). Analysis of individual cell lines
expression of HOXD10 and HOXD11 are shown in the lower panel.
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HOXD9-13. HOX genes are usually expressed temporally during development, and inter-
est in HOX genes is fuelled by work in the ﬁeld of cancer stem cells. In this cell model,
overall expression of HOX genes was relatively low. There is some suggestion that HOXD3
expression may be elevated in IOSECMY C.KRAS/BRAF cell lines. HOXD10-13 were more
highly expressed than HOXD1,3,4 & 8. There was some evidence that expression of
HOXD10 and HOXD11 was reduced in the transformed cell lines, relative to the IOSE
cultures, but the large standard deviations observed in the grouped analyses suggested
that the two cell lines were displaying diﬀerent patterns of expression of this gene. In-
deed, when cell lines were considered individually, it was observed that IOSE11 displayed
highest levels of expression of both of these genes, and that expression was progressively
reduced in the oncogene-expressing, neoplastically transformed cells.
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Figure 4.51: Gene expression of genes local to the 3q25 susceptibility locus
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The ﬁnal susceptibility locus is on chromosome 3p25. The gene nearest to the 3p25
susceptibility is TiPARP. In both independent cell lines, this gene was downregulated in
IOSECMY C and IOSECMY C.KRAS cell lines (Figure 4.51). SSR3 was also signiﬁcantly
downregulated in all oncogene-expressing cell lines.
4.7 Conclusions and Discussion
Despite the discovery of the ovary-speciﬁc M¨ ullerian inhibiting substance receptor type II,
an in vivo model which accurately reﬂects epithelial ovarian cancer (EOC), a disease which
is late-onset and histologically heterogeneous, has yet to be established. Therefore, in this
Chapter, I describe an in vitro approach to modelling early ovarian neoplasia. Normal
ovarian surface epithelial (NOSE) cells were isolated from patients with histologically nor-
mal ovaries and characterised to conﬁrm the origin of the cells and the non-tumourigenic
nature of the cell lines (Chapter 3). In this Chapter, the sequential introduction of deﬁned
genetic elements into NOSE cell lines is described, as an in vitro model of ovarian cancer
development. Genes were selected that are known to be altered in EOC specimens, namely
hTERT, C-MYC, KRAS and BRAF.
hTERT
The human telomerase gene (hTERT) is expressed in the majority of malignant EOCs
[Brustmann, 2005]. However, ectopic expression of hTERT alone did not induce anchorage-
independent growth or the expression of ovarian cancer markers (CA125 and E-Cadherin)
in three independent NOSE cell lines. The immortalised NOSE cell lines (IOSE) also
maintained a normal diploid karyotype post-immortalisation. Thus, although expression
of hTERT extended the in vitro lifespan to over 200 days, telomerase expression not in-
duce any other features of a transformed phenotype. This is consistent with previous
models describing immortalisation of NOSE cells with hTERT alone or in combination
with a small interfering RNA targetting p53 or pRb [Li et al., 2007]; [Yang et al., 2007a];
[Yang et al., 2007b]. Recently, it has been reported that dysregulation of cyclin D1 or cdk4
alone or in combination with ectopic expression of hTERT was insuﬃcient to immortalise
OSE cells and that dysregulation of all 3 elements is required [Sasaki et al., 2009]. This is
in contrast to the results reported here and by this laboratory previously [Li et al., 2007].
It may be that diﬀerent culturing media have an inﬂuence on the potential to immortalise
cells. Also, patient age was not reported in the study by Sasaki and colleagues; but cells
from elderly patients do have a reduced in vitro lifespan and may perhaps be more diﬃcult
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to immortalise. In IOSE cells high levels of endogenous cyclin D1 were observed, suggest-
ing that IOSE cells were eﬃciently transducing extracellular growth signals. However,
this signal did not result in enhanced entry into mitosis as levels of cdk4, cyclin A and
cyclin E were lower in the IOSE than in the transformed cell lines. This suggests that
IOSE cells exhibit more dependency on external growth factors for stimulating entry into
mitosis than the transformed cell lines. Cell lines expressing oncogenes appeared to have a
cell cycle signalling cascade which was activated in the absence of high levels of cyclin D1,
suggesting the oncogene-expressing cells enter mitosis independently of external growth
factor signalling.
IOSE cells are a good alternative model of primary normal ovarian surface epithelial cells,
which can only be maintained in vitro as short-term cultures. It remains to be determined
whether extended passaging in vitro will introduce karyotypic abnormalities and cause cells
to acquire transformed characteristics, though hTERT-immortalised cell lines can undergo
extensive passaging without signs of malignant transformation [MacKenzie et al., 2000].
hTERT is not expressed in normal adult somatic cells but is often expressed in cancer
cells, and so has considerable potential as a therapeutic target that is speciﬁc for tu-
mour cells. Inhibition of telomerase induces cell death of ovarian cancer cells in vitro
[Saretzki et al., 2001]. Transgenic cell lines engineered to express hTERT, such as IOSE
cell lines, oﬀer a model system for the testing of gene-speciﬁc therapeutics in a tightly
controlled in vitro system. Additionally, the hTERT promotor has been employed in the
development of oncolytic viruses and was demonstrated to sensitize ovarian cancer cells to
cisplatin in an in vitro model [Takakura et al., 2009]. Bilsland and colleagues utilised the
hTERT promotor to drive bacterial nitroreductase (NTR) in an adenoviral suicide gene
therapy model and were able to selectively sensitise cancer cells to a prodrug (CB1954,
converted to a highly toxic compound by the NTR gene) [Bilsland et al., 2003].
C-MYC
Copy-number increases at 8q24 (the C-MYC locus) are common events in ovarian can-
cers and are found in 35−76% of malignant EOCs analysed by ﬂuorescent in situ hy-
bridization and comparative genomic hybridization [Dimova et al., 2006] (and references
therein). C-MYC ampliﬁcation occurs less frequently in benign/low malignant poten-
tial subgroups than in malignant EOCs [Dimova et al., 2006]. C-MYC ampliﬁcation has
also been correlated to platinum resistance [Wasenius et al., 1997]. Additionally murine
models and in vitro models of EOC have demonstrated an important role for C-MYC
[Orsulic et al., 2002]; [Sasaki et al., 2009]. Thus, the eﬀect of overexpressing C-MYC in
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phenotypically normal IOSE cell lines was tested. Overexpression of C-MYC in three
IOSE cell lines (IOSECMY C) induced features of a neoplastic phenotype. IOSECMY C
cells showed rates of anchorage-independent growth that exceeded or were comparable to
ovarian cancer cell lines, and anchorage-independent growth was positively correlated to
relative C-MYC mRNA expression. IOSECMY C were more proliferative than IOSE cell
lines but were not more invasive. Therefore, IOSECMY C cell lines are partially trans-
formed OSE cells. These cell lines are a novel tool for testing environmental factors that
are suspected to have a role in EOC initiation or early development. Such factors that
could be investigated include organismal ageing (described in Chapter 5), steroid hormones
or chemical carcinogens. Similarly, by comparing the phenotypic eﬀects of introducing or
knocking down speciﬁc genes in IOSE and IOSECMY C, it would also be possible to inves-
tigate the role of novel genes that are suspected to play a role in EOC susceptibility or
early tumourigenesis.
In normal human cells, there are few reports of anchorage-independent growth induction by
expression of hTERT and C-MYC alone [Drayton et al., 2004]. This present study is the
ﬁrst to report that co-expression of hTERT and CMYC induces anchorage-independent
growth in normal ovarian surface epithelial cells. This phenotype was observed in multiple
cell lines (n=3) and multiple CMYC-overexpressing clones (n=7). Previous report have
described the induction of anchorage-independent growth in the presence of other onco-
genic elements [Sasaki et al., 2009]. The data described here suggests that NOSE cells
are inherently more susceptible to transformation in vitro and in vivo, and this may be a
hint as to why human ovarian tumours progress very rapidly. Divergent techniques used
for immortalisation and transformation make it diﬃcult to directly compare phenotypic
data across diﬀerent in vitro studies. Furthermore, protocols for in vitro and in vivo tu-
mourigenicity assays vary signiﬁcantly between studies (Table 4.3). To better understand
the susceptibility of NOSE cells to transformation relative to other cell types, it would be
necessary to transform diﬀerent cell types using the same genetic elements, and to assay
the transformed phenotype using consistent protocols. It is also true that this model rep-
resents NOSE cell transformation in a highly mitogenic microenvironment (see Chapter
3). The mitogenic culture environment of NOSE-CM reﬂects the conditions of OSE cells
trapped within an inclusion cyst, with direct contact to the mitogenic ovarian stroma.
To understand this more fully it would be necessary to isolate OSE in diﬀerent types of
culture medium, transform the cells in vitro with hTERT, C-MYC and KRAS/BRAF
and compare the in vitro tumourigenicity with the data reported here. Indeed, Weinberg
and colleagues isolated diﬀerent types of normal mammary epithelial cells by culturing
breast biopsies in two diﬀerent types of cell culture medium. The primary cultures were
maintained in the diﬀerent media and transformed in vitro with hTERT+SV40t+HRAS,
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and the resulting tumours in mice were of distinct histologies. Following in vitro transfor-
mation, one cell type was much more tumourigenic than the other: this cell type formed
tumours when 104 fold fewer cells were injected into mice, and formed metastastic deposits
[Ince et al., 2007]. This demonstrates that simply altering culture medium components
can have profound eﬀects on the outcome of in vitro models of transformation.
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Table 4.3: Previous transformation models. Direct comparisons are diﬃcult due to variation in
genes used, and protocols for in vitro and in vivo tumourigenicity assays.† CFE = colony formation
eﬃciency, where number of colonies was reported instead of CFE, the CFE was calculated using the
formula described in the Materials and Methods. In brackets the number of cells plated/injected
are indicated. DN-p53 = dominant negative p53 allele.
KRAS/BRAF
Expression of activated RAS or RAF in most normal cells will induce a tumour sup-
pression pathway which triggers cellular senescence [Denoyelle et al., 2006]. Denoyelle
and collegues investigated the mechanisms involved in senescence induced by infection of
oncogenic HRAS and BRAF alleles into human melanocytes. Mutated forms of both these
genes are frequently found in naevi (moles) and melanocytes harbouring RAS or RAF mu-
tations senesce prematurely, thus suppressing the tumourigenic eﬀects of these mutations.
This study observed diﬀerences in the features of senescence initiated by these two genes -
ﬁrstly BRAFV 600E-induced senescence took signiﬁcantly longer to occur than senescence
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induced by HRASG12V . Secondly, HRASG12V -induced senescence caused extensive disrup-
tion of the endoplasmic reticulum even before classical senescence markers, such as positive
staining for β-galactosidase, are detectable. This response appeared to be in part due to
activation of the ER-associated unfolded protein response (UPR). Despite activating a
downstream target, ERK, to the same extent as HRASG12V , BRAFV 600E does not induce
an ER-associated UPR and hence diﬀerent processes are involved in BRAFV 600E-induced
cell senescence [Denoyelle et al., 2006].
In this present study, mutant alleles of KRAS and BRAF were introduced into IOSE
and IOSECMY C cell lines. The most commonly found mutation in EOCs for each gene
was selected (G12V for KRAS, V600E for BRAF). It was anticipated that both genes
would induce senescence of phenotypically normal cells, as described above. However,
surprisingly, 2/3 IOSE cell lines were able tolerate expression of mutant KRAS in mul-
tiple clones tested (n=6). In contrast, mutant BRAF alleles induced higher rates of
senescence than KRASmut in all 3 IOSE cell lines. This may suggest that an oncogene-
induced senescence (OIS) response in IOSE cells is mediated mainly through BRAF and
the MAPK pathway. Indeed, BRAFV 600E expression did activate MAPK signalling more
than upstream KRASG12V as at ERK1/2 was more elevated in CMYC/BRAF cell lines
than CMYC/KRAS cell lines. This was in contrast to the observations of Denoyelle and
colleagues, which suggests that KRAS and HRAS may have diﬀering roles in cellular
senescence. Expression levels of BRAFV 600E mRNA were consistently lower than expres-
sion levels of KRASG12V observed in selected clones, which suggests that elevated levels of
BRAFmut were less tolerable than elevated levels of KRASmut in the two IOSE cell lines
tested. Double mutants expressing mutant BRAF also had the highest rates of anchorage-
independent growth and 3D proliferation. In combination, these data suggest that in this
model, expression of BRAFV 600E was associated with more potent oncogenic signalling
than KRASG12V .
cDNA microarrays have been used to demonstrate that immediate transcriptional re-
sponses to RAS includes not only activation of RAF and the MAPK pathway, but also
other downstream eﬀectors including the PI3K pathway and Ral-GDS (see Figure 4.52).
In comparison, activated RAF in human mammary epithelial and OSE cells evokes a
transcriptional response mediated almost entirely through MAPK pathway, with a sig-
niﬁcant involvement by autocrine signalling. Inhibition of the epidermal growth factor
(EGF) receptor reduces cells transcriptional response to RAF activation by around one-
half [Schulze et al., 2004]. In this present study, elevated expression of EGFR was ob-
served in the IOSECMY C.BRAF clones, which may be indicative of activation of an EGFR-
dependent positive feedback mechanism. Activation of EGF-associated proteins appears to
play a vital role in RAF-associated transformation, since autocrine-loop activated EGFR
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was necessary for cells to evade a normal apoptotic response upon detachment from the
extracellular matrix [Schulze et al., 2001]. Incessant stimulation of EGFR may therefore
be acting in synergy with the expression of mutant KRAS/BRAF alleles in the NOSE
transformation model, to promote the development of the neoplastic phenotype observed.
Figure 4.52: MAPK and PI3K pathways and downstream signalling, image from Dilworth
[Dilworth, 2002]. The two pathways are closely interlinked, as RAS can activate PI3K, and thus
also activated additional transformation pathways such as PKC, RAC/cdc42 and SGK. The poly-
oma middle T antigen (MT, red); a potent viral inducer of neoplastic transformation in mammalian
cells; can activate both the MAPK and PI3K pathways, via son-of sevenless (SOS) and the SH2
domain in the p85 subunit of PI3K.
KRAS/BRAF mutation status in EOCs could potentially be used to design tailored tu-
mour therapies. In ovarian cancer cell lines harbouring mutations in KRAS or BRAF
it has been demonstrated that inhibition of MEK results in increased rates of apoptosis
and inhibition of growth [Pohl et al., 2005]. This response was absent in ovarian cancer
cell lines with wild type KRAS and BRAF. This suggests that regardless of other path-
ways that are activated by a constitutively active allele of KRAS, the MAPK pathway
is essential for the survival of the cells lines carrying mutations in either of these genes
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[Pohl et al., 2005]. As it is known that the proliferative response to RAS is mediated
through many other pathways such as the phosphatidylinositol 3-kinase (PI3K) pathway,
these data are interesting from a clinical perspective, since targeted inhibition of a single
pathway could inhibit tumour growth [Schulze et al., 2004]. Indeed, many components
of the MAPK/PI3K pathways, particularly mTOR, are being investigated as therapeutic
targets in clinical trials currently underway. The cell line models developed in this project
could be used as a controlled system in which new drug therapies targetting the MAPK
pathway could be developed and tested.
It is not uncommon for cancer cell lines harbouring KRAS mutations to be highly sus-
ceptible to inhibition of MAPK signalling or siRNA knockdown of the KRAS gene. This
phenomenon is termed ‘oncogene addiction’ [Scholl et al., 2009]; [Singh et al., 2009]. As
KRAS signalling is involved in many important metabolic pathways, inhibition of KRAS
is likely to have high toxicity. RNAi screens testing for genes which are synthetic lethal
in combination with a mutant KRAS alleles have identiﬁed enzymes involved in mitosis
(including PLK1 and APC) and STK33 as candidate therapeutic targets for targetted in-
duction of apoptosis. The synthetic lethal approach was used to identify PARP inhibition
as targetted treatment for BRCA1/2 patients with tumours that are deﬁcient in DNA
repair [Farmer et al., 2005]. PARP inhibitors proved to be highly eﬀective therapies in
clinical trials [Fong et al., 2009].
Mutant RAS and RAF activate distinct pathways in the cell and hence enable the cell to
acquire diﬀerent transformation-associated characteristics. Previous in vitro and in vivo
models have employed eﬀector-speciﬁc RAS allele to demonstrate that the many pathways
activated by oncogenic RAS play distinct roles in tumour development [Gire et al., 2000];
[Janda et al., 2002]. BRAFV 600E was a more potent inducer of senescence in IOSE cells,
and MAPK signalling in IOSECMY C cells. BRAF expression in IOSECMY C cells was
also associated with enhanced proliferation in 3D, relative to expression of mutant KRAS.
Janda and colleagues have previously found that PI3K pathway activation was required to
induce proliferation of mammary epithelial cells in 3D collagen gels [Janda et al., 2002].
However, in this study, reduced proliferation in 3D culture was associated with expression
of KRASG12V . Phenotypic data described here suggests that in ovarian epithelial cells,
KRAS/BRAF have distinct functional roles and induce diﬀerent phenotypes in vitro.
There is also, unsurprisingly, much cross-over in the phenotypic eﬀects of these oncogenes
as both genes enhanced features of transformation in IOSECMY C cell lines in anchorage-
independent growth and invasion assays. Furthermore, expression of mutant KRAS and
BRAF both induced commitment to an epithelial phenotype in IOSE/IOSECMY C cells,
as measured by observation of cell morphology and cytokeratin-7 expression. Gene ex-
pression assays conﬁrmed that there were distinct sets of genes and also many genes in
191Chapter 4 4.7 Conclusions and Discussion
common in the transcriptional responses to prolonged (20 passages in culture) expression
of KRASG12V or BRAFV 600E.
4.7.1 Modelling Ovarian Cancer In Vitro
In 1999, Hahn and colleagues ﬁrst created tumour cells in vitro by the introduction of
viral and human oncogenes [Hahn et al., 1999]. Since that ﬁrst study, the transformation
of many other cell types has been reported, of which many are described in Table 4.3.
For ovarian cancer, three studies to date have reported diﬀerent approaches to modelling
EOC development in vitro [Kusakari et al., 2003]; [Liu et al., 2004]; [Sasaki et al., 2009].
All three models use normal ovarian surface epithelial cells. Kusakari and colleagues
immortalised OSE cells by expressing SV40T and hTERT. Subsequent overexpression of
ERBB2 or HRASmut created cell lines that were more resistant to apoptosis induced
serum-starvation than parental cell lines, and formed undiﬀerentiated tumours in mice
[Kusakari et al., 2003]. Liu and colleagues took OSE cells that had been immortalised by
hTERT plus SV40t, and introduced mutant HRAS and KRAS alleles. Transformed cells
formed tumours in mice that were positive for CA125. Transformed cells also displayed
upregulated expression of a number of cytokines, and were sensitive to apoptosis induction
by blocking antibodies against IL-1β and IL8 [Liu et al., 2004].
In these two models, cells displayed tumourigenic features in vitro and expressed epithelial
and/or ovarian cancer markers in vivo. However, these models are limited by the fact that
SV40 is not found to be involved in human EOCs, and the molecular eﬀects of SV40 are
not yet fully understood. In 2009, Sasaki and colleagues took a more biologically relevant
approach to modelling EOCs in vitro and transformed OSE cell lines with oncogenic
versions of genes that have been shown to be involved in EOCs. They included p53
AKT, PIK3CA, PTEN, C-MYC and KRAS. In their model, OSE cells were immortalised
with cyclinD1, cdk4 and hTERT. This group found that the overexpression of AKT, or
knockdown of PIK3CA/PTEN, conferred in vivo tumorigenic potential on IOSE cells
that already express a dominant negative allele of p53 in combination with KRASG12V
[Sasaki et al., 2009]. However, the tumours formed in mice were mainly sarcomatous or
poorly diﬀerentiated. Although tumours were cytokeratin-18 positive, CA125 was not
detected in culture supernatant, or in xenograft tumours.
This present study aimed to add to this body of work by looking speciﬁcally at the MAPK
pathway. As with previous studies, this work has been performed using NOSE cells. How-
ever, it is now becoming widely accepted that EOCs are heterogeneous in origin and so in
future, this will need to be incorporated into studies that model ovarian cancer develop-
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ment in vitro (Table 4.4). For example, up to 40% of endometrioid and clear cell tumours
are associated with endometrioitic plaques [de la Cuesta et al., 1996], and so a cell biology
model of these subtypes would ideally focus on transforming endometrial epithelial cells in
parallel to transformation of the OSE, using genes known to be altered in these subtypes,
namely PTEN and mismatch repair genes [Martini et al., 2002]; [Dinulescu et al., 2005].
An as yet unquantiﬁed proportion of high-grade serous EOCs appear to arise as primary
fallopian tube neoplasms [Jarboe et al., 2008] and so it would be valuable to transform
fallopian tube epithelia and the OSE by altering BRCA1/2 and p53 to create an in vitro
model of this subtype. By comparing all of these models, it may be possible to glean some
much needed insight into the real origins of all EOC subtypes and to learn more about
what genetic alterations may be involved in the earliest stages of tumour development for
all EOC histotypes.
PTEN, β-catenin, HOXA10, p16, MMR genes OSE, EEC Endometrioid
PIK3CA, p16, MMR genes
KRAS, HOXA11
KRAS, BRAF
BRCA1/2, TP53, HER2, HOXA9
Genetic alterations
OSE, EEC Clear Cell
OSE Mucinous
OSE Low-grade/borderline serous
OSE, FTE High-grade serous
Cell(s) of Origin Histological Subtype
Table 4.4: In vitro cell biology modelling of EOC subtypes may require distinct in vitro models.
OSE = ovarian surface epithelium; FTE - fallopian tube epithelium; EEC = endometrial epithelial
cells.
3D in vitro models are arguably a more biologically more relevant tool for studying trans-
formation than traditional 2D monolayer cultures. Spheroids are thought to be reminiscent
of earliest stages of tumour development, when small avascular nodules of transformed cells
develop in the normal tissue [Sutherland and Durand, 1976]; [Ghosh et al., 2005]. In this
study, transformed ovarian epithelial cell lines were grown as 3D spheroids and the pro-
liferation rates were compared to the same cells grown in 2D. IOSE cell lines underwent
growth arrest in 3D culture and proliferated slowly in spheroid cultures. This suggests
that the IOSE cells in 3D are in a more functionally relevant state, as OSE cells in vivo
are generally non-proliferative. However, the transformed cell lines had increased rates
of 3D proliferation. This eﬀects was not detected in 2D Alamar Blue proliferation as-
says. This may be due to the fact that parental IOSE cells proliferate rapidly in 2D and
so it is not possible for derivative cell lines to exceed the proliferation rate of parental
cell lines. Alternatively, the proliferative eﬀect induced by KRAS/BRAF expression may
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only be apparent in 3D spheroid cultures, as previously found for breast epithelial cells
[Janda et al., 2002]. Signiﬁcant diﬀerences in IOSE and IOSECMY C proliferation were
detectable in 2D using BrdU incorporation, but were not detected by the Alamar Blue
approach, suggesting Alamar Blue is a less sensitive method of detecting diﬀerences in
cell proliferation between cell lines. However, the Alamar Blue technique has two major
advantages over other, (endpoint) proliferation assays (such as MTT): (1) proliferative
rates can be analysed over extended periods of time (2) proliferative rates of cells in 2D
and 3D can be analysed.
4.7.2 Identiﬁcation of Novel Genes Dysregulated During Neoplastic Pro-
gression of the OSE
Transcriptome proﬁling can be used to compare total gene expression proﬁles of two or
more test groups (e.g. cancer versus normal; subtype X versus subtype Y; early stage
versus late stage). A list of ‘top’ ranked diﬀerentially expressed genes (by fold change or
signiﬁcance) can then be identiﬁed. These genes are novel markers to distinguish the test
groups. Often a gene expression signature is created in which the expression of a group
of genes is used as a predictive or discriminatory tool. In ovarian cancer, gene expression
microarray proﬁling has been used to identify genes associated with BRCA1/2 status,
molecular signatures of clinical outcome, chemotherapeutic response, tumour diﬀerentia-
tion and histological subtype [Jazaeri et al., 2002]; [Jazaeri et al., 2003]; [Lu et al., 2004];
[Berchuck et al., 2005]; [Jazaeri et al., 2005]; [Tothill et al., 2008]; [Berchuck et al., 2009].
The genes that have been implicated in EOC, discovered through gene expression mi-
croarray studies are listed in Table 4.5. Each gene expression study has described genes
that are signiﬁcantly diﬀerentially expressed in each data set. Unfortunately, there is little
cross-over between the reported genes between studies, and functional data to follow-up
candidate genes is rarely reported. Genes reported as important in EOC include regu-
lators of mitosis, genes in the MAPK pathway (particularly in the low grade tumours),
regulators of proliferation, ECM components, β-catenin signalling molecules and genes
involved in immune signalling. Reassuringly, we have observed some of these genes to be
similarly dysregulated in our model, including DUSP1, DUSP6, CCNE1, and UBE2C.
Due to the rarity of early EOC specimens, there are few reports describing proﬁling of
gene expression changes that occur during the early stages of tumourigenesis of the OSE
[Marchini et al., 2008]. Therefore, in this study, the transcriptomic changes associated
with early neoplastic progression in an in vitro model of ovarian cancer development
were proﬁled. This is the ﬁrst time that the transcriptomic consequences of hTERT plus
CMYC +/- KRASmut or BRAFmut have been proﬁled in NOSE cells. The gene expression
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Lu  et al., 
2004
Included genes involved in the Notch, Rb
and MAPK pathways and cell adhesions
NOTCH3, E2F, RAC-GAP1, 
HN1, CLDN3
4 genes distinguished 
all EOCs from OSE
EOCs - various 
stage/grade/ 
subtype, OSE 
brushings
Berchuck
et al., 
2009
Incl. genes involved in T-cell signalling, 
ATP metabolism, proliferation, RNA 
processing, cell adhesion
MAL, APMCF1, PRPS2, 
L3MBTL, HNMT, RANBPM, 
DGCR2
7 genes were 
independent 
predictors of poor 
survival
Stage I, II, III, IV 
and low-
malignant 
potential tumours
Marchini
et al., 
2008
Regulation of mitosis and DNA 
replication
CCNE1, MCM5
Profiles relate to 
histology or 
differentiation
Stage I and 
borderline serous 
tumours
Homeobox genes, N/P-Cadherins, β-
catenin signalling pathway associated 
genes, ECM genes, proliferation genes
Novel HGS subtype: HOXA7, -
A9, -A10, -D10, HGMA2, 
CDH2/3, COL4A5, CLDN6
β-catenin signalling pathway     
associated genes
Low-grade endometrioid: 
BMP4, CCND1, CD44, FGF9, 
EPHB3, MMP7, CST1
Tothill et 
al. 2008 MAPK-associated genes
Low-grade serous:DUSP4, 
DUSP6, SERPIN5A, MAP3K5, 
SPRY2
Six molecular 
subtypes identified, 
including a novel 
high-grade serous 
(HGS) subtype that 
has mesenchymal 
features
Serous and 
endometrioid 
tumours of the 
ovary, 
peritoneum and 
fallopian tube
Amylase proteins Serous: AMY2B, CHI3L1
β-catenin signalling Endometrioid: 16q31, 14q32
Oxidation/reduction, regulation of 
ATPases, retinol binding
Clear cell: GPX3, GLRX, 
FXYD2, RBP4
Marquez 
et al. 
2005
Immune response, mucosal proteins,  
cell adhesion
Mucinous:TFF1, AGR2, 
LGALS4, CEACAM6, CTSE
Profiles of serous 
EOCs resemble that 
of FTE cells, 
mucinous EOCs
resemble colonic 
epithelia, 
endometrioid and 
clear cell resemble 
the endometrium
EOC histotypes, 
NOSE brushings, 
FTE cells, 
colonic mucosa, 
normal 
endometrium
ECM components/ ECM remodelling 
proteins
DCN, Col6A3, SPARC
Topoisomerases, spindle formation TOP1, TOP2A, ZWINT
Genes involved in cell cycle progression, 
RTK and MAPK signalling, matrix 
assembly
DOC1, CAV1, DUSP1, ITM2A,  
KLF4
Jazaeri
et al. 
2005
Oxidising enzymes and negative 
regulators of proliferation (higher in post-
chemo)
ADH1B, ADH1C, ALDH2, 
CDKN1C, ADAMTS1
760 genes 
differentially 
expressed in primary 
chemosensitive v 
post-chemotherapy. 
230 genes in primary 
chemoresistant v 
post-chemotherapy. 
85 genes in primary 
chemosensitive and 
chemoresistant
tumours
Primary 
chemosensitive, 
post-
chemotherapy 
and 
chemoresistant
tumours
Interferon-inducible genes
IFTIM1/2, HLA-DRB1/5, CD74, 
HLA-DRA, HLA-DPA, BRF2, 
SGK, FOS
20q13
(incl. STK15, MYBL2, UBE2C, 
RAE1, CCNE1, CCHB1, NEK2, 
BUB1, TOP2A)
RUNX1/AML1
WNT2/SFRP4
UBL-1, HE4
Xp11.23
(incl WAS, PCTK1, UBE1)
Gene(s) / Chromosomal 
Region(s)
Jazaeri
et al. 
2003
Jazaeri
et al. 
2002
Ref.
Centrosome-related genes, genes 
involved in progression through the cell 
cycle and mitotic checkpoints, Aurora-
like/related proteins
99 genes differentially 
expressed in Grade I 
and Grade III tumours
Grade I and 
Grade III serous 
papillary 
carcinomas
Transcription factors, promote 
proliferation
Wnt/β-catenin signalling
Possible roles in homologous 
recombination and protease inhibition
Many, including proteins involved in 
ubiquitination, chromosomal 
maintenance, and the endoplasmic 
reticulum
Function
BRCA1/2 associated 
tumours have distinct 
profiles
BRCA1+, 
BRCA2+ founder 
mutation carriers; 
non-mutation 
carriers; IOSE 
culture
Observation Samples 
compared
Table 4.5: Previous gene expression studies of EOC tumour specimens have identiﬁed many
candidate markers of disease, as well as markers or proﬁles associated with diﬀerences in histology,
tumour grade, diﬀerentiation and chemotherapeutic response.
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array data were used to identify novel genes associated with early transformation of the
OSE. The best candidates emerging from this model are: THBS1, FEZ1, PITX1, RGS4,
MOCOS, CTGF and HIST1H4C. These genes were among the top 30 most signiﬁcant
changes observed in both IOSE11 and IOSE19 transformed with deﬁned genetic elements.
Furthermore, all of these genes showed some changes in expression associated with the
expression of CMYC alone, suggesting these changes are characteristic of the earliest
stages of transformation of the OSE.
Novel Tumour Suppressor Genes with a Role in Early EOC Development
Thromobospondin-1 (THBS1) expression was reduced up to 68.8-fold in the IOSE cell lines
that expressed oncogenic elements. This suggests that THBS1 is a candidate tumour sup-
pressor gene for EOC . This gene has been identiﬁed as an inhibitor of angiogenesis in
many types of cancers, including pancreatic and renal cell carcinomas [Laklai et al., 2009];
[Zubac et al., 2009]. THBS1 is widely expressed in adult tissues, with the highest expres-
sion seen in bone and the mammary gland (Figure 4.53). THBS1 is expressed in normal
adult ovaries, and in tumour specimens, loss of THBS1 is associated with enhanced tu-
mour vasculature and poorer patient survival [Alvarez et al., 2001]; [Secord et al., 2007];
[Papadaki et al., 2009]; [Zubac et al., 2009]. In vivo THBS1 null mice grow larger tumours
than control mice injected with the same ovarian cancer cells [Greenaway et al., 2009].
Loss of THBS1 expression may be associated with tumours harbouring aberrant MAPK
signalling. One study employed chemical inhibition of the MAPK pathway, which selec-
tively inhibited growth and increased apoptosis of EOC cell lines carrying mutant KRAS or
BRAF alleles. THBS1 was one of the genes that was signiﬁcantly upregulated in treated
cells [Pohl et al., 2005]. Furthermore, knockdown of HER-2/neu in breast and ovarian
cancer cell lines resulted in restored expression of THBS1. In 2003, a study from Wein-
berg and colleagues observed that levels of THBS1 and VEGF were correlated in an in vivo
tumourigenicity assay with mammary epithelial cells and kidney cells that expressed the
SV40 early region, hTERT, CMYC and HRASG12V . Knocking down THBS1 in the less
tumourigenic cell lines increased tumour formation in mice. Furthermore, overexpression
of CMYC was essential for the repression of THBS1 expression [Watnick et al., 2003].
THBS1 is an interesting gene for further study in in vitro models of ovarian cancer.
Loss of THBS1 in this model is an early event, but clinical studies have shown that
loss of protein expression in tumours is correlated to late-stage disease behaviour and pa-
tient outcome. In invasive EOCs, THBS-1 expression, detected by immunohistochemistry,
was associated with increased survival compared to tumours not expressing this protein
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Figure 4.53: Thrombospondin-1 is expressed in a large number of normal adult tissues. THBS1 is
highly expressed in bone marrow, the mammary gland, liver and colon. The graph shows the ratio
of observed number of expressed sequence tags (ESTs) to the expected number of ESTs for that
tissue. Data were downloaded from the Tissue-speciﬁc Gene Expression and Regulation website
http://bioinfo.wilmer.jhu.edu/tiger/
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[Alvarez et al., 2001]; [Secord et al., 2007]. This information could be used clinically to
identify the patients who may require the most aggressive therapy, or perhaps targetted
therapy to inhibit angiogenesis. Indeed, therapeutic potential of THBS1 has already been
explored in an orthotopic model of ovarian cancer. A synthetic peptide ABT-510, mimics
THBS1 and treatment with this drug reduced tumour size and metastasis in THBS1 null
mice. The tumours in ABT-510-treated mice had less developed vasculature and reduced
hypoxia [Greenaway et al., 2009].
Another candidate gene identiﬁed is FEZ1, on chromosome 8p22. This gene has not
been widely studied in ovarian tumours, but one recent study found that expression
of FEZ1 is very low/absent in 38% of EOCs [Califano et al., 2009]. Generally, loss of
8p22 is commonly detected in cancers, and FEZ1 may be lost in up to 60% of human
epithelial tumours [Ishii et al., 1999]. Loss of FEZ1 was associated with lymph node
metastasis in breast cancer and may occur by promotor methylation or somatic muta-
tion, resulting in loss of mRNA expression or truncation of the transcript respectively
[Chen et al., 2009]; [Ishii et al., 1999]. FEZ1, or fasciculation and elongation protein zeta
1, is involved in regulation of cell growth; FEZ1 hemizygous or null mice are more
susceptible to spontaneous and chemical induced carcinogenesis [Vecchione et al., 2007];
[Baﬀa et al., 2008]; FEZ1 null cells demonstrate altered progression through the cell cycle
and appear to exit mitosis more rapidly thatn FEZ1+/+ cells; and loss of FEZ1 results
in lower Cdk1 levels, which subsequently results in missegregation of chromosomes during
mitosis [Vecchione et al., 2007]. Therapeutically, FEZ1 is also an interesting candidate.
In cancer cells lacking this gene, re-expression of FEZ1 reduces in vivo tumourigenicity
and inhibits cell growth in vitro [Ishii et al., 2001]; [Vecchione et al., 2002].
A third candidate tumour suppressor was also identiﬁed in this study, namely RGS4 (reg-
ulator of G-protein signaling 4). Loss of expression of RGS4 has been shown to promote
breast cancer migration and invasion [Xie et al., 2009]. In an orthotopic model of pancre-
atic cancer, RGS4 expression was reduced at the invasive front and metastases, relative
to primary tumours [Niedergethmann et al., 2007]. Breast cancer cell lines engineered to
stably express RGS4 demonstrate impaired tumour growth in vivo, due to the attenuated
invasive capacity of the cells [Xie et al., 2009].
Finally, CTGF (connective tissue growth factor) was also identiﬁed as a candidate tumour
suppressor gene in EOC. CTGF is expressed in a variety of adult tissues, including bone,
bone marrow and small intestine, and also the adult ovary (Figure 4.54). In embryonic
mice, CTGF is expressed predominantly in endothelial cells and blood vessels of the lung
and cardiovascular system, and also in the brain [Friedrichsen et al., 2003]. Furthermore,
in adult mice, strong expression of CTGF was observed in the mesenchyme surround-
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ing ovarian follicles, suggesting that CTGF may have a role in follicular development
[Friedrichsen et al., 2005].
This gene was expressed highly in IOSE cell lines, but expression was reduced by 86%
in IOSECMY C cells, 77 and 78% in the IOSECMY C.KRAS/BRAF cell lines (relative to
IOSE). One previous study has found that reduced CTGF was associated with enhanced
invasiveness of ovarian cancer cell lines in vitro [Barbolina et al., 2009]. Interestingly, these
researchers also observed that CTGF expression was reduced in 3D cultures relative to the
same cells grown in 2D. 100% of primary OSE samples expressed CTGF, whereas around
50% of ovarian cancer showed reduced expression of this gene [Barbolina et al., 2009].
CTGF is a mediator of tumour-stroma interactions, but the mechanisms by which CTGF
modulates epithelial tumourigenicity is likely to be complex and appears to involve TGF-β
signalling, which is pro- or anti-tumourigenic, depending on the context. In other types of
epithelial carcinomas, increased CTFG has been shown to be associated with aggressive
tumour behaviour, and is upregulated in invasive tumour models compared to non-invasive
counterparts [Liu et al., 2008]; [Mazzocca et al., 2009]. In hepatocellular carcinoma, for
example, CTGF expression is associated with increased invasiveness, and inhibition of the
TGF-β receptor inhibits CTGF expression, tumour stroma development and metastasis
[Mazzocca et al., 2010]. However, it is of note that the in vitro modelling described in this
chapter did not incorporate a stromal component, and a heterotypic model plus stimulation
with TGF-β would be a more appropriate model for studying this pathway.
Novel Oncogenes Associated with Early Ovarian Cancer Development
PITX1 (paired-like homeodomain transcription factor 1) mRNA expression was low in the
IOSE but elevated in IOSECMY C and clones co-expressing mutant KRAS/BRAF. Previ-
ously, both overexpression and downregulation of this gene in tumours has been reported
[Chen et al., 2008]. In a murine model of ovarian granulosa cell tumours, PITX1 was over-
expressed in transformed cells relative to normal ovarian samples [Boerboom et al., 2006].
Overexpression of this gene was found in 5/9 invasive pituitary tumours [Wierinckx et al., 2007].
Furthermore, PITX1 has been identiﬁed as a potential suppressor of mutant RAS activ-
ity in prostate, bladder and colon cancer cells [Kolfschoten et al., 2005]. It may be that
expression of this gene is an endogenous tumour suppressive mechanism to attempt to
counteract the eﬀects of ectopically enhanced MAPK signalling in partially transformed
cell lines. Studies in larger numbers of ovarian tumours will be necessary to determine
whether this gene is relevant in EOC.
MOCOS (molybdenum cofactor sulfurase) is a second candidate oncogene identiﬁed in
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Figure 4.54: Connective tissue growth factor is expressed in a large number of normal adult tissues.
CTGF is highly expressed in bone, bone marrow, small intestine, soft tissue, stomach and spleen.
CTGF is expressed in the normal ovary. The graph shows the ratio of observed number of expressed
sequence tags (ESTs) to the expected number of ESTs for that tissue. Data were downloaded from
the Tissue-speciﬁc Gene Expression and Regulation website http://bioinfo.wilmer.jhu.edu/tiger/
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this study. This gene was overexpressed in 5/6 cell lines expressing oncogene(s), relative
to IOSE. This gene has not been widely described. The same is true for HIST1H4C
(histone cluster 1, H4C) which has been identiﬁed as a susceptibility gene in therapy-
related myeloid leukemia [Bogni et al., 2006]. Histone modiﬁcations can contribute to
carcinogenesis by modulating transcription of local genes by aﬀecting the strength of DNA-
histone binding, and thus aﬀecting access of DNA transcription machinery to the gene
regions. Not interactions between MOCOS and CMYC/RAS/RAF have been reported
to date.
It is of note that many of the most signiﬁcant genes identiﬁed in this model are extracellu-
lar matrix genes (Thromobospondin-1, Collagen I and III subunits) and genes involved in
recruitment of stromal cells (Thromobospondin-1) or genes involved in invasion of the local
microenvironment (RGS4). It appears that many genes identiﬁed in this study are associ-
ated with the exploitation of the local microenvironment, which is perhaps not surprising
as the 3D spheroid cultures are thought to represent tumour cell nodules preceeding the
development of vasculature. Stromal components can be potent tumour therapies. The
most eﬀective drug therapies that aim to kill the cancer cells directly will always induce the
strongest natural selection, and so inherently promote the development of a resistant pop-
ulation. However, natural selection acting on public goods, that is shared, stromal factors
(e.g. angiogenesis promotors), will be lower, as only a small proportion of the tumour cell
population need to make ‘public goods’ for the entire tumour to beneﬁt. Thus, targetted
inhibition of public goods is less likely to result in tumour resistance and therefore more
likely to be an eﬀective tumour therapy.
Gene expression microarrays oﬀer a rapid way to characterise transcriptomic changes in
cell biology models. Working with in vitro models removes the eﬀect of sampling a small
portion of a tumour, the gene expression proﬁle of which may not represent changes found
throughout the entire tumour. In vitro models can also be closely controlled to examine
the eﬀects of speciﬁc genetic alterations without the complexities of an in vivo system such
as stromal contamination and inter-tumour heterogeneity. However, interesting changes in
gene expression identiﬁed in in vitro model must be rigorously validated to ensure ﬁrstly
that the eﬀect is real in the model system and secondly, to test that the gene is diﬀerentially
expressed in normal and malignant ovarian cells in vivo. Once diﬀerential expression in
clinical specimens has been established, the next challenge is to establish that the gene
is functionally relevant and elucidate the mechanisms by which the candidate gene acts.
It would be of interest to see whether the candidate EOC TSGs and oncogenes described
above are also dysregulated in 2D cultures of the same cells, to validate the hypothesis that
culturing in 3D induces the expression of genes associated with recruitment of a tumour
stroma.
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4.7.3 Other Genes of Interest Deregulated in this Model
Although the focus of this study was to identify novel genes involved with transformation
of the OSE, these data could be used in other studies e.g. by comparing the proﬁles with
EOC cell lines/tumour proﬁles to identify additional oncogenes/tumour suppressor genes
important in EOCs. One could also compare the proﬁles with fallopian tube lines (normal
and transformed) to try and elucidate the true cellular origins of EOCs. Furthermore, one
could use these data to further explore the molecular mechanisms by which KRAS/BRAF
contribute to neoplastic transformation in this model. The pro-tumourigenic eﬀects of
KRAS/BRAF were enhanced in a CMYC-overexpression background, compared to when
KRAS/BRAF mutant alleles were expressed in IOSE cell lines. In 2008, McMurray and
colleagues described the importance of identifying those genes that are only deregulated
when multiple oncogenes are expressed together, but the expression of this group of genes
did not change when the oncogenic elements were expressed singly [McMurray et al., 2008].
In this present study, it was possible to identify those genes that were regulated by mu-
tant KRAS or BRAF expression in a CMYC background. For KRAS these genes in-
clude: CST3, BSG, CAMK1, CES2, CABC1 and BBS2. For BRAF these genes include:
HOXC8, SAMSN1, STX10, XAB2, SUZ12 and CCS. Whether these genes are expressed
in IOSE lines expressing only mutant KRAS/BRAF is not yet known, but would be im-
portant to know to elucidate a role for these genes in the increased invasion and anchorage-
independent growth observed in the double-mutant lines.
4.7.4 Expression of Genes Implicated in Genetic Susceptibility to Ovar-
ian Cancer
This is a model of initiation and early-stage development of EOCs. Therefore, it follows
that some of the genes dysregulated in this model are also candidate EOC susceptibil-
ity genes. Five regions have recently been identiﬁed as containing genetic susceptibility
loci [Song et al., 2009] and [S.Gayther, personal communication]. One such susceptibil-
ity region for EOC is 8q24. The 8q24 region is a hotspot for single nucleotide poly-
morphisms (SNPs) that are associated with susceptibility to cancer. SNPs found within
this region have been linked to breast, prostate, colorectal and ovarian cancer suscepti-
bility (Figure 4.55) [Tomlinson et al., 2007]; [Eeles et al., 2008]; [Ghoussaini et al., 2008];
[Thomas et al., 2008]; [S.Gayther, personal communication]. The CMYC proto-oncogene
is located in this region, and represents an enticing candidate gene as it is involved in many
types of cancer and is commonly overexpressed or ampliﬁed. CMYC is known to be in-
volved in EOC, as described above, and once the causal variant at this locus is identiﬁed,
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and correlations between CMYC expression, genotype and phenotype could be readily
assayed.
Figure 4.55: Chromosome 8q24 is a hotspot for cancer susceptibility loci.
DDEF1 at 8q24 was diﬀerentially expressed in the model of NOSE cell transformation.
Both probes for this gene showed reduced expression in the cell lines expressing CMYC
plus mutant alleles of KRAS or BRAF. DDEF1 was also downregulated in IOSECMY C
compared to IOSE cell lines. This suggests that both cell lines were behaving as tumour
suppressor genes in this model. DDEF1, or development and diﬀerentiation enhancing
factor 1 (also known as ASAP1), may have a role in cell growth and remodelling of the
cytoskeleton by binding SRC and phosphatidylinositol biphospates (a key molecule in the
PI3K pathway) [Ha et al., 2008]. This gene has been reported to be overexpressed in a
panel of 25 high grade uveal melanomas, in which ampliﬁcation of the 8q24 region is com-
mon [Ehlers et al., 2005]. These data contrast with the observations in this present study,
although the eﬀects of diﬀerent genes are likely to vary between tissues, and expression of
DDEF1 in normal and malignant ovarian specimens has not yet be reported.
At the 9p22 locus, the gene nearest to a susceptibility association is BNC2. In a genome
wide susceptibility study (GWAS), 12 SNPs showed genome-wide signiﬁcance at this locus,
some of which were located within the coding region of the BNC2 (basonuclin 2) gene,
as shown in Figure 4.56 [Song et al., 2009]. In the current study, BNC2 expression was
reduced by 62% in the cell lines overexpressing CMYC, and by 74% and 79% in the
cell lines expressing mutant KRAS or BRAF. This suggests that loss of BNC2 may be
associated with cancer progression, and that BNC2 may act as a tumour suppressor gene.
BNC2 has been previously identiﬁed as a putative tumour suppressor gene in glioblastoma
and esophageal carcinoma [Nord et al., 2009]; [Akagi et al., 2009]. Work in this laboratory
has also found that expression of BNC2 is reduced in a panel of 23 ovarian cancer cell
lines when compared to 42 normal ovarian surface epithelial cell lines [M. Notaridou,
unpublished data]. BNC2 is a nuclear protein, widely expressed in many diﬀerent cell
types and has multiple mRNA and protein isoforms. Functionally, this gene appears to
have a role in mRNA processing within the nucleus, although the mechanistic role of
this gene in carcinogenesis remains poorly understood [Vanhoutteghem and Djian, 2006];
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[Vanhoutteghem and Djian, 2007].
BNC2
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Figure 4.56: Many EOC susceptibility loci fall within or near to the BNC2 gene. The SNP with
the most signiﬁcant association with ovarian cancer risk is shown in red. High linkage disequilibrium
is indicated by dark shading in the haplotype map. From [Song et al., 2009]
Also at the 9p22 locus is the CNTLN gene. In this model, CNTLN was upregulated in
IOSECMY C, IOSECMY C.KRAS/BRAF. CNTLN or centlein is a component of centrosomes;
but so far work on this gene has not been published. More investigation is required to
establish whether or not this gene is diﬀerentially expressed in normal ovarian epithelial
cells compared to epithelial ovarian cancer cells. At the 9p22 locus, BNC2 is currently
the most interesting candidate gene for functional analysis.
At the chromosome 19p13 locus, the gene nearest to a susceptibility association is MERIT40.
This gene did not appear to show diﬀerential expression in this transformation model, al-
though it represents an interesting candidate gene for ovarian cancer as it interacts with
BRCA1 [Feng et al., 2009]; [Shao et al., 2009]; [Solyom et al., 2009]. Early investigations
have suggested that this gene may be upregulated in ovarian cancer cell lines relative
to primary normal ovarian surface epithelial cell lines [M. Notaridou, unpublished data].
At this locus, two other genes were dysregulated in the transformation model - NR2F6
was upregulated in the cell lines expressing mutant KRAS/BRAF alleles in combination
with CMYC, as was MRPL34. NR2F6 is also an interesting candidate for EOC. This
gene may have a role in the immune system [Hermann-Kleiter et al., 2008], but also ap-
pears to interact with steroid hormones (luteinizing hormone and oestrogen) in rat models
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[Raccurt et al., 2005]; [Zhang and Dufau, 2000]. Interestingly, expression of this gene is
elevated in pregnant rats, and the gene product binds a hormone-responsive element in the
oxytocin promotor, antagonsising the action of oestrogen [Chu et al., 1998]. The role of
steroid hormones in EOC development is strongly supported by epidemiological data, but
the mechanisms by which hormones eventually cause EOC are poorly understood, partic-
ularly in the case of BRCA1/2 tumours which are largely speciﬁc to hormone-responsive
cells. MRPL34 is a mitochondrial ribosomal protein, and there is little published infor-
mation regarding this gene’s speciﬁc function or role in cancer.
At the chromosome 3p25 locus, two genes nearby to the susceptibility SNP are down-
regulated in the transformation model. These genes are TiPARP and SSR3. The SSR3
gene is poorly characterised. This signal sequence receptor is an endoplasmic reticu-
lum receptor with a role in protein traﬃcking. TiPARP is TCDD-inducible polyADP-
ribose polymerase. PARP proteins catalyze the addition of polyADP-ribose groups onto
other proteins, and TiPARP appears to selectively act on histones [Ma et al., 2001];
[Katoh and Katoh, 2003]. Little is known about this gene, but its role in DNA struc-
ture make it an exciting candidate for functional analyses. It has been shown that in
breast and ovarian cells with mutant BRCA1/2, targetted inhibition of PARP can selec-
tively kill the cancer cells. This synthetic lethality is due to the fact that cells deﬁcient in
functional BRCA1/2 protein can only repair DNA damage by a non-homologous recombi-
nation mechanism, in which PARP has an indispensable role [Farmer et al., 2005]. PARP
inhibitors have been shown in clinical trials to be highly eﬀective therapies for BRCA1/2
breast and ovarian carcinomas [Fong et al., 2009]. Whether PARP and TiPARP interact
directly or are part of a common pathway is unclear, and further studies are required
to unravel the mechanism by which loss of TiPARP may contribute to tumourigenesis.
However, it is known that altered histone ribosylation occurs during the repair of DNA
strand breaks and chromatin remodelling during DNA replication. Increased DNA DSBs
increases the ribosylation of histones by PARPs. PARP expression is also activated by
DNA strand breaks [Boulikas, 1989]. Histone poly(ADP)-ribosylation is also required for
chromatin unfolding during repair [Althaus et al., 1990]; [Boulikas, 1990]. The N-terminal
zinc-ﬁnger domain of PARP molecules bind to the DNA strand breaks, thus activating
the catalytic domain of the molecule. PARP molecules displace histones from the DNA,
thus allowing DNA strand breaks to be repaired [Althaus et al., 1994]. Thus PARP down-
regulation could contribute to tumourigenesis by preventing access of the cellular repair
machinery to the site of DSBs, thus increasing the chance of cell division without complete
repair of DNA DSBs.
Finally, a susceptibility association at chromosome 2p31 contains a cluster of HOXD genes.
HOXA genes are a distinct family of homeobox genes that have been previously implicated
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in ovarian cancer [Cheng et al., 2005]; [Ota et al., 2009]; [Widschwendter et al., 2009]. Dys-
regulation of HOXD genes in EOC has not yet been reported, but it is known that
HOXD genes are involved in limb and digit development (in particular HOXD10-13)
[Tsai et al., 1990]; [Sugie et al., 2009]. There was some suggestion that HOXD3 is up-
regulated in the IOSECMY C.KRAS cell lines relative to IOSE cultures. HOXD3 has pre-
viously been shown to promote invasiveness, motility and metastatic activity of lung
cancer cells by modulating the expression of adhesion molecules (integrin α-v β-3 and
E-cadherin) [Ohta et al., 2006]. HOXD3 has also been implicated as a promotor of an-
giogenesis and mediator of ECM remodelling during wound healing [Hansen et al., 2003];
[Boudreau and Varner, 2004]. However, in the present study, overall expression of most
HOX genes was very low, and close to background signal, and so further investigation
would be required to test expression levels of this gene in normal and malignant ovarian
cells. Recent data from this laboratory conﬁrm that HOXD3 is not expressed at high
levels in ovarian cell lines [M.Notaridou, unpublished data]. Transformation of IOSE11
was associated with reduced expression of HOXD10 and HOXD11, suggesting loss of these
genes could be implicated in transformation of the OSE. However, as this observation did
not replicate the the IOSE19 model, further testing would be required to see if this is a
real association.
The majority of the genes described above displayed high correlation of expression values
across the technical and biological replicates. These results suggest that transformation
models may be valuable tools in researching the functional eﬀects of susceptibility genes
that emerge from GWASs, particularly models which focus on early carcinogenesis, when
it is most likely that susceptibility genes play a role. In the analyses described here, it
is assumed that the functional eﬀects of susceptibility SNPs in non-coding regions are
mediated by a gene located immediately upstream or downstream of the locus. However,
this is likely to be an incorrect assumption in many cases, as it is known that non-coding
SNPs are likely to be modiﬁers, and that such elements can modify gene expression of
genes located on any part of that chromosome, or indeed, throughout the genome.
It is notable that a high proportion of the genes at each loci are dysregulated in this
cell transformation model. There were 794 genes were diﬀerentially expressed in cell lines
expressing mutant KRAS/BRAF compared to the IOSECMY C cell lines. With the as-
sumption that there are 20,000 genes in the human genome, this suggests that 0.04% of
genes are dysregulated in this cell model. This equates to approximately 1 in every 25
genes which further suggests that there is a higher than average distribution of dysregu-
lated genes at some susceptibility loci. This calculation does make many assumptions, as
genes are not distributed evenly throughout the genome, but it may suggest that some
susceptibility loci are transcriptional repressors or enhancers which aﬀect many expression
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of many nearby genes.
Limitations of the Model
In vitro cell biology modelling of disease has many limitations that may restrict the ap-
plicability of these approaches to understanding human disease. Primarily, the process
of cell culture selects for cells that are able to grow in 2D, on tissue culture plastics, at
concentrations of O2 and nutrients that greatly exceed physiological levels. In this thesis
I describe the use of 3D and heterotypic models (Chapter 5) to try and recreate some of
the features of the tissue in vivo that are lost in 2D monocultures, such as O2 and nu-
trient gradients, geometry and cell shape and heterogeneity of cell types. The 3D models
could be improved further by including additional cell types for example, or by the use of
synthetic scaﬀolds that can be engineered to release growth factors or hormones gradually.
A major limitation of this model in particular is that only a subset (∼20%) of ovarian
cancers contain genetic alterations in KRAS/BRAF, and ovarian cancer itself is a rela-
tively rare disease. Thus, arguably, any potential biomarkers that emerge from this study
may only be applicable to the detection of a small proportion of ovarian tumours. How-
ever, the IOSE and IOSECMY C model represents a valid in vitro model of the earliest
neoplastic changes in the OSE that is applicable across histotypes, as C-MYC ampliﬁca-
tion/overexpression may occur in up to 76% of EOC specimens and is not restricted to
one subtype [Dimova et al., 2006]. Furthermore, C-MYC overexpression is more common
in malignant tumours, which have the worst prognoses and so would beneﬁt most from
early detection.
A further limitation of this study is that the in vivo tumourigenicity of the transformed cell
lines is not known. Xenografts of the spheroid cell lines into immuno-compromised mice
would be an ideal way to study the early stages of transformation in vivo and study some
of the complex processes that are diﬃcult to model in vitro such as stromal recruitment
and metastasis.
4.7.5 Implications for Epithelial Ovarian Cancer
In ovarian cancers, BRAF mutations are rarely found in high-grade tumours. KRAS muta-
tions occur in high-grade and low-grade serous tumours, as well as the mucinous subgroup.
We are currently investigating whether the gene expression proﬁles described here can be
used to derive a gene expression signature that correlates to patient prognosis, as low-grade
tumours have better prognoses than the high-grade counterparts [Shih and Kurman, 2004];
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[Berchuck et al., 2009]. Furthermore, it appears that high-grade and low-grade tumours
evolve via distinct molecular pathways, and a ‘good-prognosis’ signature could be used
clinically to classify tumours with ambiguous histopathological features. As current treat-
ments for EOC comprise aggressive surgery and platinum-based therapeutics, it would
be of beneﬁt to accurately classify the patients who could receive a milder but eﬀective
treatment regimen.
The current biomarker used in clinical practise for the detection of EOCs and monitoring
of ovarian cancer patients is CA125. This is a marker of diﬀerentiated M¨ ullerian epithelia,
is frequently upregulated in ovarian cancers and detection of CA125 in blood sera is
used clinically for EOC detection and monitoring ovarian cancer patients post-treatment.
However, this is not a very reliable marker of EOC, and is not commonly expressed in
mucinous ovarian cancers [Koebel et al., 2008]. Many ovarian tumours do not overexpress
this marker, and as this is also a marker of other normal gynaecological epithelia, it
can be elevated in blood serum of women with benign conditions. There is therefore
a real need for novel biomarkers of early EOCs. Such biomarkers may be speciﬁc to a
subtype, or may be applicable to the majority of EOCs. Although there is extensive disease
heterogeneity, some biomarkers are expressed by all subtypes [Koebel et al., 2008]. This
also appears to be reﬂected at the genetic level. Recent work in this and other laboratories
has identiﬁed susceptibility loci that increase a woman’s relative risk of developing EOC
[Song et al., 2009]. Some of these loci are speciﬁc to the serous subtype; others however,
appear to be applicable to all EOCs [Simon Gayther, personal communication].
The list of candidate genes identiﬁed in this study represents a panel of candidate biomark-
ers associated with early neoplastic development of the ovarian surface epithelium. Such
biomarkers require thorough in vitro testing and validation. It is hoped that by using more
functionally relevant 3D models, the biomarkers that emerge are more likely to translate
to human disease, although this has yet to be fully evaluated. By using overexpression
of CMYC, which is common in all EOCs and not restricted to one histotype, it is hoped
that the candidate genes described here may be applicable to ovarian tumours of diﬀerent
histologies. It was also found that genes located near candidate susceptibility loci for EOC
may be dysregulated early in EOC development. It is hoped that these in vitro tools will
be of value in the functional follow-up of these susceptibility loci.
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A Role for Senescent Fibroblasts
in Early Transformation of the
Ovarian Surface Epithelium
5.1 Introduction
Ovarian epithelial cells make up a small proportion of the organ, yet account for over 90%
of all ovarian malignancies. The majority of the organ consists of the ovarian stroma, also
called the ovarian cortex. Within the stroma there are many diﬀerent cell types including
ﬁbroblasts, endothelial cells, pericytes; there are also many diﬀerent extracellular matrix
proteins; and, in pre-menopausal ovaries, developing follicles and the associated granulosa
cells (the major producer of oestrogen in the ovary). In this Chapter I investigate the
role of stromal cells in tumourigenesis of the epithelium, speciﬁcally the changes in the
ﬁbroblastic component that occur during ageing.
The ovary undergoes many changes with advancing age, particularly during the menopause.
The organ shrinks in size and becomes quiescent, and no longer contains maturing follicles
and granulosa cells. The regular cycle of ovulation, wound rupture and repair, ceases.
Morphological changes in ovaries are more frequent with advancing age, including cortical
inclusion cysts and deep invaginations of OSE into the ovarian cortex [Cai et al., 2006].
Additionally, throughout the body, cellular changes also occur that are associated with
ageing, namely cellular senescence, either as a result of telomere shortening (replicative
senescence, RS), oncogene activation (oncogene induced senescence, OIS) or other geno-
toxic stresses (stress-induced premature senescence, SIPS). Genotoxic stresses include ex-
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posure to cytotoxic drugs, DNA damage and oxidative stress. Senescence has a protective,
anti-tumourigenic eﬀect in younger organisms, as a cellular response to oncogene activa-
tion/overexpression or other genotoxic stresses, yet there is a growing body of evidence
demonstrating that senescent cells can have pro-tumourigenic properties and in fact pro-
mote tumourigenesis of neighbouring cells. Campisi and collegues succinctly describe this
paradox as antagonistic pleiotropy: the senescence-response has a tumour-suppressive
function early in life, but accumulation of senescent ﬁbroblasts can promote epithelial
tumour initiation in post-reproductive years [Krtolica et al., 2001].
Age 15-19
Epithelial
Non-Epithelial
Age 45-49
Non-Epithelial
Epithelial
Figure 5.1: Incidence of epithelial tumours increases with age. Epithelial tumours are rare in
children and young adults, but make up the majority of tumours diagnosed in adults.
Epidemiological evidence also supports the ‘pro-tumourigenic senescent stroma’ eﬀect -
epithelial tumours are rare in children but common in adults (Figure 5.1). Several in vitro
and in vivo models have found that senescent ﬁbroblasts can promote epithelial tumouri-
genesis. The initiating events in ovarian tumourigenesis are currently poorly understood,
and most EOC cases are diagnosed in women over the age of 60. I thus hypothesised that:
• Senescent ﬁbroblasts promote neoplastic transformation of the ovarian surface ep-
ithelium, relative to pre-senescent ﬁbroblasts.
To address this hypothesis I proposed:
• To isolate ﬁbroblasts from the normal ovary and generate a phenotypically normal
immortalised ovarian ﬁbroblast cell line
• To establish 2D heterotypic models and study the eﬀect of pre-senescent and senes-
cent ovarian ﬁbroblasts on the invasion, migration, anchorage-independent growth
and proliferation rates of partially transformed ovarian surface epithelial cells
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• To establish heterotypic 3D cultures of ovarian stromal-epithelial cells to study pro-
liferation of ovarian epithelial cells in 3D heterotypic spheroid cultures
5.2 Isolation and Immortalisation of Normal Ovarian Fi-
broblasts
There is limited published evidence of in vitro normal ovarian ﬁbroblast (NOF) culture
and immortalisation. Thus, primary NOF cultures were established and immortalised in
order to facilitate the study of stromal-epithelial interactions in the normal ovary. Primary
NOFs were isolated from normal ovarian tissue. A biopsy was taken from the centre of
a normal ovary, the tissue was then placed into a P100 dish and minced using a sterile
scalpel. Growth of colonies and explants was observed using phase-contrast microscopy.
Fibroblastic colonies were identiﬁed by their characteristic elongated cellular morphology
and scattered colony morphologies. Fibroblastic colonies were isolated by ring cloning and
established as primary ﬁbroblast cell lines. Immunoﬂuorescent staining was performed
with an anti-Fibroblast Surface Protein (FSP), anti-vimentin (VIM) and anti-cytokeratin-
7 (Ck7) antibodies, to screen for pure ﬁbroblast clones. One clone was selected, this cell line
showed strong expression of FSP and vimentin, whereas Ck7 was not expressed, suggesting
that the cells were ﬁbroblastic in origin (Figure 5.2). It is possible that other stromal
cell contaminants could have been present in the initial culture. The lack of endothelial
cell contamination was conﬁrmed by negative staining for FactorVIII. Granulosa cells
could also have contaminated the ﬁbroblast cell line. Granulosa cells are associated with
developing oocytes and are major producers of steroid hormones and growth factors in
the ovary, particularly during oocyte development. One could test for granulosa cell
contamination by staining for inhibin, a glycoprotein commonly and speciﬁcally produced
by ovarian granulosa cells and granulosa cell tumours [Lapphn et al., 1989]. However, as
it would not be anticipated that granulosa cells would express FSP, it was concluded that
there was no granulosa cell contamination in the NOF cell line.
The lifespan of primary NOFs was restricted to under 30 days. The limited in vitro
lifespan of the primary NOF cell line was extended by the ectopic expression of the cat-
alytic subunit of human telomerase (hTERT) as described in Chapter 4. The hTERT-
expressing derivative cell line was maintained in culture for over 140 days without signs
of replicative senescence (arrested cell division; a ﬂattened and enlarged cellular mor-
phology) (Figure 5.2a). By PCR-ELISA, NOFs showed no telomerase activity before the
introduction of hTERT; but after hTERT infection, telomerase activity was detectable
and telomere terminal restriction fragment lengths were increased by 2kbp (Figure 5.2b).
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Figure 5.2: Extension of in vitro lifespan of primary normal ovarian ﬁbroblasts (NOFs). (a)
Ectopic expression of hTERT increased in vitro lifespan of NOFs from <30 days to >140 days. (b)
Relative telomerase activity (relative to an internal positive control) is negligible in cell extracts
from primary NOFs but elevated in immortalised NOFs (INOF) cultures, and telomere terminal
restriction fragment length is increased by 2kb following introduction of hTERT. (c) NOFs and
INOFs both exhibit characteristic ‘spotty’ staining with an anti-ﬁbroblast surface protein (FSP)
antibody. Both cell lines do not express cytokeratin 7 (Ck7). Smooth muscle actin (SMA) is
expressed in approximately 30% of INOF cells (white arrowhead), indicating a transition towards
an activated-ﬁbroblast phenotype following immortalisation. Both NOF and INOF cells expressed
p16 in the nucleus and cytoplasm (arrows). 100% of NOF and INOF cells express vimentin (VIM).
DAPI (blue) stains cell nuclei, Evan’s blue (red) stains the cell cytoplasm, and green ﬂuorescence
denotes positive staining. Exposure times were constant for each antigen. Note the elongated,
spindled morphology of ﬁbroblast cells compared to the more triangular/cuboidal morphology of
ovarian epithelial cultures.
This suggested that NOFs had been immortalised. Neither NOFs nor immortalised NOFs
(INOFs) showed evidence of tumourigenic transformation as shown by the absence of
anchorage independent growth (20,000 cells/well).
Immunoﬂuorescent staining of cells after hTERT immortalisation showed that INOFs
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maintained expression of ﬁbroblastic markers (FSP and vimentin) and did not express
an epithelial cell marker (Ck7), showing that ﬁbroblastic characteristics were maintained
post-immortalisation. Around 30% of INOF cells expressed smooth-muscle actin (SMA),
(which indicates an activated phenotype); but SMA expression was absent in the primary
NOFs (Figure 5.2c). This is consistent with the ﬁndings of previous studies that show
an activated phenotype in ﬁbroblasts (from other organs) following immortalisation and
exposure to serum during routine tissue culture [Iyer et al., 1999]; [Chang et al., 2004].
p16 expression was also examined by ﬂuorescent immunostaining. INOFs maintained
nuclear and cytoplasmic p16 expression, suggesting that loss of this cell-cycle checkpoint
is not required for immortalisation.
5.2.1 Fibroblast Growth Medium Conditions
Normal ovarian ﬁbroblast cultures were established in basic medium (BM: Medium 199:
Medium MCDB105 with 15% foetal bovine serum and 1% L-glutamine) which has been
used to culture epithelial and stromal cells isolated from endometrial and ovarian tumour
specimens [Grun et al., 2009]. For the growth of NOF cells, basic medium was supple-
mented with ﬁbroblast growth factor and insulin, and the morphology and colony forma-
tion ability of INOF cultures evaluated. Previous reports of in vitro ﬁbroblast cultures
have supplemented medium with these two supplements [Liu and Wu, 2009] 1.
The addition of insulin (5µg/ml) alone, or in combination with ﬁbroblast growth factor
(FGF, 10ng/ml) did not signifcantly aﬀect colony formation of INOF cells relative to basic
medium alone. The addition of FGF, alone or with insulin, visibly increased colony size;
but when cultured with BM+FGF, INOF colony formation eﬃciency was signiﬁcantly
reduced (Figure 5.3 a,c). None of media tested had a visible eﬀect on the morphology of
INOF cells. Cells maintained an elongated morphology and colonies were characteristically
‘swirly’ in all media tested (Figure 5.3b). Since there were no signiﬁcant improvements in
the clonogenicity or morphology of the INOF cell line following supplementation of BM
with insulin or FGF, INOFs were maintained in basic medium for all of the experiments
described below. INOFs cells were susceptible to changes in the source of foetal bovine
serum (Figure 5.3c), thus INOF cells were maintained in the same serum they had been
originally isolated in, and all new batches of serum were quality checked before use.
1https://bcprd.lonza.com
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Figure 5.3: Supplementing ﬁbroblast medium does not signiﬁcantly improve INOF culture clono-
genicity or morphology. (a) Colony formation eﬃciencies, one representative plate shown. Colonies
are stained blue by Coomassie staining. Colonies were largest when ﬁbroblast growth factor was
added to the medium (b) Colony morphology was ‘swirly’ in each medium tested, and cell shape
was elongated and characteristically mesenchymal. (c) Number of colonies formed in the four types
of media tested. *P=0.03. (d) INOF cells have a lower colony formation eﬃciency in Lonza foetal
bovine serum (FBS) compared to Invitrogen FBS. NOSE cells were not susceptible to the change
in FBS.
5.3 Senescent Fibroblasts Enhance the Transformed Pheno-
type of IOSECMY C cells
The purpose of these experiments was to model the eﬀects of an ageing stromal microenvi-
ronment on the in vitro transformed phenotype of ovarian epithelial cells. The particular
aspect of ageing that was of interest was cellular senescence and how the accumulation of
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senescent ﬁbroblasts may aﬀect the neoplastic phenotype of epithelial cells. I hypothesised
that either senescent ﬁbroblasts create a pro-tumourigenic cue that can aﬀect neighbour-
ing epithelial cells, or that normal cells inhibit transformation of nearby epithelia and that
this inhibitory eﬀect is attenuated upon ﬁbroblast senescence.
Immortalised cell lines, including the INOF cell line created for this study, are resistant
to replicative senescence, and so it was necessary to artiﬁcially induce senescence. This
can be achieved using two approaches (1) oncogene activation or (2) chemical exposure.
In other cell types senescence is induced in vitro and in vivo by introducing mutant al-
leles of KRAS, BRAF or knocking-down expression of p16INK4A [Krtolica et al., 2001];
[Michaloglou et al., 2005]; [Denoyelle et al., 2006]. The response to these molecular alter-
ations varies between cell type, thus I decided to use chemical exposure because senescence
induction typically shows less cell-type-speciﬁc variation in eﬀectiveness. Two chemical
methods used to induce senescence are short-term exposure to bleomycin sulfate or hy-
drogen peroxide, the latter of which has been widely described and characterised in many
cell types, and was therefore the agent I chose to use. Exposing normal cells to hy-
drogen peroxide (H2O2) induces a senescence response that is considered to be biologi-
cally similar to replicative senescence observed in ageing organisms [Krtolica et al., 2001];
[Bavik et al., 2006]. Senescence was induced in INOFs by exposing the cells to low dose
(80µM), non-toxic levels of H2O2 (Figure 5.4). At this dose up to 80% of cells expressed
senescence-associated-β-galactosidase (SA-β-gal) (Figure 5.4a). H2O2 exposure reduced
proliferation of INOFs by 30%, suggesting that either SA-β-gal-positive cells were dis-
playing early signs of senescence but were not yet fully growth arrested, or that the SA-
β-gal-negative cells outgrew the SA-β-gal-positive cells during the course of the growth
assay.
The eﬀect of pre-senescent (PSN) and senescent (SEN) ﬁbroblasts on the neoplastic phe-
notype of ovarian epithelial cell was then investigated. In these experiments, the three
immortalised ovarian surface epithelial (IOSE) cell lines, plus the IOSECMY C cell lines
(that stably overexpress C-MYC, described in Chapter 4) were used. These cell lines were
selected because the hypothesis of these experiments is that the ageing microenvironment
may contribute to earliest stages of tumour development, and these two groups of cell lines
represent an in vitro model of early neoplastic changes in the ovarian surface epithelium.
The following phenotypic assays were chosen to measure any changes in the neoplastic
phenotype of the IOSE and IOSECMY C cell lines that may be induced by the two types of
ﬁbroblasts: (1) invasion assays, (2) migration assays, (3) anchorage-independent growth
assays and (4) proliferation assays (in 2D and 3D).
Firstly, the invasive and migratory phenotypes of IOSE and IOSECMY C cells were mea-
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Figure 5.4: Induction of senescence in immortalised normal ovarian ﬁbroblasts by exposure to
hydrogen peroxide. (a) 80µM induced senescence-associated-β-galactosidase (SA-β-gal) expression
in 70-80% of INOF cells without the toxicity observed at higher doses. When incubated with the
X-gal substrate at pH6, cells expressing SA-β-gal become blue. (b) In a growth assay, the growth
of INOFs is reduced by 30% following exposure to 80µM H2O2.
sured using untreated pre-senescent (PSN) and H2O2-treated senescent (SEN) ﬁbroblasts
as chemoattractants, with 10% serum included as a positive control. Firstly, assays were
performed to identify any diﬀerences in IOSE migration and invasion when PSN or SEN ﬁ-
broblasts were plated as a chemoattractant. In migration assays, the motility of one of the
three IOSE cell lines (IOSE19) was inhibited by co-culturing with PSN or SEN ﬁbroblasts,
compared to the serum control (P=0.006 and 0.003 respectively, two-tailed paired T-test);
but there were no diﬀerences in the ability of IOSE19 cells to migrate towards either a
PSN or SEN ﬁbroblast chemoattractant (P=0.934) (Figure 5.5a). Neither PSN nor SEN
ﬁbroblasts had any eﬀect on the invasive properties of IOSE cells, the invasiveness of IOSE
cell lines was not signiﬁcantly diﬀerent in co-cultures or the serum control (Figure 5.5b).
The IOSECMY C cells were then tested in the same way, to see if migration and invasion of
these cells would be aﬀected by the diﬀerent ﬁbroblast chemoattractants. In contrast to
the IOSE results, there was a 5.7 to 7.2-fold reduction in transwell migration of all three
IOSECMY C cell lines in co-cultures with PSN ﬁbroblasts, relative to the serum control
(P≤0.01). Furthermore, IOSECMY C cells co-cultured with SEN ﬁbroblasts showed 3.8
to 14.9-fold more migration than when cultured with PSN ﬁbroblasts as a chemoattrac-
tant (P≤0.01). In one case migration was double that of the serum control (Figure 5.5
c,e). The eﬀects of co-cultured ﬁbroblasts on the invasive ability of IOSECMY C cells were
less pronounced, although two of the three IOSECMY C cell lines were signiﬁcantly more
invasive when co-cultured with SEN compared to PSN ﬁbroblasts (P≤0.05) (Figure 5.5d).
Conditioned medium (CM) was harvested from PSN and SEN ﬁbroblast cultures used to
establish anchorage-independent growth assays with the diﬀerent epithelial cells. IOSE
cells did not display any anchorage-independent growth in PSN or SEN ﬁbroblast CM. CM
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Figure 5.5: Pre-senescent (PSN) and senescent (SEN) ﬁbroblasts diﬀerentially regulate the mi-
gratory and, to a lesser extent, invasive phenotype of IOSECMY C but not IOSE cells. 10% foetal
bovine serum (FBS) was included as a positive control in all experiments. (a) PSN or SEN ﬁbrob-
last chemoattractants both inhibited the migration of IOSE19. The other IOSE cell lines showed
no signiﬁcant diﬀerences in migratory ability. (b) PSN or SEN ovarian ﬁbroblasts, when plated as
a chemoattractant, do not aﬀect the invasive ability of IOSE cell lines. (c) In migration assays,
normal, PSN ovarian ﬁbroblasts inhibited motility of all three IOSECMY C cell lines, relative to
10% FBS. SEN ﬁbroblasts signiﬁcantly enhanced migration of all C-MYC-overexpressing cell lines.
(d) SEN ﬁbroblasts signiﬁcantly enhanced invasive ability of two C-MYC-overexpressing clones,
relative to PSN ﬁbroblast cells. (e) Stained migration assay membranes, representative ﬁelds of
view. (*P≤0.05, ** P≤0.01, by two-tailed paired T-tests). Error bars = standard error of the
mean.
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Figure 5.6: Anchorage-independent growth is enhanced when IOSE19CMY C cell lines are grown in
conditioned medium (CM) from senescent ﬁbroblasts compared to CM from pre-senescent ﬁbrob-
lasts. 0.33% Noble agar gels were prepared using conditioned medium that had been ﬁltered and
then supplemented with NOSE-CM supplements. In conditioned medium, anchorage-independent
growth rates were signiﬁcantly lower than in NOSE-CM alone.
from SEN ﬁbroblasts signiﬁcantly enhanced anchorage-independent growth of IOSE19CMY C
(P≤0.05) (Figure 5.6). This observation was consistent with the previous ﬁndings that
the neoplastic phenotype of IOSE19CMY C cells is enhanced by SEN ﬁbroblasts, relative to
PSN ﬁbroblasts. The invasion, migration and anchorage-independent growth data suggest
that ﬁbroblasts secrete soluble molecules that are chemoattractive to and can modulate
growth of IOSECMY C cell lines. In conditioned medium, anchorage-independent growth
rates of IOSECMY C cells were signiﬁcantly lower that in NOSE-CM alone, suggesting
that even conditioned medium from senescent ﬁbroblasts contains factors which inhibit
anchorage-independent proliferation of IOSE cells that overexpress CMYC. However, in
IOSE19CMY C and to some degree in IOSE11CMY C, conditioned medium from SEN ﬁbrob-
lasts was less inhibitory to anchorage-independent growth than CM from PSN ﬁbroblasts.
218Chapter 5 5.4 3D Heterotypic Models
5.4 3D Heterotypic Models
In an ovary, particularly in an inclusion cyst, the OSE comes into close contact with the
ovarian stroma. Thus, three-dimensional (3D) heterotypic models were created to mimic
the close interactions of ovarian epithelial and stromal cells (Figure 5.7). Using the static
3D modelling approach described in Chapters 3 & 4, 3D multicellular INOF spheroids
were generated by culturing ﬁbroblasts on polyHEMA-coated tissue culture plastics. IN-
OFs began to form spontaneous aggregates within 48 hours of culture in non-adherent
conditions. 7-day multicellular INOF spheroids appeared robust and smooth when vi-
sualised by phase-constrast microscopy. A large range of spheroid sizes was observed in
all cultures (Figure 5.8). Examination of formalin-ﬁxed, paraﬃn embedded sections of
INOF spheroids, stained with hematoxylin and eosin (H&E), revealed that central regions
of spheroids contain abundant matrix protein (Figure 5.8b). Acellular hylanised nodules
were also observed, with apoptotic cells distributed throughout a matrix-rich core. Pe-
ripherally, spindled cells with elongated nuclei and an eosinophilic cytoplasm, surrounded
the spheroid. Pre-senescent and senescent ﬁbroblast spheroids were indistinguishable by
H&E staining (Figure 5.8). This is not surprising given that senescent cells in vivo are
only identiﬁable by staining for speciﬁc senescence markers.
Epithelium                 
Senescent Fibroblast          
Pre-senescent Fibroblast 
Basement Membrane 
Extracellular Matrix Protein
Post-Menopausal Ovary
Inclusion 
Cyst
Heterotypic 3D Culture
Figure 5.7: Heterotypic models aimed to mimic ovarian stromal-epithelial interactions. Within
inclusion cysts in particular, ovarian epithelial and stromal cells are in close contact. Stromal cells
are also responsible for the synthesis of the bulk of the extracellular matrix protein in the organ.
Spheroids were stained for vimentin, smooth muscle actin, cytokeratin 18 and collagen
IV by immunohistochemistry, and compared to immortalised ovarian surface epithelial
spheroids and normal ovarian tissue specimens. INOF spheroids expressed vimentin and
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Figure 5.8: Three-dimensional (3D) models of INOF cells. Formalin-ﬁxed, paraﬃn-embedded
spheroids were stained by H&E for analysis of spheroid structure. Representative images of each
culture are shown. (a) A small PSN and (b) a large SEN ﬁbroblast monoculture spheroids consist
of spindled cells and abundant matrix protein. Hylanised nodules of matrix protein (arrow) and
apoptotic cells are visible within central regions of larger spheroids. For both SEN and PSN
ﬁbroblasts, a wide range of spheroid sizes is observed when 3D cultures are generated using this
technique (D=diameter).
collagen IV, and did not express cytokeratin-18. (Figure 5.9). This was reﬂective of the
ovarian stroma in ovarian tissue specimens. A subset of INOF cells in spheroids also
expressed smooth-muscle actin (SMA), but only expressed at low levels in vivo and also
expressed by ∼ 1/3 INOF cells in 2D (see above). The aim of this experiment was to ﬁnd
good markers to distinguish epithelial and ﬁbroblastic populations in heterotypic cultures;
but only cytokeratin-18 (Ck18) reliably distinguished ovarian ﬁbroblasts and epithelial
cells. A commonly described ﬁbroblastic marker, vimentin, was not discriminatory be-
tween epithelial cells and ﬁbroblasts in samples of normal ovarian tissue or in 3D spheroid
cultures. Desmin and ﬁbroblast surface protein (FSP) were also tested, but did not re-
liably distinguish between IOSE and INOF due to cross-reactivity with IOSE cells, or
poor staining of INOF spheroids. In vitro and in vivo OSE cells exhibit epithelial and
mesenchymal characteristics, makes it diﬃcult to distinguish OSE cells from ﬁbroblasts
(Chapter 3 and references therein). No marker was identiﬁed that could reliably and eﬃ-
ciently stain ovarian ﬁbroblasts but not OSE in vitro or in vivo by immunohistochemistry,
thus, dual staining of Ck18 plus the marker of interest would be the appropriate approach
for analysis of heterotypic cultures.
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Figure 5.9: Immunohistochemical staining of immortalised ovarian surface epithelial (IOSE) and
immortalised normal ovarian ﬁbroblast (INOF) spheroids and normal ovarian tissue. IOSE and
INOF spheroids express vimentin (Vim). OSE cells and ovarian stroma are also positive for this
matrix protein. INOF spheroids and ovarian stroma are both positive for smooth muscle actin
(SMA), but IOSE do not express this antigen. However, under 50% of INOF cells express SMA
and staining is weak-moderate, suggesting this is not a good marker to distinguish INOF from IOSE
cells. Epithelial cells and ﬁbroblasts express collagen IV in 3D and in vivo. Finally, cytokeratin-18
(Ck18) was expressed by IOSE spheroids and OSE in vivo (arrowhead), but not detected in INOF
spheroids or the ovarian stroma in vivo.
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5.4.1 Senescent Fibroblasts Promote Epithelial Proliferation in 3D Het-
erotypic Models
3D Heterotypic Cultures: polyHEMA Coated Plastics
Day 0
Day 7
Day 21
Processing into paraffin
PolyHEMA 
coated flask
Fibroblasts 
(senescent/pre-
senencent)
Epithelial 
cells
Heterotypic 
multicellular 
spheroids
Figure 5.10: Schematic of heterotypic co-culture experiment plan. Fibroblast spheroids were
created by culturing cells on polyHEMA coated plastics. After 7 days, epithelial cells were inocu-
lated into the culture. The heterotypic cultures were then grown for a further 14 days before the
spheroids were harvested and processed into paraﬃn.
To create heterotypic 3D models of ovarian ﬁbroblast and epithelial cells, 7-day old
spheroid cultures of INOFs were inoculated with IOSE cells at a ratio of 4:1 INOF:IOSE
cells (see schematic, Figure 5.10). After 14 days of co-culture, spheroids were formalin-
ﬁxed and paraﬃn embedded. The paraﬃn-embedded samples were then sectioned. One
section was stained with H&E and spheroid structures were examined (Figure 5.11). Cen-
tral hylanised regions of abundant matrix protein were seen in all heterotypic 3D cul-
tures. Spheroids consisted of two morphologically distinct populations of cells, with either
spindled or plump cell morphologies, although the boundaries between the two popu-
lations were not distinct. When IOSE cells were cultured with SEN ﬁbroblasts (n=3),
nuclear atypia was observed within the population of plump, peripheral cells (Figure
5.11). Features such as prominent nucleoli and irregular or enlarged nuclear shape and
‘giant’ mononuclear cells budding oﬀ the spheroids were observed. These atypical fea-
tures were not present when IOSE cells were cultured with PSN ﬁbroblasts (n=3) (Figure
5.11a). There was also a trend for more numerous prominent nucleoli and mitoses in
the plump cell populations when IOSECMY C and SEN ﬁbroblasts were co-cultured, com-
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pared to IOSECMY C co-cultures with PSN ﬁbroblasts (Figure 5.11b & d). Finally, when
IOSE11CMY C and IOSE19CMY C were co-cultured with PSN ﬁbroblasts, there was marked
apoptosis in the central regions of spheroids; these regions were absent in co-cultures with
SEN ﬁbroblasts.
100µm
(d) (c)
(a)
P
C
(b)
200µm 200µm
Figure 5.11: 3D models of ovarian stromal-epithelial interactions, paraﬃn-embedded spheroids
stained by hematoxylin and eosin. Representative images of each culture are shown. (a)
IOSE19/PSN co-culture. The spheroid is mainly cellular, with some regions of matrix accumula-
tion. There is no visible boundary between the two cell types. (b) IOSE4CMY C/PSN heterotypic
culture. In the periphery (P), cells are have reduced matrix protein and are loosely attached. Cells
in this region are likely to be the IOSE4CMY C cells. In the core (C), it is likely that the cells
are predominantly ﬁbroblasts. Extracellular matrix deposition is observed (acellular eosinophilic
regions). (c) IOSE11/SEN ﬁbroblast 3D co-culture. Note the ‘giant’ cell (arrow) budding oﬀ
the surface of the spheroid (inset). (d) IOSE19CMY C/SEN ﬁbroblast 3D co-culture. The large
peripheral region of plump cells contain some mitotic ﬁgures (arrows).
In IOSE/INOF spheroids, epithelial cells were identiﬁed by positive staining for Ck18.
Ck18-positive cells formed a peripheral region surrounding the ﬁbroblast ‘core’ (see Figure
5.12). Dual immunohistochemical staining for Ck18 and the proliferation marker MIB-1
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enabled identiﬁcation of the actively proliferating epithelial proportion of the culture. The
proliferating epithelial population was measured and calculated as a ratio of proliferating
cells in the total epithelial population (Figure 5.13). This was compared to a 2D indirect
co-culture proliferation assay. In this assay, epithelial cells and ﬁbroblasts were co-cultured
for 14 days, with ﬁbroblasts cultured inside a permeable insert (pore size 1µm). In 3D
co-cultures, IOSECMY C cells were 0.03-12.8-fold more proliferative than parental IOSE
cells. In heterotypic spheroids established with SEN ﬁbroblasts there was a statistically
signiﬁcant, 1.4-4.7-fold increase in the relative percentage of dual positive Ck18+/MIB-1
cells for IOSECMY C cell lines (n=3) compared to IOSECMY C/PSN co-cultures (P≤0.05).
There was also a trend for an increase (1% to 6% increase) in the proliferation of IOSE
cells in co-culture with PSN ﬁbroblasts, although this did not reach statistical signiﬁcance.
In 2D proliferation assays there were no signiﬁcant diﬀerences in the proliferation of IOSE
or IOSECMY C cell lines when cultured with PSN or SEN ﬁbroblasts. This suggests that
ﬁbroblast regulation of IOSE proliferation may require direct cell-cell interactions of the
two cell types.
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Figure 5.12: Three-dimensional (3D) modelling of stromal-epithelial interactions - analysis of
proliferation in the epithelial component by dual staining for MIB1 (pink nuclear stain) and
cytokeratin-18 (CK18, brown cytoplasmic stain). Unstained cells are counterstained blue. (a)
IOSE11/PSN co-culture. Cytokeratin-positive cells are located at the peripheral region of the
spheroid (arrowhead). Note: Non-speciﬁc staining of matrix protein does occur but can be distin-
guished by the absence of cellular structure. (b) IOSE11/SEN co-culture. Note Ck18+ epithelial
cells located peripherally within spheroids. A single Ck18+/MIB1+ dual positive cell (arrow) is
visible in this section (arrow). (c) IOSE19/SEN co-culture. The central Ck18- population and
peripherally located Ck18+ cells within the spheroid are apparent. Some peripheral Ck18+ (ep-
ithelial) cells dual stain for MIB1 (pink nuclei). Some Ck18+ cells are located in central regions of
the spheroid (arrows), indicating that IOSE19CMY C cells may be capable of invading into ﬁbrob-
last spheroids. (f) Ck18- cells (ﬁbroblasts, C) closely interact with the population of Ck18+ cells
(epithelial cells, A, B). Note the spindled morphology and elongated nucleus of Ck18- cells, (e.g.
cell C), compared to the plump morphology and rounded nuclei of Ck18+ cells. Cell A is positive
for Ck18 and negative for MIB1; cell B is dual Ck18+/MIB1+ positive. (d) IOSE19CMY C/PSN
spheroids, stained only for MIB1 (here MIB1 positive cells have brown nuclei) illustrate how it
is not possible to determine the cell type of each positive nuclei, thus necessitating the use of
dual staining. (e) Control tissue, dual stained for MIB1 and Ck18. A dual positive cell is visible
(arrowhead).
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Figure 5.13: Proliferation of epithelial cell lines in 2D and 3D co-culture assays. (a) 2D pro-
liferation assay. Epithelial cells were co-cultured with pre-senescent (PSN) or senescent (SEN)
ovarian ﬁbroblasts for 14 days, and then total cell numbers were determined using crystal violet
staining. No signiﬁcant diﬀerences in proliferation were detected in co-culture with PSN or SEN
ﬁbroblasts (α=0.01). (b) 3D co-culture; measurements of proliferative epithelial proportion of 14-
day heterotypic spheroid cultures. Analysis of dual stained Ck18+/MIB1 cells reveals enhanced
proliferation in epithelial cell lines when co-cultured in 3D with SEN or PSN ﬁbroblasts, this
was statistically signiﬁcant for the three IOSECMY C cell lines. The proportion of MIB1 cells is
calculated relative to the total Ck18+ population of the culture.
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5.5 Discussion
As early as 1889, it was recognised that even highly aggressive tumour cells would only
thrive in a permissive microenvironment [Paget, 1889] and many studies have since demon-
strated that the phenotype of cancer cells can be modulated by the environment. In
more recent years, researchers have begun to focus on the role of the local microenvi-
ronment in the earliest stages of carcinogenesis: in tumour initiation. Epithelial ovar-
ian cancers are most commonly diagnosed in post-menopausal women. The life-history
of the most common subtype (high-grade serous) suggests that these tumours progress
rapidly [Brown and Palmer, 2009]. Two of the most well described risk factors for ep-
ithelial ovarian cancer are the protective eﬀect of pregnancy and oral contraceptive use
[Pike et al., 2004]; [Purdie et al., 2003]. It is hypothesised that this is due to the reduction
in the number of ovulations, and thus repeated rupture and repair of the ovarian surface
epithelium (OSE). A reduced number of ovulations over a lifetime equates to a reduced
number of opportunities for the OSE to be exposed to the mitogenic, hormone-rich milieu
of the ovarian stroma [Fathalla, 1971]. However, the majority of ovarian carcinomas occur
in women at least ten years after menopause, and the natural history of high-grade serous
tumours (the most common histopathological subtype) points to rapid, aggressive tumour
growth.
This poses the question: does a trigger exist in the ovarian stroma of postmenopausal
women that plays a role in the development of ovarian surface epithelial tumours? A main
contender for this trigger would be hormonal factors; yet the post-menopausal ovary is
no longer a major producer of steroid hormones. Not only do post-menopausal ovaries
no longer produce oestrogen (due to the loss of granulosa cells), but androgen produc-
tion also declines [Couzinet et al., 2001]. Therefore, the ovarian stroma no longer contains
high levels of the major mitogenic hormones found in pre-menopausal ovaries. It has been
postulated that elevated levels of gonadotrophin detected in post-menopausal women may
stimulate proliferation of the OSE [Landen et al., 2008]; [Smith and Xu, 2008]. However,
epidemiological, in vitro and in vivo data exploring a role for gonadotrophins are contra-
dictory. This may be due diﬃculties in distinguishing the eﬀects of gonadotrophins from
the eﬀects of repeated ovulation (gonadotrophins released from the pituitary gland trigger
ovulation).
Age-related changes in gross morphology are observed in post-menopausal ovaries (in-
creased number of inclusion cysts and deep invaginations of OSE into the ovarian stroma)
and have been hypothesised to play a role in transformation [Cai et al., 2006]. In this
present study, it was hypothesised that age-related changes in ovarian stromal ﬁbroblasts
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may be providing a molecular pro-tumourigenic cue in the post-menopausal ovary. This
trigger may act in synergy with early tumourigenic events in epithelial cells (e.g. tumour
suppressor gene inactivation, the activation of proto-oncogenes) but may have no eﬀect on
normal ovarian surface epithelial (OSE) cells. Here the earliest stages of OSE transforma-
tion were modelled using non-neoplastic hTERT-immortalised ovarian surface epithelial
(IOSE) cells, and partially transformed IOSECMY C cell lines (overexpressing C-MYC).
IOSE and IOSECMY C cells were co-cultured with pre-senescent and senescent ovarian ﬁ-
broblasts. Senescent ﬁbroblasts were able to promote migration of all the IOSECMY C
cell lines tested but not the IOSE cells. A motile phenotype is associated with neoplastic
transformation, and does not require the additional ability to degrade the extracellular ma-
trix which is required for increased invasion. Indeed, senescent ﬁbroblasts only increased
the invasive ability of the IOSECMY C clones with the most aggressive in vitro pheno-
type. Furthermore, anchorage-independent growth was enhanced in IOSE19CMY C cells
when cultured in conditioned media from senescent ﬁbroblast cells, in comparison with
conditioned media from non-senescent ﬁbroblasts. Thus, in three independent cell lines,
senescent ﬁbroblasts were able to promote diﬀerent features of the neoplastic phenotype of
IOSECMY C cells, relative to the pre-senescent counterparts. Since pre-senescent/senescent
ﬁbroblasts did not diﬀerentially aﬀect the migration, invasion, 2D/3D proliferation or
anchorage-independent growth of IOSE cells, it was concluded that the pro-tumourigenic
eﬀect of senescent ﬁbroblasts is conditional on, and only has an eﬀect in synergy with,
oncogenic mutation in the epithelium. These data also suggest that the regulation of neo-
plastic epithelial cells by senescent ﬁbroblasts is mediated, in part, by soluble, secreted
factors that are chemoattractive to partially transformed ovarian epithelial cells.
In three-dimensional heterotypic cultures, senescent ﬁbroblasts signiﬁcantly enhanced pro-
liferation of IOSECMY C cell lines relative to co-cultures with pre-senescent cells. Parental
IOSE cell lines were not regulated in this way, although there was a trend for more MIB1-
positive epithelial cells to be observed in co-culture with PSN ﬁbroblasts. Further experi-
ments, with larger numbers of replicates, would need to be performed to validate whether
or not PSN/SEN ﬁbroblasts can signiﬁcantly diﬀerentially regulate IOSE proliferation in
3D spheroid co-cultures. Interestingly, nuclear atypia was observed in IOSE cells cultured
with senescent ﬁbroblasts, but these features were absent in the same cells cultured with
pre-senescent ﬁbroblasts. This may suggest that even the earliest neoplastic changes in
the OSE (modelled here by the IOSE cells) may be susceptible to the pro-tumourigenic
cue provided by the ovarian stroma, although it may be necessary to culture ﬁbroblasts
and primary OSE to investigate this further. The eﬀects are also likely to be very subtle
and thus challenging to detect. Since invasion and migration of IOSE were not regulated
by ﬁbroblasts, it can be concluded that IOSE cell invasion and migration is not inﬂuenced
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by the ageing stromal microenviroment in this in vitro model.
The experiments described above provide in vitro evidence that senescence of normal
ovarian stromal ﬁbroblasts can enhance features of a neoplastic phenotype in partially
transformed ovarian surface epithelial (OSE) cells. The data also provides in vitro evidence
that normal (pre-senescent) ﬁbroblasts may be inhibitory to neoplastic transformation of
the OSE. This model is summarised in Figure 5.14. The interactions between epithelial
and stromal cells are dynamic and bi-directional [Yang et al., 2006] and are likely to be
essential for tumour initiation and maintenance. They therefore represent new sources of
discovery for novel therapeutic targets for epithelial ovarian carcinomas.
The eﬀects of ﬁbroblasts on epithelial cells observed in this study reﬂect previous ﬁnd-
ings by groups working on diﬀerent types of cancer. Previous reports have shown that
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Figure 5.14: A model of the role of the ageing microenvironment in EOC development. Somatic
mutations in the OSE may arise pre-menopausally, following the repeated cycles of rupture and
repair associated with repeated ovulation. However, in the younger ovary, pre-senescent ﬁbrob-
lasts (green) inhibit proliferation and further neoplastic progression of the mutant cell. Ovulation
also promotes inclusion cyst formation. During ageing, senescent ﬁbroblasts (purple), secreting
pro-tumourigenic factors, gradually replace pre-senescent ﬁbroblasts, eventually creating a mi-
croenvironment that is permissive for tumour initiation.
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normal ﬁbroblasts and a normal tissue microenvironment can inhibit early tumourige-
nesis, and that ﬁbroblast senescence results in a loss of inhibition of tumourigenesis
or promotion of epithelial transformation [Olumi et al., 1999]; [Parrinello et al., 2005];
[Studebaker et al., 2008]. Krtolica et al., demonstrated that senescent ﬁbroblasts could
enhance in vitro proliferation and induce in vivo tumour formation of premalignant and
malignant human and murine epithelial cell xenografts [Krtolica et al., 2001]. Some of
the factors that can mediate the diﬀerential eﬀects of normal and senescent ovarian ﬁ-
broblasts have been identidied. A recent study of senescent foreskin ﬁbroblasts, by Pa-
zolli et al., identiﬁed osteopontin as a mediator of in vitro and in vivo growth stim-
ulation [Pazolli et al., 2009]. Other molecules to have been identiﬁed in senescent ﬁ-
broblasts as eﬀectors of the pro-neoplastic phenotype include MMP-3, VEGF, AREG,
HGF and IL-6 (summarised in Table 5.1) [Parrinello et al., 2005]; [Bavik et al., 2006];
[Coppe et al., 2006]; [Studebaker et al., 2008].
Whether or not the pro-oncogenic factors released by senescent ﬁbroblasts will vary by
tissue has yet to be determined. However, the morphological hallmarks of senescence (ﬂat-
tened morphology and β-galactosidase expression) are universal, suggesting there may be
overlap in the molecular features of senescence between organs. Recent proﬁling of proteins
secreted by senescent ﬁbroblasts, using antibody and gene expression arrays, found many
of the factors produced by senescent ﬁbroblasts are also involved in inﬂammation and
tissue remodelling [Coppe et al., 2008]; [Pazolli et al., 2009]. Senescent ﬁbroblasts may be
a mediator of the ‘wound that does not heal’ theory of carcinogenesis, which links inﬂam-
mation and related changes in tissue structure to tumour formation, since many of the
phenotypic changes associated with transformation are also associated with wound heal-
ing (e.g. ectopic proliferation, production of pro-angiogenic factors, increased invasion and
migration). Sites of chronic wounds and inﬂammation have a high proportion of senescent
cells and are prone to neoplastic transformation. In early neoplasia, the development of a
‘wound-healing-like’ or ‘activated’ stroma may be stimulated by epithelial signalling but
could also be due to inherent biological changes in the stroma itself.
Furthermore, the pathways activated in the epithelial cells in response to exposure to senes-
cent ﬁbroblasts are not yet known. Senescent ﬁbroblasts may stimulate one or multiple
growth/oncogenic signalling pathways in the epithelial cells, and so a candidate approach
could be used in which single pathways are inhibited with chemical inhibitors or blocking
antibodies. In this study it could be of interest to examine whether the MAPK pathway
is involved in the increased migration and proliferation of the IOSECMY C cell lines, since
it is described in Chapter 4 that activation of the MAPK pathway can promote neoplastic
transformation of IOSE cells in combination with overexpression of CMYC. One could
test this hypothesis by incubating the cells with an EGFR blocking antibody or an ERK
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inbibitor e.g. U0126. One could screen multiple signalling pathways in this way, though
in co-cultures such an approach would also inhibit the same pathways in the ﬁbroblasts.
To avoid this, dominant-negative constructs could be used to target speciﬁc candidate
pathways.
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Table 5.1: Senescent ﬁbroblasts in epithelial tumourigenesis: A review of the literature SF=
senescent ﬁbroblasts
Although it is widely accepted that oncogene-induced senescence, replicative senescence
and stress-induced premature senescence occur in vitro and in vivo, there are few studies
to date that quantify the eﬀect in vivo. Two studies analysed skin biopsies from baboons
and found that around 15% of cells in ageing primates were senescent [Herbig et al., 2006];
[Jeyapalan et al., 2007]. However, the proportion of senescent cells that accumulate in
the stroma of diﬀerent human organs has yet to be determined. As part of these studies,
antibodies against β-galactosidase and p16 were tested extensively to try and quantify the
proportion of senescent ﬁbroblasts in formalin-ﬁxed, paraﬃn-embedded ovarian specimens
from women of diﬀerent ages. However, neither approach was successful in identifying
the senescent stromal component of ageing ovaries. β-galactosidase antibodies that have
eﬃciencies comparable to the β-galactosidase bioactivity assay, or a new alternative marker
that is speciﬁc to senescent cells and can be applied to paraﬃn-embedded tissue are much
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needed for the quantiﬁcation of actual rates of senescence in human tissues.
Implications for Epithelial Ovarian Cancer
This is the ﬁrst time that the role of senescent ﬁbroblasts in early ovarian cancer develop-
ment has been investigated. An in vitro transformation model of epithelial ovarian cancer
has previously identiﬁed a secreted molecule, Gro-1, which in turn induces senescence of
the ﬁbroblasts in vitro. Gro-1 was shown to induce senescence in ovarian and mammary
ﬁbroblasts and increased in vivo tumourigenicity of co-injected OSE cells expressing SV40
large-T antigen [Yang et al., 2006]. This model illustrates a role for senescent stromal
ﬁbroblasts in tumour maintenance and demonstrates the ability of transformed epithelial
cells to signal to the neighbouring stroma to induce remodelling of the local microenviron-
ment to support neoplasic progression. This study also found that senescent ﬁbroblasts
were commonly located adjacent to malignant ovarian cancer epithelial cells. It appears
that, once again, ovarian cancers are an exception to the ‘norm’, in other epithelial can-
cers, senescent cells are common in benign tumours but rare in malignant carcinomas
[Collado et al., 2005].
In this Chapter, I have described the creation of a phenotypically normal ovarian ﬁbrob-
last (NOF) cell line. The primary ﬁbroblast cell line had a restricted in vitro lifespan
(under 30 days). This was around half that observed for the in vitro lifespan of NOSE
cell lines described in Chapter 3. The restricted lifespan may be due to the population
bottleneck caused by sub-cloning, although NOSE19 was generated by sub-cloning and
yet could still be maintained in culture for over 50 days and 9.7 population doublings. Al-
ternatively, this may be a cell-type speciﬁc eﬀect, or due to the diﬀerences in the growth
medium. It was therefore necessary to immortalise the primary NOFs, thus creating
a novel immortalised normal ovarian ﬁbroblast (INOF) cell line. This cell line also re-
mained ﬁbroblastic and phenotypically non-transformed during passaging in vitro. With
the exception of the study by Yang and colleagues, described above, all other reports of
stromal-epithelial interactions in ovarian cancer have utilised ﬁbroblasts from other organs
[Wang-Johanning et al., 2007]; [Noskova et al., 2009]. The Yang et al. study does not de-
scribe details of ﬁbroblast isolation and immortalisation, and so this present study is the
ﬁrst to do so. The application of an INOF cell line to the study of stromal-epithelial in-
teractions in epithelial ovarian cancer demonstrated here represents an organotypic model
for the investigation of heterotypic interactions in normal and malignant ovaries. Staining
for the expression of extracellular matrix (ECM) protein markers in 3D ovarian ﬁbroblast
cultures was consistent with the proﬁle of the ovarian stroma in normal tissue specimens.
This suggests, therefore, that culturing ovarian ﬁbroblasts by this technique has an ad-
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vantage over commercially available gels in that it more closely mimics the complex and
heterogeneous extracellular matrix of the organ.
This Chapter describes stromal-epithelial interactions in a model of early neoplastic trans-
formation of ovarian epithelial cells. Within ovarian cortical inclusion cysts, epithelial cells
are in close contact with the hormone-rich milieu of the ovarian stroma, since there is no
longer the barrier of the basement membrane beneath the OSE. These close interactions
were imitated by establishing three-dimensional co-cultures of pre-senescent and senescent
ovarian ﬁbroblasts, and OSE cells that overexpress the CMYC oncogene. There is still
dispute in the literature regarding the cell of origin for epithelial ovarian carcinomas; cur-
rent data suggest that for the most common EOC subtype, high-grade serous, the ovarian
surface epithelium (OSE) or the epithelia at the fallopian tube ﬁmbrae are both sites of
ovarian tumour initiation, particularly in BRCA mutation carriers [Callahan et al., 2007];
[Callahan et al., 2007]; [Roh et al., 2009]; [Hirst et al., 2009]. However, the bias towards
ﬁnding occult primary tumours in the fallopian tubes of prophylactic-oophorectomy spec-
imens from BRCA1/2 mutation carriers may be due to the fact that the fallopian tubes
of this high-risk group are examined more rigorously than those in non-mutation carri-
ers. Epithelial cells from other M¨ ullerian epithelia have also been suggested as possible
origins of EOC (e.g. cells lining inclusion cysts and the subsequent tumours that arise
at these sites), although empirical data to support this hypothesis have yet to be found
[Dubeau, 1999]; [Dubeau, 2008]. Heterotypic three-dimensional models, as described here,
provide an ideal basis for studying interactions between ovarian stroma and OSE, or ec-
topically located endometrial or tubal epithelia in order to understand more fully the true
origins of invasive ovarian carcinomas.
By mimicking the processes of early ovarian tumour development in a microenvironment
that closely resembles this process in vivo, it is hoped that such models can ultimately be
used to identify new markers associated with tumour initiation and progression. By trying
to replicate speciﬁc biological features of disease, such as dimensionality and heterogenity
of cell types, the candidate biomarkers that emerge from such models may be of relevance
to human disease. Currently, over 40% of EOCs are diagnosed at a late stage (III or IV),
and for these patients ﬁve-year survival rates are ∼30%. Only a minority of epithelial
ovarian tumours are diagnosed when disease is restricted to the ovary, but for this group,
ﬁve-year survival rates are much higher (over 70%) (Thames Cancer Registry, 1992-1996).
Mortality from ovarian cancer could be reduced by the discovery of biomarkers of the dis-
ease at its earliest stages; however, the molecular events that occur during early stages of
tumourigenesis of the ovarian surface epithelium are still poorly understood. This model
has demonstrated a role for senescent ovarian ﬁbroblasts in tumourigenesis of the ovarian
surface epithelium, and could readily be manipulated to test the role of senescent ﬁbrob-
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lasts at later stages of tumour development. Cell context is proving increasingly important
in governing cell behaviour, and interactions at the interface of tumour epithelium and
tumour stroma or transformed and non-transformed epithelial cells are a resource for the
discovery of new therapeutic targets [Hogan et al., 2009]. It is hoped that an increased
understanding of the signalling between ovarian epithelial cells and senescent ﬁbroblasts
in tumour initiation and maintenance may ultimately provide a novel approach for the
development of novel biomarkers and therapeutic targets.
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Conclusions & Future Directions
Understanding of molecular events that occur during the early stages of epithelial ovarian
cancer (EOC) has been hindered by both the shortage of early-stage tumour specimens,
and the lack of good in vitro models of disease. Understanding EOC development is all
the more challenging when one considers that the disease is relatively rare and extremely
heterogeneous, necessitating stratiﬁcation of tumours (there are 4 main subtypes). Addi-
tionally, diﬃculties in the culture of primary ovarian cells has hindered in vitro studies.
Most in vitro models of EOC have utilised viral oncoproteins to induce malignant trans-
formation of the ovarian surface epithelium (OSE). This present study, therefore, aimed to
create a more biologically relevant model of OSE transformation. To do this, there were
three important features of the project:
1. To develop three-dimensional modelling tools as a more biologically relevant model
of the OSE and of ovarian tumourigenesis
2. To transform ovarian surface epithelial cells with oncogenes that are known to be
altered in ovarian tumour specimens
3. To consider the contribution of the stromal microenvironment to the development
of epithelial ovarian cancers
This project has demonstrated, for the ﬁrst time, that NOSE cells and NOSE cells har-
bouring deﬁned genetic alterations can be established as three-dimensional models. Three-
dimensional in vitro models more closely recreate in vitro the geometry and the complex
cell-cell, cell-ECM interactions of tissue in vivo. This thesis details the establishment of
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models of neoplastic progression in epithelial ovarian cancer. Firstly, a step-wise model of
transformation of normal ovarian surface epithelial cells was developed using genes that
are known to be altered in ovarian tumour specimens. This model represents an in vitro
model of early ovarian cancer development. Phenotypic heterogeneity was detectable in
vitro and observed to be associated with the introduction of diﬀerent genes. In 3D, features
of tumourigenic cells in vivo were detected - such features were not identiﬁable in tradi-
tional 2D monolayer cultures. Gene expression microarrays were then used to examine
the transcriptional changes associated with transformation driven by the diﬀerent onco-
genes. Molecular heterogeneity was observed, and a gene lists generated that represent
novel candidate biomarkers of early EOC development. Genes of interest for further study
include THBS-1, CTGF, PITX1, MOCOS, RGS4 and FEZ1. Some of these genes have
already been studied in EOC tumour specimens or in in vitro models, all represent bio-
logically interesting candidates for validation of the functional roles in EOC development.
Furthermore, some genes located within EOC susceptibility loci were also dysregulated in
the IOSE cell lines that expressed CMYC +/- mutant KRAS/BRAF alleles, suggesting
that genes such as BNC2 and TiPARP are involved in early development of EOCs.
Additionally, a 3D heterotypic model were developed using a new immortalised ovarian
ﬁbroblast cell line. This model was used to demonstrate that age-related stromal changes
may have a role in ovarian epithelial tumourigenesis, linking an epidemiological observation
(most EOCs occur in post-menopausal, older women) to a functional eﬀect modelled in
vitro. The models presented here represent novel in vitro tools for the study of speciﬁc
genes that are thought to have a role in EOC development, or for the development and
validation of novel therapeutic agents or targets. The results also provide some much-
needed insight into the early events that occur during EOC development in vivo, and
also how the molecular and phenotypic heterogeneity observed in EOC specimens may
correlate to the speciﬁc genetic alterations that drive tumour initiation and progression.
Major emphases on the establishment of new cell lines and organotypic techniques char-
acterise this body of work. Consequently, the reagents described here could readily be
applied to many of the remaining unanswered questions surrounding EOC development.
For example: what proportion of high-grade serous EOCs originate in the OSE, and what
proportion originate in the fallopian tube epithelia? How does the hormonal microenvi-
ronment aﬀect stromal-epithelial interactions anf transformation of the OSE? How would
diﬀerent genetic alterations (e.g. loss of BRCA1/2) aﬀect transformation of the OSE?
Do low-moderate susceptibility alleles aﬀect the stromal microenvironment? Do diﬀerent
genetic alterations in the OSE diﬀerentially alter susceptibility to the inﬂuence of the
stroma?
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The gene expression proﬁles described in Chapter 4 may provide some insight into the
molecular biology of early transformation of NOSE cells. Such genes (e.g. thrombospondin-
1) may be candidate therapeutic targets that may be speciﬁc for tumours harbouring those
speciﬁc genetic alterations, which could be tested in the 3D polyHEMA modelling sys-
tem described in this thesis. Moderate-throughput screens could be performed using the
cell lines generated in this model and ovarian cancer cell lines that are genotyped for
KRAS/BRAF mutations or C-MYC ampliﬁcation. Lentiviral gene delivery would ensure
the highest rates of transduction, and using a 3D screen would enhance the likelihood of
identifying potentially therapeutic genes (for gene therapy) or gene/pathway targets (for
drug development).
6.0.1 Future Directions
The list of candidate genes identiﬁed in this study represents a panel of candidate biomark-
ers associated with early stages of tumour progression. These genes are also potential
biomarkers for the early detection of the disease and/or novel therapeutic targets. Such
markers would require rigorous validation in vitro and in vivo. This work is part of a large
body of work ongoing in the Department of Gynaecology at UCL. Genomic and proteomic
tools are being used to identify novel candidate biomarkers of early ovarian cancer using
both patient tumour/serum samples and in vitro modelling approaches. The best candi-
date biomarkers will ultimately be validated in serum samples from preceeding a diagnosis
ovarian cancer, using the unique UKCTOCS cohort of over 200,000 women.
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Gene  Log FC  Adjusted 
P Val 
Gene Name 
VIPR1  -4.01  3.75E-12  vasoactive intestinal peptide receptor 1 (VIPR1). 
FEZ1  -2.68  1.02E-11  fasciculation and elongation protein zeta 1 (zygin I) (FEZ1), transcript variant 1. 
PITX1  3.44  1.14E-11  paired-like homeodomain transcription factor 1 (PITX1). 
CCL2  -2.12  1.37E-11  chemokine (C-C motif) ligand 2 (CCL2). 
RGS4  -2.64  1.44E-11  regulator of G-protein signalling 4 (RGS4). 
VGF  3.11  2.28E-11  VGF nerve growth factor inducible (VGF). 
OSR1  -2.57  2.64E-11  odd-skipped related 1 (Drosophila) (OSR1). 
UBE2C  2.31  3.20E-11  ubiquitin-conjugating enzyme E2C 
(UBE2C), transcript variant 3. 
MOCOS  2.98  5.09E-11  molybdenum cofactor sulfurase (MOCOS). 
SERPINA9  -2.29  5.09E-11  serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9 
(SERPINA9), transcript variant B 
SLC9A3R1  -1.77  7.20E-11  solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1 
(SLC9A3R1). 
THBS1  -3.49  9.22E-11  thrombospondin 1 (THBS1). 
CTGF  -2.17  1.06E-10  connective tissue growth factor (CTGF). 
SERPINA3  2.70  1.44E-10  serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 
(SERPINA3). 
TIGA1  3.26  1.52E-10  TIGA1 (TIGA1). 
OLAH  -2.79  1.67E-10  oleoyl-ACP hydrolase (OLAH), transcript variant 1. 
SYT11  -2.85  1.86E-10  synaptotagmin XI (SYT11). 
ZNF342  1.88  2.07E-10  zinc finger protein 342 (ZNF342). 
SLCO4A1  1.70  2.19E-10  solute carrier organic anion transporter family, member 4A1 (SLCO4A1). 
TNFAIP6  1.61  2.83E-10  tumor necrosis factor, alpha-induced protein 6 (TNFAIP6). 
LETMD1  1.88  2.83E-10  LETM1 domain containing 1 (LETMD1), transcript variant 2. 
COL3A1  2.31  2.88E-10  collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant) 
(COL3A1). 
MYLK  -1.69  2.88E-10  myosin light chain kinase (MYLK), transcript variant 8. 
GDF15  1.84  2.88E-10  growth differentiation factor 15 (GDF15). 
HIST1H4C  1.88  3.83E-10  histone cluster 1, H4c (HIST1H4C). 
VWF  -1.26  3.86E-10  von Willebrand factor (VWF). 
RASD1  -1.34  4.32E-10  RAS, dexamethasone-induced 1 (RASD1). 
GPR177  -2.40  4.73E-10  G protein-coupled receptor 177 (GPR177), transcript variant 1. 
UBE2C  2.11  4.79E-10  ubiquitin-conjugating enzyme E2C (UBE2C), transcript variant 6. 
DLK2  1.68  4.79E-10  delta-like 2 homolog (Drosophila) (DLK2), transcript variant 2. 
CABC1  2.03  4.81E-10  chaperone, ABC1 activity of bc1 complex homolog (CABC1), nuclear gene encoding 
mitochondrial protein. 
GPM6B  1.98  4.94E-10  glycoprotein M6B (GPM6B), transcript variant 1. 
TAGLN  -3.59  4.94E-10  transgelin (TAGLN), transcript variant 2.   267 
LOC645688  1.52  5.72E-10  PREDICTED:  similar to 60S ribosomal protein L12 (LOC645688). 
PCDH18  1.63  5.87E-10  protocadherin 18 (PCDH18). 
MAD2L1  1.98  5.95E-10  MAD2 mitotic arrest deficient-like 1 (yeast) (MAD2L1). 
GAL  1.21  6.33E-10  galanin prepropeptide (GAL). 
FBL  1.56  6.60E-10  fibrillarin (FBL). 
ITGAV  -1.75  6.60E-10  integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) (ITGAV). 
LOC650298  1.58  6.71E-10  PREDICTED:  similar to 40S ribosomal protein S26 (LOC650298). 
DLEU1  1.59  6.72E-10  deleted in lymphocytic leukemia, 1 (DLEU1) on chromosome 13. 
CTGF  -2.11  6.86E-10  connective tissue growth factor (CTGF). 
LOC651894  1.96  6.89E-10  PREDICTED:  similar to ribosomal protein S12 (LOC651894). 
LOC728554  1.48  7.14E-10  PREDICTED:  similar to THO complex 3 (LOC728554). 
IL27RA  1.39  7.24E-10  interleukin 27 receptor, alpha (IL27RA). 
HBEGF  -1.46  7.31E-10  heparin-binding EGF-like growth factor (HBEGF). 
GJB2  -2.03  8.04E-10  gap junction protein, beta 2, 26kDa (GJB2). 
MAPK13  -1.68  8.19E-10  mitogen-activated protein kinase 13 (MAPK13). 
GABBR2  -1.91  8.66E-10  gamma-aminobutyric acid (GABA) B receptor, 2 (GABBR2). 
PTGES  2.28  8.72E-10  prostaglandin E synthase (PTGES). 
VAMP8  -2.83  8.87E-10  vesicle-associated membrane protein 8 (endobrevin) (VAMP8). 
SERPINB2  -1.49  9.88E-10  serpin peptidase inhibitor, clade B (ovalbumin), member 2 (SERPINB2). 
YZ87G11  -1.93  1.24E-09  (insert cDNA clone YZ87G11) 
EIF2A  1.66  1.24E-09  eukaryotic translation initiation factor 2A, 65kDa (EIF2A). 
TMEFF2  2.03  1.24E-09  transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFF2). 
GPR4  -1.32  1.24E-09  G protein-coupled receptor 4 (GPR4). 
KCTD10  -1.51  1.28E-09  potassium channel tetramerisation domain containing 10 (KCTD10). 
NUAK1  -1.55  1.36E-09  NUAK family, SNF1-like kinase, 1 (NUAK1). 
PRC1  1.70  1.46E-09  protein regulator of cytokinesis 1 (PRC1), transcript variant 2. 
CPS1  1.42  1.54E-09  carbamoyl-phosphate synthetase 1, mitochondrial (CPS1). 
CYGB  1.25  1.60E-09  cytoglobin (CYGB). 
IGFBP5  -1.79  1.60E-09  insulin-like growth factor binding protein 5 (IGFBP5). 
ADAMTS9  -2.22  1.64E-09  ADAM metallopeptidase with thrombospondin type 1 motif, 9 (ADAMTS9). 
HMGB2  1.87  1.76E-09  high-mobility group box 2 (HMGB2). 
LOC127295  1.51  1.76E-09  PREDICTED:  similar to 60S ribosomal protein L36 (LOC127295). 
PPAPDC1A  -1.37  1.88E-09  phosphatidic acid phosphatase type 2 domain containing 1A (PPAPDC1A). 
CCNA1  -1.93  2.28E-09  cyclin A1 (CCNA1). 
TMEM38B  1.15  2.64E-09  transmembrane protein 38B (TMEM38B). 
ITGB1  -1.58  2.80E-09  integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes 
MDF2, MSK12) (ITGB1) 
LOC91561  1.88  2.80E-09  PREDICTED:  similar to ribosomal protein S2, transcript variant 3 (LOC91561). 
KRT17  1.57  2.80E-09  keratin 17 (KRT17). 
MYBPC1  1.78  2.80E-09  myosin binding protein C, slow type (MYBPC1), transcript variant 4.   268 
IL1RAPL1  -1.31  2.82E-09  interleukin 1 receptor accessory protein-like 1 (IL1RAPL1). 
IMPDH2  1.83  3.04E-09  IMP (inosine monophosphate) dehydrogenase 2 (IMPDH2). 
CCNB1IP1  2.01  3.04E-09  cyclin B1 interacting protein 1 (CCNB1IP1), transcript variant 2. 
RAB3IL1  1.17  3.22E-09  RAB3A interacting protein (rabin3)-like 1 (RAB3IL1). 
C20orf75  -1.34  3.36E-09  chromosome 20 open reading frame 75 (C20orf75). 
GPR56  -1.84  3.43E-09  G protein-coupled receptor 56 (GPR56), transcript variant 2. 
MLLT11  -1.55  3.48E-09  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); 
translocated to, 11 (MLLT11). 
H19  2.40  3.48E-09  H19, imprinted maternally expressed transcript (H19) on chromosome 11. 
BMP2  -1.76  3.56E-09  bone morphogenetic protein 2 (BMP2). 
TAGLN  -2.90  3.56E-09  transgelin (TAGLN), transcript variant 2. 
FEZ1  -1.00  3.57E-09  fasciculation and elongation protein zeta 1 (zygin I) (FEZ1), transcript variant 2. 
FOXQ1  2.86  3.60E-09  forkhead box Q1 (FOXQ1). 
RPS26L  2.18  3.97E-09  PREDICTED:  40S ribosomal protein S26-like (RPS26L), misc RNA. 
MFAP4  2.10  4.24E-09  microfibrillar-associated protein 4 (MFAP4). 
RMND1  0.92  4.49E-09  required for meiotic nuclear division 1 homolog (S. cerevisiae) (RMND1). 
SLITRK4  -1.67  4.49E-09  SLIT and NTRK-like family, member 4 (SLITRK4). 
DNAJC12  2.36  4.79E-09  DnaJ (Hsp40) homolog, subfamily C, member 12 (DNAJC12), transcript variant 1. 
PAPPA  -2.45  4.79E-09  pregnancy-associated plasma protein A, pappalysin 1 (PAPPA). 
TMEM5  1.22  4.79E-09  transmembrane protein 5 (TMEM5). 
GPR56  -1.68  4.86E-09  G protein-coupled receptor 56 (GPR56), transcript variant 3. 
SLFN11  2.29  4.95E-09  schlafen family member 11 (SLFN11). 
PTTG1  2.37  4.95E-09  pituitary tumor-transforming 1 (PTTG1). 
CTSC  -1.15  4.95E-09  cathepsin C (CTSC), transcript variant 1. 
LIAS  1.04  4.95E-09  lipoic acid synthetase (LIAS), nuclear gene encoding mitochondrial protein, transcript 
variant 1. 
NAT10  0.92  4.97E-09  N-acetyltransferase 10 (NAT10). 
IL1RL1  2.05  5.49E-09  interleukin 1 receptor-like 1 (IL1RL1), transcript variant 2. 
SHMT1  1.04  5.68E-09  serine hydroxymethyltransferase 1 (soluble) (SHMT1), transcript variant 1. 
CXCL6  -2.76  5.68E-09  chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) (CXCL6). 
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Gene  Log FC  Adjusted 
P Val 
Gene Name 
THBS1  -5.79  1.47E-14   thrombospondin 1 (THBS1). 
CTGF  -3.48  1.98E-13   connective tissue growth factor (CTGF). 
NKD2  3.90  1.98E-13   naked cuticle homolog 2 (Drosophila) (NKD2). 
PITX1  3.59  4.50E-13   paired-like homeodomain transcription factor 1 (PITX1). 
RGS4  -3.49  4.50E-13   regulator of G-protein signalling 4 (RGS4). 
ADFP  -4.86  4.50E-13   adipose differentiation-related protein (ADFP). 
TAGLN  -5.18  1.36E-12   transgelin (TAGLN), transcript variant 2. 
PCOLCE  3.92  1.72E-12   procollagen C-endopeptidase enhancer (PCOLCE). 
MMP9  3.69  1.72E-12   matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) (MMP9). 
COL1A2  -3.63  1.72E-12   collagen, type I, alpha 2 (COL1A2). 
FEZ1  -2.85  1.72E-12   fasciculation and elongation protein zeta 1 (zygin I) (FEZ1), transcript variant 1. 
DNAJC12  3.58  2.68E-12   DnaJ (Hsp40) homolog, subfamily C, member 12 (DNAJC12), transcript variant 1. 
VGF  3.19  2.83E-12   VGF nerve growth factor inducible (VGF). 
MOCOS  2.95  4.52E-12   molybdenum cofactor sulfurase (MOCOS). 
CD9  -2.30  4.90E-12   CD9 molecule (CD9). 
FRMD6  -2.40  5.67E-12   FERM domain containing 6 (FRMD6). 
TAGLN  -3.08  8.23E-12   transgelin (TAGLN), transcript variant 2. 
PALLD  -2.76  8.23E-12   palladin, cytoskeletal associated protein (PALLD). 
VCAM1  -2.63  8.72E-12   vascular cell adhesion molecule 1 (VCAM1), transcript variant 1. 
PRSS23  -2.40  1.04E-11   protease, serine, 23 (PRSS23). 
HIST1H4C  2.43  1.12E-11   histone cluster 1, H4c (HIST1H4C). 
MSLN  -2.64  1.13E-11   mesothelin (MSLN), transcript variant 2. 
LBH  -1.88  1.16E-11   limb bud and heart development homolog (mouse) (LBH). 
MGC23985  -2.32  1.43E-11   similar to AVLV472 (MGC23985). 
CTGF  -3.40  1.69E-11   connective tissue growth factor (CTGF). 
TYMS  2.69  1.72E-11   thymidylate synthetase (TYMS). 
PTGS1  -1.91  1.80E-11   prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) 
(PTGS1), transcript variant 2. 
TIGA1  2.57  2.16E-11   TIGA1 (TIGA1). 
PKP2  -1.67  2.45E-11   plakophilin 2 (PKP2), transcript variant 2a. 
CADM3  -1.74  3.12E-11   cell adhesion molecule 3 (CADM3). 
UBE2C  3.54  3.12E-11   ubiquitin-conjugating enzyme E2C (UBE2C), transcript variant 3. 
OLAH  -2.05  3.34E-11   oleoyl-ACP hydrolase (OLAH), transcript variant 1. 
PLAT  -2.28  3.34E-11   plasminogen activator, tissue (PLAT), transcript variant 1. 
F2R  -1.81  3.48E-11   coagulation factor II (thrombin) receptor (F2R).   270 
GABBR2  -2.83  4.00E-11   gamma-aminobutyric acid (GABA) B receptor, 2 (GABBR2). 
ADFP  -3.06  4.04E-11   adipose differentiation-related protein (ADFP). 
FBLN5  -2.44  4.19E-11   fibulin 5 (FBLN5). 
OSR1  -2.71  4.45E-11   odd-skipped related 1 (Drosophila) (OSR1). 
PYCARD  -1.76  4.80E-11   PYD and CARD domain containing (PYCARD), transcript variant 1. 
MAD2L1  2.89  5.14E-11   MAD2 mitotic arrest deficient-like 1 (yeast) (MAD2L1). 
PRICKLE1  -2.42  5.14E-11   prickle homolog 1 (Drosophila) (PRICKLE1). 
GPM6B  1.85  5.14E-11   glycoprotein M6B (GPM6B), transcript variant 1. 
MXRA5  -2.11  5.14E-11   matrix-remodelling associated 5 (MXRA5). 
PRC1  2.68  6.06E-11   protein regulator of cytokinesis 1 (PRC1), transcript variant 2. 
FBLN5  -2.27  6.06E-11   fibulin 5 (FBLN5). 
MYLK  -2.24  8.27E-11   myosin light chain kinase (MYLK), transcript variant 8. 
DARC  -1.96  8.74E-11   Duffy blood group, chemokine receptor (DARC), transcript variant 2. 
RRM2  1.63  8.89E-11   ribonucleotide reductase M2 polypeptide (RRM2). 
CDKN2A  -1.31  9.16E-11   cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) (CDKN2A), transcript 
variant 1. 
VIPR1  -2.44  9.52E-11   vasoactive intestinal peptide receptor 1 (VIPR1). 
ITM2A  -2.16  1.02E-10   integral membrane protein 2A (ITM2A). 
IL1B  1.90  1.20E-10   interleukin 1, beta (IL1B). 
GPR177  -2.60  1.26E-10   G protein-coupled receptor 177 (GPR177), transcript variant 2. 
RASL11B  1.90  1.26E-10   RAS-like, family 11, member B (RASL11B). 
PTGS2  2.50  1.28E-10   prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 
(PTGS2). 
ANXA8  -1.78  1.29E-10   annexin A8 (ANXA8). 
SLFN11  2.06  1.42E-10   schlafen family member 11 (SLFN11). 
HMMR  1.66  1.49E-10   hyaluronan-mediated motility receptor (RHAMM) (HMMR), transcript variant 2. 
CSF3  2.49  1.53E-10   colony stimulating factor 3 (granulocyte) (CSF3), transcript variant 1. 
FN1  -1.94  1.53E-10   fibronectin 1 (FN1), transcript variant 3. 
GINS2  1.65  1.56E-10   GINS complex subunit 2 (Psf2 homolog) (GINS2). 
  1.46  1.56E-10  AGENCOURT_14354957 NIH_MGC_191  cDNA clone IMAGE:30413554 5 sequence 
OSAP  -1.93  1.56E-10   ovary-specific acidic protein (OSAP). 
HTRA1  -1.51  1.56E-10   HtrA serine peptidase 1 (HTRA1). 
TK1  1.65  1.77E-10   thymidine kinase 1, soluble (TK1). 
OIP5  1.71  1.86E-10   Opa interacting protein 5 (OIP5). 
SYNCRIP  -1.48  1.86E-10   synaptotagmin binding, cytoplasmic RNA interacting protein (SYNCRIP). 
DNAJC12  3.20  2.01E-10   DnaJ (Hsp40) homolog, subfamily C, member 12 (DNAJC12), transcript variant 2. 
LOC652846  -1.79  2.05E-10  PREDICTED:  similar to Annexin A8 (Annexin VIII) (Vascular anticoagulant-beta) (VAC-beta) 
(LOC652846). 
DBNL  -1.52  2.05E-10   drebrin-like (DBNL), transcript variant 2. 
DKK3  -2.51  2.06E-10   dickkopf homolog 3 (Xenopus laevis) (DKK3), transcript variant 1. 
EXTL2  -1.55  2.21E-10   exostoses (multiple)-like 2 (EXTL2), transcript variant 1. 
WDR51A  1.68  2.21E-10   WD repeat domain 51A (WDR51A).   271 
SHMT1  1.40  2.40E-10   serine hydroxymethyltransferase 1 (soluble) (SHMT1), transcript variant 1. 
KIAA0101  3.68  2.50E-10   KIAA0101 (KIAA0101), transcript variant 1. 
PTTG1  2.87  2.50E-10   pituitary tumor-transforming 1 (PTTG1). 
IL1A  1.72  2.50E-10   interleukin 1, alpha (IL1A). 
UBE2C  3.24  2.50E-10   ubiquitin-conjugating enzyme E2C (UBE2C), transcript variant 6. 
LOC644029  1.44  2.53E-10  PREDICTED:  similar to 60S ribosomal protein L7a (LOC644029). 
SGSH  -1.73  2.83E-10   N-sulfoglucosamine sulfohydrolase (sulfamidase) (SGSH). 
WDR1  -1.17  3.30E-10   WD repeat domain 1 (WDR1), transcript variant 1. 
SVIL  -1.71  3.41E-10   supervillin (SVIL), transcript variant 1. 
KLF2  -1.71  3.68E-10   Kruppel-like factor 2 (lung) (KLF2). 
PTPN2  1.19  3.78E-10   protein tyrosine phosphatase, non-receptor type 2 (PTPN2), transcript variant 2. 
PGCP  -1.56  3.86E-10   plasma glutamate carboxypeptidase (PGCP). 
PLOD2  -2.07  3.95E-10   procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2), transcript variant 1. 
PTGES  3.20  3.98E-10   prostaglandin E synthase (PTGES). 
MELK  1.81  4.32E-10   maternal embryonic leucine zipper kinase (MELK). 
CTXN1  -1.70  4.32E-10   cortexin 1 (CTXN1). 
C11orf1  1.35  4.38E-10   chromosome 11 open reading frame 1 (C11orf1). 
TEAD4  1.48  4.53E-10   TEA domain family member 4 (TEAD4), transcript variant 3. 
IL11  2.27  4.89E-10   interleukin 11 (IL11). 
ITGB1  -1.77  4.89E-10   integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 
(ITGB1), transcript variant 1D. 
PLTP  1.48  4.94E-10   phospholipid transfer protein (PLTP), transcript variant 2. 
GAL  2.02  4.94E-10   galanin prepropeptide (GAL). 
GIPC1  -1.14  5.06E-10   GIPC PDZ domain containing family, member 1 (GIPC1), transcript variant 3. 
LOC645688  1.45  5.16E-10  PREDICTED:  similar to 60S ribosomal protein L12 (LOC645688). 
RFC4  1.65  5.51E-10   replication factor C (activator 1) 4, 37kDa (RFC4), transcript variant 1. 
KCNK6  -1.39  5.66E-10   potassium channel, subfamily K, member 6 (KCNK6). 
LOC148915  1.21  5.77E-10  PREDICTED:  similar to Nonhistone chromosomal protein HMG-17 (High-mobility group 
nucleosome binding domain 2) (LOC148915). 
 Appendix B: Manuscripts
Published and In Press
.1 In vitro Three-Dimensional Modelling of Human Ovar-
ian Surface Epithelial Cells.
282 
Cell Prolif. 
 
2009, 
 
42
 
, 385
 
–
 
393 doi: 10.1111/j.1365-2184.2009.00604.x
 
© 2009 The Authors 
Journal compilation © 2009 Blackwell Publishing Ltd.
 
385
 
Blackwell Publishing Ltd
 
ORIGINAL ARTICLE
 
Three-dimensional modelling of human NOSE cells
 
In vitro
 
 three-dimensional modelling of human ovarian surface epithelial cells
 
K. Lawrenson*, E. Benjamin†, M. Turmaine‡, I. Jacobs*, S. Gayther* and D. Dafou*
 
*
 
Gynaecological Cancer Research Laboratories, UCL Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, 
UK, 
 
†
 
Department of Histopathology, Royal Free/UCL Medical School, London, UK, and 
 
‡
 
Department of Anatomy and Developmental Biology, 
University College London, London, UK
Received 30 March 2008; revision accepted 15 July 2008
 
Abstract
 
Objectives
 
:
 
Ninety percent of malignant ovarian
cancers are epithelial and thought to arise from the
ovarian surface epithelium (OSE). We hypothesized
that biological characteristics of primary OSE cells
 
would more closely resemble OSE 
 
in vivo
 
 if estab-
lished as three-dimensional (3D) cultures.
 
Materials and methods
 
: OSE cells were cultured as
multicellular spheroids (MCS) (i) in a rotary cell
culture system (RCCS) and (ii) on polyHEMA-
 
coated plastics. The MCSs were examined by electron
 
microscopy and compared to OSE from primary
tissues and cells grown in 2D. Annexin  V FACS
 
analysis was used to evaluate apoptosis and expression
of extracellular matrix (ECM) proteins was analysed
by immunohistochemical staining.
 
Results
 
: On polyHEMA-coated plates, OSE sphe-
roids had deﬁned internal architecture. RCCS MCSs
had disorganized structure and higher proportion of
apoptotic cells than polyHEMA MCSs and the
same cells grown in 2D culture. In 2D, widespread
expression of AE1/AE3, laminin and vimentin were
undetectable by immunohistochemistry, whereas
strong expression of these proteins was observed in
the same cells grown in 3D culture and in OSE on
primary tissues.
 
Conclusions
 
: Physiological and biological features
of OSE cells grown in 3D culture more closely
resemble characteristics of OSE cells 
 
in vivo
 
 than
when grown by classical 2D approaches. It is likely
that establishing 
 
in vitro
 
 3D OSE models will lead
to greater understanding of the mechanisms of neo-
plastic transformation in epithelial ovarian cancers.
 
Introduction
 
Human ovaries are covered with a monolayer of ﬂat/
cuboidal mesothelial-type cells referred to as the ovarian
surface epithelium (OSE). These cells are widely con-
 
sidered to be the origin of epithelial ovarian cancers, which
 
represent about 90% of all malignant ovarian tumours
(1–3). Understanding biological and molecular character-
istics of OSE and the earliest stages of ovarian tumour
development has been hampered in the past by lack of a
 
suitable 
 
in vitro
 
 model of normal OSE (NOSE). This is
partly because primary OSE cells have proved difﬁcult to
establish in culture and have a short lifespan 
 
in vitro
 
.
Since the ﬁrst description of OSE cultures in 1984, opti-
mization of collection techniques and culture media has
increased 
 
in vitro
 
 lifespan of these cells (4–6). However,
there remain limitations to culturing NOSE cells as standard
two-dimensional (2D) monolayers. For example, NOSE
cells can lose some of their epithelial characteristics, even
 
when cultured in enriched media (6). Primary NOSE
cell cultures show considerable phenotypic plasticity and
can exhibit both epithelial (for example, presence of
 
desmosomes; collagen IV , laminin and cytokeratin
production) and mesenchymal characteristics (collagen I,
collagen III and vimentin production) (5,7).
Three-dimensional (3D) culture systems enable the
propagation of cells in a microenvironment that re-
sembles 
 
in vivo
 
 conditions more closely than traditional
 
2D cultures. 
 
In vivo
 
, epithelial cells are surrounded by a
complex extracellular matrix (ECM). They contact and
communicate with a host of different cell types through
receptors distributed throughout the entire cell surface.
However, in 2D monocultures, clonally derived cells only
 
communicate along a small proportion of their membrane.
Cells that are traditionally difﬁcult to culture in 2D, such
as primary hepatocytes, can often be maintained 
 
in vitro
 
for longer periods when grown in 3D cultures (8). There
is now substantial evidence to suggest that 3D cultures
more closely resemble the 
 
in vivo
 
 microenvironment than
2D cultures, and that culturing cells in 3D can cause pheno-
typic and molecular changes that reﬂect 
 
in vivo
 
 biology of
the cells more closely than 2D (9–11).
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Several different approaches can be used to establish
3D cell culture models. For example, cells can be grown
in 3D using ECM protein gel scaffolds (such as collagen
gels). Other techniques prevent cell adherence to tissue
culture plastics and hence, encourage cells to adhere
to each other; such systems include the rotary cell culture
system (RCCS) or poly-2-hydroxyethyl methacrylate
(polyHEMA)-coated tissue culture plastics. However,
few studies have directly compared different 3D culture
techniques. In one study, Ghosh 
 
et
 
 
 
al
 
. cultured melanoma
cells in collagen gels and found that gene expression
proﬁles were similar to those of cells in 2D; yet when cells
were grown on polyHEMA-coated plates, they observed
differential expression of > 150 genes (10) and many of
the genes upregulated in polyHEMA 3D cultures were
consistent with their upregulation 
 
in vivo
 
 (10). Hence,
different 3D culture techniques are not equivalent in their
effectiveness.
To date, there are no reports describing 3D culturing
of NOSE cells. There are some reports of culturing ovarian
cancer cells in 3D, in particular, tumour cell aggregates
derived from ascites (11–13). The purpose of the current
study was to evaluate biological effects of two different
3D culturing techniques on culture of primary normal
ovarian surface epithelial cells and to establish a 3D model
of NOSE cells that could be used to study the earliest
stages of neoplastic transformation in epithelial ovarian
cancer. In evaluating these 3D models, we compared
morphological and biological characteristics of cells with
the same cells grown in 2D cultures and of NOSE from
primary tissue samples. We hypothesized that by allowing
NOSE cells to form 3D structures, we would maintain a
phenotype that more closely resembles NOSE cells
 
in vivo 
 
than in 2D culture.
 
Materials and methods
 
Tissue samples
 
Primary NOSE cells were collected and established as
previously described (6). Two primary cell isolates (NOSE4
and NOSE11) were established from cells obtained during
total laparoscopic hysterectomy with bilateral salpingo-
oophorectomy procedures. NOSE4 cells were from a
62-year-old-woman diagnosed with endometrioid endo-
metrial cancer stage I and cervical clear cell carcinoma;
NOSE11 cells were from a 49-year-old-woman with
ovarian stromal and endometrial hyperplasia. Another
line, NOSE19L3 was derived from cells from an ovarian
cytobrushing from a 39-year old patient undergoing total
abdominal hysterectomy for cervical cancer. In all cases,
ovarian epithelia were veriﬁed as histologically normal
with no evidence of hyperplasia nor neoplasia.
 
Cell culture and reagents
 
All NOSE cell cultures were maintained in medium
(NOSE-CM) comprising MCDB105:Medium 199 (1 : 1)
supplemented with 15% foetal bovine serum, 10 ng/ml
epidermal growth factor, 0.5  mg/ml hydrocortisone,
5 mg/ml insulin, and 34 mg protein/ml bovine pituitary
extract, (all Sigma, St Louis, MO, USA). Primary NOSE
cells were collected by brushing the surface of normal
ovaries with a sterile cytobrush, which was then agitated
in 5 ml of NOSE-CM to release the cells. Suspensions
were plated into 25-cm
 
2
 
 tissue culture ﬂasks and left for
7 days to allow cells to grow. Cell culture medium was
changed every 2–3 days until cultures reached 80–90%
conﬂuence, at which point they were subcultured. Cells
were grown as 3D multicellular spheroids (MSC) either
in RCCS (Synthecon, Houston, TX, USA) or in plastic
dishes coated with 2.5% solution of polyHEMA (Sigma),
prepared in 95% ethanol, also from Sigma.
 
In vitro phenotypic analysis of cell cultures
 
Population doubling rates were measured for 1 
 
×
 
 10
 
5
 
cells, in triplicate. Cultures were passaged and population
doublings (PD) calculated using the following formula:
PD = log (total cell number at each passage/initial cell 
number)/log2.
Assays for anchorage independent growth were per-
formed by plating 2 
 
×
 
 10
 
4
 
 cells in complete medium
containing 0.3% Noble Agar (Sigma) over a base layer of
complete medium containing 0.6% Noble Agar. Five
replicates were plated for each primary NOSE cell line.
As control, anchorage independent growth was evaluated
simultaneously for the TOV112D endometrioid ovarian
cancer cell line. After 4  weeks, cells were ﬁxed with
methanol and stained with 1% p-iodonitrotetrazolium
violet (Sigma). Colony formation was observed and
number of colonies containing > 50 cells were counted.
Colony forming efﬁciencies (CFE %) were calculated
using the following formula:
CFE = [(number of colonies counted)/(number of cells 
plated)] 
 
×
 
 100%.
 
Immunoﬂourescent cytochemistry/immunohistochemistry
 
All three primary cell isolates (NOSE4, NOSE11 and
NOSE19L3) were conﬁrmed as epithelial by immuno-
ﬂuorescent cytochemistry, performed using standard
protocols. The following antibodies were used (all diluted
1 : 1000): AE1/AE3 (Dako Corporation, Carpinteria, CA, 
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USA), cytokeratin 7 (CRUK, London, UK), BerEp4 (Dako),
CA125 (Dako), E-cadherin (Cell Signaling, Danvers,
MA, USA), FSP (Sigma), and Factor VIII (Lab Vision,
Fremont, CA, USA). All cell cultures tested were found to
express epithelial markers (AE1/AE3, BerEP4, ck7), and
did not express endothelial cell (Factor VIII) and ﬁbro-
blast (FSP) markers. Cells were weakly positive for
ovarian cancer-associated  marker  CA125. This obser-
vation is consistent with ﬁndings of another study: 50%
of NOSE cell cultures express CA125 in the ﬁrst few
passages (14). Staining for CA125 was also observed in
primary ovaries from which NOSE4 and NOSE11 were
derived. Immunohistochemistry for 2D and 3D cultures
was performed using standard protocols at the CRUK
Histology Service.
 
Apoptosis assays
 
MCSs from 3D cell clusters were washed in phosphate-
buffered saline and trypsinized at 37 
 
°
 
C to create single
cell suspensions; 2D cultures were trypsinized and centri-
fuged, and cell pellets resuspended in FACS buffer,
according to manufacturer’s instructions (Roche, Basel,
Switzerland). Samples were run on a Becton Dickinson
FACS Scan (Franklin Lakes, NJ, USA) and the
annexin V-positive cell population was measured.
 
Transmission electron microscopy/scanning electron 
microscopy
 
Cells were either grown on glass coverslips or, for 3D cul-
tures, cell clusters were harvested and media aspirated.
Cells were washed once with phosphate-buffered saline
from VWR (West Chester, PA, USA) then ﬁxed with 2%
paraformaldehyde, 1.5% glutaraldehyde in 0.1 M cacodylate
 
buffer (pH 7.3) for 1–2 h (all from Sigma). Samples were
then washed in 0.1 M cacodylate buffer and post-ﬁxed
with 1% osmium tetroxide (Sigma) in 0.1
 
 M
 
 cacodylate
buffer (pH 7.3) for 1 h at 4 
 
°
 
C, before washing twice in
0.1 M cacodylate buffer, then water for 5 min. Samples
were stained with 0.5% uranyl acetate (Sigma) for 20 min
then washed in water before dehydration with increasing
concentrations of ethanol. Samples were then embedded
in agar resin, sectioned and examined on a JEOL (JEOL
Ltd, Tokyo, Japan) 1010 transmission electron microscope.
For scanning electron microscopy, samples were ﬁxed as
for transmission electron microscopy, post-ﬁxed with 1%
osmium tetroxide in 0.
 
1
 
 M cacodylate buffer (pH 7.3) for
45 min at 4 
 
°
 
C and dehydrated with increasing concentra-
tions of ethanol. Samples were then critically point dried,
mounted on carbon stubs and gold-coated before viewing
using a JEOL 7401 series FEGSEM.
 
Results
 
The aim of this study was to establish 3D 
 
in vitro
 
 models
of NOSE cells and to compare morphological and bio-
logical characteristics with the same cells grown as 2D
cultures, and with primary ovarian tissues. We ﬁrst estab-
lished and characterized three primary NOSE cell isolates
(NOSE4, NOSE11, NOSE19L3) grown as 2D monolayers.
Cell cultures 
 
in vitro
 
 had growth characteristics typical of
NOSE cell cultures (Table 1) (6). NOSE11 cells had the
shortest population doubling time and the longest lifespan
of the three primary cell isolates. This may be because
NOSE4 cells were derived from a postmenopausal woman
and, therefore, are likely to have reduced lifespan 
 
in vitro
 
.
NOSE19L3 was a clone isolated from cell brushing thus,
originates from a smaller initial population, hence the
reduced lifespan observed in this culture.
Table 1. Patient information and growth characteristics of normal primary ovarian epithelial cells (OSE)
Primary cell line
Patient characteristics Cells grown as 2D monolayers 3D multicellular spheroids
Age Menopausal status PD timea (hours) Maximum no. of PDs CFE in soft agarb
Average MCS 
diameter (μm) (range)c
NOSE4 62 Post 82.4 7.6 0 78.25
(32.70–152.00)
n = 11
NOSE11 48 Peri 57.2 17.8 0 91.053
(80.92–252.40)
n = 11
NOSE19L3 39 Pre 83.6 9.7 0 171.98
(63.90–125.60)
n = 5
aPopulation doubling (PD) times calculated from the exponential growth phase; bcolony forming efﬁciency (CFE); cmulticellular spheroids (MCS) 
grown in 3D by polyHEMA coating of tissue culture plastics, size measured under the scanning electron microscope. 
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Establishing and characterizing 3D NOSE cell cultures
 
All three primary cell isolates formed MCSs when cultured
for 14 days either on polyHEMA-coated plates or in
the Rotary Cell Culture System (Fig. 1). MCSs appeared
solid and smooth by light microscopy. MCSs grown on
polyHEMA-coated plates (PH-MCSs) were typically 70–
170 
 
μ
 
m in diameter (Table 1). NOSE19L3 cells formed
signiﬁcantly larger PH-MCS than NOSE4 or NOSE11
cells (
 
P 
 
< 0.0001 and 
 
P
 
 = 0.025, respectively; two-tailed
 
unpaired 
 
t
 
-test). MCSs formed in the RCCS (RCCS-MCS)
grew to 1–2 mm in diameter.
We examined the internal architecture of MCSs fol-
lowing parafﬁn wax embedding, sectioning, and staining
with haematoxylin and eosin. For all three primary cell
cultures, PH-MCSs had deﬁned internal architecture: a
central core of matrix protein, surrounded by aligned
elongated cells. The cells formed a ring around the matrix
core, often with a ‘cap’ to one side, with resemblance to
papillary structures sometimes observed on the surface of
Figure 1. Haematoxylin and eosin-stained
sections of multicellular spheroids from three-
dimensional (3D) cultures. Normal ovarian
surface epithelium (NOSE) cells form smaller
3D multicellular structures when cultured on
polyHEMA-coated plates (PH-MCSs) (a,b)
compared to culturing in the rotary cell culture
system (RCCS-MCSs) (c,d). The matrix cores of
PH-MCS are clearly visible (black arrows); cells
form either a ring around the matrix or a ‘cap’ on
one side (white arrow). PH-MCSs show architec-
tural resemblance to 3D structures observed on
the surface of the ovary in vivo (e,f), where
surface papillary projections consist of epithelial
cells around stromal cores with matrix protein
(black arrows). Scale bars represent 0.1 mm.
Table 2. Differential expression of pan-cytokeratin (AE1/AE3), laminin, vimentin and collagen IV , detected by immunohistochemistry in two- (2D)
and three-dimensional (3D) cultures and in primary normal ovarian tissues. Graded shading denotes extent of staining. White denotes negative
staining; crosshatched grey denotes weak or focal staining; light grey represents that 20–50% cells stain positive; and dark grey shading indicates
over 50% cells stain positive. 
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normal ovaries 
 
in vivo
 
 (Fig. 1). The matrix core often
contained degenerate nuclear debris. When cells were
grown in RCCS, resulting MCSs had a less organized
arrangement of cells. Cells within RCCS spheroids tended
to be more rounded with a 1–2 cell deep layer of cells
around the edge of the clusters which had an elongated
morphology (Fig. 1).
 
Ultrastructure of PH-MCS
 
PH-MCS were architecturally interesting, so we used
transmission and scanning electron microscopy to study
their ultrastructure and of the same cells grown in 2D.
Desmosomes, which are characteristic of epithelial cells,
were present in all 2D and 3D cultures (Fig. 2a). In PH-
MCSs, outer cells (up to 8 cell layers but sometimes only
1–2 cells thick) were elongated and aligned. Peripheral
cells were also longer in shape compared to cells located
towards the core of the spheroid, where cells were rounder
and less densely packed (Fig. 2b). Transmission electron
microscopy of PH-MCSs revealed that cells towards the
 
centre tended to have extensive and dilated rough endo-
plasmic reticulum, well-developed Golgi apparatus and
open nucleolus. Some cells appeared to have formed a
discontinuous basement membrane and matrix-like material
in the extracellular space. This ECM material was abun-
dant in the core of the MCSs.
When examined by scanning electron microscopy (SEM),
cells on the outer surface of PH-MCS had a ﬂattened
morphology and very few surface features. Although
microvilli were absent, there were often many surface
projections connecting adjacent cells amongst PH-MCS.
Two-dimensional monolayers also had very few surface
features; cells were unremarkable, with the exception of
long surface projections extending between cells, similar
to those seen on PH-MCSs. Absence of microvilli may
have been due to loss of polarization as a result of culturing
the cells on glass. It may be possible to overcome this by
growing NOSE cells with oestrogen, ovarian stromal
ﬁbroblasts or on collagen or ﬁbronectin-coated plates to
attempt to maintain polarization and microvilli formation
(15,16). Dead cells were observed both on the surface of
Figure 2. Transmission and scanning electron micrographs of normal ovarian surface epithelium (NOSE) cells in culture and from primary
tissues. (a) A high-power electron micrograph of two-dimensional (2D) NOSE cultured cells. Bundles of intermediate ﬁlaments can be seen, with the
formation of desmosomes between adjacent cells (white arrow). (b) A low-power electron micrograph of multicellular structures cultured on poly-
HEMA-coated plates (PH-MCS) showing the ﬂatter and closely opposed cells at the periphery forming concentric rings (such as cell B). Cells within
the inner region of the PH-MCS have a more rounded morphology and are less tightly packed (cell A). Note the cells towards the core of the MCS
are full of electron dense vesicles (white arrow), which may illustrate a trend to a more secretary phenotype towards the centre of the multicellular
clusters. Extracellular material (M) is abundant in the cores of PH-MCS. (c) Section of quiescent ovarian epithelium. Note the cuboidal shape of cell,
condensed chromatin within the nuclei (N), basement membrane (black arrow), desmosomes (white arrow) and age-related storage: lipofuscin (L).
In vivo NOSE cells are mostly quiescent (unless at the site of follicular rupture, following ovulation). (d) A low power SEM image of a PH-MCS
showing surface morphology. The ﬂattened surface cells form a patchwork with no obvious orientation. The number of surface protrusions varied
from a few to many between cells (black arrows). 
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the PH-MCS and in 2D cultures. Early-stage cell death
was identiﬁable by holes in the membrane and later-stage
degraded cells were observed budding off the PH-MCSs
and 2D cultures.
 
Expression of ECM proteins in 2D and 3D cultures
 
Previous studies have shown that culturing cells in 3D may
alter cell–cell interactions, including expression of ECM
proteins, receptors and corresponding degradative enzymes.
NOSE cells reportedly produce a variety of ECM molecules
 
in vitro
 
 (17). Therefore, we used immunohistochemistry to
determine whether any of these proteins were differentially
expressed between 2D and 3D cultures (Fig. 3). Fibronectin
was expressed in 2D and 3D cultures in all three cell
cultures. For 2 out of the 3 cell cultures, weak focal
vimentin staining was observed in 2D cultures around some
mitoses. However, strong positive vimentin characterized
all 3D cultures and OSE 
 
in vivo
 
. Laminin and AE1/AE3
were not expressed in 2D cultures, but strong expression
of these markers was observed PH-MCSs, RCCS-
MCSs and in epithelium of normal ovarian tissue. Fibrous
ﬁbronectin, laminin and vimentin ﬁlaments were observed
between cells, suggesting that these proteins play a role
in maintaining the structure of MCSs. For the markers
tested, staining intensity did not vary according to
spheroid size.
 
Apoptosis in 2D and 3D cultures
 
We characterized the proportion of apoptotic cells in the
cultures using annexin V and propidium iodide staining,
followed by FACS analysis (Fig.  4). Propidium  iodide
staining identiﬁes the necrotic component of cell cultures;
annexin  V recognizes externalized phosphatidylserine,
which is a measure of early stages of apoptosis. In RCCS-
MCSs, the proportion of cells positive for annexin V was
at least 2.5-fold that of 2D cultures and PH-MCSs. For
Figure 3. Expression analysis of candidate markers by immunohistochemistry of normal ovarian surface epithelium (NOSE) cells from
representative two- (2D) and three-dimensional (3D) cultures and in primary NOSE from tissue sections of normal ovaries. A summary of the
results of these analyses are given in Table 2. Here, staining patterns suggest that primary NOSE from normal ovarian tissues express a range
of extracellular matrix proteins (e.g. vimentin, ﬁbronectin, laminin). Staining proﬁles of 3D cultures more closely resemble that of primary
OSE than 2D cultures. Scale bars represent 0.1 mm. 
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two cell cultures, we did not observe any signiﬁcant dif-
ference in proportion of apoptotic cells in PH-MCSs
compared to 2D cultures. For one primary cell isolate
(NOSE19L3), there was signiﬁcantly more apoptosis
in PH-MCS (
 
P
 
  =  0.0470 using two-tailed paired 
 
t
 
-test)
compared to 2D cultures. This may be due to the shorter
population doubling time for this culture or due to loss
of apoptotic cells from 2D cultures during washing and
harvesting. We found signiﬁcant differences in proportions
of annexin  V-positive cells in RCCS-MCSs compared to
2D cultures and PH-MCS for all three cell cultures
(NOSE4, 
 
P
 
 = 0.0176; NOSE11, 
 
P
 
 = 0.0164; and NOSE19L3,
 
P
 
  =  0.0152, using two-tailed paired 
 
t
 
-tests). For one
culture  (NOSE11), we observed by propidium  iodide
staining, a signiﬁcantly larger necrotic component in
RCCS-MCSs compared to 2D and PH-MCSs (
 
P
 
 = 0.0242,
two-tailed paired 
 
t
 
-test). Thus, for this culture there was a
statistically signiﬁcant increase in the proportion of cells
at all stages of apoptosis in RCCS cultures compared to
cultures grown in 2D or on polyHEMA-coated plates.
Indeed, cells at all stages of apoptosis were distributed
throughout the RCCS-MCSs (Fig. 4).
 
Discussion
 
To the best of our knowledge, this paper describes for the
ﬁrst time the development and characterization of a 3D
model of normal ovarian surface epithelial cells. The OSE
is typically described as a monolayer of cells, but it none-
theless has a 3D architecture that cannot be replicated by
culturing primary NOSE cells in 2D on adherent plastic
surfaces. In this study, we show that NOSE cells form 3D
structures (MCSs) when cells are prevented from adhering
to tissue culture surfaces either by chemical treatment of
 
tissue culture vessels or by maintaining cells in constant
rotation. In the RCCS, NOSE cell clusters were larger and
had a chaotic internal structure compared to cells grown on
polyHEMA-coated plastics. NOSE cells grown in poly-
HEMA-coated vessels formed concentric layers around a
core of matrix protein. These data suggest that in a static
microenvironment, NOSE cells spontaneously form
organized 3D multicellular structures.
There are other reports describing 3D cell aggregates
of other cell types in which two distinct regions of cells
are observed: an inner area of cells that are smaller and
less proliferative than surrounding cells on the periphery
of MCS (10,18). In one study, Freyer and Sutherland
found that cells on the surface of MCSs formed from
mouse mammary tumour cells were similar in size to an
exponentially growing 2D cell culture, but with 60% less
cells in S phase (19). Our observations of the structure of
RCCS-MCSs (by light microscopy) and PH-MCSs
(by light and transmission electron microscopy) are
consistent with these ﬁndings: instead of a continual
reduction in cell size from the outer to inner core of
spheroids, we found clear distinction in morphology
between cells on the outer layers compared to cells
within the spheroids. Cells within MCS also appeared
to be rounder in shape compared to elongated cells at the
periphery.  Other studies have found differences in cell
size and morphology at different regions of MCSs (10,19).
Measurements of apoptosis between 2D and 3D
cultures suggest a greater proportion of cells grown in the
RCCS are apoptotic when compared to 2D and poly-
HEMA 3D cultures. This was conﬁrmed by the observa-
tion of many apoptotic nuclei distributed throughout the
RCCS-MCS. An explanation for this is unclear, but it
could be that the continual motion of spinning the cells in
Figure 4. Variation in levels of apoptosis in two- (2D) and three-dimensional (3D) cultures. (a) Levels of apoptosis (as measured by annexin V
expression) are signiﬁcantly higher in 3D multicellular spheroids (MCS) grown in the rotary cell culture system (RCCS-MCS) compared to 2D cultures
and MCS grown on polyHEMA-coated plates (PH-MCS). Error bars = standard error of the mean (SEM). (b) Apoptotic cells (arrow) are visible
throughout the RCCS-MCS, and are not localized to a necrotic ‘core’ of MCSs. Scale bar represents 0.1 mm. 
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the RCCS causes mechanical damage which in turn
induces apoptosis. Thus, increased levels of apoptosis
observed in RCCS-MCSs may be an experimental artefact.
Apoptosis is generally low in the ovarian epithelium 
 
in vivo
 
since these cells are usually quiescent (except immediately
after rupture of a mature follicle). Unlike some cancer
cell spheroids, extensive apoptosis and necrosis is not
localized to the cores of the clusters. Conditions at the
centre of the RCCS-MCS are unlikely to be hypoxic in
comparison to the 
 
in vivo
 
 microenvironment – the oxygen
concentration in the pelvis is 5.5% (measured at the cervix)
and cells were cultured in 20% oxygen (20), further
suggesting that increased rates of apoptosis observed in
RCCS-MCS were a consequence of mechanical damage.
Indeed, we have observed that prolonged culture in the
RCCS can result in spheroids that consist only of cells
that have degenerated (unpublished data).
Transmission electron microscopy of PH-MCSs
revealed that cells contained swollen endoplasmic reticulum
and Golgi apparatus and had an open nucleolus. Cells
within PH-MCS were actively producing and appeared to
be secreting a basement-membrane-like matrix, which was
abundant in the core of the MCSs. ECM molecules play
a vital role in tissue architecture and are vital for the
formation of hepatoma spheroids (21). Both RCCS-MCSs
and PH-MCSs produced an abundance of ECM proteins
laminin, ﬁbronectin and vimentin, but did not express
collagen IV . Two-dimensional cultures showed widespread
expression of ﬁbronectin and collagen IV but not laminin,
and vimentin was only expressed focally at mitoses in 2
out of the 3 primary cell cultures. These patterns of protein
expression reﬂect the phenotypic plasticity that is charac-
teristic of NOSE cells: in both 2D and 3D, cells show both
epithelial (collagen IV , laminin, cytokeratin) and mesen-
chymal (vimentin) features.
In general, cells demonstrate considerable plasticity and
have an ability to respond dramatically to their environ-
ment. A transcriptome that promotes growth within an
organism is unlikely to provide the cell with an optimal
phenotype for growth in 2D. Since the 1970s, 3D culture
techniques have been considered to be an invaluable tool
for studying cancer cell growth. Some studies have sug-
gested that multicellular tumour spheroids grown either in
spinner ﬂasks or on polyHEMA-coated plates are repre-
sentative of the early stages of tumour growth prior to
vascular involvement (10,22). Furthermore, many studies
point to the downstream pathways of cancer cell interac-
tions with the ECM as important therapeutic targets (23).
Thus, 3D models, such as those presented here, are likely
to represent useful tools to examine the roles of different
genes involved in the earliest stages of tumorigenesis.
More complex, heterotypic cultures containing ovarian
stromal ﬁbroblasts and endothelial cells will assist in
 
developing our understanding of the role of interactions
between different cell types during epithelial tumouri-
genesis. There is a need for more biologically relevant
 
in vitro
 
 models of epithelial ovarian cancer since 
 
in vivo
modelling of this disease has had limited success (24,25).
Despite the discovery of ovary-speciﬁc Mullerian-inhibiting
substance receptor type II, an in vivo model that accurately
reﬂects epithelial ovarian cancer: a disease that is late-onset
and histologically heterogeneous, has yet to be established.
By mimicking the processes of early ovarian tumour
development in an microenvironment that closely resem-
bles this process in vivo, it may be possible to identify new
proteins associated with tumour progression that represent
biomarkers for early detection of disease and/or novel
therapeutic targets.
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Abstract
Most epithelial ovarian cancers are diagnosed postmenopausally, although the well-established epidemiological risk
factors (parity, oral contraceptive use) are premenopausal. We hypothesized that accumulation of senescent fibro-
blasts, together with concomitant loss of presenescent fibroblasts within the ovarian cortex, promotes initiation
and early development of ovarian cancer from ovarian surface epithelial (OSE) cells. To test this, we established
immortalized OSE (IOSE) cell lines that mimic early neoplastic transformation by overexpressing the CMYC oncogene
(IOSE
CMYC) and normal ovarian presenescent (PSN) and senescent (SEN) fibroblast cell lines. We then evaluated the
ability of PSN and SEN fibroblasts to transform IOSE and IOSE
CMYC after coculture. SEN fibroblasts significantly
enhanced neoplastic development of IOSE
CMYC cells; there was an up to 15-fold increase in migration of IOSE
CMYC
cells cocultured with SEN fibroblasts compared with PSN fibroblasts. Conditioned medium from SEN fibroblasts pro-
moted anchorage-independent growth of IOSE
CMYC cells. We studied fibroblast-epithelial cell interactions in hetero-
typic three-dimensional spheroid models. Dual immunohistochemical staining of spheroids for a proliferation marker
(MIB-1) and cytokeratin-18 indicated that SEN fibroblasts induce approximately a five-fold increase in proliferation of
IOSE
CMYC cellsrelativetococultureswithPSN fibroblasts.SEN, but not PSNfibroblasts, alsoinducednuclear atypia in
epithelial cells in three-dimensional spheroids. These data suggest for the first time that the accumulation of senes-
cent, or loss of presenescent fibroblasts, can promote neoplastic development of partially transformed OSE cells
in vitro and illustrates the power of using three-dimensional heterotypic modeling to gain better insights into the etiol-
ogy underlying the development of epithelial ovarian cancer.
Neoplasia (2010) 12, 317–325
Introduction
More than 80% of all epithelial ovarian cancers (EOCs) are diagnosed
in postmenopausal women older than 60 years [1,2]. However, the
strongestepidemiologicalriskfactorsforEOCarepremenopausalfactors
(oral contraceptive pill use and parity) [3,4]. High-grade serous tumors
are the most common histopathologic subtype of the disease but are
rarely diagnosed at an early stage, suggesting that these tumors progress
rapidly. One hypothesis to explain postmenopausal disease development
is that some as yet unknown microenvironmental trigger initiates prolif-
eration in dormant epithelial cells that harbor somatic mutation(s). One
possible trigger could be age-related changes (senescence) occurring in
ovarian stromal fibroblasts, which work in synergy with early genetic
changes in the epithelium to promote EOC development.
Abbreviations: NOF, normal ovarian fibroblast; INOF, immortalized NOF; SEN,
senescent NOF; PSN, presenescent NOF; OSE, ovarian surface epithelium; IOSE,
immortalized ovarian surface epithelium
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Volume 12 Number 4 April 2010 pp. 317–325 317As an organism ages, senescent fibroblasts accumulate in the tissue
stroma, gradually replacing presenescent cells [5,6]. In vitro and in vivo
models have demonstrated that normal fibroblasts in a normal tissue
microenvironment can inhibit early tumorigenesis but that fibroblast
senescence results in a loss of inhibition of tumorigenesis and/or pro-
motion of epithelial transformation [7–9]. For example, senescent
fibroblasts enhance epithelial neoplastic progression in vitro and pro-
mote theformation oftumor xenografts invivo inmodels ofmammary,
prostate, and keratinocyte tumors [10–13]. Senescent cells do not di-
videbutremainmetabolicallyactive,andtheprofileofsecretedproteins
in senescent cells differs substantially from their nonsenescent counter-
parts [14]. The induction of senescence induces a senescence-associated
secretory phenotype;senescent fibroblastssecretea multitude of growth
factors (including vascular endothelial growth factor), extracellular ma-
trix proteins, proteases, chemokines, and cytokines [14,15]. It is likely
that these molecules act in paracrine to affect the phenotype of neigh-
boring epithelium, directly and indirectly, through remodeling of the
extracellular matrix and/or through interaction with other cell types
(e.g., inflammatory or endothelial cells) [8,16].
The aim of the current study was to investigate the role of aging
fibroblasts in the initiation and development of EOCs, using a three
dimensional model of cellulartransformation of theovarian surface epi-
thelium (OSE). We have previously established three-dimensional cell
culture models of normal, primary OSE cells and demonstrated their
biological similarities to primary tissues [17]. In the current study, we
created a three-dimensional heterotypic model of ovarian stromal-
epithelial cell interactions, and of the earliest stages of OSE transforma-
tion, to test the hypothesis that accumulation of senescent fibroblasts,
withconcomitantlossofpresenescentstromalcells,contributestotrans-
formation of ovarian epithelial cells. The results imply a role for senes-
cent fibroblasts in promoting early tumorigenesis of OSE and further
suggest that the ovarian stromal microenvironment may have a crucial
role in the development of EOCs.
Materials and Methods
Cell Culture, Retroviral Production, and Transduction
Primary normal ovarian surface epithelial (NOSE) cell isolates
NOSE4, NOSE11, and NOSE19L3 have been previously described
[17]. All ovarian epithelial cell cultures were maintained in NOSE
medium (NOSE-CM) [17]. Normal ovarian fibroblast (NOF) cells
were isolated from a patient undergoing total abdominal hysterectomy
for endometrial carcinoma. The ovary was confirmed as free of dis-
ease by a gynecological pathologist (E.B.). A tissue sample was excised
from the ovary and washed twice with phosphate-buffered saline (PBS;
from VWR, Lutterworth, UK) to remove loosely attached epithelial
cells. Tissue was then minced and incubated at 37°C/5% CO2 for 7
to 14 days to allow colony growth. Colonies with fibroblastic morphol-
ogies were isolated. Fibroblast cultures were maintained in basic me-
dium MCDB105/Medium 199 (1:1 ratio; both Sigma, St Louis, MO),
15% fetal bovine serum (FBS), and 1% L-glutamine (both Invitrogen,
Paisley, UK). To induce senescence, cells were exposed for 2 hours
to 80 μM of hydrogen peroxide solutions (VWR) diluted in culture
medium. β-Galactosidase bioactivity assays were performed as previ-
ously described [18]. Senescent fibroblasts were freshly prepared for
replicate experiments.
293T cells at 70% confluence were cotransfected with the
pVPack10A1, pVPackGP, and pBabe.hygro.hTERT/ pWZL.Blast.
CMYC (Addgene) vectors using FuGene6 transfection reagent (Roche,
Basel, Switzerland) at ratio of 3:1, reagent/DNA. The medium was
replaced 16 hours after transfection, and cultures were incubated for
a further 48 hours before retroviral supernatants were harvested and
stored at −80°C. To infect recipient cells, 3 ml of supernatant and
4 μg/ml DEAE-dextran (Sigma) were added to NOSE/NOF cells
at 30% to 50% confluence. Cells were split the following day, and
positive cells were selected with 10 to 30 U/ml hygromycin B (Merck,
Darmstadt, Germany)/2 to 3 μg/ml blasticidin (Sigma).
Immunofluorescent Cytochemistry and Immunohistochemistry
Immunofluorescent cytochemistry was performed using standard
protocols. The following antibodies were used at 1:1000 dilutions:
AE1/AE3 (Dako Corporation, Carpinteria, CA), cytokeratin 7 (CR-
UK, London, UK), BerEp4 (Dako), CA-125 (Dako), E-cadherin (Cell
Signaling, Danvers, MA), and fibroblast surface protein (FSP; Sigma).
Alexa Fluor 488–coupled secondary antimouse or antigoat antibodies
(Invitrogen) were used for antigen detection. Cells were counterstained
with Evans Blue (Sigma) diluted in H2O. Immunohistochemistry of
three-dimensional cultures was performed using standard protocols at
the UCL Advanced Diagnostics Laboratory. For analysis of MIB-1 and
cytokeratin 18 (Ck18) dual staining, the proportion of MIB-1
+/Ck18
+
cellswerecalculatedrelativetothetotalCk18
+populationoftheculture,
using the following formula: relative % dual positive cells = (number
of MIB-1
+/Ck18
+ cells)/(total number of Ck18
+ cells)] × 100%.
Telomere Length and Telomerase Activity Assays, In Vitro
Analysis of Tranduced Clones
To detect telomere length and telomerase activity, the TeloTAGGG
Telomere Length Assay and Telomerase PCR ELISA
PLUS from Roche
were used according to the manufacturer’s protocols. For calculation of
relative telomerase activity, an hTERT-immortalized fibroblast cell line
(1BR3) was included as a positive control. Population doubling rates
were measured for 1 × 10
5 cells, in triplicate. Cultures were passaged,
and population doublings(PD)were calculatedusing thefollowing for-
mula: PD = log (total cell number at each passage/initial cell number)/
log2. Anchorage-independent growth assays were performed as previ-
ously described [17]. Anchorage-dependent growth was assayed by plat-
ing 100 cells in six replicates onto 100-mm plates. Cells were refed
three times a week for 2 weeks and then fixed with methanol and
stained with Coomassie blue (Sigma). Colonies containing more than
10 cells were counted, and colony formation efficiencies were calcu-
lated using the following formula: colony-forming efficiency (CFE) =
[(number of colonies counted)/(number of cells plated)] × 100%.
Real-time Polymerase Chain Reaction
RNA extractions were performed using the QIAgen RNA extraction
kit with on-column DNase treatment. Samples were quantified and
reverse-transcribedusingrandomhexamerprimers,accordingtostandard
protocols. For real-time polymerase chain reaction (PCR), samples were
run according to manufacturer’s protocols: a FAM-labeled real-time
probe for CMYC (HS00153349_m1; Applied Biosystems, Carlsbad,
CA) was used with 18SrRNAprobe as an internal control. Samples were
analyzed on an ABI 7900HT Fast Real-time PCR System (Applied Bio-
systems) and analyzed using the ΔΔCt relative quantification method.
Flow Cytometry
Cell cultures were trypsinized and centrifuged, and cell pellets were
resuspended in FACS buffer, with or without an anti–Annexin-FITC–
labeled antibody, according to the manufacturer’s instructions (Roche).
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NJ), and the Annexin V–positive population was measured. For cell
cycle analysis, cells were incubated with 1 mM 5-bromo-2-deoxyuridine
(BrdU; Sigma) for 2 hours. Cells were then washed in PBS and fixed
by dropwise addition of 70% ethanol with constant agitation. Sam-
ples were incubated at 4°C overnight before extraction of nuclei using
standard pepsin digestion protocols.P e l l e t e dn u c l e iw e r ei n c u b a t e dw i t h
an anti-BrdU antibody (Becton Dickinson), washed twice with IFA
(10 mM HEPES pH 7.4, 150 mM NaCl, 0.1% sodium azide [all
Sigma]; 4% FBS [Lonza, Basel, Switzerland]) and then incubated with
an Alexa Fluor 488–coupled secondary antibody (Invitrogen). Washed
nuclei were resuspended 100 μg/ml propidium iodide (Sigma) in PBS
and analyzed as above.
Heterotypic Assays (Invasion, Migration, and
Three-dimensional Cell Culture)
Standard invasion and migration assays were modified to use pre-
senescentandsenescentovarianfibroblasts asa chemoattractant.Atotal
o f9×1 0
4 fibroblasts were plated in 24-well plates. The following
day, the cells were washed twice with PBS, and then 500 μlo fs e r u m -
free medium was added. Migration chambers (Greiner, Frickenhausen,
Germany) or rehydrated invasion chambers (Millipore, Billerica, MA)
were placed atop the fibroblast monolayers, and 3 × 10
4 (for migra-
tion assays) and 12.5 × 10
4 (for invasion assays) epithelial cells were
plated within the chamber. Assays were incubated at 37°C/5% CO2
for 24 hours before detection of invaded/migrated cells. For invasion
assays, invaded cells were detached from the membrane and lysed,
and a quantitative fluorimetric dye was added, using reagents from
the 24-well Chemicon QCM ECMatrix fluorimetric Invasion Assay
Kit (Millipore). Relative fluorescence units were read on a Varioskan
Flash plate reader (Thermo Scientific, Waltham, MA), and average val-
uesofanegativecontrol(nocells)werededucedfromeachtestwell.For
migrationassays,migratedcellswerequantifiedasabove,ormembranes
were stained in situ with 1% crystal violet (Sigma) in 100% methanol,
washed twice with distilled water, and air-dried. The migrated cells
were counted in 10 fields of view per membrane. In all experiments,
10% FBS as a chemoattractant was also plated as a positive control.
Cells were grown as three-dimensional multicellular spheroids on
plastic dishes coated twice with a 1.5% solution of poly-2-hydroxyethyl
methacrylate (polyHEMA) from Sigma, prepared in 95% ethanol (also
Sigma). Fibroblasts were plated onto polyHEMA-coated plates and al-
lowed to form spheroids for 7 days before the culture was inoculated
with epithelial cells at a ratio of 4:1 fibroblasts-epithelial cells. Three-
dimensional heterotypic cultures were maintained in basic medium for
2 weeks and fed twice weekly before multicellular aggregates were
harvested, fixed in neutral-buffered formalin (VWR), processed into
paraffin, and stained by standard immunohistochemical techniques (at
the CR-UK Histology Service). For two-dimensional indirect coculture
assays, epithelial cells were plated into 24-well plates, and fibroblasts
were seeded into permeable tissue culture inserts (Greiner) at a ratio of
4:1 fibroblasts-epithelial cells. After 24 hours, the two cell types were
coculturedandmaintainedfor14dayswithtwice-weeklyrefeeding.Epi-
thelial cells were then fixed with methanol and stained with crystal violet
(5 mg/ml in 2% ethanol), and cells lysed with 2% SDS/dH2O. Absor-
bance was then read at 595 nm on a Varioskan Flash plate reader.
Statistical Analysis
Where indicated, 2-tailed paired Student’s t-tests were performed.
Results
Normal Ovarian Fibroblasts Can Be Immortalized by the
Ectopic Expression of hTERT
PrimaryNOFshavealimitedproliferativecapacityinvitro.Toaddress
this, we used ectopic overexpression of the catalytic subunit of human
telomerase (hTERT) to extend the life span of primary NOF cells be-
yond 100 days without signs of replicative senescence (Figure 1A).
hTERT infected NOFs expressed telomerase, whereas primary NOFs
showed no telomerase activity, suggesting that NOFs had been im-
mortalized (INOFs; Figure 1B). Neither NOFs nor INOFs showed
any evidence of tumorigenic transformation, evaluated by anchorage-
independent growth. INOFs maintain expression of vimentin and FSP
and did not express the epithelial cell marker Ck7 (Figure 1C). There
was no expression of smooth muscle actin (SMA) in primary NOFs,
but SMA expression in INOFs indicated an activated phenotype, which
is consistent with other studies that show fibroblasts from other organs
become activated after hTERT immortalization (Figure 1C) [19,20].
INOFs also maintained p16 expression, suggesting that loss of this cell
cycle checkpoint is not required for immortalization. Similar observa-
tions have been reported after immortalization of human mammary epi-
thelial cells, embryonic lung fibroblasts, and ovarian surface epithelial
(OSE) cells [21–25]. As part of this study, we also hTERT-immortalized
OSE (IOSE) cells derived from three different, normal, primary OSE
cultures (IOSE4, IOSE11, and IOSE19) using previously described
methods [17,24]. We confirmed that the primary OSE and IOSE cells
used in this study exhibit both epithelial and nonneoplastic character-
istics (Figure W1).
CMYC Overexpression Induces Neoplastic Transformation
of IOSE Cells
AcomplementaryDNAencodingfull-lengthCMYCwasintroduced
into IOSE cells by retroviral transduction to induce the early stages of
neoplastic transformation. CMYC messenger RNA expression levels
were increased 80 to 500-fold in CMYC-infected IOSE cell lines
(IOSE4
CMYC, IOSE11
CMYC,a n dI O S E 1 9
CMYC). IOSE
CMYC cells
displayed altered cell morphology with cell size decreased, cell shape
more cuboidal, and cells more classically epithelial than IOSE cells.
IOSE
CMYC cells were tightly packed into a monolayer in traditional
two-dimensional cultures and lost the mesenchymal scattering pheno-
type that is characteristic of IOSE cells (Figure 2A). IOSE
CMYC cells
also showed increased CFEs in anchorage-dependent and anchorage-
independent growth assays (P ≤ .01; Figure 2, B and C). CMYC
messenger RNA levels correlated with anchorage-independent CFE
(Pearson’s coefficient test, r
2 =0 . 8 ,P =. 0 1 5 6 ,α = 0.05). Flow cytome-
try showed significant reductions in the percentage of apoptotic cells
in IOSE
CMYC cell lines compared with the IOSE cell lines (P ≤ .05;
Figure 2D). A significantly greater proportion of IOSE
CMYC cells was
in G2 phase of the cell cycle (P ≤ .05; Figure 2E). These characteristics
are all consistent with the suggestion that IOSE
CMYC cells had under-
gone neoplastictransformation,although neither IOSEnor IOSE
CMYC
cells expressed the ovarian cancer markers E-cadherin and CA-125,
suggesting that IOSE
CMYC cells were only partially transformed.
Senescent Fibroblasts Enhance the Neoplastic Phenotype of
IOSE
CMYC Cells
We induced senescence in INOF cells by exposing the cells to low
dose levels of hydrogen peroxide (H2O2). H2O2 exposure reduced pro-
liferation of INOFs by approximately 30% and induced senescence,
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effects of H2O2-treated senescent fibroblasts (SEN) and untreated pre-
senescent fibroblasts (PSNs) on the invasive and migratory phenotypes
of IOSE and IOSE
CMYC cells. There was a 5.7- to 7.2-fold reduction
intranswell migration for all threeIOSE
CMYC cell linescoculturedwith
PSN fibroblasts relative to a serum control (P ≤ .01). In contrast,
migration levels increased 3.8- to 14.9-fold compared with serum con-
trols when IOSE
CMYC cells were cocultured with SEN fibroblasts
(Figure 3B). SEN fibroblasts also increased the invasive ability of
IOSE
CMYC cells compared with PSN fibroblasts (P ≤ .05; Figure 3C).
Neither PSN nor SEN fibroblasts had any significant effects on the
invasiveormigratorypropertiesofIOSEcells.Finally,whenweusedcon-
ditioned medium (CM) from cultured SEN fibroblasts in anchorage-
independent growth assays, we found that it increased the tumorigenic
phenotype of IOSE19
CMYC cells relative to the same cells grown in
CM from PSN fibroblasts (P ≤ .05). Colony formation efficiencies of
IOSE
CMYC cells grown in PSN-CM or SEN-CM were significantly re-
duced relative to cells grown in standard growth medium (NOSE-CM,
P ≤ .05; Figure 3D).
Senescent Fibroblasts Enhance Epithelial Proliferation in
Three-dimensional Heterotypic Culture Models
Three-dimensional spheroid models of INOFs were generated by
culturing cells on polyHEMA-coated tissue culture plastics. INOFs
formed spontaneous aggregates within 48 hours of culture in non-
adherent conditions. Examination of formalin-fixed, paraffin-embedded
sections of 7-day-old INOF spheroids, stained with hematoxylin and
eosin (H&E), revealed that the central regions of spheroids contain pre-
dominantly acellular hyalinized nodules with apoptotic cells distributed
throughout a matrix-rich core. Peripherally, spindled cells with elongated
nuclei and an eosinophilic cytoplasm surround the spheroid. PSN and
SEN fibroblast spheroids were indistinguishable by H&E staining.
Seven-day-old INOF spheroid cultures were inoculated with IOSE
cells (INOF/IOSE cells ratio of 4:1) to establish three-dimensional
fibroblast-epithelial cell models. H&E examination of stained sections of
these heterotypic three-dimensional cultures showed central hyalinized
cores of abundant matrix protein (Figure 4, A and B). Spheroids con-
sisted of two morphologically distinct populations of cells, with either
spindled or plump cell morphologies. When IOSE cells were cultured
with SEN fibroblasts, we observed nuclear atypia within populations of
plump, peripheral cells and features such as irregular/enlarged nuclei,
prominent nucleoli and “giant” mononuclear cells within peripheral
regions of the spheroids (Figure 4A) .T h e s ea t y p i c a lf e a t u r e sw e r en o t
present in spheroids generated from IOSE cells cultured with PSN
fibroblasts. There were also more prominent nucleoli and mitoses in
theplumpcellpopulationsfromSEN-IOSE
CMYC cocultures compared
withPSN-IOSE
CMYC cocultures(Figure4B).Finally,whenIOSE
CMYC
cells were cocultured with PSN fibroblasts, we saw marked apoptosis
Figure 1. Extended life span of primary NOFs after hTERT immortalization. (A) Ectopic expression of hTERT increases the number of PDs of
NOFs to more than 30 PDs in INOFs. (B) Telomerase activity (relative to an internal positive control) is negligible in cell extracts from primary
NOFs but elevated in INOF cultures, and telomere terminal restriction fragment lengths are increased by approximately 2 kb after introduc-
tion of hTERT. (C) NOFs and INOFs both exhibit “spotty” positive staining with an anti-FSP antibody, which is characteristic of fibroblasts.
Both cell lines stain negative for Ck7. SMA is expressed in approximately 30% of INOF cells indicating a transition toward an activated
fibroblast phenotype with immortalization. Primary NOF cells did not express SMA, and this was independent of cell density. Both NOF
and INOF cells express p16 in the nucleus and cytoplasm (arrows). 4′,6-Diamidino-2-phenylindole (blue) stains cell nuclei, Evan’sb l u e( r e d )
stains the cell cytoplasm, and green fluorescence denotes positive staining. Note the spindled morphology of fibroblast cells. Exposure
times for immunofluorescent images were constant for each antigen. Error bars, SEM.
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IOSE
CMYC cocultures (data not shown).
IOSE/INOF spheroids were compared with normal ovarian tissues
after staining for several epithelial and fibroblast markers. Only cyto-
keratin 18 (Ck18) reliably distinguished between ovarian fibroblasts
and epithelial cells. The fibroblasticmarkers vimentin, desmin, and pro-
line-4-hydroylase did not accurately discriminate between epithelial cells
and fibroblasts in normal ovarian tissue samples and spheroid cultures
(data not shown). In IOSE/INOF spheroids, epithelial cells could be
identified by Ck18 staining; IOSE cells formed a single cell layer sur-
roundingthefibroblast“core,”reminiscentoftheOSEmonolayerinvivo
(Figure4C).However,inINOF-IOSE
CMYCcocultures,IOSE
CMYCcells
formed multiple cell layers surrounding the fibroblast core, with some
Ck18
+ cells invading into the central regions of the spheroid (Figure 4,
E and F). Dual immunohistochemical staining for Ck18 and the pro-
liferation marker MIB-1 highlighted the actively proliferating epithelial
proportion of culture (Figure 4, C–F). In three-dimensional cocultures,
IOSE
CMYC cells were 0.03- to 12.8-fold more proliferative than IOSE
cells. In SEN-IOSE
CMYC spheroids, there was a 1.4- to 4.7-fold increase
in the relative percentage of IOSE
CMYC cell staining positive for both
Ck18 and MIB-1 relative to PSN-IOSE
CMYC cocultures (Figure 4G).
SEN/PSN fibroblasts did not significantly affect the proliferation of
epithelial cells in two-dimensional cocultures (Figure 4H).
Discussion
The two most well-described risk factors for EOCs are the protective
effects conferred by pregnancy and oral contraceptive use [3,4]. It has
been postulated that both act by reducing the number of ovulations
throughout a woman’s lifetime, thus limiting the extent of rupture
and repair of the OSE [26]. However, ovarian cancer usually occurs
several years after menopause, and the natural history of high-grade
serous tumors (the most common histopathologic subtype) suggests
rapid and aggressive tumor growth. The microenvironmental trigger
for this is unlikely to be hormonal factors, given that postmenopausal
ovariesnolongerproducemitogenicsteroidhormones(neitherestrogens
nor androgens) [27]. Postmenopausal ovaries often show age-related
histopathologic changes, such as increased numbers of inclusion cysts
and deep invaginations of OSE into ovarian stroma, and it has been
hypothesized that these may be associated with neoplastic transforma-
tion [28]. We hypothesized that loss of presenescent stromal fibroblasts
and/or an accumulation of metabolically active but senescent fibroblasts
Figure 2. Immortalized OSE (IOSE) cell cultures overexpressing CMYC (IOSE
CMYC cells) show features of neoplastic transformation.
(A) The fibroblast-like elongated morphology of IOSE cultures changes to a more typically epithelial (cuboidal) morphology on CMYC
overexpression. Commitment to an epithelial phenotype is a hallmark of EOC cells. OSE cells in vitro and in vivo are able to switch
among epithelial, mesenchymal, and mesothelial phenotypes. (B) Overexpression of CMYC increases colony formation efficiency in both
anchorage-independent growth assays and in anchorage-dependent colony formation assays (C). (D) Staining with an anti–annexin V anti-
body followed by flow cytometry analysis reveals significantly fewer apoptotic cells in IOSE
CMYC cultures compared with parental cell lines.
(E) Cells were incubated with BrdU, and nuclei were stained with anti-BrdU. InCMYC-overexpressingcultures, there were significantlylarger
proportions of cells in the G2 phase of the cell cycle compared with IOSE counterparts. In panels B to E, the differences for each phenotypic
assay between IOSE and IOSE
CMYC cells were statistically significant (P ≤ .05). Error bars, SEM.
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transformation of dormant, partially transformed ovarian epithelial cells,
and that this is a possible explanation for the late-stage development
of ovarian cancers from an otherwise inactive organ. In support of this
hypothesis, we show for the first time that cellular changes in ovarian
stromal fibroblasts can promote neoplastic transformation of OSE cells.
This paracrine trigger acts in synergy with early genetic events in par-
tially transformed OSE cells but has little or no effect on untransformed
OSE cells.
We modeled the earliest stages of OSE transformation by over-
expressing the CMYC oncogene in hTERT-immortalized OSE cells
(IOSE
CMYC) because both hTERT and CMYC are commonly over-
expressed in EOCs [29,30]. IOSE
CMYC cell lines show evidence of
anchorage-independent growth but not invasion, confirming that they
are only partially transformed. We observed some variability in the re-
sponseofdifferentcelllinestoCMYCoverexpression,althoughthepheno-
t y p i ct r e n d sw e r et h es a m ef o ra l lt h r e ec e l ll i n e s ;t h i sv a r i a t i o nm a yb e
the result of subtle differences in the underlying genetic background of
the individuals from which the different cell lines were established, influ-
encing the phenotype. When we tested the effects of coculturing IOSE
and IOSE
CMYC cells with PSN and SEN fibroblasts, we found that
SEN fibroblasts had a significant effect on increasing neoplastic transfor-
mation of IOSE
CMYC cells compared with PSN fibroblasts; neither PSN
nor SEN fibroblasts appeared to transform IOSE cells. In anchorage-
independent growth assays, we also found that conditioned medium
taken from cultured SEN fibroblasts had the ability to promote the
neoplastic phenotype of IOSE
CMYC cells relative to the conditioned
medium harvested from PSN fibroblasts. Taken together, these data
suggest that the regulation of neoplastic epithelial cells by PSN/SEN
fibroblasts is mediated, at least in part, by soluble, secreted factors.
Key to performing these studies was our ability to generate and char-
acterize an immortalized NOF (INOF) cell line. To our knowledge,
this represents the first report detailing the generation of such a line.
We were able to confirm the normal, nontransformed, and fibroblastic
nature of this cell line, suggesting that it is a relevant model of NOFs.
Senescent fibroblasts were also created from the same INOF cell line
after exposure to hydrogen peroxide, and so it is unlikely that any of
the experimental differences we see between SEN and PSN fibroblasts
are the result of differences in the genetic background of cells taken
from different individuals.
Figure 3. Effects of PSN and SEN fibroblasts on the phenotype of IOSE
CMYC cells. (A) Exposing INOFs to hydrogen peroxide (H2O2)i n d u c e s
a senescence response that is biologically similar to replicative senescence observed in aging organisms. β-Galactosidase bioactivity con-
firms senescence induction in INOFs: (i) 60% to 80% of SEN stain blue, (ii) untreated PSN fibroblasts do not stain, and (iii) crystal violet
growth assay (absorbance at 595 nm is relative to cell number) show that PSN fibroblasts are more proliferative than SEN fibroblasts. (B) In
a migration assay, PSN fibroblasts inhibited motility of IOSE
CMYC clones relative to 10% FBS. SEN fibroblasts significantly enhanced migra-
tionofallCMYCclonesrelativetoaPSNfibroblastchemoattractant.(C)SENfibroblastsenhancedinvasiveabilityofIOSE
CMYCclonesrelative
to PSN fibroblast cells. (D) IOSE19
CMYC cells proliferate significantly more in an anchorage-independent growth assay when incubated with
conditioned medium from SEN fibroblasts relative to PSN fibroblast conditioned medium. In both SEN/PSN–conditioned media, colony
formation efficiency of IOSE
CMYC cell lines was reduced relative to standard growth medium (NOSE-CM) (*P ≤ .05,**P ≤ .01 by Student’s
paired t-test). Error bars, SEM.
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peroxide has been described previously, and senescent cells have sub-
sequentlybeenshowntoexhibitmanyofthefeaturesthatareincommon
with replicative senescence (e.g., β-galactosidase expression, G1 arrest,
enlarged morphology, transcriptomic changes) [12,23,31]. Other mech-
anisms of inducing cellular senescence can be considered including
exposure to bleomycin sulfate, but there is no evidence in the literature
to suggest that bleomycin offers an advantage over hydrogen peroxide
[12]. The limited life span of primary ovarian fibroblasts meant that their
immortalization using hTERTwas a necessary step, but immortalized
cells bypass replicative senescence, hence the need to perform chemically
induced senescence. This study therefore has its limitations because it is
unclear how closely stress-induced premature senescence in vitro,s u c ha s
that induced by hydrogen peroxide, reflects age-related senescence in vivo.
We were able to examine the morphological and biological char-
acteristics of epithelial-fibroblast interactions and to confirm the
neoplastic-promoting effects of senescent fibroblasts after creating a
three-dimensional heterotypic model of the ovary. This is the first time
that a heterotypic three-dimensional model of the normal ovary has
been described. In three-dimensional cultures, senescent fibroblasts en-
hanced proliferation and nuclear atypia in IOSE
CMYC cells relative to
presenescent and, to a lesser extent, the proliferation of IOSE cell lines.
Figure 4. Three-dimensional (3D) in vitro modeling of stromal-epithelial interactions. (A) In SEN-IOSE three-dimensional cocultures, “giant”
cells (arrow) were observed within peripheral regions of the spheroids. Spheroids contained abundant matrix protein “M.” (B) In SEN-
IOSE
CMYC three-dimensional coculture, there was a large peripheral region of plump cells containing some mitotic figures (arrows). (C–F)
INOF-IOSE cocultures dual stained for MIB-1 (pink nuclear stain, proliferation marker) and Ck18 (brown cytoplasmic stain). Unstained cells
are counterstained with hematoxylin (blue). (C) In SEN-IOSE cocultures, cytokeratin-positive cells are located in the peripheral region of the
spheroid (arrowhead). A Ck18
+/MIB-1
+ dual-positive cell (arrow) is visible in the largest spheroid. (D) In PSN-IOSE cocultures, nonspecific
staining ofmatrix protein canbedistinguishedbytheabsenceofcellular structure. (E) SEN-IOSE
CMYCthree-dimensional coculture viewedat
low magnification shows the central Ck18-negative staining fibroblastic population “F” and peripherally located Ck18-positive stained cells
within the spheroid. Some peripheral Ck18-positive stained cells, dual stained for MIB-1 (pink nuclei), can also be seen. (F) In SEN-IOSE
CMYC
three-dimensional cocultures negative Ck18 stain fibroblasts “C” closely interact with the population of Ck18-positive staining epithelial
cells “A” and “B.” Note the spindled morphology and elongated nucleus of Ck18-negative cells (e.g., cell C) compared with the plump mor-
phology and rounded nuclei of Ck18-positive cells. Cell A is positive for Ck18 and negative for MIB-1; cell B is positive for both Ck18 and
MIB-1. (G) Analysis of dual-stained Ck18/MIB-1–positive cells reveals enhanced proliferation in IOSE
CMYC cells when cocultured three-
dimensionally with SEN fibroblasts compared with PSN fibroblasts (*P ≤ .05, Student’s paired t-test). The proportion of MIB-1 cells is cal-
culated as a ratio of the total Ck18
+ population of the culture. (H) Two-dimensional (2D) indirect coculture; crystal violet staining. Epithelial
cells do not show significant differences in rates of proliferation when cocultured with SEN or PSN fibroblasts.
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ian epithelia may render cells susceptible to a tumor-promoting trigger
from the microenvironment. Our data also suggest that the synergistic
relationship between senescent fibroblasts and epithelial cells may con-
tinue as tumorigenesis progresses. This is consistent with studies by
Yang et al. [32] who have shown that inducing senescence in fibroblasts
increases the in vivo tumorigenicity of coinjected OSE cells expressing
SV40 large-Tantigen.
If the results of these studies are real, and the accumulation of
metabolically active senescent fibroblasts does act as the microenviron-
mental trigger for ovarian cancer development, then it raises the
question, “what are the secretary factors responsible for epithelial cell
transformation?” Some candidates have been identified from previous
studies, including osteopontin, stromal cell–derived factor (SDF-1),
vascular endothelial growth factor, amphiregulin, hepatocyte growth
factor, and interleukin-6, all of which have been shown to act as medi-
ators of the differential paracrine effects of presenescent and senescent
fibroblasts [9,11–13,15]. The tumor-promoting effects of the condi-
tioned medium from SEN-IOSE
CMYC cocultures compared with the
medium from PSN-IOSE
CMYC cocultures suggest a possible biological
comparison that could be used to identify such factors in the future.
In conclusion, we have used an in vitro model of early-stage neo-
plastic transformation of normal ovarian epithelial cells to test the hy-
pothesis that the accumulation of senescent fibroblasts in aging ovaries
can act as a trigger to the rapid development of ovarian cancers—this
is consistent with many well-established epidemiological risk factors
for ovarian cancer. These effects may be due to the loss of an inhibitory
factor, secreted by normal fibroblasts, which inhibits carcinogenesis
of epithelial cells harboring mutation(s). Thus, loss of this inhibitory
signal on fibroblast senescence may create a microenvironment that is
permissive for tumor development. Alternatively, senescent fibroblasts
may produce factors that promote transformation of neoplastically
transformed epithelia. Support for this hypothesis has come from the
analysis of human ovarian tumors, which have been shown to contain
a large number of senescent fibroblasts within the tumor stroma; this
may also suggest a role for senescent fibroblasts in the maintenance
of ovarian tumors [32]. However, testing such a hypothesis in vivo in
normal ovaries is challenging. There are no reports of the rates of cel-
lular senescence in human ovaries and to study this would probably
require mass sectioning and analysis of large numbers of normal ovaries
to identify senescent cells. This may be possible using a β-galactosidase
bioactivity assay, which enables sensitive detection of senescent cells in
frozen tissue specimens. Another way to address the hypothesis, and
a focus of future studies, is to evaluate the tumorigenic phenotype of
three-dimensional heterotypic models of senescent and presenescent
fibroblasts with partially transformed normal ovarian epithelial cells
after implantation into immunosuppressed mice.
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